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Abstract
Phase III trials for new tuberculosis treatment regimens require large numbers
of participants and can take over five years to complete. A surrogate marker
for poor outcome (failure at end of treatment or recurrence following suc-
cessful treatment), the established endpoint in such trials, could shorten trial
duration and reduce trial size. Culture results after two months of treatment
have shown the most promise but, prior to this research, no formal evaluation
had been performed.
In this thesis, culture results during treatment are evaluated as prognostic
and surrogate markers for poor outcome using data on 6974 patients from
twelve tuberculosis treatment randomised controlled multi-arm trials con-
ducted in East Africa and East Asia.
A strong association was found between culture results during treatment
and poor outcome. Nevertheless, culture results were not good patient-specific
predictors of poor outcome with low sensitivities and specificities.
Existing meta-analytic methods for evaluating surrogate markers are not
wholly suited to this setting of multi-arm trials with binary true and surrogate
endpoints. Extending these methods, the two month culture was found to be a
good surrogate marker using data from Hong Kong trials and the three month
culture was found to be a good surrogate marker using data from East African
trials. These results are an indication that cultures during treatment do cap-
ture some of the treatment effect. Further work is needed in understanding
the differences between the Hong Kong and East African trials.
The meta-analytic methods for evaluating surrogate markers in this thesis
included a graphical representation that permitted a clear visual evaluation
of the surrogate. Methods developed in this thesis for modelling the relation-
ship between the treatment effects on the true and surrogate endpoints were
not satisfactory. The deficiencies were not overcome with the two extensions
proposed. Further work is needed in developing a more appropriate model.
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Chapter 1
Introduction
1.1 Tuberculosis: Preventable, Curable and Unre-
lenting
Tuberculosis (TB) is the world's oldest infectious disease and over the cen-
turies has been responsible for more mortality, morbidity and human suffering
that any other (Youmans, 1979). The bacilli causing TB, Mycobacterium tuber-
culosis, has been detected in Andean Mummies dating from 140 AD (Konomi
et al., 2002), in Egyptian Mummies dating from 1000 BC (Zink et al., 2003), in
bones from an infant and a woman in the Eastern part of the Mediterranean
from 7000 BC (Hershkovitz et al., 2008) and in the bones of extinct North
American bison dating from 15000 BC (Rothschild et al., 2001). In his Apho-
risms, Hippocrates (ca. 460 BC - ca. 370 BC) identifies tuberculosis (phthisis
in Greek) as a widespread disease that was almost always fatal, particularly if
'the hairs of the head fall off'l. There are two probable references to TB in the
Old Testament of the Bible during the period when the Israelites lived among
the Egyptians around 1440 BC (Daniel and Daniel, 1999). Many specimens
of ancient drawings and pottery from around the world show people with
physical deformities characteristic of TB.
More recently, in the United States of America, in the middle of the nine-
teenth century as many as a quarter of all deaths reported were caused by
diseases of the lung (Dubas and Dubas, 1996) and even in 1930, TB was the
1Hippocrates. Aphorisms. eBooks @ Adelaide. 2007. http://ebooks.adelaide.edu.au
/h/hippocrates/aphorisms/. Retrieved 23 Apr 2009.
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most frequent cause of death or disability for those aged between 15 and 45.
TB was also the single biggest cause of death and disease in England in the
nineteenth century with mortality at times over 400 per 100,000 of population
per year (Dubas and Dubas, 1996).
In 1882 M. tuberculosis was discovered by Robert Koch. Deaths due to TB
dropped in both England and the United States over the first half of the twen-
tieth century, largely due to improvements in living conditions and nutrition
following the end of the industrial revolution (Dubas and Dubas, 1996).
At the beginning of the 20th century, a character in a play by George
Bernard Shaw, A Doctor's Dilemma, described the treatment for TB in England
at that time as "a huge commercial system of quackery and poison" (Iseman,
2002). Philip D'Arcy Hart's review of chemotherapy for TB published in 1946
states that 'principal measures recommended at this time [the turn of the cen-
tury] were rest, sometimes tempered with exercise, and plentiful diet, often to
the point of overfeeding'. The author also notes 'It was a time when a drug
was seldom dropped, although it was a routine procedure to add one' (Hart,
1946). Itwas not until 1944 that Streptomycin, the first truly effective treatment
against tuberculosis (Hart, 1946) was discovered in the United States leading
to great celebration (including patients apparently dancing in the wards in a
New York Hospital, Reichman (1999)). Following a small study of 24 patients
showing benefit (Hinshaw and Feldman, 1945), a small quantity of strepto-
mycin was made available to the British Medical Research Council (MRC) on
the other side of the Atlantic. This lead to what is generally regarded as the
first randomised controlled trial (Medical Research Council, 1948) using the
methods developed by Sir Austin Bradford Hill (Hill, 1937), and the first con-
trolled trial of streptomycin for pulmonary tuberculosis (PTB) in man. Thus
begun a series of studies based largely around this tool of the randomised
controlled trial that took place over the next forty years to determine the most
effective regimen to treat TB. For the first time in history, TB became a curable
disease and, by the 1970s, a highly effective six month regimen was identified.
The development of short-course chemotherapy (described as such to contrast
with the 18-month regimens in use in the 1960s and 1970s) is largely a re-
sult of the work of the MRC (Iseman, 2002; Murray, 2004; Raviglione and Pio,
2002).
In 1986, the MRC's highly influential TB research units closed down and
attention shifted to other disease areas as it was widely believed that there
was no need for new anti-tuberculosis agents-all that was required to defeat
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tuberculosis was the correct implementation of the recommended treatment
regimens. In 1999, an entire 50-page supplement to the International Jour-
nal of Tuberculosis and Lung Disease, written by three of the key scientists
involved-a statistician, a biochemist and a microbiologist, was devoted to
the work of these units and made this point:
'When the [MRC TB] units were closed in 1986, all of the mea-
sures necessary for successful programmes for the control of tu-
berculosis had been delineated. .. These tools were then available
to national organisations and to international organisations such
as the World Health Organisation (WHO) and the International
Union Against Tuberculosis and Lung Disease (IUATLD), to im-
plement in control programmes.'
Fox et a1. (1999)
Unfortunately, the tools available at the time were insufficient to prevent
the resurgence of the TB epidemic.
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Figure 1.1: New TB case notification rates per 100,000 in Zambia
from 1964 to 2000. Data from Mwaba et a1. (2003).
Figure 1.1 shows new TB case notification rates in Zambia from 1964 to
1996. Notification rates had leveJled during the 1960s, 70s and 80s and it is
the introduction and spread of HIV in the 1980s in Zambia that caused the
steep increase in the late 1980s (Maartens and Wilkinson, 2007).
History has shown that the aforementioned control of tuberculosis has not
been achieved:
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'The eradication of TB has proven to be an elusive goal, often
in individual patients as well as in large populations'
(Wallis et al., 1999)
1.2 The Need for New Anti-Tuberculosis Drugs
Today almost one third of the world's population are infected with TB and
approximately 8 million of these will develop active TB. There are 9.2 million
new cases and 1.7 million people die every year from TB despite a cure being
available for as little at US $10. The emergence of drug resistant strains of
M. tuberculosis and the HIV epidemic have fuelled the increase with TB being
the leading cause of death among people infected with HIV (World Health
Organization, 2008; Stop TB Partnership, 2006; World Health Organization,
2006).
In response to this renewed threat, the WHO declared TB a global emer-
gency as far back as April 1993. It has been shown that cure rates of up to
95% can be achieved in a clinical trial setting (Fox et al., 1999; World Health
Organization, 2008) and at this time it was recognised that to effectively con-
trol tuberculosis, well-organised tuberculosis diagnostic and treatment ser-
vices were required. To meet this need, WHO and its partners introduced the
directly observed therapy, short course (DOTS) strategy (World Health Or-
ganisation, 1994), replacing this with an expanded DOTS framework in 2002
(World Health Organisation, 2002). This expanded framework has five ele-
ments:
1. Sustained political commitment to increase resources,
2. Access to quality-assured TB sputum microscopy for case detection,
3. Standardised short-course chemotherapy to all cases of TB under proper
case-management including direct observation of treatment,
4. Uninterrupted supply of quality-assured drugs,
5. Recording and reporting of treatment outcome.
Standardised short-course chemotherapy (as recommended by World Health
Organization (2003» consists of four medications taken daily for two months
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followed by two medications taken for a further four months. DOTS is labour-
intensive for health staff and, while six months of treatment is significantly
short than the eighteen or twenty-four month regimens recommended be-
fore the introduction of short-course chemotherapy (British Medical Research
Council, 1962), it is still a significant burden on the patient (particularly as pa-
tients can be taking up to eleven separate pills every day (Camp et al., 2006»
and is difficult to implement where health services are poorly accessible.
An average treatment success rate of 84.5% was observed in the WHO
DOTS 2005 cohort (patients diagnosed worldwide with active TB in 2005,
treated using DOTS and followed up into 2006), but this figure was only 74%
in the African Region dropping below 60% for some African countries (World
Health Organization, 2008). A treatment success is defined as a patient who
has completed at least six months of treatment with a negative smear at the
end of treatment in addition to a negative smear before the end of treatment
or who has not had a positive smear after the fifth month of treatment (World
Health Organization, 2008). National TB programmes are judged by their
treatment success rates.
Low success rates may be due to poor adherence or limited access to health
care facilities. Symptoms of TB usually disappear within the first few months
of treatment and therefore many patients can be reluctant to continue to take
their treatment for the full course of six months (Munro et al., 2007) although
six months of treatment is necessary to reduce rates of relapse and acquired
drug resistance. A simpler, shorter regimen is needed to improve compliance
and improve treatment outcomes. It has been demonstrated that this is not
possible with the existing drugs in use today (Fox et al., 1999). New drugs
are also needed to combat increasing rates of drug resistance and the complex
co-infection of TB and HIV.
With the WHO as the leading partner, the Stop TB Partnership was estab-
lished in 2000 to realise the goal of the elimination of TB by 2050. To raise
awareness of TB, the Stop TB Partnership launched World TB Day in 2000 on
the 24th of March which has since been repeated annually. The Partnership
produced the Global Plan to Stop TB 2006-2015, building on the Partnership's
first plan for 2001-2005, which sets out activities and goals for all levels of
political and community involvement to bring TB under control.
Responding to the need for new drugs as expressed in the Global Plan and
by other authors (O'Brien and Nunn, 2001), the Global Alliance for TB Drug
Development (GATDD) was also formed in 2000 with the mission to 'acceler-
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ate the discovery, development and equitable distribution of new drugs' pri-
marily to 'shorten the duration of TB treatment or otherwise facilitate its suc-
cessful completion' (Global Alliance for TB Drug Development, 2001). Their
aim is to register such a new compound by 2010 (The Working Alliance for TB
Drug Development, 2000). One such candidate drug is Moxifloxacin which is
being investigated in a Phase III clinical trial (REMoxTB) coordinated by UCL
and the MRC Clinical Trials Unit under the auspices of the GATDD with re-
cruitment having started in the middle of 2008. The trial uses a non-inferiority
design.
There are currently seven compounds in clinical development for the treat-
ment of TB (Casenghi and von Schoen-Angerer, 2006; Spigelman, 2007), four
of which are new drug candidates with novel mechanisms of action (Rivers
and Mancera, 2008), as well as a number of compounds in the pre-clinical and
discovery stages . The possibility of using a high dose of a compound from
the rifamycin family may also lead to shorter, intermittent regimens (Rosen-
thal et al., 2007).
It is clear that there will be an increasing number of late phase clinical
trials being conducted over the next few years as more and more compounds
enter the clinical stage of drug development.
1.3 The Need for Surrogate Markers
In the scientific blueprint for TB drug development produced by the GATDD
in 2001, several barriers to TB drug development are explored, highlighting
particularly the lack of infrastructure and experience in phase III clinical trials.
They identify surrogate markers for long-term response as a way to streamline
phase III trials (Global Alliance for TB Drug Development, 2001). A surrogate
marker (synonymous in this thesis for surrogate endpoint, see discussion in sec-
tion 2.2) is one that is used as a substitute for the usual final endpoint in a
clinical trial and must therefore capture any effect of the trial intervention on
this final endpoint.
Tuberculosis is unique among infectious diseases in that failure to culture
bacilli in a sputum sample is not necessarily indicative of cure-a patient
needs to remain smear or culture negative for a period of several consecu-
tive months to be declared cured (World Health Organization, 2008). In a
TB clinical trial, patients need to be followed up for from twelve to twenty-
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four months after the end of treatment to be assessed for final endpoint of
poor outcome to treatment (failure during treatment or relapse after the end of
treatment). This period of extensive follow-up is costly and can mean that a
TB trial could take five or more years to complete (e.g. Jindani et al., 2004).
Recurrence rates under clinical trial conditions are often less than 5% (Fox
et al., 1999) and therefore large numbers of patients are required in a trial,
even to show non-inferiority (Nunn et al., 2008). It has been suggested that
the total time required to develop a new TB drug from discovery to regula-
tory approval would be 20 years-. This is all because 'there are no accepted
surrogate markers for efficacy' (Spigelman, 2007).
A properly validated surrogate marker for response to anti-tuberculosis
drugs would result in trials without the need for extensive follow-up for re-
lapse which are therefore shorter in duration and cheaper. Such a marker
would ultimately speed the drug development process aiding the Stop TB
partnership and the GATDD in their aims.
1.4 The Scope of this Thesis
The aim of this research is to identify and evaluate prognostic and surrogate
markers for poor outcome of treatment for TB. As is demonstrated in Chapter
3, the markers that have shown most promise historically and in recent years
are culture results during treatment. Much has been written about the use of
culture results to predict relapse (Global Alliance for TB Drug Development,
2001; Desjardin et al., 1999; Wallis et al., 2000) or in some cases substitute
for relapse in a clinical trial (Sirgel et al., 2000) but the evidence for these
claims is ambiguous. This research project will focus primarily on the formal
evaluation of culture results during treatment as prognostic and surrogate
markers for poor outcome.
The statistical literature on evaluating prognostic and surrogate markers is
reviewed in Chapter 2. Chapter 3 begins with an overview of the diagnosis,
treatment and progression of TB disease before reviewing the literature on
possible prognostic and surrogate markers for poor outcome. The data used
for the analyses in this thesis are introduced and described in Chapter 4, and
the results of some exploratory analyses presented. Culture positivity during
treatment is evaluated as a prognostic marker in Chapter 5 and evaluated as a
2Personal communication from Amina Jindani.
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surrogate marker in Chapter 6. In Chapter 7, methods for evaluating surrogate
markers are extended to better account for some of the specific complexities
of the data used in this thesis. These methods are also compared using a
simulation study. All of these results are brought together in the discussion
in Chapter 8 and conclusions drawn.
Appendix A contains some additional figures and tables of detailed results
where only summary tables have been presented in the main body of the
thesis. Appendix B gives the derivation of the reliability ratio in different
situations to be used in analyses in Chapter 7. Appendix C contains a glossary
of terms used in this thesis and Appendix 0 lists the mathematical notation
used to describe the methods used in this thesis.
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Chapter 2
The Evaluation of Prognostic
and Surrogate Markers
2.1 Introduction
In this chapter, the statistical literature on evaluating prognostic and primarily
surrogate markers is summarised and reviewed with particular focus on those
methods which are likely to be appropriate for use in this thesis.
Any discussion of surrogate endpoints must involve a review of the 'con-
troversial issues arising when surrogate endpoints are used as study out-
comes' (Fleming et al., 1998). The benefits promised by the idealised concept
of a surrogate endpoint-shorter, cheaper, smaller trials-are not in question;
the controversy relates to the actual process of the evaluation of surrogate
endpoints and the subsequent use of apparently 'validated' markers.
The literature is littered with examples of failed surrogates. These are
markers that were used as surrogates in clinical trials on the basis of poor
evidence, to demonstrate the efficacy of an experimental regimen. They were
subsequently found not to be surrogates and the results from the clinical trials
therefore of little use. It is the use of surrogate markers before they have
been thoroughly evaluated as such that has fuelled the negative perception of
surrogate markers for long term response.
To circumvent this controversy, the guidelines covering Statistical Princi-
ples for Clinical Trials (ICH E9, International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals For Human Use,
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1998) prepared by the International Conference on Harmonisation of Techni-
cal Requirements for Registration of Pharmaceuticals for Human Use (ICH) in
1998 gives the following three criteria which are necessary for the evaluation
of a surrogate endpoint:
1. 'The biological plausibility of the relationship,
2. the demonstration in epidemiological studies of the prognostic value of
the surrogate for the clinical outcome, and
3. evidence from clinical trials that treatment effects on the surrogate cor-
respond to effects on the clinical outcome.'
International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals For Human Use (1998)
These three requirements are distilled from much of the literature de-
scribed below, but form the basis of any statistical validation of a surrogate
endpoint and will be referred back to in subsequent chapters of this thesis. A
similar list of criteria or 'provisos' is given in Boissel et al. (1992).
There is now regulation by the US Food and Drug Administration (FDA)
that can grant accelerated marketing approval for drugs on the basis of tri-
als using surrogate endpoints and this was used to quickly approve new an-
tiretroviral (ARV) drugs for HIV for which the efficacy was later shown using
relevant clinical outcomes (Bucher et al., 1999).
In section 2.2, clear definitions of the various terms in use are given. Fol-
lowing these definitions, section 2.3 surveys some examples of surrogates that
have been used in other disease areas, both correctly and incorrectly. Section
2.4 reviews methods for evaluating prognostic markers. Section 2.5 introduces
the seminal Prentice criteria for surrogate endpoints and reviews the literature
exploring these criteria.
The move away from the hypothesis tests of the Prentice criteria towards
quantifying the proportion of treatment effect captured by a surrogate marker
is summarised in section 2.6. Section 2.7 looks at one particular trial design
using a surrogate endpoint. Section 2.8 reviews the most recent body of statis-
tical work in this area by a group of Belgian statisticians and section 2.9 covers
related methods developed to evaluate surrogate markers in the disease area
of HIV.
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2.2 Definitions
Most authors refer to one of these three definitions in any discussion of sur-
rogate markers:
• Prentice, 1989. The first attempt to provide a clear statistical definition
of a surrogate endpoint was made by Prentice (1989) in a paper pub-
lished alongside three other papers summarising the use of surrogate
endpoints in clinical trials in three separate disease areas. The introduc-
tion to this series of four papers provides a typically weak definition
of a surrogate endpoints as 'one that an investigator deems as corre-
lated with an endpoint of interest but that can perhaps be measured at
lower expense or at an earlier time than the endpoint of interest' (Her-
son, 1989). Other definitions in this same series suggest that a surro-
gate endpoint is one that is 'sufficiently well correlated' (Ellenberg and
Hamilton, 1989) or that 'relates in some way' (Hillis and Seigel, 1989) to
the clinical endpoint. In actuality, each of these definitions describe a
prognostic marker. Prognosis is the 'estimation of the relative probability
of the various possible outcomes of a disease' (Walter, 1998) whatever
the treatment given.
Prentice argued that a surrogate endpoint should be considered in the
context of the treatment comparison, as this is the purpose of an in-
tervention clinical trial, and redefined a surrogate endpoint to be 'a re-
sponse variable for which a test of the null hypothesis of no relationship
to the treatment groups under comparison is also a valid test of the cor-
responding null hypothesis based on the true endpoint' (Prentice, 1989).
This definition has become widely accepted and is the most common
starting point for a discussion on the evaluation of surrogate endpoints.
Prentice was careful to highlight the fact that a surrogate is only defined
with respect to a particular treatment comparison .
• Temple, 1995. Temple (1995) defined a surrogate endpoint as 'a labora-
tory measurement or a physical sign used as a substitute for a clinically
meaningful endpoint that measures directly how a patient feels, func-
tions or survives. Changes induced by a therapy on a surrogate endpoint
are expected to reflect changes in a clinically meaningful endpoint.' This
definition emphasises the need to have a clearly defined final endpoint
for which the surrogate will be a substitute for, and that it is the changes
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due to the therapy in the surrogate, rather than absolute values, that
should be related to changes in the final endpoint .
• Biomarkers Definitions Working Group, 2001. A working group of the US
National Institute of Health on Biomarkers and Surrogate Endpoints de-
fines a biomarker as 'a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic pro-
cesses, or pharmacologic responses to a therapeutic intervention' and
defined a surrogate endpoint as 'a biomarker that is intended to sub-
stitute for a clinical endpoint' (Biomarker Definitions Working Group,
2001). They go on: 'A surrogate endpoint is expected to predict clinical
benefit (or harm or lack of benefit or harm) based on epidemiologic, ther-
apeutic, pathophysiologic, or other scientific evidence.' Under this def-
inition it is clear that a biomarker is a more general term and must meet
additional conditions to qualify as a surrogate endpoint. A biomarker is
merely an indicator of some treatment induced response, but a surrogate
must predict some meaningful clinical benefit.
Some authors use the term surrogate marker as a synonym for surrogate
endpoint, while some authors discourage this terminology in the context of
trials and treatment comparisons as it detracts from the role of a surrogate
as a substitute for a hard clinical endpoint (Biomarker Definitions Working
Group, 2001; Burzykowski et al., 2005). In this thesis, these two terms will be
considered to be synonymous.
Freedman et al. (1992) describe intermediate endpoints as 'biological mark-
ers or events that may be assessed or observed prior to the clinical appearance
of the disease, and that bear some relationship to the development of that
disease.' With this definition, they are effectively proposing the term 'inter-
mediate endpoints' to refer to candidate surrogate endpoints that have not
yet been validated. Boissel et al. (1992) define an intermediate endpoint as 'a
response variable which is statistically correlated with the clinical endpoint'
which can then 'qualify' as a surrogate 'if it can be used as an appropriate
alternative to a clinical endpoint in a clinical trial'. This is in contrast with an
auxiliary endpoint which is defined as one that cannot fully substitute for the
final endpoint, but can perhaps augment the clinical event information thus
strengthening the true endpoint analyses (Fleming et al., 1994).
Lassere et al. (2007b) links Biomarker Definitions Working Group (2001)
and Temple (1995)by contrasting patient outcomes which directly reflect 'how a
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patient feels, functions or survives' with biomarkers which are 'disease-centred
variables of biological and pathological processes'. The authors propose a
scoring system (ranging from 0 to 15) for evaluating surrogate endpoints con-
cluding that a surrogate endpoint is effectively a biomarker that can also be
described as a patient outcome.
A meeting was initiated jointly by the Special Programme for Research and
Training in Tropical Disease (TOR) and the European Commission in Geneva,
Switzerland in June 2008 to discuss and evaluate the role of biomarkers and
surrogate endpoints in the management of patients with tuberculosis. The re-
port from this meeting included a useful table giving a number of definitions
used which is reproduced below.
• Biomarker (biological marker). A measurable characteristic that is objec-
tively measured and evaluated as an indicator of normal biological pro-
cesses, pathological processes, or physiological or pharmacological re-
sponses to a therapeutic intervention.
• Biosignature. A group of biomarkers used together that form highly mul-
tiplexed biosignatures.
• Surrogate end-point. A biomarker that is intended to substitute for a clini-
cal end-point based on epidemiological, therapeutic, pathophysiological
or other scientific evidence.
Predicts clinical outcome in terms of benefit, or harm or lack of benefit.
• Clinical end-point. A characteristic or variable that reflects the final out-
come of disease in terms of function, effect, progress, recovery, survival
or death.
• Surrogates of protection. Validated markers of correlates of protection.
• Correlates of protection. Measurable sign(s) in a host in response to an
infectious agent indicating whether the individual is being protected
against becoming infected and/or developing disease.
Reproduced with permission from Zumla et al. (2008)
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2.2.1 Defining, Evaluating, Qualifying or Validating?
Prentice (2005) is clear, that he proposed his original criteria to give a means of
defining a surrogate marker and that 'evaluating whether a certain biomarker,
or short-term clinical outcome can reasonably serve as a replacement for a
true endpoint T, is quite another matter'. Many authors talk about sur-
rogate marker validation (e.g. Freedman et al., 1992; De Gruttola et al., 1997;
Buyse and Molenberghs, 1998; Lassere et al., 2007b) or qualification (e.g. Bois-
sel et al., 1992), although the single published textbook on surrogate endpoints
(Burzykowski et al., 2005) is entitled 'The Evaluation of Surrogate Endpoints'.
Wagner et al. (2007), from a regulatory perspective, distinguishes between
assay method validation as 'determining the range of conditions under which
the assay will give reproducible and accurate data' and biomarker qualification
as the 'evidentiary process of linking a biomarker with biological processes
and clinical endpoints'. On the basis of these definitions, the authors argue
that the term qualification should be used in preference to validation. The
authors state that a biomarker that is to be used as a surrogate marker will
require substantial qualification. They break the process of qualification into
four stages naming the final stage as 'surrogacy'.
Berger (2004) prefers the term 'validation', although the author notes that
'it is common to assume that the Prentice criteria imply that the use of the
now validated surrogate endpoint will lead to valid inference for the true clinical
endpoint'. The author unsuccessfully attempts to discover an inconsistency
in Prentice's work, but makes an important point with regard to the use of
the term validation. To avoid these connotations, the word evaluation has been
preferred in this thesis.
2.3 Examples
There many examples of surrogate endpoints that are used in different disease
areas, a number of which have subsequently been shown to be very poor
surrogates in later research. A selection of these surrogates are detailed here.
• Ventricular arrhythmia as a surrogate for death following myocardial infarc-
tion. It is known that ventricular arrhythmia is associated with an almost
four-fold increase in the risk of death related to cardiac complications.
Three drugs (encainide, flecainide and moricizine) were found to sup-
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press arrhythmia and were approved by the FDA and more than 200,000
persons per year took these drugs in the US. Beginning enrolment in
1987, the Cardiac Arrhythmia Suppression Trial (CAST) evaluated these
three drugs in patients who had had a myocardial infarction (The Car-
diac Arrhythmia Suppression Trial (CAST) Investigators, 1989; Ruskin,
1989). Importantly, this trial did not use the accepted surrogate end-
point, but the final clinical endpoint (death) to evaluate these therapies.
The trial was stopped early after finding an increased risk of death in all
three treatment arms. Ventricular arrhythmia was accepted as a surrogate
marker on the basis of statistical correlation without a proper evaluation
of whether it was a valid surrogate.
• Bone Mineral Density as a surrogate for bone fracture in osteoporosis. Bone
mineral density was proposed as a surrogate endpoint for bone fracture
in osteoporosis in post-menopausal women, with higher bone mineral
density reflecting fewer fractures. A randomised controlled trial con-
ducted in 202 women (Riggs et al., 1990) showed that treatment with
sodium fluoride increased bone mineral density by 35% over five years.
The trial also showed that the same treatment resulted in 50% more ver-
tebral and non-vertebral fractures when compared to placebo. The con-
clusions were that sodium fluoride increases bone mineral density, but
also causes the bones to become more brittle leading to more fractures .
• Blood pressure as a surrogate for a coronary event. Phase III trials of new
therapies for the treatment of hypertension use the surrogate endpoint
of blood pressure as the endpoint. Blood pressure in itself is not a an
endpoint that directly reflects how a patients 'feels, functions or sur-
vives' (see section 2.2) and, in fact, it is intended that these therapies will
prevent episodes of congestive heart failure and other coronary events
(Berger, 2004; Temple, 1999).
2.4 The Evaluation of Prognostic Markers
2.4.1 Introduction
Before surveying the literature on the statistical evaluation of surrogate mark-
ers, this section examines approaches to evaluate markers for use in prognosis.
As described in section 2.2, a prognostic marker is used for predicting disease
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outcome. In the context of this thesis, the aim is to evaluate markers for long-
term response to treatment for tuberculosis. These markers will therefore be
used to classify individuals as having a fair outcome to treatment or as having
a poor outcome to treatment. In this section, we use the binary variable T to
denote the final treatment outcome, the true endpoint:
T = {O for fair outcome; .
1 for poor outcome.
Much of this theory comes from the Pepe (2003), Feinstein (2002) and Erdreich
and Lee (1981). Appendix 0 gives a list of notation used throughout the thesis.
(2.1)
2.4.2 The Evaluation of binary prognostic markers
The simplest type of prognostic marker is one, denoted by 5, that is binary:
S = {O for a negative marker result;
1 for a positive marker result.
(2.2)
2.4.2.1 Statistics to quantify prognostic value
There are three different pairs of statistics, with each statistic denoted by a
three-letter acronym, that can be used to describe a binary prognostic marker.
2.4.2.1.1 True positive and false positive fractions The true positive fraction
(TPF) and the false positive fraction (FPF) are defined as follows:
TPF = P[S = liT = I].
FPF = P[S = liT = OJ.
(2.3)
(2.4)
The FPF is the proportion with a positive result among those who have a fair
outcome and the TPF is the proportion with a negative result among those
who have a poor outcome. Without loss of generality, in this thesis, a positive
marker value is intended to indicate a poor outcome and a negative marker
value is intended to indicate a fair outcome. Therefore, a case where 5 = 1
and T = 1 is a true positive and conversely, a case where S = 1 and T = 0 is a
false positive.
A good prognostic marker will be one for which the TPF is high and the
FPF is low. The TPF is also known as the sensitivity and 1 - FPF as the
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specificity.
2.4.2.1.2 Positive and negative predictive values The positive predictive value
(PPV) and the negative predictive value (NPV) are defined as follows:
PPV = P[T = liS = 1],
NPV = P[T = OIS = 0].
(2.5)
(2.6)
The PPV is the fraction of those with a positive result that go on to have a poor
outcome to treatment and the NPV is the fraction of those with a negative
result that are go on to have a fair outcome. A good prognostic marker will
have a high PPV and a high NPV.
It is important to note that, unlike FPF and TPF, the predictive values
are affected by the proportion of the total that have a poor outcome, that
is p = P[T = 1]. This be seen by looking at a useless marker, S', that is
completely independent of the true endpoint, (P[T = tlS* = s] = P[T = tD.
For such a marker PPV = P[T = 11S* = 1] = P[T = 1] = P and NPV =
P[T = 015*= 0] = P[T = 0] = 1 - p. The PPV will always be bounded below
by the overall probability of a poor outcome. Consider a very good prognostic
marker with TPF=P[S = liT = 1] = 0.98 and FPF=P[S = liT = 0] = 0.05 but
the proportion of those that fail treatment is low, p = 0.02. Then:
PPV = P[T = liS = 1], (2.7)
P[T = 1] I
= P[S = liT = 1]P[S = 1]' by Bayes theorem, (2.8)
= TPF P (29)
pTPF + (1 - p)FPF .
= 0.29, (2.10)
NPV = P[S = OIT = 0] P[T = 0] (2.11)
P[S = 0]
I-p
= (1 - FPF) p(I _ TPF) + (1 _ p)(1 _ FPF) (2.12)
= 0.999. (2.13)
A low PPV could be the result of a small probability of a poor outcome
or a poor prognostic marker (in this example it was the former). A high
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PPV could be the result of a large probability of a poor outcome or a good
prognostic marker.
In spite of this drawback, PPV and NPV answer a more practical question
than the TPF and the FPF for a clinician treating a patient having just received
the result of the test. Given a positive marker result, the PPV is the probability
that this patient will go on to have a poor outcome and given a negative
marker result, the NPV is the probability that this patient will go on to have
a fair outcome.
2.4.2.1.3 Positive and negative diagnostic likelihood ratios Likelihood ra-
tios are another way of describing a prognostic marker. The positive diagnostic
likelihood ratio (DLR+) and the negative diagnostic likelihood ratio (DLR-) are
defined are follows:
DLR+ = TPF = PIS = liT = 1]
FPF PIS = nr = 0]'
DLR- = 1 - TPF = PIS = OIT = 1]
1 - FPF PIS = OIT = 0]"
(2.14)
(2.15)
These two statistics are the ratio of the likelihood of the marker being
positive or negative in those who have a poor outcome versus those who
are a fair outcome. Unlike the two previous pairs, these two ratios can take
values in the interval (0,00). A perfect prognostic marker has DLR+ = 00
and DLR- = o. DLR+ > 1 indicates that a positive marker result is more
likely in an individual who will have a poor outcome than one who will have
a fair outcome and this is clearly desirable. Similarly, DLR- :s 1 indicates
that a negative marker result is more likely in an individual who will have a
fair outcome than one who will have a poor outcome, and this is also clearly
desirable. These two likelihood ratios are functions of the TPF and the FP F
alone and therefore, unlike the predictive values, do not depend on the overall
probability of a poor outcome, p.
Define the odds of a poor outcome prior to knowledge of the prognostic
marker, 7r(T), and the odds of a poor outcome given the prognostic marker,
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n(TIS), as:
P[T = 1]
n(T) = P[T = OJand
n(TIS = 5) = P[T = liS = 5].
P[T = OIS = 5J
(2.16)
(2.17)
It follows that:
n(TIS = 1) = DLR+n(T) and
n(TIS = 0) = DLR-n(T),
(2.18)
(2.19)
and therefore DLR+ and DLR- quantify the change in odds and are therefore
Bayes factors relating the prior and the posterior distributions.
These likelihood ratios are not used extensively in practice and are more
appropriate for case-control studies (Pepe, 2003). They will therefore not be
considered further in this thesis.
2.4.2.2 Empirical estimation of prognostic statistics
If, considering the data in question, the proportion of the response to treat-
ment has not been fixed in advance (this proportion would be fixed in a case-
control study), these quantities can be estimated empirically from the following
table:
T=O T=l
S=O a b n8 = a + b
S=l c d nf = c +d
n{; = a + c n{; = b+ d N=a+b+c+d
Here, for example, a patients have negative marker result and a fair out-
come to treatment (these are true negatives) and b patients also have a negative
marker result but have a poor outcome to treatment (these are false negatives).
The statistics can be estimated as follows:
- d
TPF=b+d'
- dPPV = --d'c+
FPF= _c_,
a+c
- aNPV= --b'a+
(2.20)
(2.21)
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where, for example, fPF denotes an estimate of the statistic TPF.
2.4.2.3 Regression based estimators
Regression modelling is a more sophisticated method for estimating the statis-
tics to quantify prognostic value. It allows for the adjusting for covariates and,
importantly for the application in this thesis, for clustering within groups.
To estimate the TPF and the FPF, a model can be fit as follows:
g (P[S = liT]) = a + f3T, (2.22)
where gO is a link function of choice and a and f3 are the model parameters
to be estimated. The logit link function is the usual link function chosen and
it will be used in this thesis from this point. The parameter estimates from
this model give:
logit P(fPF) = a: + ~,
10gitP(m) = &.
(2.23)
(2.24)
Similarly, to estimate the PPV and the NPV, the following model can be
fit:
g (P[T = liS]) = ry + JS, (2.25)
where ry and J are the model parameters to be estimated. The parameter
estimates from this model give:
logit p(pPV) = 1 + 6,
logit P(l - ffF) = 1.
(2.26)
(2.27)
Additional covariates, X, can be included in the models to give estimates
of these statistics adjusted for these covariates. Clustering effects can also be
incorporated into the regression model using random effects.
2.4.2.3.1 Comparing prognostic markers Given two prognostic markers SA
and SB, if TPF(SB) > TPF(SA) and FPF(SB) < FPF(SA), then SB is clearly
superior to SA. It is not so straightforward to compare prognostic markers if
only one of these two conditions hold.
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Pepe (2003) show that the statements (i) and (ii) below are equivalent and
therefore a marker that is superior in TPF and FPF is also superior in PPV
and NPV.
(i) TPF(SB)
(ii) PPV(SB)
> TPF(SA) and FPF(SB)
> PPV(SA) and NPV(SB)
< FPF(SA),
> NPV(SA).
Prognostic markers can be compared using a regression model. Let:
{
0 for test A and
Is = 1 for test B, (2.28)
and fit the model:
g (P[S = liT]) = (itA + ItBIS) + (f3A + f3BIs)T, (2.29)
where S is the combined results from the two tests (SA
SBI1s = 1). The parameter estimates from this model give:
SII5 = 0 and
In(oTPF(B, A)) = &B + ~B'
In(oFPF(B, A)) = ~B'
(2.30)
(2.31)
where oTPF(B,A) is the odds ratio comparing TPF(SB) with TPF(SA) and
oFPF(B,A) is the odds ratio comparing FPF(SB) with FPF(SA):
TPF(SB)(l - TPF(SA))
oTPF(B,A) = TPF(SA)(l- TPF(SB))'
FPF(B A) _ FPF(SB)(l - FPF(SA))
o ,- FPF(SA)(1- FPF(SB))'
(2.32)
(2.33)
2.4.3 The Evaluation of continuous and categorical prognostic
markers
In this section we consider evaluating a continuous prognostic marker, S.
Given a point of dichotomy, c, a binary test can be defined as follows:
positive if S ~ c,
negative if S < c.
(2.34)
(2.35)
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The TPF and FPF can therefore be defined as;
TPF(c) = P[S ~ ciT = 1]
FPF(c) = P[S ~ ciT = 0].
(2.36)
(2.37)
2.4.3.1 Receiver Operating Characteristic (ROC) Curve
Which point of dichotomy, c, leads to the most effective binary prognos-
tic marker? The superior point of dichotomy will be that which maximises
TPF(c) while minimising FPF(c). The point which maximises TPF(c) will
not necessarily be the same as that which minimises FPF(c), but the Receiver
Operating Characteristic (ROC) curve is used to explore the effect of varying the
point of dichotomy (Erdreich and Lee, 1981). The ROC curve is the set of all
possible values of TPF and FPF across the range of S:
ROC = {(FPF(c), TPF(c)) ,c E (-oo,oo)}. (2.38)
The following results follow from the definitions of TPF(c) and FPF(c):
lim TPF(c) = lim FPF(c) = I,
c~-oo c~-oo
lim TPF(c) = lim FPF(c) = O.
c~oo c~oo
(2.39)
(2.40)
Let ROC(t) be the function that maps t = FPF(c) onto TPF(c). Both TPF(c)
and FP F (c) are monotone increasing functions of c and therefore the function
ROC(t) = TPF(c) is an increasing function of t = FPF(c) with domain and
range on the unit interval with ROC(O) = 0 and ROC(I) = 1.
For a wholly uninformative prognostic marker, S', TPF(c) = FPF(c) and
the ROC curve for this marker will by the line ROC(t) = t. This diagonal
line is called the chance line. The ROC curve of any prognostic marker can
therefore be compared to this line since it must satisfy ROC(t) ~ tVt E [O,IP.
Figure 2.1 shows a ROC curve for a simulated prognostic marker.
One of the key advantages with the ROC curve is that no assumptions are
made about the distribution of the continuous marker, S. The ROC curve is
invariant to a strictly increasing transformation of S . The ROC curve is a plot
of TPF against FPF. A similar curve can be defined for PPV and NPV, but
IThis inequality, that TPF(c) 2: FPF(c), follows from the assumption that a positive marker is
intended to indicate a poor outcome to treatment and therefore the probability of a poor outcome
given a positive result is greater than the probabilitiy of a poor outcome given a negative result.
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False Positive Fraction
0.8 1.0
Figure 2.1: Example receiver operating characteristic curve evalu-
ating a simulated prognostic marker.
this has not been found to be particularly insightful when it has been explored
(Pepe, 2003)
Despite being a useful tool for displaying the value of a prognostic marker,
there is still no definitive measure for identifying the point of dichotomy that
maximises the prognostic value of the marker or for comparing markers, al-
though there are a number of useful summary measures (see Figure for graph-
ical representation) .
• Kolmogorov-Smirnov distance. The maximum vertical distance between
the ROC curve and the chance line is a useful summary measure for a
prognostic marker. This distance is defined as:
KS = max IROC(t) - tl = max ITPF(c) - FPF(c)l·
IE [0,1] cE ( -00,00)
(2.41)
A perfect marker has KS = 1 and the uninformative marker has KS = O.
A good choice of the point of dichotomy could be the point at which this
maximum distance is achieved, that is c' where ITPF(c*) - FPF(c*)1 =
KS .
• Symmetry point, tsym. The symmetry point is defined as the point on
the ROC curve where sensitivity is equal to specificity, ROC(tsym) =
1 - tsym. A perfect prognostic marker will have tsym = 0 and for an
uninformative marker, tsym = 0.5.
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• Area Under the Curve (AUC). This is the most widely used summary
measure and is defined as:
{I
AUC = la ROC(t) dt. (2.42)
A perfect marker has AUC = 1 and the uninformative marker has
AUC = 0.5.
• ROC(to). It may be important to allow no more than a certain propor-
tion of false positives, to. The highest proportion of true positives will
therefore be ROC(to) and the desired point of dichotomy will be that at
which this is achieved. The point ROC(to), where to = 0.1, is shown on
the graph.
• tIl ROC(tl)=rl· In a situation of low prevalence, it may be important to
have a T P F of no less than a certain value, rl. In this case, the lowest
TPF will be tl where R0C(tl) = rland the desired point of dichotomy
will be that at which this is achieved.
• Partial Area Under Curve (pAUC(to)). If only markers with a false pos-
itive fraction of less than a certain value, to, are of interest, the partial
AVe is a useful measure for summarising the behaviour of the marker
in this region. It is defined as:
to
pAUC(to) = la ROC(t) dt. (2.43)
This area is shaded on the graph for to = 0.1.
2.4.3.2 Binormal Curve
The binormal curve is the parametric model for ROC curves. Assuming the
prognostic marker is normally distributed conditional on the true endpoint,
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(SIT = 0) '" NU~0,er6) and (SIT = 1) "" N(1l1,erf), then:
TPF(c) = P[S ~ ciT = 1] = <I> (1l0er~ c), (2.44)
FPF(c) = P[S ~ ciT = 0] = <I> (1l1er~ c), (2.45)
ROC(t) = TPF(c) = <I> C~o-Ill :;1<I>-1(t)) (2.46)
= <I> (a + b<I>-l(t)), (2.47)
where a = (1l0 - l~d/ era and b = erd ero.Thebinormal curve is defined as
(2.48)
The binormal curve provides a good approximation to a wide range of ROC
curves that can occur in practice (Pepe, 2003). Since the ROC curve is invariant
to strictly increasing functions of S, the binormal assumption states that there
exists a strictly increasing transformation that transforms the distribution of
SIT into a normal distribution. This is a fairly weak assumption explaining
the wide-ranging use of the binormal curve and shows that the ROC displays
the relationship between distributions SIT = 1 and SIT = 0, rather than the
distributions themselves (Pepe, 2003).
The area under the binormal curve AUCb can be calculated from the esti-
mates of the parameters of the binormal curve:
(2.49)
2.4.3.3 The ROC curve for ordinal prognostic markers
The ROC curve can be defined for a ordinal prognostic marker,S, with ordinal
categories 51, 52, .. 'Sk :
TPF(c) = P[S ~ ciT = 1] (2.50)
FPF(c) = P[S ~ ciT = 0]. (2.51)
ROC = {(FPF(Si), TPF(Si)),i E {1,2, .... k}}. (2.52)
One of the key advantages in using the ROC curve for an ordinal marker
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is that no 'value' is assigned to categories of the marker and therefore no
assumption is made about the relative 'distance' between the categories. It
doesn't matter whether, for example, the categories are none, slight, moderate
and high or poor, unsatisfactory, satisfactory, and excellent, the ROC curve will
be the same.
This can be seen by defining the binormal curve for an ordinal marker. Let
Y be the unobserved continuous latent variable for which only thresholds,S,
are observed. That is
5 = Si ==> Y = Y E (Si-l,S;], (2.53)
where So is nominally -00 and sk+l is nominally +00 . Given the binormal
assumption, YIT can be transformed to have a normal distribution and there-
fore a binormal curve can be fit to the data. Therefore, the binormal curve for
an ordinal marker 5 will be the same whatever the underlying unobserved
variable actually is. Assuming that the binormal curve fits the data, AUCb is
an estimate of the area under the curve for the unobserved continuous vari-
able which could therefore be more useful than the empirical AUC calculated
from the categorical marker.
2.4.4 Explained variability: Pseudo-Re Statistics
In ordinary least squares (OLS) regression used for a continuous dependent
variable, prognostic markers are commonly evaluated using the R2 statistic.
This is a measure of the proportion of variation in the dependent variable
that is explained by the model and is interpreted as the combined prognos-
tic strength of the explanatory variables in the model. This statistic does not
translate unambiguously to a logistic regression model where the dependent
variable is binary. A number of authors have proposed pseudo-R' statistics that
measure the proportion of variation explained by the model. Unlike the OLS
R2 statistic, there is no convincing evidence that anyone of these statistics
definitively measures the proportion of explained variation and should in-
stead be used as scales with which to compare different models (Long, 1997;
Long and Freese, 2006). Four pseudo-Re statistics have been selected on the
basis of their relative ease of interpretation and acceptability for use in this
thesis. For each of these statistics, as with positive and negative predictive
values, the probability of T = 1 is modelled conditional on the surrogate, S,
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(whether binary or categorical) using logistic regression.
• McFadden's R2. Also known as the likelihood-ratio index, McFadden's R2
compares the log-likelihood of the full model with all parameters with
that of the null model with only the intercept. It is defined to be
In the logistic regression models used in this thesis, the trial effect is
including in the model to control for between-trial variation but is not
considered to be a prognostic factor. A more useful statistic, denoted by
R~eft would be comparing the log-likelihood of the full model with that
of the model containing only the trial effect:
R21 _ 1 _ In L(MFull)MeF - L .In (MTrial)
This can be interpreted as a measure of the improvement in the strength
of prediction resulting from the addition of the culture result.
• Efron's R2. Defining ft = P(T = Ilx) as the predicted probability of a
poor outcome given the explanatory variables, x, Efron's R2 is defined
to be
R2 = 1 _ Li (Ti - fti)2.
El L (Ti - f)2
This expression is comparable to that for the OLS R2 statistic in that the
model residuals are squared, summed, and divided by the total variabil-
ity in the dependent variable. Model residual from a logistic regression
model are very different since the dependent variable is binary and so
this comparison is limited.
• McKelvey and Zaooina's R2. Considering the binary dependent variable,
T, as the realisation of a continuous latent variable y* = x{3 + e, McK-
elvey and Zavoina's R2 is defined to be
R
2 _ Var(g*)
M&Z - - -Var(g') + Var(e)
The variance of the error term (Var(e)) cannot be calculated since y'
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is not observed and is therefore assumed to be n2/3 as recommended
by Long and Freese (2006) as the variance of the logistic distribution.
Using simulations to give a result that is perhaps not surprising, it has
been shown that McKelvey and Zavoina's R2 most closely approximates
the R2 obtained by fitting the linear regression model on the underlying
latent variable (Hagle, 1992; Windmeijer, 1995).
• Count R2. Treating individuals with a predicted probability of 0.5 or
greater as having a predicted outcome T = 1 and those with a predicted
probability of less than 0.5 as having a predicted outcome T = 0, the
count R2 is simply the proportion of individuals for whom their pre-
dicted outcome matches their actual outcome. The model with no ex-
planatory variables will always have a count R2 equal to the proportion
of positive or negative outcomes in the population, whichever is greater
(the model will either predict all individuals with a positive or all with
a negative outcome). The count R2 must therefore be compared to that
from the model with no explanatory variables. It is defined to be
R2 _ Number Correct
C - Total
2.5 The Prentice Criteria
Having presented some methods for the evaluation of prognostic markers,
subsequent sections in this chapter are devoted to the more complex and more
controversial methods for the evaluation of surrogate markers. The first area
for consideration, both logically and chronologically, must be The Prentice Cri-
teria.
In addition to providing a clear definition described in section 2.2, Prentice
(1989) proposes three operational criteria for identifying surrogate endpoints
for a time-to-event clinical endpoint, T.
1. He introduces the notion that a surrogate endpoint should fully cap-
ture the effect of the treatment on the true endpoint and expresses this
mathematically:
Ar(t;5,Z) == AT(t;5), (2.54)
where T is the true time-to-event endpoint, AT is the hazard function, 5
is the surrogate endpoint and Z is an indicator variable corresponding
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to the treatment. The hazard function conditional on 5 and Z should be
equal to the hazard function conditional on 5 only for all t.
He provides two additional restrictions:
2. The surrogate must, in some way, be associated with the true endpoint:
(2.55)
and
3. The effect of the treatment on the distribution of the surrogate must alter
the average endpoint risk:
(2.56)
with the expectation taken with respect to S.
Prentice shows that if these three conditions hold, then the null hypothe-
sis that there is no treatment effect on the true endpoint is equivalent to the
null hypothesis that there is no treatment effect on the surrogate endpoint.
These three conditions are commonly known collectively as the Prentice Cri-
teria (although the exact number and the order that they are given can differ
between authors). The third condition is sometimes omitted when discussing
the Prentice criteria (for example, the entry on Surrogate Endpoints in the
Encyclopedia of Biostatistics, Fleming et al. (1998»; indeed, Prentice himself
describes it as 'innocuous'. It is nevertheless important and 'necessary to
avoid pathological relationships for (non-binary) 5 in which [criterion 1] and
[criterion 2] hold, but the dependence of the hazard rate on 5 does not effect
the marginal hazard for T (averaged over 5) at any rate of T ' (Prentice, 2005)
Though the criteria are given in terms of a time-to-event true endpoint, T,
these criteria can be restated for a binary endpoint, T, using probabilities:
1. P(T = 115 = 5, Z = z) == P(T = 115 = 5),
2. P(T = 115 = 5) t= P(T = 1),
3. E [P(T = tiS = 5,Z = z)] t= E [P(T = tiS = 5)]
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2.5.1 Exploration of the Prentice Criteria
2.5.1.1 The Difference between Correlates and Surrogates
Baker and Kramer (2003)explore the relationship between correlation and sur-
rogacy. They use a simple graphical method to show for Gaussian endpoints
that even when the surrogate is perfectly correlated with the true endpoint
within each of the two treatment groups, the difference in means of the sur-
rogate between treatment groups can be in the opposite direction to the dif-
ference in means on the true endpoint resulting in conclusions based on the
surrogate endpoint contradicting conclusions based on the true endpoint. A
simulated example of this is given in Figure 2.2 on the next page.
In this example, the candidate surrogate and true endpoints are perfectly
correlated within each of the treatment and control groups respectively. De-
spite this, the mean surrogate outcome in the treatment group (equal to 267
and marked on the graph) is larger than the mean surrogate outcome in the
control group (154)while the mean true outcome in the treatment group (160)
is smaller than the mean true outcome in the control group (256), leading to
conflicting conclusions for the effect of the experimental treatment. The ex-
perimental treatment appears to lead to a decrease in the true endpoint and
an increase in the surrogate endpoint, despite these two being perfectly corre-
lated within treatment group.
The authors conclude that only when the relationship between the surro-
gate and the true endpoint is the same within each treatment group do the
null hypotheses based on the surrogate endpoint and the true endpoint cor-
respond. This is equivalent to the first Prentice criterion that the surrogate
marker captures the full effect of the treatment on the true endpoint.
As perfect correlation is not a sufficient condition, neither it is necessary,
as the second Prentice criterion requires only that the surrogate is in some
way associated with the true endpoint.
Fleming and DeMets (1996) also point out that a commonly held miscon-
ception is that if an outcome correlates well with the true endpoint then it can
be used as a valid surrogate. They perform a systematic review of the use and
evaluation of surrogates in several disease areas concluding that in practice,
the Prentice Criteria are rarely met for surrogates that are in use and, despite
this danger, it is rare for a surrogate endpoint to be carefully validated. They
note that a surrogate marker that captures only 50% of the treatment effect
is as uninformative as tossing a coin. They illustrate some examples where a
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Figure 2.2: A simulated example showing a candidate surrogate
marker that correlates perfectly with the true endpoint, but would
be a disastrous surrogate. Highlighted are the mean surrogate
in the control group (154) and the treatment group (267) and the
mean true endpoint in the control group (256) and the treatment
group (160).
marker correlated with the true endpoint would fail as a surrogate, using the
language of disease causal pathways. A disease may have several causal path-
ways that result in the clinical endpoint. The surrogate may be in the pathway
of only a subset of these and the intervention may act on a different subset
such that the surrogate does not fully capture the treatment effect. The in-
tervention may also have unintended or unrecognised mechanisms of action
on the clinical endpoint independent of the disease process and the surrogate
endpoint. The authors show that the ideal setting for a valid surrogate oc-
curs when the surrogate is on the only causal pathway of the disease process
and the entire effect of the intervention is mediated through the surrogate. To
identify such a situation requires considerable understanding of the disease
and the intervention.
2.5.1.2 Criticism of the Prentice Criteria
Despite Prentice's work frequently and rightly being described as 'seminal'
(e.g., Taylor and Wang, 2002; Weir and Walley, 2005) or 'landmark' (Buyse
and Molenberghs, 1998), there has been much criticism.
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Freedman et al. (1992)extend the Prentice Criteria for a binary rather than
time-to-event clinical outcome using logistic regression to model the prob-
ability of the true endpoint occurring conditional on the surrogate and the
treatment group. They propose a two-step procedure testing first for an in-
teraction between the surrogate endpoint and the treatment group. If the
interaction is found to be statistically significant then the performance of the
surrogate marker is dependent on the treatments being compared and there
is therefore evidence invalidating the surrogate.
An interaction between the marker and the treatment is sometimes desir-
able. Itmay be the case that an experimental treatment has an important effect
on the true endpoint when compared to the control treatment in those with a
positive marker result, but there is no effect in those with a negative marker
result. In this scenario, the marker could be used to tailor the treatment strat-
egy for individual patients (those with a positive marker result respond to the
experimental treatment, but those with a negative marker result do not). This
marker, however, cannot be used as a valid surrogate.
If there is no evidence of interaction, the second step involves fitting the
model with no interaction term and testing for a treatment effect. If there is a
significant treatment effect then there again is evidence invalidating the sur-
rogate. A statistically significant result in a test of a null hypothesis provides
evidence against the null hypothesis, but failure to achieve a statistically sig-
nificant result does not constitute evidence in favour of the null hypothesis.
Since the Prentice Criteria are based on hypothesis tests, the authors observe
that this procedure of testing the Prentice Criteria only provides a means of
dismissing undesirable intermediate endpoints rather than identifying valid
surrogate endpoints. Prentice defends his criteria pointing out that they are
for defining when an intermediate endpoint can serve as a surrogate and that
evaluation is a completely different matter (Prentice, 2005). Indeed, 'the main
challenge with validating surrogate endpoints in a hypothesis testing frame-
work is evaluating the surrogate endpoint when the Prentice Criterion cannot
be rejected' (Baker, 2006a).
The use of hypothesis testing in the Prentice criteria does mean that only
failed surrogates can be identified; there is no framework for accepting a true
surrogate (as failure to reject the null hypothesis could be due to insufficient
information rather than it necessarily being correct).
Buyse and Molenberghs (1998) suggest that a surrogate endpoint would
be useful only if there was no evidence to reject the hypothesis test evaluating
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the first Prentice criterion in a large number of studies and that the Pren-
tice Criteria are 'necessary and sufficient to establish the validity of binary
surrogate endpoints, but not of more complex surrogate endpoints'. Prentice
refutes this stating that the authors have 'evidently overlooked' the third Pren-
tice criterion (Prentice, 2005) without identifying the specific mistake in their
algebra. He argues that the three Prentice criteria together do ensure equality
of hypothesis tests for both binary and non-binary surrogates.
Berger (2004)neatly summarises the process required in evaluating surro-
gate markers: 'If improvement in a [candidate] surrogate endpoint does not
itself confer patient benefit, then consideration must be given to the extent to
which improvement in a surrogate endpoint implies improvement in the true
clinical endpoint of interest'. The author proposes a 'validity criterion' which
corresponds to Prentice's definition of a surrogate endpoint (see section 2.2),
that 'a valid between-group analysis of the surrogate endpoint constitutes also
a valid analysis of the true clinical endpoint'. Following Buyse and Molen-
berghs (1998), he claims that the Prentice Criteria do not imply the 'validity
criterion'. He attempts to construct a counter-example where the Prentice cri-
teria are met but the 'validity criterion' is not. He succeeds, but manages to
do so by ignoring the third Prentice criterion which his counter-example does
not satisfy. This appears to be because, rather than using Prentice's original
paper, he is using Molenberghs et al. (2001) for his list of the Prentice criteria
where the third criterion is not included.
It is clear that the condition of a surrogate fully capturing the treatment
effect on the true endpoint is difficult to satisfy. Fleming (1994)instead suggest
the Prentice criteria are restrictive and should rather be 'an ideal to be kept
in mind'. He suggests that when the candidate for surrogacy does not fully
capture the treatment effect on the true endpoint, but does capture some of
the treatment effect, the candidate endpoint should be termed an auxiliary
endpoint and propose that information on this endpoint can be used to add
weight to the standard analysis or to aid imputation of missing data. Cox
(1983)proposed a similar idea, before any of this discussion around surrogate
endpoints, in the context of right-censored survival data.
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2.6 The Proportion of Treatment Effect and Other
Summary Measures
2.6.1 The Proportion of Treatment Effect
Following their criticisms, Freedman et a1. (1992) attempt to overcome the
problems with the Prentice Criteria and quantify surrogacy by defining Pro-
portion of Treatment Effect, PTE, that is an estimate of the proportion of the
effect of the treatment on the true endpoint that is captured by the surrogate.
They fit the following two models:
Tk = a1 + b, Zk + £k
Tk = a2 + b2Zk + C2Sk + fk'
where Tk is the true clinical endpoint, Sk is the surrogate endpoint and Zk is
the treatment indicator for the kth patient. T and S are both Gaussian normal.
They define:
PTE = [,1 ~ [,2.
b1
Conceptually, the PTE is the proportion of the treatment effect on the true
endpoint that is 'explained' or 'removed' on adjusting for the surrogate. If
the surrogate captures the entire treatment effect, it would be expected that [,2
were very small and therefore PTE==1. If the surrogate fails to capture any of
the treatment effect, it would be expected that [,2 ==[,1 and therefore PTE==O.
An obvious drawback with this proportion is that it will not necessarily
be less than one, nor will it necessarily be positive and so is not strictly a
'proportion'. Buyse and Molenberghs (1998) shows the treatment effect on the
surrogate and true endpoint must be in the same direction otherwise the PTE
will lie outside the interval [0,1]. Hughes (2002) observes that if the treatment
has adverse effects on the true endpoint that are not mediated through the
candidate surrogate endpoint, the PTE will be artificially inflated and a poor
surrogate will appear to capture a large proportion of the treatment effect.
Freedman et a1. (1992) suggest that a surrogate could be deemed impor-
tant if the lower limit of this confidence interval of the PTE is greater than a
critical value such as 0.5 or 0.75. Using Fieller's theorem to calculate standard
errors, they show that, to make meaningfully precise estimates of the PTE,
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unadjusted treatment effects on the true endpoint must be more than 4 times
their standard errors.
Lin et al. (1997) extend this idea, defining the PTE for a time-to-event out-
come using the proportional hazards model and constructing appropriate con-
fidence intervals. A letter in response to this paper (Flandre and Saidi, 1999)
reviews several papers where the PTE has been used to evaluate surrogate
endpoints. They observe a large range of values for the PTE and very wide
confidence intervals, highlighting several examples where even the point es-
timate of the PTE lies outside the range [0,1]. The authors recommend that
the use of the PTE should be discontinued. Table 2.1 gives a number of exam-
ples of the use of the PTE showing the huge variability and large confidence
intervals.
True Surrogate
Treatment
PTE
Endpoint Endpoint (95% Cl)
Coronary Serum Cholesterol Choles- 0.50
Heart Disease at 1 year" -tyramine (0.07,5.91)
75% drop in HIV1-RNN AZT 0.59 (0.13,1.12)
Progression HIV1-RNA with CD41J AZT 0.79 (0.27,1.45)
to Net CD4+%C AZT 0.74
AIDS RNA levels at week 16a AZT+ddI 1.83 (0.79,2.90)
RNA levels at week 16a AZT+ddC 2.49 (0.83,4.16)
"Freedman et al. (1992)
hO'Brien et al. (1996)
'Choi et al. (1993)
dOelta Coordinating Committee and Virology Group (1999)
Table 2.1: Some examples of the use of the Proportion of Treatment Effect
(PTE)
Bycott and Taylor (1998) follow on from the work of Lin et al. (1997) eval-
uating the statistical properties of the PTE using Monte Carlo simulations
showing that the PTE has 'tremendous variability' and may in fact have con-
siderable bias towards zero. The authors also show that the case when PTE
has reasonable precision, when the treatment effect is strong, is the very situ-
ation when it seems most unlikely that a surrogate endpoint will capture all
of the treatment effect!
De Gruttola et al. (1997) look at the calculation of the PTE when the treat-
ment has many intended and unintended mechanisms of action. In this situa-
tion it is unlikely that this surrogate would be in all of the causal pathways (as
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earlier discussed by Fleming and DeMets (1996». They show that a surrogate
endpoint that captures only a small fraction of the change in the true end-
point induced by the treatment may appear to capture a proportion close to
1 if there are unintended and unrecognised treatment effects on the true end-
point not mediated via the surrogate. They conclude by saying that, for the
PTE to be identifiable and even for a surrogate to be reliable 'it is required that
the biology of disease and all important effects of this intervention (including
adverse effects) be fundamentally understood' (De Gruttola et al., 1997).
2.6.2 Extensions of the PTE
Li et al. (2001) also criticise the PTE, highlighting the fact that the numerator
and denominator are estimated from two separate models that are unlikely
to hold simultaneously. They propose a method for estimating the overall
treatment effect and that explained by the surrogate basing both estimates on
one model only. They decompose the risk of failure tT, = 1) to a patient prior
to taking treatment, showing that it can be explained by three components:
(i) the reduction in risk captured by the surrogate, (ii) the reduction in risk
not captured by the surrogate and (iii) the remaining risk to the patient after
treatment. They then propose a summary measure, quantifying the reduction
in risk captured by the surrogate, rather than the proportion of treatment
effect. Using a log-linear model for a binary true endpoint, the Risk Reduction
is the estimate of the reduction in risk captured by the surrogate divided by
the estimate of the total reduction in risk. Consider the model:
(2.57)
where Sk is the surrogate endpoint, Tk the true endpoint and Zk is the treat-
ment indicator for patient k. The authors show that the proportion of the
reduction in risk explained by the surrogate is:
(2.58)
where E(~s) is the expectation of the difference in the surrogate marker be-
tween the treatment and the placebo groups in the trial. This method uses
estimates from the same model and the authors give an explanation for the
proportion if it lies outside the interval [0,1] (if the direction of the treatment
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effect and the surrogate effect on the risk are in the same direction the ra-
tio will be less than 1) but note that intended and unintended effects of the
treatments are not distinguished.
Chen et al. (2003) propose another alternative to compute the PTE again
using estimates from only one model. They use Cox regression models, al-
lowing for time-varying covariates, and state that the procedure proposed by
Li et al. (2001) using log-linear models allowing only for time-independent co-
variates is too restrictive and not as applicable in the evaluation of surrogate
endpoints.
Qu and Case (2006) extend these methods to quantify the treatment effect
mediated through multiple surrogates acting on multiple disease pathways,
accounting for the causal relationships between these surrogates, although
the same authors later state that this method has 'similar disadvantages' to
the PTE and those described above (Qu and Case, 2007).
Wang and Taylor (2002) propose another alternative based on a similar
idea to Li et al. (2001). They propose a measure, F, as the reduction in risk
due to the change in the surrogate induced by the treatment divided by the
total reduction in risk between treatment groups, but estimating these risks
differently to Li et al. (2001). F is estimated based on the distribution of
the true endpoint given the treatment and the surrogate endpoint and the
distribution of the surrogate endpoint given the treatment. They suggest that
this measure has better properties than the PTE and is more generalisable as
it is not tied to a linear model and so can be estimated with more flexibility
and fewer assumptions. For binary true and surrogate endpoints, Sand T,
where Z is the treatment indicator, their measure is:
F = [P{T = liz = O,S = 1) - P{T = 0IZ = O,S = 0)]
P{S = liZ = 0) - P{S = liZ = 1)
P{T = liZ = 0) - P{T = liZ = 1)' (2.59)
and a complementary form:
F' = [P{T = liz = I, S = 1) - P{T = 0IZ = I, S = 0)]
P(S = liZ = 0) - P(S = liZ = 1)
P(T = liZ = 0) - P(T = liZ = 1)' (2.60)
Taylor and Wang (2002) consider the PTE and joint models for longitudinal
and survival data. They suggest that the PTE described by Lin et al. (1997)
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is generally not appropriate since it is calculated from estimates from two
models that are unlikely to hold simultaneously and often the PTE is greater
than one or negative. They propose another PTE based on estimates from only
one joint model of a longitudinal surrogate with a failure time true endpoint.
Sarkar and Qu (2007) propose the excess relative odds as a replacement for
the PTE using regression calibration in the presence of measurement error to
remove some of the bias.
Ditlevsen et al. (2005) propose the Mediation Proportion as a parallel con-
cept to the PTE for epidemiological observation studies. The formula given is
basically the same (and therefore retains the same drawbacks as the PTE) ex-
cept that it is the proportion of the effect of an exposure rather than a treatment
than is being estimated.
Beyond the PTE, none of these measures have been extensively taken up
and used in surrogate marker evaluation. A great deal of work has been done
in developing measures that purport to summarise the strength of a surrogate
marker, but setbacks have been frequent and a question mark hangs over this
whole area.
The final words in this section surveying the plethora of attempts to quan-
tify the value of a surrogate are from Laurence Freedman, writing nearly ten
years after first proposing the PTE:
'It would be misleading to conclude this article without ex-
pressing strong reservations regarding the use of [the PTEl, as an
ultimate test of the validity of a surrogate endpoint for a new clin-
ical trial; ... the method can be usefully applied only in limited
situations, for how often do we encounter treatment effects of 5
standard errors or more?
... In general, I feel that the methods described here will find
more useful application in identifying intermediate endpoints in
epidemiology than in placing a stamp of approval on surrogate
endpoints for clinical trials.'
(Freedman, 2001)
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2.7 Trial Design based on the use of a Surrogate
Endpoint
Day and Duffy (1996) use surrogate endpoints in the design of a trial to com-
pare the effect of different breast screening frequencies on breast cancer mor-
tality rate. The authors state that it had been demonstrated in previous trials
that screening by mammography reduces breast cancer mortality in women
over 50 years of age. In this trial, the intention was to compare different breast
screening frequencies. They comment that, since the purpose of the trial is 'to
resolve subsidiary issues', it would be 'perverse' to use the standard primary
endpoint of breast cancer mortality and instead design the trial using a sur-
rogate endpoint as the primary endpoint of efficacy. This is a rare example of
the use of a surrogate endpoint as a complete substitute for the true endpoint
in a clinical trial in practice and led to some interesting discussion.
The surrogate endpoint used is a combination of tumour size, malignancy
grade and lymph node status (expressed as a predicted mortality) and the au-
thors show, using data from a previous clinical trial of frequency of screening
undertaken in Sweden, that survival from cancers is independent of screen-
ing frequency after adjusting for these three variables and therefore that the
surrogate endpoint satisfies the Prentice criteria for this particular trial. The
authors show that the use of predicted mortality is more powerful than the
use of observed mortality in estimating the hazard ratio between interven-
tions since the observed mortality is estimated from the binary outcome of
death whilst the predicted mortality is based on the continuous probability of
death calculated from three categorical variables. They show that, using this
surrogate as the primary endpoint, the trial is reduced in size by a factor of
between 2.5 and 3 and the trial duration is reduced from 20 years to 5 years.
Begg and Leung (2000a) criticise Day and Duffy (1996) citing two resulting
'conundrums'. Firstly, the trial design suggests that it is always better to use
predictions based on surrogates rather than the true endpoint that is being
studied and secondly, the degree by which the predicted endpoint leads to
more powerful estimates is inversely proportional to the square of the correla-
tion between the true endpoint and the surrogate, implying that better surro-
gates are those which are only weakly correlated with the true endpoint. The
authors consider these two results counter-intuitive and propose two 'princi-
ples' that should be kept in mind in the evaluation of surrogate endpoints:
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firstly that the 'best attainable inference' for comparing treatments is based
on their effect on the true endpoint and secondly, that the results of a trial
using the surrogate endpoints should be 'concordant' with those that would
have been found if the true endpoint had been used. The authors also con-
clude that the Prentice criteria are not a useful basis for evaluating surrogate
endpoints.
The authors Day and Duffy and also Prentice respond to this paper (Day
and Duffy, 2000; Prentice, 2000). Day and Duffy emphasise two critical as-
sumptions. Firstly, that the Prentice criteria is satisfied for these variables- and
secondly that the effect of the treatment on breast cancer mortality acts only
though the variables on which the surrogate endpoint of predicted mortality
is based and therefore the surrogate which is based on three categorical vari-
ables will have greater power. They also point out that a surrogate can never
be generally applicable and is only valid for the treatments in question-a fact
that they suggest Begg and Leung have overlooked. In his comments, Pren-
tice notes that if the Prentice criteria hold then all of the treatment effect on
the true endpoint is captured by the surrogate endpoint and any further vari-
ability in the true endpoint not explained by the surrogate is simply 'noise'.
Therefore, if the Prentice criteria do truly hold, when the surrogate and the
true endpoint are only weakly correlated, then there is much noise in the true
endpoint and the increase in power in using the surrogate over using the true
endpoint is great as shown by Begg and Leung.
Begg and Leung respond to these comments (Begg and Leung, 2000b) re-
jecting the proposition that, in a 'gold standard' analysis, a true clinical end-
point can have a component of 'noise'. They argue that the situation where
only the true endpoint and not the surrogate endpoint is affected by noise,
and the situation where there is no treatment effect on the surrogate which is
not mirrored in the true endpoint are unrealistic.
Berger (2004)supports Begg and Leung in their criticism. The author refers
to any precision that a surrogate endpoint offers over the true endpoint that
does not reflect patient benefit as 'pseudo-precision'.The authors link this with
their 'validity criterion' (see section 2.5.1): 'The idea that pseudo-precision
could be treated as actual precision led us to consider the possibility that per-
2The Prentice Criteria had been satisfied on these variables in a different clinical trial. This
exchange shows that Prentice Criteria can never be tested in a clinical trial where a surrogate
endpoint has been substituted for the true endpoint (since the true endpoint has not been mea-
sured) and therefore the applicability of any surrogate from one trial to the next must always be
taken with some degree of trust.
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haps the Begg and Leung criticism was in fact a criticism not of the relevance
of the Prentice criteria but rather if the statement that the Prentice criteria
imply the validity criterion' (Berger, 2004).
2.8 The Belgian Paradigm
2.8.1 The Relative Effect and the Adjusted Association
Buyse and Molenberghs (1998) also criticise the PTE proposed by Freedman
et al. (1992) pointing out that the denominator of the proportion is the estimate
of the treatment effect on the true endpoint. It is likely that the imprecision
of this estimate will be the motivation for the search for a surrogate and so,
correspondingly, the PTE will generally be too poorly estimated and the con-
fidence limits large as has been shown (see Table 2.1 on page 45). Following
Freedman et al. (1992), the authors also emphasise that it is important to test
for interaction between the treatment and the surrogate as the first step.
If the Prentice Criteria are proposed for defining a surrogate endpoint
(Prentice, 2005), these authors propose criteria for validating or evaluating a
surrogate endpoint. They initially consider the case of the true and surrogate
endpoints being binary and fit the following two models:
10git(P(SkIZk)) = uzs + ttZk
10git(P(TkIZk)) = urr + f3Zk,
where, as before, Zk is the treatment given to the kth patient with Tk and Sk
the corresponding true and surrogate endpoints. For this purpose, illS and
uzr are nuisance parameters estimated from the model.
The authors propose two new quantities: the relative effect (RE) and the
adjusted association (AA). The RE is defined as f3/ tt. The RE is simply the ratio
of the log-odds ratio of true endpoint for the treatment effect and the log-odds
ratio of the surrogate endpoint for the treatment effect. They propose that a
surrogate should be called valid at the population level if RE is close to one or
perfect if the RE is equal to one.
The AA is an estimate of the association between the true and surrogate
endpoints adjusting for the treatment, equal to the log odds ratio of the true
endpoints for the surrogate conditional on the treatment, or the coefficient 'Yz
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from the following model
The authors suggest that a surrogate with a value of AA which is very
large should be called valid at the indioidual leoel and perfect if the value of AA
is infinite.
The RE captures the association between the surrogate and the true end-
point at the trial-level and so is of more interest to the trialist looking at an
overall treatment effect whereas the AA captures the association at the subject-
specific-level and so is of more interest to the clinician dealing with individual
cases of the condition. Bringing these two measures together, the authors de-
fine a perfect surrogate as one for which the surrogate is perfect at both the
subject-specific and population levels.
The authors also extend their methods appropriately to take account of
surrogate and true endpoints that are continuous, fitting the two models:
SklZk = wzs + ItZk + eSk
TklZk = wzr + f3Zk + eTk'
whereeskandeTk are zero mean correlated error terms with Var(esk) = Var(eTk) =
1 and Cov(eSk,eTk) = p. Again, RE=f3/ It and the AA is the association between
the two endpoints adjusting for the treatment, AA=p. The PTE proposed by
Freedman et al. (1992) in this situation is therefore equal to p(lt/ f3)=AA/RE.
The authors suggests that PTE is less desirable since it is a composite quantity.
This paper brought an important development in the statistical evalua-
tion of surrogate endpoints, namely the separation into individual-level and
trial-level surrogacy. If the trial-level surrogacy is of most interest then the
individual-level parameter can be viewed almost as a nuisance parameter.
The trial-level parameter would then be used rather than having to consider
a composite parameter that combines the two resulting in a more noisy pa-
rameter as was the case earlier. It is clear that the RE depends greatly on the
scale of the continuous variables 5 and T and is therefore not really a useful
measure (Taylor and Wang, 2002), but the principles (giving rise to what, in
this thesis, is called the Belgian Paradigm) that were the basis of the continuing
work described below became very influential.
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2.8.2 Meta-Analysis
These ideas are further explained in Buyse et al. (2000b) pointing out that the
confidence limits for RE are smaller than for PTE since the denominator of
the ratio is the treatment effect on the surrogate which will usually be mea-
sured with more precision than the treatment effect on the true endpoint, but
admit that despite this, the confidence interval is still wide. In this paper, the
authors suggest that, rather than using the RE as a criteria for validating a
surrogate endpoint, it 'may be useful to predict the effect of treatment upon
the true endpoint, having observed the effect of treatment upon the surrogate
endpoint'. For a useful prediction, the RE must be estimated with precision
requiring a large number of observations-a number that is not usually avail-
able in a single trial. It is necessary to evaluate a marker across a number of
trials and treatment comparisons to have any confidence in the value of the
marker. A marker that has been evaluated as a surrogate across a number of
trials carries much greater weight than one which has only been validated in a
single trial. These authors therefore recommend extending these ideas to the
meta-analysis of several trials.
The notion of the RE is extended by Buyse et al. (2000a) for multiple trials.
These authors propose extending the models above across i = 1, ... , N trials
each with k = 1, ... , n, subjects for Gaussian normalS and T:
SiklZik = us, + lXiZik + eSik
TiklZik = ur, + f3iZik + erik'
where us, and ur, are trial-specific intercepts, Ai and f3i are trial-specific treat-
ment effects for trial j and ESik and Erik are correlated normally distributed
error terms with zero mean and covariance matrix:
L = (CTSS I7sr).
. I7rr
The authors proposed fitting a linear mixed model with random intercepts
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and slopes assuming:
where the first term on the right-hand side are the fixed effects and the sec-
ond term are the random effects are assumed to follow a mean zero normal
distribution with covariance matrix
(
dss dST
D= drT
The purpose of validating a surrogate endpoint will be to predict the treat-
ment effect on the true endpoint. The authors therefore derive the following
measure:
They suggest a surrogate should be called valid at the trial level if«: is 'suf-
ficiently close to one' and perfect if equal to one. In analogy to the treatment
adjusted association (AA) defined above, the authors derive a second measure
as the association between the endpoints conditional on the treatments given:
They suggest a surrogate should be called valid at the individual level if Rrndiv
is 'sufficiently close to one' and perfect if equal to one. The situation with
RTrial ~ I, indicating that the surrogate and true endpoints were associated at
the trial-level, and RTndiv « 1 , would cast doubt over the biological plausibil-
ity of the relationship at the individual-level.
Molenberghs et al. (2001) extend this approach to consider the case when
one of the surrogate and true endpoints is binary and the other continuous.
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For the single-trial case, they propose formulations for the RE and the AA
using several different models including a probit formulation considering the
binary variable as a latent variable and one proposed by Dale (1986). Their
methods involve the use of copulas to describe the joint distribution of the true
and surrogate endpoints which add considerable complexity over the simple
case where both the true and surrogate endpoints are Gaussian normal (as
the joint distribution is simply multivariate normal). The authors extend this
probit formulation to the multi-trial case deriving analogous measures R~rial
and Rttldiv for this combination of endpoints. Renard et al. (2002) consider
the case when both endpoints are binary and define Rttld as the correlation
between the two latent variables 5 and t using a bivariate probit model. In
the context of longitudinal surrogate or true endpoints (or both), Alonso et al.
(2003) propose the variance-reduction factor (VRF) and Alonso et al. (2004a)
propose R~ as replacements for«.
Gail et al. (2000) propose a similar meta-analytic approach, drawing on
Daniels and Hughes (1997). They introduce methods for a more general class
of models, not necessarily assuming both Gaussian endpoints, and use boot-
strap methods to take into account the uncertainty in estimating variance
components in the model. Hughes (2002) highlight the importance of joint
models to further understand the individual-level association and commends
the methods developed by Gail et al. (2000).
Molenberghs et al. (2002) summarise the Single-trial and multi-trial ap-
proaches described in this section for a non-statistical audience applying the
methods to five case studies. They identify a strong drawback to the RE that
its calculation from data on a single trial requires the unverifiable assump-
tion that it should be constant across a class of trials, that is the relationship
between the treatment effects on the surrogate and true endpoint is multi-
plicative. They also show that the PTE is an combination of three different
quantities-the RE, the AA and a nuisance parameter-and that therefore the
PTE is ill defined except in trivial cases. The authors also encourage the use
of meta-analysis, noting that it is possible to calculate the measure R~rinl in
most settings, but that the choice of an individual-level measure of agree-
ment, RTtldiv' is not universal and it depends on the type of joint model of the
surrogate and true endpoint that is used.
Alonso et al. (2006) also echo this point stating that one the of the draw-
backs of the meta-analytic methods based within the Belgian paradigm is that
'different settings required different definitions [of RTtld]" The authors con-
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tinue:
'Estimating individual-level surrogacy... has frequently been
based in a variance-covariance matrix coming from the distribu-
tion of the errors. However, if we move away from the normal
distribution it is not always clear how we can quantify the asso-
ciation between both endpoints after adjusting for treatment and
trial effects and, as a result, several different parameters have been
proposed showing a clear lack of a unified approach.'
(Alonso et al., 2006)
The authors then offer a unified approach and propose the likelihood reduc-
tion factor, LRF. Consider, for the ith trial, the two generalised linear models:
gT {E (TikIZik)} = al + b1Zi
gT {E (TiklZik' Sik)} = a2 + b2Zi + C2Si'
for some link function gT. Let Gf denote the log-likelihood ratio test statistic
comparing these two models at trial i (minus twice the difference in the log
likelihoods). Then:
1 N (G2)LRF = 1- - £exp __ I. •
N i=1 n,
(2.61)
Linking in with the work on information gain by Kent (1983), the authors
explain that the LRF can be thought of as a generalisation of RTnd based on
the information gain in the true endpoint using the surrogate. The authors
shows that (i) LRF E [0,1], (ii) LRF = 0 if Sand T are independent in each
trial, (iii) as LRF --? I, there is usually a deterministic bijection between
Sand T effectively implying perfect surrogacy, and (iv) LRF reduces to the
maximum likelihood estimator of RTndwhen Sand T are normally distributed.
The authors note that LRF may be bounded above by LRFmax < 1 if T follows
a discrete distribution and so propose LRFadj = LRF / LRF max which will
always be bounded above by 1. Here LRFmax is the best LRF value for the
best possible fitted model.
The authors link the LRF back to the first of Prentice's criteria (equa-
tion 2.54 on page 38). The LRF is, in some way, quantifying the extent to
56
which the criterion is met and is therefore more appealing that the simple hy-
pothesis test of whether or not the criterion is satisfied. In this way, the LRF
bridges the gap between the Prentice criteria and the Belgian paradigm. Qu
and Case (2007) review this work developing the LRF showing that it does
reflect the association between T and S adjusted for the treatment linking
back with the original single-trial measure the adjusted association proposed by
Buyse and Molenberghs (1998) that was the basis for Rrnd'
Alonso and Molenberghs (2007) observe that it is not clear what exactly
the LRF is estimating how to interpret it in practice. They propose a new
quantity, R~, derived from an information theory foundation:
R2 _ EP(T) - EP(TIS)
h - EP(T) , (2.62)
where EP(T) is the entropy power of T and EP(TIS) is the conditional entropy
power of T given S:
1
EP(T) = -( )n exp (2h(T)),
2rre
1
EP(TIS) = -( )n exp (2h(TIS)),
2rre
(2.63)
(2.64)
where h(T) is the entropy of T and h(TIS) is the conditional entropy of T given
S. For T discrete, the entropy and conditional entropy are defined as:
H(T) = ET [logP(T = t)],
H(TIS) = e, [ET [logP(T = tiS = s)]].
(2.65)
(2.66)
For T continuous, the entropy and conditional entropy are defined as:
hd(T) = ET [-log/T(t)],
hd(T) = Es [ET [-log!TIS(tIS = s)]] ,
(2.67)
(2.68)
where T has probability density function, /T(t), and TIS = 5 has probability
density function hls(tlS = s). R~ is therefore a measure of the amount of
uncertainty in T that is expected to be removed if S is known. R~ has the
same properties as the LRF described above numbered (i) to (iii). The authors
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extend the definition to a meta-analytic framework:
N
R~= 1 - L It;e-2I;(S;,T.),
;=1
(2.69)
where I(S, T) = h(T) - h(TIS) is the mutual information and It; > OViare some
scale parameters, Lit; = 1. The exact values that the scale parameters take
is undefined and is described as 'the subject of future research'. The authors
show that the LRF is a consistent estimator of R~ and therefore 'sharpens the
interpretation of the LRF'. The authors go on to give an explanation of R~tJd;v
from an information theory perspective and, using Fane's inequality, that the
quality of a surrogate depends on the power entropy of the true endpoint and
implying that 'for some endpoints the search for a good surrogate can be a
dead end street unless T and S are extremely closely related'. This applica-
tion of information theory to surrogate marker evaluation is clearly a very
exciting development, but has unfortunately arrived too late for use in this re-
search project. This work has subsequently been summarised in Molenberghs
et al. (2008) and Pryseley et al. (2007), but to quote Alonso and Molenberghs
(2007): 'we believe more research will be needed to comprehensively map
out the whole impact information theory can have on the validation of sur-
rogate markers'. The application of information theory to surrogate marker
evaluation will therefore not be considered further in this thesis.
Tilahun et al. (2007) discuss computational issues in evaluating surrogate
endpoints across a number of trials using these methods. They note the lack
of implementation of these methods in statistical software and include some
SAS macros and R functions for fitting these models. Abrahantes et al. (2004)
explore the effect of the choice of hierarchical units in evaluating surrogate
endpoints across a number of trials that may themselves have data from sev-
eral centres or several countries.
2.9 Meta-analysis using Trial-Level Summary Esti-
mates in the context of HIV
Hughes et al. (1995) propose two different meta-analyses to investigate a sur-
rogate. Firstly, the authors suggest quantifying the level of surrogacy of the
potential surrogate within in each trial, perhaps using the PTE (this paper was
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published before the widespread criticism of this measure), and calculating a
weighted average across all trials using precision of the estimate as weights.
The second method that the authors propose is a graphical approach: they
suggest plotting the difference in average surrogate marker levels (the treat-
ment effect on the surrogate, S) against the relative risk of clinical outcome
(the treatment effect on the binary true endpoint, T) with a point plotted for
each trial with error bars. This method provides a way to visually assess sur-
rogacy by looking for a linear relationship between the treatment effect on the
surrogate endpoint and the treatment effect on the true endpoint. The authors
are also keen to stress the importance of defining the true endpoint before be-
ginning to identify surrogate endpoints. This is particularly an issue in HIV
since the definition of 'HIV-related disease progression' varies considerably.
This is also discussed by Hughes (2005).
Daniels and Hughes (1997) build on this second approach by modelling
this association across trials and assessing the reliability of such a model to
predict a treatment difference on the true endpoint given a treatment differ-
ence on the surrogate endpoint. Given 9; and 1'; as estimates of the treatment
differences on the true and surrogate endpoints respectively from the ith trial,
the authors initially suggest the simple linear model
f3 = 0 corresponds to the situation where the treatment difference in the
surrogate in no way predicts the treatment effect on the true endpoint, thus
invalidating it as a surrogate marker. If f3 =1= 0, T2 = 0 corresponds to situation
where the treatment difference in the true endpoint can be perfectly predicted
from the treatment difference in the surrogate endpoint. This model also takes
into account treatment effect mediated through a mechanism independent of
the surrogate in the parameter It. If It =1= 0, then there is a non-zero fraction of
the treatment effect on the true endpoint that is not captured by the surrogate.
The authors consider the treatment difference on the surrogate as a random
effect in this model and use a Bayesian approach to fit the model. They high-
light the importance of sensitivity analyses to assess the influence of each trial
in the overall analysis. They emphasise the importance of Prentice's second
criterion that the treatment has some effect on the surrogate endpoint and of
having a large spread in magnitude of 8; and 1; leading to a better under-
standing of the relationship between the two. This point shows a conflict with
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the Belgian paradigm where they suggest that a treatment need not have a
real effect on the surrogate and that 'fluctuations around zero in individual
trials can be very strongly predictive of the effect on the true endpoint' (Buyse
et al., 2000a). In conclusion, Daniels and Hughes (1997) state that their pro-
posed meta-analysis is relatively simple to apply and that it is particularly
useful in situations where individual studies lack power to provide strong
conclusions on their own.
Hughes et a1. (1998) look to evaluate initial changes in CD4 count as a sur-
rogate marker for progression to AIDS and death using the two meta-analysis
methods proposed by Hughes et al. (1995), including data from 15 clinical
trials involving 24 treatment comparisons. They first calculate a weighted av-
erage of the PTE. Whilst the confidence interval for this average is reasonably
narrow, the authors observe that the estimates of the PTE were outside the
range (0,1) and that some of the confidence intervals were very wide, in some
cases completely containing the range( -2,2), showing that some of these es-
timates have very poor precision. Secondly, the authors plot log hazard ratio
for progression to AIDS or death for the treatment effect against difference
in mean change in CD4 count for the treatment effect with a point plotted
for each treatment comparison. They identified five comparisons that fell in
the upper right-hand quadrant or lower left-hand quadrant and these indi-
cated opposite effects on the surrogate and the true endpoint. They found
that, for all five of these, there was no significant difference between the treat-
ments in the hazard of clinical progression and so concluded that the lack of
concordance merely reflected chance variation. The authors also fitted linear
regression models to these data calculating predictions and 95% prediction
intervals for the log hazard ratio of outcome given a particular difference in
mean change in CD4 count.
The authors observe that the first approach is not likely to be valuable in in-
dividual studies due to the imprecision of the PTE within studies and favour
the second approach noting that it allows clinical trials of similar sizes and
similar numbers of events equal emphasis regardless of the size of the treat-
ment effect whereas the first method tends to give greater weight to studies in
which there is the greatest statistical significance for the treatment difference
on the true endpoint. The authors suggested that the small PTE implied that
there were other mechanisms of drug action that were not captured by CD4
count and concluded that CD4 cell count changes over 6 months are only a
weak partial surrogate for clinical progression over 2 years. Another meta-
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analysis of HIV trials (HIV Surrogate Marker Collaborative Group, 2000) also
used this graphical method to assess surrogacy.
2.10 Discussion
The different approaches to surrogate marker evaluation are varied. Prentice
(1989) provided a clear definition of a surrogate, and proposed three criteria
that any candidate surrogate must satisfy. Freedman et a1. (1992) proposed
the PTE as a means of quantifying the proportion of treatment effect on the
true endpoint explained by the surrogate=effectively measuring the extent
to which the Prentice criteria are satisfied. This generated a lot of research
activity and a large number of similar measures were proposed with varying
success.
Buyse and Molenberghs (1998) and Buyse et a1. (2000a) introduce two im-
portant paradigm shifts. These authors firstly propose the distinction between
individual-level surrogacy and trial-level surrogacy, and secondly develop
methods for moving the task of evaluation from a single trial to a meta-
analytic approach. It had been previously stated by many authors that a
surrogate marker must be evaluated across a number of treatment compar-
isons and a number of trials, but Buyse and Molenberghs were among the
first to develop reliable methods for doing this. These methods were straight-
forward for Gaussian true and surrogate endpoints, the situation that they
concentrated on, but not for other types of endpoints. Other authors have
since proposed a number of extensions for other types of endpoints that tend
to involved more complex methods. Daniels and Hughes (1997) propose a dif-
ferent meta-analytic approach that allows greater flexibility, accommodating
a many different types for the surrogate and true endpoints.
The evaluation of surrogate markers in this thesis will focus on multi-trial,
meta-analytic methods. Single-trial methods will also be used, but the results
from the meta-analytic approach of a number of trials will give a more reliable
answer.
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Chapter 3
Prognostic and Surrogate
Markers for Poor Outcome
after Treatment for
Tuberculosis
3.1 Introduction
In Chapter 2, the statistical literature on the evaluation of prognostic and
surrogate markers was reviewed and summarised. This chapter focuses on
prognostic and surrogate markers for poor outcome after treatment for TB,
identifying and reviewing those that have been suggested in the literature.
Before looking at the literature on predictors for response after treatment
of tuberculosis, it is important to understand something of the nature and
progression of TB disease. As noted in Chapter 2, before any discussion of
markers, it is also necessary to examine and define a clear clinical endpoint
for which a candidate surrogate will be a substitute. TB is unique among in-
fectious diseases in that failure to culture the causative agent, Mycobacterium
tuberculosis, in a specimen (a sputum sample for pulmonary TB) is not a suffi-
cient condition for cure. It is therefore important to briefly look at the diagno-
sis of tuberculosis (section 3.2), the action of anti-tuberculosis drugs (section
3.3), and the clinical endpoint (section 3.4) before looking in more detail at
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the published work on prognostic and surrogate markers for poor outcome to
treatment (section 3.5).
Since sections 3.2 to 3.4 are general sections setting the scene, no system-
atic review was performed. They do not constitute exhaustive reviews of each
topic, they include discussion of the important issues and reference the im-
portant papers relevant to the aim of this chapter, leading into section 3.5.
3.1.1 Latent Tuberculosis
It is estimated that one third of the world's population is infected with the
Mycobacterium tuberculosis, but less than one percent (14.4 million people) of
these were active cases (World Health Organization, 2008).
All persons who have inactive or latent infection are at continued risk for
activation of the disease (Global Alliance for TB Drug Development, 2001)-
an estimated 10% will go to develop active disease (Kato-Maeda and Small,
2000), but persons who have recently been infected or who have certain clinical
conditions (such as HIV infection) are at increased risk of progression to active
disease (Blumberg et al., 2005). While all infectious diseases involve a period
of incubation or latency after exposure, tuberculosis is unlike most in that the
delay between infection and disease is extremely varied and can range from a
few weeks to a lifetime (Fine and Small, 1999). It is therefore important that
diagnostic procedures distinguish between active and latent tuberculosis. In
this thesis, discussion of tuberculosis disease will always refer to active disease
unless otherwise stated.
3.1.2 Extra-pulmonary Tuberculosis
The most common form of tuberculosis is pulmonary tuberculosis (PTB), but
Mycobacterium tuberculosis can also affect other parts of the body. Other forms
include tuberculosis meningitis (tuberculosis of the central nervous system),
tuberculosis of the lymph nodes, spinal tuberculosis and miliary tuberculo-
sis (disseminated tuberculosis of the circulatory system). Chemotherapy is
directed at the bacteria rather than the host and should therefore be effec-
tive against any form of the disease (Youmans, 1979). In practice, this is not
necessarily the case and different variants of extra-pulmonary tuberculosis are
commonly treated differently (Fox et al., 1999). Extra-pulmonary disease is
therefore usually an exclusion criteria for PTB trials. This thesis focuses on
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PTB and discussion of TB will refer to PTB unless otherwise stated. Cases of
extra-pulmonary TB will be excluded from analyses where diagnosed.
3.2 Diagnosis of Tuberculosis
One of the five elements of the WHO-recommended DOTS strategy (see Chap-
ter 1) relates to case detection emphasising the importance of good diagnostics
for TB disease. While it is true that a diagnostic marker serves a different pur-
pose that a prognostic marker, markers for diagnosis can also sometimes be
used for prognosis. This is generally the case in TB, where diagnosis usually
involves assessing whether M. tuberculosis bacilli is present in the lungs, and
assessing prognosis involves monitoring the decline of bacilli in the lungs.
Those markers which are used for diagnosis therefore form the pool from
which to identify prognostic markers and ultimately surrogate markers.
3.2.1 Radiography
In the first few decades of the twentieth century, the most common method for
the diagnosis of tuberculosis was with fluoroscopy: 'a dangerous procedure
in which the patient stood so that an X-ray image of his chest appeared on
a fluorescent screen without a film' (Mitchison, 2005). Images on film were
introduced later allowing for the possibility of showing individual slices of
cavities or other lesions.
It is common for previously unsuspected pulmonary tuberculosis to be
detected on the inspection of a chest X-ray (Youmans, 1979) although many
lung disorders may appear as pulmonary tuberculosis in a chest X-ray. Newer
tomographic techniques to show sequential slices of cavities such as com-
puterised axial or nuclear magnetic resonance tomography are particularly
valuable in distinguishing between tuberculosis and, for example, cancerous
lesions (Mitchison, 2005). Despite this, it can be difficult to distinguish be-
tween lesions of tuberculosis that are no longer active (indicating previous ac-
tive infection that has become inactive) and active tuberculosis cavities. Any
radiographic finding can therefore only be provisional.
One study found that, among the 17 study patients with culture-positive
pulmonary tuberculosis and verified AIDS, only one patient had radiographic
evidence typical of adult onset tuberculosis (Pitchenik and Rubinson, 1985).
This suggests manifestation of tuberculosis differs between patients who are
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HIV positive and those who do not, adding further complications to the X-ray
image as a diagnostic tool.
The X-ray is commonly used for active case finding (Schluger and Rom,
1994), identifying those with undiagnosed suspected tuberculosis who can
then be sent to give a sputum sample for a confirmatory smear or culture test.
University College London Hospital has a mobile X-ray clinic mounted on the
back of a lorry that is used to visit at-risk groups (such as those in homeless
shelters and prisons) and diagnose TB1. In a current cluster-randomised trial
in South Africa, evaluating the impact of isoniazid prevention therapy on TB
incidence, the X-ray is used as the first tool for identifying active TB2.
3.2.2 The Guinea-Pig Test
Guinea-pig inoculation was the established diagnostic tool when culture meth-
ods were inefficient (Marks, 1972). Tests involving animals are costly and
undesirable and therefore, with improved culture methods, are no longer rec-
ommended on ethical grounds. The guinea-pig test is highly sensitive and
there could be case for its use when an invasive procedure is used on a pa-
tient to obtain only scanty material in extra-pulmonary TB(Morris and Barton,
1983).
3.2.3 Tuberculin Skin Test
The tuberculin skin test (TST, also known as the tuberculin sensitivity test or
Purified Protein Derivative (PPD) Test) is another diagnostic tool that is widely
used in developed countries including the United States of America and the
United Kingdom. It does not distinguish between active and inactive infection
and therefore predominantly is used to diagnose latent disease and primary
infection (Shingadia and Novelli, 2003). A positive TST result indicates that
the subject has been exposed to TB at some point in their life, but has not
necessarily ever had active disease. It is known to have low sensitivity in
immunocompromised patients, requires patients to return 72 hours after the
test to have the result read and it is thought that the results are affected by the
BCG vaccine (Frieden et al., 2003).
lUCLH Mobile x-ray unit. http://www.uclh.nhs.uk/GPsthealthcare+professionals /Clin-
ical+services/Infectious+diseases+(Hospital+for+ Tropical+Diseases)/Infectious+diseases+-
+Mobile+x-ray+urut. Retrieved 23 Apr 2009.
2Thibela TB: CREATE. http://www.tbhiv-create.org/about/studies/thibela. Retrieved 23 Apr
2009. Personal communication from Katherine Fielding, Co-investigator.
65
3.2.4 Sputum Microscopy
The most widely used method of diagnosing tuberculosis in developing coun-
tries is by establishing the presence of acid-fast bacilli (AFB) in sputum using
microscopic examination after staining. The sample is stained and examined
under a microscope for the presence of M. tuberculosis bacilli. The number of
visible bacilli can be counted and the smear graded on a scale from negative
to heavily positive.
This is a comparatively quick way to diagnose tuberculosis, does not re-
quire expensive equipment and can therefore be carried out in most clinics
across the world. The original procedure of direct field microscopy was re-
placed by fluorescence microscopy because it is five times more rapid with
greater specificity (Mitchison, 2005) (and it is recommended today that the re-
placement of fluorescence bulbs with light-emitting diodes improves longevity
at reduced cost (Khan et al., 2007»; but apart from this one improvement,
the technology has remained largely unchanged since its introduction in the
1880s (Perkins et al., 2006). Smear sensitivity can depend greatly on the qual-
ity of the sputum and the skill of the laboratory technician carrying out the
test. A randomised controlled trial in Pakistan showed women (but not men)
were more likely to test smear positive for TB if they were given 'sputum-
submission guidance' in addition to prevailing practice (Khan et al., 2007).
While not particularly sensitive, direct smears have been found to be very
specific for diagnosing tuberculosis (Mitchison et al., 1975). In studies, smear
sensitivity for M. tuberculosis is commonly found to be around 50%, but speci-
ficity upwards of 95% (Schluger and Rom, 1994). A key problem with the
smear test is that it does not distinguish between viable and non-viable bacilli
(Youmans, 1979), although this is more of a problem for assessing disease pro-
gression than diagnosing TB. Smear examination cannot distinguish between
the M. tuberculosis complex and other mycobacterium (Lee et al., 2003) and
is also less sensitive in immunocompromised patients (Raviglione et al., 1992)
due to their typically lower bacillary burden (Alisjahbana and van Crevel,
2007). Despite a low sensitivity, it is an attractive tool for public health pro-
grammes since it is sufficiently specific, gives a response in a short period of
time and requires only one piece of equipment (Perkins et al., 2006).
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3.2.4.1 Smear-Negative Pulmonary Tuberculosis
The low sensitivity of sputum microscopy leads to the phenomenon of smear-
negative pulmonary tuberculosis. Patients who are smear-negative and culture-
positive are less infectious (although studies have shown that smear-negative
patients should not be considered non-infectious (Behr et al., 1999)), have a
lower bacillary load and are recommended to be treated with the same regi-
mens as patients who are smear-positive (World Health Organization, 2003).
Smear negativity is more common in patients who are HIV positive (Long
et al., 1991; Behr et al., 1999).
3.2.5 Culture Examination
Culture are more sensitive than smears and are of a comparable specificity, but
provide results more slowly (Mitchison, 2005). If M. tuberculosis is present in
the sputum, colonies will form on the medium. Only active, replicating bacilli
will grow and methods exist to determine whether or not the growth is indeed
M. tuberculosis. The culture result will tend to provide more information than
the smear test as the actual number of colony forming units (CFUs) can be
counted.
Culture growth on solid media is therefore the recognised diagnostic test
for the presence of active tuberculosis. One positive culture for M. tuberculosis
is required to determine a definite case of tuberculosis under WHO definitions
of tuberculosis cases and treatment outcomes (World Health Organization,
2008) but, in countries where culture is not routinely available, one sputum
smear positive for AFB is insufficient, two are required for a definite case.
Well equipped labs are required for culture growth and examination and,
since the doubling time of the bacilli M. tuberculosis is long at approximately
20 hours (Youmans, 1979), results may not be available until 2 months after
the sample was taken (Portun et al., 2007).
It is common for patients to be recruited into a clinical trial on the basis
of their smear test results due to the speed of the test, but their response to
treatment would be assessed on the basis of sputum culture results (e.g., East
African/British Medical Research Council, 1978a; Jindani et al., 2004).
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3.2.5.1 Automated Liquid Culture Systems
First described in 1977 (Middlebrook et al., 1977), automated culture systems
provide a less labour intensive and higher capacity diagnostic alternative. One
of the first liquid culture systems was the BACTEC 460 (Becton Dickinson,
Sparks, MD, USA). This was not used widely due to radioactive elements and
other problems including the hazardous procedure of handling syringes and
the high cost of the instrument (Hasegawa et al., 2002). In the past decade, the
BACTEC MGIT 960 system (Becton Dickinson, Sparks, MD, USA) has been
introduced. This system is non-invasive, non-radiometric, does not involve
sharps and is fully automated. Both of these systems have been shown to
have sensitivities comparable to solid culture methods while producing results
much faster (Hanna et al., 1999).
The mycobacterial growth indicator tube (MGIT) is a recent diagnostic
system for the rapid detection of M. tuberculosis in sputum. Processed sputum
is inoculated into a liquid culture medium in the MGIT tube. A light at the
bottom of the tube is activated if microbial growth is detected. The degree
of positivity of a sample is measured in the time it takes the sensor to be
activated, the time to detection (TID). It has been shown that MGIT can detect
the presence of M. tuberculosis in as short a time as two days (Epstein et al.,
1998).
Some have suggested that solid culture methods are no longer necessary
(Sharp et al., 2000), though higher contamination rates have been found in
automated liquid culture systems than in solid culture methods (Hasegawa
et al., 2002), up to 20% for the MGIT system compared to the generally ac-
cepted rate of 2%-5% on Lowenstein-jensen solid medium (Diraa et al., 2003).
While the MGIT system is cheaper than the earlier BACTEC 460, the cost is
still estimated to be US $7 compared to US $0.10 per AFB stain (Diraa et al.,
2003). Whilst the MGIT is highly accurate in the detection of mycobacteria, an
individual TID value depends on the size of the innoculum and the quality
of the sputum in addition to the bacillary burden of the patient (Epstein et al.,
1998).
Other automated liquid culture systems include the MB/Bact system (Organon
Teknika, Boxtel, The Netherlands) and MB-Check (Nippon Roche Ltd., Tokyo,
Japan).
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3.2.6 Novel Diagnostic Markers
There are a large number of novel diagnostic tests that have been introduced
in the last few decades. These included interferon-gamma assays such as
the ELISPOT (Lawn et al., 2007), genetic markers (Cooke et al., 2008; Cliff
et al., 2004), culture-based assays such as MODS (Moore et al., 2006) and novel
diagnostic devices such as the Lung Flute®3.
In 1993, backed by the WHO and with initial funding from the Bill and
Melinda Gates Foundation, the independent non-profit Foundation for Inno-
vative New Diagnostics (FIND) was established with the mission to 'devel-
opment of rapid, accurate and affordable diagnostic tests for poverty-related
diseases in the developing world". Their initial focus was on tuberculosis
only and have since supported the search for new diagnostic methods for use
in both the community health clinic and the technologically-equipped central
laboratory.
3.3 Drug Action during Treatment
The main chemotherapy regimen for tuberculosis recommended by the WHO
is a six month regimen consisting of an intensive phase of two months of iso-
niazid (H), pyrazinamide (Z), rifampicin (R) and ethambutol (E) taken daily
followed by a continuation phase of four months of isoniazid and rifampicin
also taken daily (denoted HRZE/HR) (World Health Organization, 2003). An
eight month regimen starting with the same initial phase of HRZE but with a
continuation phase of six months of ethambutol and isoniazid has been rec-
ommended as an alternative to the six month regimen and is still used in 31
countries worldwide (13 have plans to change to the six month regimen, World
Health Organization (2008» despite a recent randomised controlled trial hav-
ing established that this eight month regimen is inferior to the standard six
month regimen (Iindani et al., 2004). Treatment with a six or eight month
regimen is called short-course chemotherapy in contrast to the earlier treatment
plans of eighteen months or more (e.g., East African/British Medical Research
Council, 1978a).
3Medical Acoustics introduces the Lung Flute®. http://www.medicalacoustics.com
/Home/LungFlute. Retrieved 23 Apr 2009.
4FIND Diagnostics - Mission, Vision and Objectives. http://www.finddiagnostics.org
/about/mission_vision.shtml. Retrieved 23 Apr 2009.
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It is postulated that there are three phases of drug action (Mitchison,
1997) corresponding to as many as four different bacterial populations in man
(Mitchison, 1985). The majority of tubercle bacilli are rapidly growing (popu-
lation 1) and are killed during the first few days of treatment. This period of
drug action is known as the Early Bactericidal Activity (EBA). Isoniazid has the
most potent EBA (jindani et al., 2003).
Remaining bacilli, termed persisters, are almost dormant, hardly metabolis-
ing and are therefore killed more slowly. It is hypothesised that these per-
sisters fall into two populations: those in an intracellular acid environment
killed most effectively by pyrazinamide (population 2) and those that have
occasional spurts of active metabolism in an extracellular neutral or alkaline
environment which are killed most effectively by rifampicin (population 3). It
is bacterial factors that determine the speed of killing rather the drug action
as it is only when a dormant bacilli begins to metabolise that it is killed by a
drug (Iindani et al., 2003). After the first few days of EBA, this period of drug
action until around the second month of treatment is called bactericidal activity.
The speed of killing gets progressively slower during the six months of treat-
ment and it is the ability of a drug to kill or sterilise the last few viable bacilli
that is termed the sterilizing activity. Rifampicin and isoniazid are the most
important drugs in the continuation phase beyond two months. There is a
fourth population of bacilli that remain completely dormant and is unaffected
by any drug.
Within the first two months, the cavities will close (Mitchison, 1996) and it
is common for the majority of patients to become culture negative (see section
3.5.3).
3.3.1 Drug Resistance
Within a population of bacilli in an infected lesion, there may be mutant bacilli
that are resistant to one or more anti-tuberculosis drugs. If such patients are
treated with one of these drugs, their lesions will soon contain only resistant
organisms and treatment will fail. It was demonstrated in 1948 that the emer-
gence of resistance to either streptomycin or para-aminosalicyclic acid (PAS)
was greatly decreased when both drugs were given in a combined treatment
(Medical Research Council, 1950). The standard treatment regimen for tu-
berculosis consists of an intensive phase of four drugs given in the first two
months. If a patient is initially resistant, or develops resistance to a particular
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drug, then this phase ensures that there are still three others drugs working
against the disease.
Despite the use of multi-drug combinations, an inadequate or poorly ad-
ministered regimen will allow a drug-resistant strain to become dominant in
the patient. Transmission of drug-resistant disease in a population is also
a significant source of new drug-resistant cases (World Health Organization,
2006). Drug-resistance often arises in areas of poorly organised or poorly
funded TB control programmes.
Mitchison and Nunn (1986) looked at the influence of initial drug resis-
tance on treatment response, reviewing controlled trials conducted in East
Africa and South-East Asia in collaboration with the British Medical Research
Council (BMRC). The authors note that the response of patients with initial
drug resistance dramatically improved with the introduction of the short-
course regimens of six months including four drugs. They show that ri-
fampicin was particularly responsible for the improvement in the response in
initial isoniazid resistance and state that, in general, 'as the number of drugs in
the regimen was increased, the failure rate fell' (Mitchison and Nunn, 1986).
Giving only two drugs to a patient who was resistant to one of the drugs
was effectively mono-therapy, but giving three or four drugs meant that there
were still at least two to which the bacilli were susceptible to. The authors
also highlight the high success rate of short-course regimens in the presence
of initial resistance to isoniazid and streptomycin. Initial rifampicin resistance
was rare, but resulted in a poor patient outcome and the authors propheti-
cally comment: 'if rifampicin resistance became widespread, itwould threaten
the success of modern short-course treatment of tuberculosis' (Mitchison and
Nunn, 1986).
Mitchison et al. (2007) notes that 'relapse cultures almost always have sus-
ceptibility patterns identical to those before treatment and respond to further
treatment with the original regimen'. There is some evidence that HIV pos-
itive patients with low CD4 counts that do relapse, may be more likely have
acquired rifampicin resistance in their relapse culture.
3.3.1.1 Multi-Drug Resistant Tuberculosis
Multi-drug resistant tuberculosis (MDR-TB) is defined as disease that is re-
sistant to the two most important anti-tuberculosis drugs: isoniazid and ri-
fampicin. The standard regimen for treating TB is then reduced to only pyraz-
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inamide and ethambutol and therefore second-line drugs are required. Second-
line drugs for treating MDR-TB are less effective than first-line drugs and
therefore must be taken for longer (usually at least 18 months), have more
associated toxicities and are more expensive. Treatment for MDR-TB needs
to be tailored to the resistance patterns of individuals patients and very few
clinical trials have been conducted to evaluate regimens for the treatment of
MDR-TB (Caminero, 2006).
2005 saw the identification of eXtensively-Drug Resistant TB (XDR-TB) in
South Africa. XDR-TB is defined as MDR-TB with additional resistance to
one fluoroquinolone and one second-line injectable (capreomycin, kanamycin
or amikacinj". There is very little treatment for XDR-TB and the prognosis is
very poor (Raviglione, 2006).
Since MDR-TB and XDR-TB require different treatment to drug-susceptible
TB and are considerably more life-threatening, it is common to consider them
almost as separate diseases.
3.4 Endpoint of Clinical Trials in Tuberculosis
The purpose of a surrogate marker is to substitute for the clinical endpoint
that is usually used in a clinical trial. It is important therefore to have an
objective and clearly defined clinical endpoint that is widely accepted to reflect
real patient benefit and treatment response. In this section, the endpoints
commonly used in clinical trials for anti-tuberculosis regimens are reviewed.
Among those who are culture negative at the end of treatment, some will
have recurrence of disease and with positive cultures some time after treat-
ment has ended. The World Health Organisation (WHO) defines a relapse
case as a 'patient previously declared cured but with a new episode of bac-
teriologically positive (sputum smear or culture) tuberculosis' (World Health
Organization, 2008). It is the continuation phase of short-course chemother-
apy that is vital to kill all or most of the persisting bacilli and therefore prevent
relapse.
Patients who do not respond to chemotherapy will remain culture positive
throughout the treatment period. In a clinical trial setting, treatment failures
at the end of treatment are rare, and therefore the primary endpoint used
sWorld Health Organisation Press Release (2006): WHO Global Task Force out-
lines measures to combat XDR-TB worldwide. http://www.who.int/mcdiacentre
/news/notes/2006/np29/en/index.html. Retrieved 23 Apr 2009.
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in a clinical trial is sometimes relapse within 12-24 months after the end of
treatment (O'Brien, 2002) and sometimes a combined endpoint of poor outcome
defined as failure at the end of treatment or relapse during 12-24 months of
follow-up (e.g. Jindani et al., 2004).
This period of extensive follow-up is costly and can mean that a TB trial
could take five or more years to complete. Relapse rates under clinical trial
conditions are often less than 5% and therefore large numbers of patients are
required in a trial, even to show non-inferiority (Nunn et al., 2008). A prop-
erly validated surrogate marker for the sterilizing activity for anti-tuberculosis
drugs would result in shorter trials with smaller sample sizes ultimately speed-
ing the drug development process considerably (Global Alliance for TB Drug
Development,2001)
3.4.1 Reinfection and Relapse
In patients who appear to be cured at the end of treatment, a small propor-
tion will have recurrent disease requiring retreatment. With the help of DNA
fingerprinting of M. tuberculosis, recurrences can be separated into exogenous
reinfections (the recurrent bacilli are of a different strain to the bacilli that the
patient was first infected with) and true relapses or endogenous reactivations (the
recurrent bacilli are of the same strain as the bacilli that the patient was first
infected with) (Verver et al., 2005). Historically, many publications and med-
ical textbooks stated that the majority of disease recurrence were relapses al-
though there has been much debate more recently (van Rie et al., 1999). An
editorial in the New England Journal of Medicine makes the following point:
If exogenous reinfection, which is clinically indistinguishable
from relapse, is common, then new regimens that effectively elim-
inate infection or treat disease will be unfairly judged in clinical
trials
Fine and Small (1999)
Estimates of the proportion of recurrences that are true relapses vary greatly
depending on the population being studied. Table 3.1 shows the different
terms that are used for recurrences or relapses and how these terms are used
in this thesis. Older publications use relapse to refer to recurrences (before it
was possible to distinguish between reinfections and reactivations), but newer
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publications often use relapse to refer to reactivations in contrast to reinfec-
tions.
Verver et al. (2005) studied TB patients in the high-TB incidence area of
Cape Town, South Africa to estimate the rate of recurrent TB attributable to
reinfection after successful treatment. They followed 897 patients treated for
TB, of whom 612 had a DNA fingerprint available at enrolment. Recurrent
disease occurred in 108 (18%) of these of whom 68 had a DNA fingerprint in
the second episode. The authors find that only 7 of the 31 (23%) recurrent
patients who completed treatment were true relapses and 33 of the 37 (92%)
recurrent patients who defaulted were true relapses.
Term Definition
Recurrence
Any repeat episode of
TB after a patient
has been declared cured.
Relapse
A recurrence that has
been identified
as a reactivation.
A recurrence of a different
(Exogenous) Reinfection strain to that which the patient
was originally infected with.
A recurrence of the same strain
(Endogenous) Reactivation as that which the patient
was originally infected with.
Table 3.1: Terms used for recurrence of disease and their definitions as used
in this thesis.
Glynn et al. (2004) fingerprinted cultures from patients who had been di-
agnosed with TB in Malawi from 1996 to 2001. The authors found 7 (58%) of
12 recurrences in HIV-positive patients were exogenous reinfections whereas
all 8 recurrences in HIV-negative patients were true relapses.
Jasmer et al. (2004) looked at recurrences in two prospective clinical trials
conducted in Canada and the US. They found that only 3 (4%) of the 75 recur-
rences with DNA genotyping results available did not match the pretreatment
strain and were therefore thought to be exogenous reinfections. They conclude
that 'recurrent tuberculosis in the United States and Canada, countries with
low rates of tuberculosis, is rarely due to reinfection with a new strain of M.
tuberculosis' .
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Chiang and Riley (2005) performed a review of literature discussing ex-
ogenous reinfection. The reviewers found considerable experimental and epi-
demiological evidence in support of the qualitative role of exogenous rein-
fection as a cause of tuberculosis, but noted the lack of good quantitative
estimates of its contribution.
A systematic review (Lambert et al., 2003) looked at thirteen studies us-
ing DNA fingerprinting to identify the occurrence of reinfection amongst re-
current disease. They found that among recurrences, reinfections did occur
in both low-incidence and high-incidence countries among both HIV-positive
and HIV-negative patients. Some studies found reinfection to be rare and
some found reinfection to account for almost all of the recurrences. The au-
thors suggest that a randomised controlled trial will still be able to compare
the efficacy of different treatment regimens provided that the incidence of re-
infection is likely to be similar in each arm of the trial. They also point out
that true relapse rates will be overestimated in both arms leading to reduced
power.
Before the introduction of DNA typing necessary for distinguishing be-
tween reinfection and reactivation, a recurrence was generally referred to as
a relapse in any published literature. This is the case with all of the study
reports for the MRC clinical trials published in the 1970s and 1980s. Because
of this confusion, the term recurrence will be used in this thesis in place of
the term relapse, unless DNA typing has been done to separate out exogenous
reinfections from endogenous reactivations.
3.5 Prognostic and Surrogate Markers in TB
There has been only limited discussion of surrogate markers for response to
treatment in TB; much of the discussion has instead focused around 'predic-
tors', 'risk factors' or 'correlates'. There has been much written about the
analysis and evaluation of surrogate markers in statistical journals (see Chap-
ter 2) and this theory has filtered through to many diseases areas. A good
example is HIV where several studies and meta-analyses have been published
looking for surrogate markers for death and progression to AIDS (e.g., HIV
Surrogate Marker Collaborative Group, 2000; Hughes et al., 1998). This has
not been the case in the disease area of tuberculosis-there has been very little
discussion of formal evaluation of surrogate markers, those authors choosing
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to use the term 'surrogate' do so with a variety of different meanings. Using
the definition from Prentice (1989), a surrogate marker should fully capture
the treatment effect on the final endpoint and its purpose is as a substitute for
that final endpoint in a clinical trial.
The papers considering predictors or prognostic markers do so with many
different objectives: to understand the action of the drugs in question or to
provide a cheap method to evaluate new therapies (Mitchison, 1993; O'Brien
and Nunn, 2001), to identify patients who are more likely to fail (Barnes et al.,
1988), to distinguish between active and latent TB (jacobsen et al., 2007), to
tailor treatment plans to individual patients (Wallis et al., 1998) or to predict
MDR-TB (Salomon et al., 1995). There has been an acceptance recently for the
need for a surrogate endpoint that can substitute for the final endpoint, but
this call has really only been made in the last decade (Global Alliance for TB
Drug Development, 2001; Burman, 2003). This divergence in the objective and
function of the prognostic marker leads to a large variety of approaches to
evaluating such markers. Some authors look for baseline factors as predictors
of poor outcome, whilst some look only for markers measured after the start
of treatment. Due to the distinction between failure at the end of treatment
and long-term failure (defined as recurrence after the end of treatment), some
authors look at predictors for short-term outcome and some look at predictors
for long-term outcome.
Most trials use recurrence or recurrence combined with treatment failure
as the endpoint in a clinical trial. The exact definition of what constitutes a
bacteriological recurrence (it has been shown that isolated positive cultures
are not necessarily indicative of recurrence, see section 3.5.3.2) or a treatment
failure varies considerably between trials (e.g. Jindani et al., 2004; Benator
et al., 2002). Other trials assess poor outcome using clinical symptoms (Epstein
et al., 1998), respiratory failure or death (Barnes et al., 1988).
All this means that the literature on markers and predictors for response
to treatment of tuberculosis is mixed and very varied. The following sections
contain a review of the literature with the published research grouped by
type of marker. A very large number of baseline risk factors for poor outcome
have been proposed, and section 3.5.1 surveys those that are most important.
Section 3.5.2 looks at some of the evidence for monthly sputum smears and
3.5.3 for monthly sputum culture results as predictors of recurrence. Section
3.5.4 looks at Early Bactericidal Activity, section 3.5.5 looks at Serial Sputum
Colony Counts and section 3.5.6 looks at other miscellaneous markers.
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Having read widely and discussed with experts in the field, it is clear
which are the important papers providing evidence for different prognostic
and surrogate markers for poor outcome. Except in the important sections
on monthly culture results and serial sputum colony counts, the reviews are
not systematic, but include the most important papers that have appeared in
recent years. Section 3.5.2, in particular, follows an ongoing discussion in the
International Journal of TB and Lung Disease (IJTLD) following recommen-
dations by the International Union against TB and Lung Disease (lUATLD)
regarding the two month sputum smear.
3.5.1 Baseline Risk Factors
Many studies have looked at baseline risk factors for treatment failure or re-
currence. By its very nature, any measurement taken at baseline cannot be a
surrogate marker as it is measured before the start of treatment. Baseline risk
factors can be used to identify patients at risk of poor outcome and may be
used for the purpose of prognosis.
The two most significant baseline risk factors for poor outcome to treat-
ment are multi-drug resistance (Wallis et al., 1999) (although the presence of
mono-drug resistance only results in slightly worse outcomes (Mitchison and
Nunn, 1986)) and HIV co-infection (Nunn et al., 1991; Chang et al., 2004).
A number of other factors have been found to be associated with treatment
outcome in different settings.
Aber and Nunn (1978) was the first paper to look at factors or markers
that could predict recurrence following treatment. Using data from two tri-
als undertaken in East Africa and one in Hong Kong, the authors looked
at the 'prognostic importance' of several pretreatment factors including age,
sex, weight and viable colony count, radiographic severity of disease, radio-
graphic extent of cavitation, baseline smear and culture results and baseline
viable count of colony forming units. In the East African studies, the extent of
cavitation was most correlated with recurrence and in the Hong Kong studies,
patient age and viable CFU count at baseline were of prognostic significance.
A study in South India found that initial drug resistance, smoking and
alcoholism were all associated with a higher risk of recurrence (Thomas et al.,
2005). In one randomised controlled trial in the US and Canada enrolling
1004 participants, it was found that ethnicity, baseline weight, cavitation on
chest radiograph and bilateral pulmonary involvement were risk factors for
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failure/recurrence in a time-to-event analysis (Benator et al., 2002). Another
trial in Poland found similar risk factors for recurrence: extensive disease,
large cavities, heavy growth on pretreatment cultures and heavy use of al-
cohol (Zierski et al., 1980). A retrospective study using a community survey
in South India found previous treatment, being male, alcoholism and being
underweight were associated with default from treatment and patients with
MDR-TB were more likely to fail treatment (Santha et al., 2002). In patients
with HIV in Zambia and Malawi, Ciglenecki et al. (2007) found more ad-
vanced HIV disease was associated with increased TB-related mortality. In
a systematic review, Slama et al. (2007) found a strong association between
smoking and TB disease and limited association between smoking and TB re-
treatment or TBmortality. Baseline risk factors found by other studies include:
cavitation on baseline radiograph (Chang et al., 2004), sex and age (Tam et al.,
2002), and alcoholism (Barnes et al., 1988).
3.5.2 Monthly Smear Results during Treatment
Both the World Health Organisation (WHO) and the International Union against
TB (IUATLD) recommend extending the intensive phase of two months of
treatment by an additional month if a patient has a positive smear at two
months. It is largely for this reason that smears are routinely taken at the end
of the intensive phase and is based on scattered evidence.
To assess the importance of this recommendation a retrospective analysis
of 726 new smear positive TB patients in one province in China was con-
ducted. The authors show that those still smear positive at two months were
more likely to fail treatment, although culture confirmation of treatment fail-
ure was not done and patients were not followed up for long-term treatment
outcome (Zhao et al., 1997). Wilkinson (1998) reviews this article, incorporat-
ing results from an earlier publication by this author showing similar results
(Wilkinson et al., 1998). The author notes that smears at 2 or 3 months have
'poor to moderate sensitivity (36-61%) and high specificity (88-90%)' and state
that the positive predictive value is very low and therefore 'a positive smear
at 2-3 months is not at all predictive of treatment failure' suggesting that it is
no longer useful (Wilkinson, 1998).
Trebucq and Rieder (1998) express concern over this suggestion to throw
'overboard' this 'excellent management tool' of the two month smear. The
authors note that the conclusions were based on retrospective cohort studies
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rather than clinical trials, but agree that 'it is not a perfect tool for identifying
those who will fail or relapse' but 'it is not such a bad tool either' and smears
should still be taken at the end of the intensive phase as it provides 'very
valuable information for evaluating the [national tuberculosis] programme
as a whole'. Barker and Millard (1999) respond by observing that there is
really no good evidence from clinical trials linking the two month smear and
treatment outcome, the only data available is from epidemiological cohort
studies.
In a retrospective case-control study in Malawi of 119 cases of TB patients
smear positive after two months of treatment and 237 matched controls smear
negative after two months, the cure rate was higher in the controls (77%) than
the cases (71%) (Salaniponi et al., 1999). Following 297 smear positive patients
in Madagascar (Ramarokoto et al., 2002), it was found that the majority of
recurrences and failures were observed in the group that were smear-positive
at two months (Of 152 patients smear-positive at two months, 16 (11%) were
recurrences or failures and of 145 patients smear-negative at two months, there
was only 1 (1%) failure).
It is clear that the smear result after two months of treatment is associ-
ated with long-term outcome to treatment. However, this association is weak
and cannot reasonably be used as a prognostic marker as the two month
smear is insufficiently sensitive for long-term outcome. It may be true that
the two month smear is strongly associated with treatment failure as assessed
with sputum smears (and it has been shown to 'strongly predict bacteriologic
[smear] results beyond three months of treatment' (Rieder, 1996)), and fun-
damentally 'old habits die hard, but evidence is accruing that smears at 2-3
months do not serve their intended purpose' (Wilkinson, 1998).
3.5.3 Monthly Culture Results during Treatment
Aber and Nunn (1978) was the first paper to look at factors or markers that
could predict recurrence following treatment. In the two East African studies,
it was found that the culture results at 3 months and at 2 months showed the
strongest association with recurrence. In the Hong Kong study, the extent of
cavitation at the end of treatment was most highly prognostic of recurrence
with the 2 month smear result also significantly associated with recurrence.
The authors conclude by pointing out that, despite the differences between
the East African and Hong Kong studies, the significant prognostic factors
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were all ultimately related to 'the bacterial content of the lesions' and that the
factors that were common to all three studies were those that 'measured the
speed of sputum conversion during treatment'. These authors only looked
at prognostic markers for recurrence and did not consider the question of
surrogacy.
In a review article (Mitchison (1996), based on an earlier letter, Mitchison
(1993)), the author looks at the correlation between proportions of patients still
culture positive at each of I, 2 and 3 months after the start of treatment with
recurrence rates across eight published multi-armed trials. He concludes that
there was 'good correlation between culture results and relapse rates', noting
that the strongest correlation was at 2 months. It is not clear what statistical
methods were used, and recurrence rates and the proportions positive at two
months for each regimen only appear to have been available in six of the eight
studies. However, across these six trials, the treatment regimen that had the
lowest proportion culture positive at two months also generally had one of the
lowest recurrence rates (suggesting the two month culture does capture some
of the treatment effect on the final endpoint of recurrence). This therefore does
indicate that the two month culture could be a useful surrogate, but clearly
cannot constitute any formal evaluation.
These three papers (Aber and Nunn, 1978;Mitchison, 1993,1996) are much
cited and are the basis for the general acceptance that being culture positive at
2 months is a good predictor for relapse (Global Alliance for TB Drug Devel-
opment, 2001), one author even going so far as to identify the 2 month culture
bacteriology as a surrogate marker on the basis of this evidence (Sirgel et al.,
2000). Fox (1981) identifies the proportion of patients who have achieved cul-
ture negative sputum at two months as a valuable clinical index of the steril-
izing activity of a regimen. In an extensive review of biomarkers in TB, Perrin
et al. (2007) state that the 2 month culture is the only potential biomarker
that has been 'validated in clinical trials' without defining precisely what is
meant by 'validated'. Spigelman (2007), writing as the President of the Global
Alliance for TB Drug Development, identifies the two month culture as 'prob-
ably the best available surrogate marker for the relapse rate'. Burman et a1.
(2006b) state that 'two-month sputum culture conversion is an appropriate
surrogate marker for the initial evaluation of a new drug regimen for tuber-
culosis treatment' basing this statement, in addition, on evidence from Study
22 conducted by the US TB Trials Consortium (TBTC).
In the report of Study 22 (Benator et al., 2002), the authors unknowingly
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test the Prentice Criteria for the two month culture result combined with base-
line cavitation in a Cox proportional hazard model. They state that the hazard
ratio for the combined failure and relapse endpoint between the two experi-
mental treatments was 1.6with 95% confidence interval (1.0,2.6), p=0.04. On
adjusting for the two month culture result and cavitation, the adjusted hazard
ratio becomes 1.34with 95%confidence interval (0.83,2.18), p=0.23. The treat-
ment effect is no longer statistically significant on adjusting for the two month
culture result and cavitation and it therefore satisfies Prentice's first criterion
(see section 2.5 on page 38). The two month culture and cavitation were both
strongly associated with the endpoint and therefore Prentice's second criterion
was satisfied (Prentice's third criterion was also satisfied). In this trial, the two
month culture result combined with cavitation satisfies Prentice's criteria for
surrogacy. This is not the case, however, in other published trials.
In the two regimens with the same continuation phase in the IUATLD
Study A (lindani et al., 2004), the proportions positive after two months of
treatment (14% on 2EHRZ/6HE and 23% on 2(EHRZh/6HE) did not ac-
curately reflect the proportions with an unfavourable long-term outcome to
treatment (5%on 2EHRZ/6HE and 5% on 2(EHRZh/6HE) indicating that the
2 month culture did not fully capture the treatment differences between the
two regimens. In this same study, across all three regimens there was a strong
association between a positive culture at 2 months and an unfavourable out-
come (Mantel-Haenszel estimate of odds ratio stratified by regimen 5.61, 95%
Cl (3.34,9.43).
There is therefore good evidence that the two month culture result is
strongly associated with treatment outcome, and some evidence suggesting
that it might be a useful surrogate marker.
3.5.3.1 Capturing treatment effect before the end of treatment
A six month anti-tuberculosis regimen consists of the two month intensive
phase followed by the four month continuation phase. Two regimens that
are being compared in a clinical trial could have a different combination of
drugs given in the intensive phase or a different combination of drugs given
in the continuation phase or both. In a clinical trial comparing two treatment
regimens, the culture result after two months of treatment is clearly only af-
fected by the first two months of treatment. The two month culture result
cannot therefore fully capture the treatment effect when the two treatments
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being compared have different drugs given in the continuation phase. (It is
also true that the two month culture result cannot capture any treatment effect
when the two treatment being compared have identical intensive phases.) The
first phase of treatment is certainly more intensive; four drugs are given to-
gether compared to only two in the continuation phase and most of the bacilli
are killed during this period. Drugs are given in the continuation phase to
kill any remaining, more persistent, dormant bacilli. The most potent part of
the anti-tuberculosis regimen is therefore the first two months and it is there-
fore reasonable to expect the two month culture result to capture a large part
of the treatment effect and therefore be a useful surrogate. Nevertheless, it
can never fully capture the treatment effect and be a perfect surrogate if the
regimens being compared differ in their continuation phases.
3.5.3.2 Isolated Positive Cultures
In some of the early TB treatment clinical trials, a very small number of pa-
tients were found to have one or two isolated positive cultures, usually of
low colony counts, during follow-up following a series of negative cultures.
Several studies have demonstrated that these isolated positive cultures are not
indicative of true recurrence, but are due to processing contamination or small
lesions opening up in a patients' lung that do not cause recurrence of disease.
The first study was a bacteriological study involving three East African
laboratories and one London laboratory (Aber et al., 1980). Sputum samples
known to be either culture negative or probably culture positive were sent to
three East African laboratories and one London laboratory. 45 (0.8%) of 5798
specimens known to be culture negative were found to be culture positive
(with low colony counts). The authors concluded that this was due to transfer
of bacilli from the positive to the negative samples and the occurrence of
transfer was mainly due to the quality of the technician.
A second study involved the examination of 405 (1.1%) isolated positive
cultures from 37,429 sputum specimens from three East African laboratories
collected during four clinical trials (Mitchison et al., 1980). Since the incidence
of these isolated positives decreased over time after the end of chemotherapy,
the authors concluded that some isolated positives arose from the lesions of
patients. Nevertheless, the authors also showed that some of the cultures
were due to transfer in the laboratory due to varying rates across the three
laboratories.
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A third study applied DNA fingerprinting techniques to 266 isolates of
Mycobacteria tuberculosis originating from 42 patients who experienced recur-
rence after the end of treatment and 42 patients who had isolated positive
cultures after the end of treatment (Das et al., 1993). Specimens included
those taken from these patients before the start of treatment. For only 5 (12%)
of the 42 recurrence patients, the fingerprint of the recurrence isolate was dif-
ferent to that from the pretreatment isolate. For 36 (90%) of the 42 patients
with isolated positives, the fingerprint of these isolated positives was different
to that of the pretreatment isolate. These results showed that the majority of
isolated positives were not true recurrences, but rather contamination from
another source.
3.5.4 Early Bactericidal Activity
The first Early Bactericidal Activity (EBA) study was carried out in Nairobi,
Kenya with the results being published in 1980 (lindani et al., 1980). Counts
of viable bacilli in overnight sputum were collected at two day intervals from
pretreatment to 14 days after treatment. Patients were given one of 22 differ-
ent combinations of anti-tuberculosis drugs (including some drugs given in
mono-therapy at different doses). Itwas found that the fall in colony forming
units (CFU, the number of colonies of M. tuberculosis growing on solid cul-
ture giving an indication of a patient's bacterial load) over the first two days
differed between drugs and between doses of these drugs. The fall in CFU
over the subsequent twelve days was reasonably similar across drug combi-
nations and so the term Early Bactericidal Activity was used to describe the
fall over the first forty-eight hours. The unit of this measure is 10glOcount per
ml of sputum per day. The EBA was therefore seen as 'the best measure for
discriminating between drugs' (Mitchison and Sturm, 1997); indeed EBA is
deemed necessary by the Food and Drug Administration for licensing a new
anti-tuberculosis drug (Iindani et al., 2003). EBA is not the only measure for
assessing the performance of a drug. Pyrazinamide has a very poor EBA but
is a vital drug in the treatment of TB (Mitchison, 2000). EBA studies are usu-
ally the one of the early studies for a new drug (e.g. Ciprofloxacin (Kennedy
et al., 1993; Sirgel et al., 1997), Moxifloxacin (Pletz et al., 2004) and the new
diarylquinoline discovered by Tibotec, TMC 207 (Rustomjee et al., 2008b».
These data were re-analysed nearly thirty years after the original study
(lindani et al., 2003) to look at the activity of the drug regimens in the 12
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days after EBA. The authors highlight the difference between the bactericidal
(occurring during the first two days) and sterilizing (the ability to prevent re-
lapse) properties of drugs are separate attributes. They suggest that sterilizing
activity may be measured by the rate of decline in CFU after two days (the
Extended EBA), but show that a study of duration eights days is insufficient to
detect differences between treatment regimens and that significant differences
were found when the study period was increased to twelve days. The authors
suggest that a study of such length would be considered unethical if patients
were on mono-therapy (due to potential development of drug resistance, see
section 3.3.1) and therefore suggest a Serial Sputum Colony Count (SSCC) study
where sputum colony counts are measured from the second day after starting
treatment to the end of the first month to assess the sterilizing activity of a
new drug in combination with other standard drugs.
3.5.5 Serial Sputum Colony Counts
A multi-centre study was initiated in 1993 at the suggestion of the WHO Steer-
ing Committee on Treatment of Mycobacterial Diseases to look at EBA and ex-
tended EBA up to five days after the start of treatment (Sirgel et al., 2000). The
authors found that isoniazid had a highly potent EBA but was almost inactive
beyond two days and stated that 'the most important implication of the study
is the possibility of assessing the sterilizing activity of anti-tuberculosis drugs
by extending the dosage period of EBA studies beyond the first 2 days'. Using
data from another study in Nairobi (Brindle et al., 1993), Brindle et al. (2001)
extended these ideas by looking at bactericidal activities of drugs during the
2-28 day period. In the original study, 122 patients with culture-positive un-
treated TB were recruited and sputum samples taken on days 0, 2, 7 ,14 and
28 after the start of treatment. One difficulty arises with extending the colony
counts to 28 days is that some patients will become culture negative by this
point. In this study, 7% of the samples were negative at 14 days and 20%
were negative at 28 days (Brindle et al., 2001). Since the period of time was
extended from an EBA study, this was known as serial sputum colony counting
(SSCC). Since the colony count is measured on the 10glOscale, the authors
fitted regression lines treating a negative culture as missing, the same as a
culture that was not available, and therefore making the incorrect assumption
that this censoring in non-informative. The authors show highly significant
differences of the SSCC from days 2 to 28 between different treatment com-
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binations, concluding that SSCC from days 2 to 28 (and perhaps extending
SSCC from days 2 to 56) is 'a powerful method of demonstrating the long
term bactericidal (sterilizing) activities of rifampicin and pyrazinamide in the
SHRZ regimen' (Brindle et al., 2001). The authors do not have any relapse
data from which to draw this conclusion, they are suggesting that the SSCC
of these two drugs corresponds reasonably well with what is known about the
abilities of rifampicin and pyrazinamide to prevent recurrence.
3.5.5.1 Analysis of Repeated Culture Counts
Data from an EBA or SSCC study consists of repeated CFUs taken at several
specific timepoints from baseline to anything up to 56 days. There is consider-
able variation between serial measurements taken on the same patient as well
as variation between patients (Sirgel et al., 2000). In the first EBA study (lin-
dani et al., 1980), CFUs were available at intervals of two days from baseline
to day 14 meaning that each patient had up to eight separate counts. In the
re-analysis of this data (lindani et al., 2003), the authors calculate the rate of
fall in 10glOCFUs per ml of sputum per day over different treatment periods
for each patient. These rates were calculated either based on the two 10glO
counts at the start and the end of the period or a the linear regression coef-
ficient based on all 10glOcounts during the period. Multiple regression was
used to model the effect of different drug combinations on these rates. They
emphasise that there are two distinct phases suggesting that the two periods
day 0 to day 2 and day 2 to day 14 were the most important capturing the bac-
tericidal and sterilizing activities of the treatment respectively. They suggest
a bi-exponential model with five parameters and two rate constants
where Cl and k} are parameters for the bactericidal activity, C2 and k2 are
parameters for the sterilizing activity of the treatment, S is the asymptotic
value for incomplete killing and t is the time from the start of treatment in
days. They include this model merely as a suggestion noting that more results
per patient over longer periods will be necessary to obtain good estimates of
all five parameters.
Other authors (Brindle et al., 2001; Sirgel et al., 2000) use a similar method
fitting straight lines over different treatment periods taking account of be-
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tween patient variability by calculating rates of individual patients first or
using weighted analyses.
A different approach of analysing SSCC data has been proposed by Gille-
spie et a1. (2002), and applied by Gillespie and Charalambous (2003) and
Gosling et a1. (2003). The authors propose fitting a single exponential curve
to the viable counts from each patient using an iterative process to remove
the point which fits least well to the curve, refitting the model to this subset
of points. This method has subsequently been widely criticised. The main
criticism being that 'iterative discarding of data points because they do not
fit an incorrect model is a source of bias rather than a help in discarding
"discrepant" results' (Mitchison, 2003). Dare and Nunn (2003) also make this
point noting that removing a data point from the analysis merely blurs the
distinction between change in loglO counts over day 0 to 2 and days 2 to 14.
Jindani et a1. (2003) also advise against this model as it only contains a single
rate parameter over the whole treatment period.
Davies et a1.(2006a) use the earlier suggestion of a bi-exponential model to
fit a hierarchical non-linear mixed effects (NLME) analysis of the SSCC data.
They propose mono- and bi-exponential models as follows:
where (h and 84 are the parameters for the first and second rates of kill.
The authors fit these models to the same data used by Brindle et al. (2001)
and show that the preferred model is 'unequivocally bi-exponential', noting
that this is consistent with the earlier work showing two different phases of
killing. The advantage of a bi-exponential model in this situation is that the
first exponential term will dominate for small t, corresponding to the steeper
rate 82 representing the EBA, and the second term will dominate for large
t, corresponding to the shallower rate 84 representing the slower sterilizing
activity. The authors choose to use this particular dataset as the sputum was
not decontaminated. In their discussion, the authors suggest that the finding
of only a single population of bacilli in several studies was due to use of
decontamination of sputum which may have been responsible for eliminating
the first population of rapidly growing bacilli. The authors show that the
second rate parameter, 83, explains the differences between treatments well
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and could therefore be a good measure of the sterilizing activity of a treatment
regimen. In this dataset, each patient only had five measurements over time
so the authors acknowledge that a model with four parameters was the most
complex that could be fitted. The modelling process does account for the
between patient variability using mixed effects, but the same problem remains
in that negative culture results are treated the same as a missing value (since
the 10glOof zero is undefined).
Davies et al. (2006b) look at optimal sampling strategies for measuring
SSCC and estimating the four parameters in the hi-exponential model. They
show that most published sampling schemes are relatively inefficient in es-
timating these parameters, suggesting instead a scheme of ten measurement
taken over the first two months with more taken during the first two weeks.
3.5.5.2 Does SSCC predict sterilizing activity?
While the hi-exponential model proposed by Davies et al. (2006a) does seem
to fit the data, allowing for the two different phases of killing and distinguish-
ing between treatment groups in the second phase of killing, there has been
no definitive study to explain how well this second rate parameter predicts
sterilizing activity. Currently, the only sure measure of sterilizing activity is
relapse after the end of treatment (Global Alliance for TB Drug Development,
2001), and there have been no published studies done where sputum samples
have been taken more regularly that monthly over the first two months in ad-
dition to patients being followed up for long-term recurrence. This point is
well made in a recent editorial in reference to extended EBA over days 2 to 7,
but applies equally to SSCC measured up to day 56:
Whether the extended bactericidal activity during days 2 to 7
does represent sterilizing activity of fluoroquinolones or any other
drug remains speculative, and awaits the study of relapse rates
following phase III clinical trials.
Donald (2006)
The REMoxTB Phase III trial that is currently enrolling, evaluating the
addition of moxifloxacin in the standard treatment regimen, should provide
some answers to this question. In one site, intensive colony counting is being
done during the first two months of treatment in addition to patients being
87
followed up for relapse. It is expected that it will be several years until com-
pletion of follow-up and when this analysis will be possible (see Nunn et al.,
2008, for more details).
3.5.6 Other Markers
3.5.6.1 Clinical Symptoms
3.5.6.1.1 Course of Fever during Treatment Before the discovery of anti-
tuberculosis drugs, it was accepted that persistent fever after several weeks
of bed rest was indicative of progressive disease (Landis, 1920). Kiblawi et al.
(1981) present the results of a retrospective study looking at the course of fever
of patients who were hospitalised and treated for tuberculosis. They grouped
patients who were febrile on admission into two categories: those whose fever
persisted for more than two weeks and those whose fever cleared up within
two weeks. They showed that the first group had significantly more patients
with far advanced disease as assessed from a pretreatment X-ray. They in-
clude an extensive review of research done up to this point and conclude by
saying that the course of fever after treatment is variable. They close by saying
'we could not demonstrate any differences in the course of fever that could
be attributed to different modern anti-tuberculosis drug regimens' thereby us-
ing one of the Prentice criteria to dismiss the course of fever as a surrogate
endpoint nine years before Prentice proposed them (Prentice, 1989).
Barnes et al. (1987) present the results of another study of 192 patients
looking at the course of fever during treatment of pulmonary tuberculosis.
They show that febrile patients are more likely to also have laboratory mark-
ers of advanced tuberculosis, and that duration of fever did not differ between
different treatment regimens. A second paper (Barnes et al., 1988) on this data
looked at prognostic markers for short-term outcome claiming to be the first
systematic attempt to do so. The authors defined an unfavourable outcome as
either respiratory failure requiring intubation or death from any cause during
the patient's initial hospitalization. They developed a scoring system calcu-
lated from six of the most important prognostic variables that they identified
that would identify those patients at greater risk of developing respiratory fail-
ure or death. The six variables were: total number of lymphocytes, percentage
of neutrophils, age, smear-positive extra-pulmonary tuberculosis, alcoholism
and cavitary disease. It is important to note that no cultures were available
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in this study. They state that their findings were similar to those in Kiblawi
et al. (1981), except that they did not find any significant association between
extent of disease and prolonged fever.
3.5.6.1.2 Weight Gain Khan et al. (2006) evaluate weight gain during treat-
ment as a marker for treatment failure using data from the randomised con-
trolled trial Study 22 conducted by the Center for Disease Control and Pre-
vention Tuberculosis Trials Consortium (Benator et al., 2002). In participants
classified as underweight at diagnosis (defined as 10% or more below ideal
body weight), the authors report a relative risk of 1.79 (95% Cl 0.96, 3.32) com-
paring rates of recurrence among those with weight gain of 5% or less during
the intensive phase of treatment and those with weight gain more than 5%.
In a multiple covariate analysis adjusting for other risk factors, sex and age,
this association was stronger (odds ratio 2.4, p = 0.03). Yew and Leung (2006)
refer to an earlier study in Tanzania showing weight gain was an unreliable
indicator of treatment response and comment that the prognostic importance
of weight gain requires further study.
3.5.6.2 Automated Culture Systems on Liquid Media
A retrospective study of 26 patients receiving anti-tuberculosis treatment looked
at the correlation of time to detection (ITO) from the MGlT automated cul-
ture system (see section 3.2.5.1 for details) with response to treatment (Epstein
et al., 1998). The authors divided these patients into 'responders' and 'non-
responders' on the basis of clinical improvement (defervescence, weight gain,
decreased cough or hsemoptysis and increased appetite). They found that
TID fell sharply over time in the first group, but not in the second group. The
authors found that the binary measure of ITO less than 20 days was a better
prognostic marker than sputum AFB smear evaluation for treatment response
although the measure of treatment response could be prone to subjectivity.
Wallis et al. (1998) conducted a study looking at 42 patients on six months
of standard treatment for pulmonary tuberculosis. The authors monitored
Mycobacterium tuberculosis antigen 85 complex and days-to-positivity (DTP)
by BACTEC in addition to sputum culture and acid-fast smear. Patients were
also followed up for six months after the end of treatment for relapse defined
bacteriologically in conjunction with symptoms or radiographic findings con-
sistent with active TB. Using the results of (Epstein et al., 1998), the authors
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define persistent disease as subjects with at least one BACTEC culture at or after
day 90 of treatment that became positive within 20 days (that is OTP -::;20).
Four subjects had persistent disease and expression of antigen 85 complex in-
creased significantly over the first two weeks of treatment only in these four
subjects. The authors also found that its concentration on day 14 was a good
predictor of persistence. Of the four who had persistent disease, two relapsed
and there were no relapse in the rest of the cohort.
Looking at 177 TB patients from a cohort study in South Africa, Carroll
et a1. (2008) evaluated OTP measures taken during the first two weeks of
treatment as predictors of subsequent smear and culture results. Defining
a response ratio, r, as an algebraic combination of OTP values over the first two
weeks of treatment, the authors found low sensitivities for r as a predictor of
culture results at 2 (45'Yo) and 3 (47%) months with high specificities (65% and
64% respectively).
Pheiffer et a1. (2008) explored the relationship between OTP and treatment
response in sputum samples from 125 patients with TB in one province in
South Africa. The authors found that those with a negative smear at two
months had had a longer OTP at diagnosis than those with a positive smear.
The authors also looked at the relationship between CFU and OTP on the
BACTEC 460 and the BACTEC MCIT 960 in sputum samples from 22 TB
patients. They found only poor correlation between OTP and 10glOCFU,
R2 = 0.22 and R2 = 0.14 for the BACTEC 460 and the BACTEC MCIT 960
respectively.
In a small sample of 39 isolates from patients with TB, Wallis et al. (1999)
found a strong association between days to positivity (DTP) using the BacT/
ALERT culture system (bio-Merieux), R2= 0.99. Palaci et al. (2007) also found
a good association between BACTEC OTP and CFU (R2 = 0.63). These results
are then 'confirming that OTP is a reliable surrogate of sputum bacillary load'
(Palaci et al., 2007). This is not true as it has been shown in Chapter 2 that
'a correlate does not a surrogate make' (Fleming and DeMets, 1996); all that
can be said is that OTP moderately correlates with CFU . There is much dis-
cussion about how OTP relates to CFU and more work is needed in this area.
Automated liquid culture systems have clear benefits over the slower more
labour-intensive solid culture methods (see section 3.2.5.1) and it is therefore
important that this relationship is understood as more and more laboratories
worldwide are using liquid culture systems.
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3.5.6.3 Immunological Markers
In a study of 10 patients, Kennedy et al. (1994) compare polymerase chain re-
action (PCR) with smear microscopy and culture results for assessing treat-
ment response in patients undergoing chemotherapy for tuberculosis. They
show that PCR detected effective treatment in most cases and suggest that it
is promising but requires further study.
A study of 19 patients (Desjardin et al., 1999) found a rapid decline in M.
tuberculosis messenger RNA (mRNA) transcribed from the 85B (alpha antigen)
gene in sputum of tuberculosis patients during the first few days of effective
treatment suggesting that this may indicate that this marker correlates well
with microbial viability. The one patient in their survey who did relapse also
had the highest levels of sputum 85BmRNA during the first fourteen days of
treatment.
In a study of 22 patients, Thomsen et al. (1999) found that PCR remained
positive much longer in patients suffering from extensive disease than in those
with less extensive disease and suggest that therefore PCR may be applicable
for monitoring the response to treatment for tuberculosis.
Chierakul et al. (2001) evaluate PCR as a predictor of outcome in 53 TB
patients in a hospital in Bangkok. Patients tended to convert to negative later
on PCR than on smear or culture, but the numbers were too few to determine
whether this reflected progress of disease during treatment and the authors
concluded that, on limited data, PCR was not useful in monitoring therapy in
smear-positive PTB patients. Levee et al. (1994) show similar results in an even
smaller group of 19 patients. Afghani et al. (1997) suggest, from a study of 94
specimens from 22 cases of smear-positive TB, that there is no great advantage
in PCR over smear in predicting culture results.
3.5.7 Joint TDRIEC Expert Consultation
A meeting was initiated jointly by the Special Programme for Research and
Training in Tropical Disease (TOR) and the European Commission in Geneva,
Switzerland in June 2008 to evaluate the role of biomarkers and surrogate end-
points in the management of patients with tuberculosis. This meeting allowed
for a comprehensive discussion on current biomarkers with the available ev-
idence supporting these markers and sources of possible future biomarkers.
Tables 3.2 on page 94 and 3.3 on page 95 show the current status of all avail-
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able biomarkers for tuberculosis and are reproduced from the report of this
meeting with permission (Zumla et al., 2008).
3.6 Discussion
As summarised in this chapter, a large number of candidate predictors, prog-
nostic markers and surrogate markers for poor outcome to tuberculosis chemother-
apy have been proposed in the literature. These can be grouped under three
headings: possible risk factors, recently proposed markers and markers with limited
evidence suggesting their potential use as surrogates.
Most of the proposed markers are possible risk factors. These are factors
that may, at best, indicate that a particular patient is more or less likely to
respond to treatment. Such risk factors include smoking, alcoholism, indica-
tors of poor adherence, HIV infection, weight and radiographic assessments
of disease and cavitation. These are independent of and measured prior to
the initiation of treatment and therefore cannot be prognostic or surrogate
markers. However, they may be useful in explaining some of the variation
in treatment response between individuals (although this variation is usually
removed with randomisation in a clinical trial) and the inclusion of important
covariates might improve the fit of statistical models.
Some of the markers are technologically advanced, recentlu proposed markers.
To measure these markers newer, advanced techniques often using expensive
laboratory facilities are required. Such markers include those immunological
and molecular markers and DTP from automated culture systems described
in sections 3.2.6 and 3.5.6. To evaluate one of these markers as a surrogate
endpoint, it must be assessed in patients during treatment in addition to pa-
tients being followed up for long-term treatment outcome. There is therefore
often none, or very little such data available and analysis of these markers
as prognostic and surrogate markers is therefore not yet possible. Typically,
such markers are prohibitively expensive for use in laboratories with limited
resources.
What remains of the list of possible markers are SSCC and monthly culture
results. Monthly sputum smear results during treatment have too low sensi-
tivity to be useful as prognostic markers and therefore will not be considered
as surrogate markers. As described in section 3.5.5.2, whilst there are indica-
tions that summary parameters of SSCC may in fact prove to predict treatment
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failure and be able to be used as a surrogate, insufficient data exists with par-
ticipants followed up for relapse in addition to having SSCC data recorded.
Extensive data do exist to evaluate monthly culture results as prognostic and
surrogate markers. Several published articles have indicated that, in particu-
lar, the two month culture result has value as a prognostic or even surrogate
marker, though actual analysis of the available data providing evidence of this
is scant. Cultures are collected in some TB control programmes and the use
of cultures as markers for treatment failure could therefore be of immediate
use. Therefore, the primary objective of this research project is to evaluate
monthly cultures as prognostic and surrogate markers for long-term response
to treatment for tuberculosis and, following the recommendations from the
literature (see section 3.5.3), the culture result at two months will provide the
focus.
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Candidate biomarker Association
Study size
and positive
treatment outcome
Chest radiography
Baseline chest X-ray Recurrence 46/938
Baseline chest X-ray Relapse 74/930
Baseline chest X-ray Relapse 4/237
Baseline chest X-ray Recurrence 24/175
Serial sputum microbiology
M2SCC Recurrence Many patients
Serial sputum CFU counts Superior sterilizing activity Few patients
Serial MGIT™or BACTECIM Anti-TB TrR,
Many patientstime to positivity failure and relapse
Early bactericidal activity None Many patients..Tfl-specific biomarkers
Sputum antigen 85B RNA Anti-TB TrR 1/18
Sputum antigen 85 TrR 2/40
Sputum antigen 85 Drug evaluation 40
Urine Mtb DNA Anti-TB TrR 20
Urine lipoarabinomannan Infection, active disease Many patients
Anti-ESAT-6, 38 kDa protein,
alanine dehydrogenase, Extent of disease, TrR 168
malate synthetase
IGRA Anti-TB TrR 5/18
Breath biomarkers
Culture plates data
19/23Active disease
Nonspecific biomarkers of Immune activation
NKT cells at diagnosis M2SCC 8/21
Sputum IFN-'Y Anti-TB TrR 15
sIL-2R Anti-TB TrR 44
sTNF-R, granzyme B
M2SCC 18/36at diagnosis
Neopterin Anti-TB TrR, relapse
11/39
31
105
C-reactive protein Anti-TB TrR, death 100
18
sICAM-1 TrR 30
suPAR Death 101
Table 3.2: Current status of TB biomarkers. Continued in Table 3.3 on the next
page.
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Candidate biomarker Association
Study size
and positive
treatment outcome
Functional studies of TB protection
ELISPOT and Vaccine effect Immune
QuantiFERON® eradication of Mtb infection Many patients
Prediction of disease
QFN in untreated contacts 5/6
(using upper bound cut-off) 6/6
TST effect
12
Whole blood killing 10
BCG effect 50
Whole blood killing AIDS effect 22
Whole blood killing Combined ART effect 15
Whole blood killing TNF monoclonal antibody effect 20
Whole blood killing Vitamin 0 effect 192
Functional studies of anti-Tfl treatment
IGRA LTBITrR 38
IGRA Anti-TB TrR 5/18
Whole blood killing Anti-TB TrR Many patients
Whole blood killing
Correlation between serial
CFU slope and M2 SCC 36
Whole blood killing Anti-TB TrR 10
Highly multiplexed assays
Transcriptomics TB disease and infection 40
Proteomics TB disease 60
Metabolomics TB disease NA
Table 3.3: Continued from Table 3.2 on the previous page. Current status of
available biomarkers in TB from the 2008 joint TDR/EC expert consultation
on biomarkers in tuberculosis. References for each study are available from
the meeting report. This table is reproduced with permission from Zumla
et al. (2008). ART, antiretroviral therapy; BCG, bacille Calmette-Guerin: CFU;
colony forming unit; ESAT, early secretory antigenic target; IFN, interferon;
IGRA, interferon-gamma release assay; IL, interleukin; LTBI, latent TB infec-
tion; MGIT™, Mycobacterium Growth Indicator Tube; M2 SCC; month-two
sputum culture conversion; Mtb, Mycobacterium tuberculosis; NA, not available;
NKT, natural killer T cells; sICAM-l, soluble intercellular adhesion molecule
type 1; suPAR, soluble urokinase plasminogen activator receptor; TrR, Treat-
ment Response; TNF, tumour necrosis factor; TST, tuberculin skin test.
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Chapter 4
Overview of Data and
Introduction to Analysis
4.1 Introduction
In the previous chapter, possible prognostic and surrogate markers for poor
outcome to treatment were summarised. It was demonstrated that culture
results during treatment are the most promising markers for which there is
data available to evaluate as prognostic and surrogate markers.
In this chapter, the data used in this thesis to evaluate culture results as
prognostic and surrogate markers will be introduced and described. In this
section the justification for the data used will be discussed. Section 4.2 sum-
marises the process of data entry and cleaning and section 4.3 describes the
definition of the clinical endpoint. The data is described in section 4.4 with
some tables and figures summarising the data presented in section 4.5.
4.1.1 Choice of Data
4.1.1.1 Trial vs. Observational Data
A surrogate marker is one which fully captures the effect of the treatment
on the true endpoint. It is therefore particularly important that the observed
treatment effect is indeed the true treatment effect and not contaminated by
other factors. Data from prospective randomised controlled trials are therefore
required for the evaluation of surrogate endpoints as this is the only known
96
way to control for unknown confounders (Lassere et al., 2007b). Retrospective
observational studies contain serious potential biases that are removed when
participants are prospectively enrolled into a trial and randomised to treat-
ment (Pocock, 1983). To assess the treatment effect, it is also important that
there is a control arm so that within-trial treatment comparisons are possi-
ble. In a clinical trial, participants enrolled will be followed-up after the end
of treatment, but this is not always possible in a purely observational study.
Follow-up is particularly important in the context of TB since relapse within
twelve to eighteen months after the end of treatment is the main endpoint in
clinical trials. For use in a clinical trial, a surrogate marker must first be eval-
uated in the context of previous clinical trials. Clinical trial data are therefore
necessary for an evaluation of a surrogate endpoint.
4.1.1.1.1 Individual Patient Data Daniels and Hughes (1997) and Gail et al.
(2000) both emphasise the importance of having individual patient data (lPO)
from clinical trials available for the evaluation of a surrogate marker, rather
than just summary statistics. The authors suggest that it is less important
to have IPD if the between-study variation is much greater than the within-
study variation. In any TB clinical trial, there is often considerable variation
in treatment outcomes and it therefore cannot be said that the within-study
variation is minimal. Having IPD for the evaluation of surrogate markers in
TB is therefore vital.
4.1.1.2 Datasets to be used
For the purpose of this research project, data will be used from selected tu-
berculosis clinical trials that were conducted by the British Medical Research
Council (MRC) during the 1970s and 1980s to identify the most effective regi-
men for treating tuberculosis. A large amount of what we know today about
the treatment of tuberculosis comes as a result of these trials. In 1999, an
entire 49-page supplement to the International Journal of Tuberculosis and
Lung Disease (IJTLD) was dedicated to these trials, (Fox et al., 1999). Other
reviews also confirm the central importance of these MRC studies (D'Esopo,
1982; Christie and Tansey, 2005).
These trials were chosen for the following reasons:
• Randomised controlled trials of lligl1 quality. The streptomycin trial con-
ducted in the UK by the MRC in the 1940s is generally regarded to be
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the first published randomised controlled trial (Hill, 1990). Subsequent
MRC TB trials were all randomised and conducted with an emphasis
on the use and development of this scientific method. In 1979, when
Archie Cochrane judged which disease area in medicine was the most
evidence-based, he gave the 'gold medal' to the tuberculosis specialists
(Cochrane, 1979). Clinical trials conducted to a high standard result in
data quality of a high standard.
• Large differences in recurrence rates between treatment arms. Since the MRC
trials were the means by which effective treatment regimens were eval-
uated, they naturally include less effective regimens leading to a high
number of recurrences. Importantly, recurrence rates differed greatly
between treatment arms within anyone trial. A large treatment effect
gives greater power for the evaluation of surrogate markers.
• Six month regimens. In common with the standard treatment recom-
mended today, most of the treatment regimens evaluated on these trials
were of duration six months. Trials arms with treatment duration other
than six months are excluded from analyses. As discussed in Chapter
2, a surrogate can never be 'generally applicable' (Day and Duffy, 2000)
and will only be valid in a trial involving the same drugs that were
used for its evaluation. For the purpose of this research project, the data
pertain to participants who were on six months of treatment using the
same drugs that are largely still in therapeutic use today and will be
used today in clinical trials (any new drug will be evaluated as part of
a regimen involving three or four other drugs from the standard regi-
men). No new drugs for the treatment of TB have been developed for
forty years (Spigelman, 2007). This means that data from historic clinical
trials can still be used to evaluate surrogate markers for use in clinical
trials being conducted today.
• Multi-arm, large Trials. Whilst authors disagree about the exact methods
of evaluating surrogate markers (see Chapter 2), there is almost unani-
mous agreement that it must be done across a number of different tri-
als. A surrogate marker that is shown to fully capture the treatment
effect across a large number of treatment comparisons and a large num-
ber of individuals wiII be of greater use and be more convincing than
one which is validated across only a handful of treatment comparisons.
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These data consist of over 7000 individuals from 12 clinical trials includ-
ing 49 different treatment regimens.
• Good Laboratory Data. For each trial, samples were sent to a central lab-
oratory supported by MRC laboratories in Britain. Contamination was
kept to a minimum, non-tuberculosis mycobacteria were generally iden-
tified as such and resulting laboratory results were of a consistently high
standard.
• Extensive Follow-up aJter the end of treatment. In all trials, participants
were followed-up for a minimum of eighteen months after the end of
treatment and sputum samples taken on a monthly or in some trials
bimonthly or trimonthly basis during this follow-up period. In some
trials, participants were given vitamin tablets after the end of treatment
as an incentive to return for follow-up visits. On treatment cards from
all trials, there is clear documentation of home visits, written correspon-
dence and visits to family and friends in order to minimise participant
loss during follow-up.
• Additional Covariates Recorded. Additional variables recorded in all or
some of the trials include: age, sex, weight, drug resistance, baseline
radiographic measurements, smear results, race and centre. In a small
number of trials, radiographic measurements were also recorded at sev-
eral points during treatment. There is great variation in clinical outcome
and culture results during treatment between participants and some of
this variability may be removed by controlling for participant covariates
(and has been found in similar work on SSCC in Davies et aJ. (2006a».
The following reasons relate to the homogeneity of the trial participants
included in these data. This homogeneity removes some complexity from
the analysis and interpretation of the results, but can have an impact on the
generalisability of conclusions drawn with the first point having the greatest
impact.
• No HIV co-injection. These trials were conducted in an era before the
existence of the human immunodeficiency virus (HIV) and so all partic-
ipants were uniformly HIV seronegative. It is known that the rifamycins
(in particular rifampicin) interact with some therapies given to treat
HIV and therefore participants with TB and HIV co-infection respond
99
to treatment differently (Blumberg et al., 2005) and prognostic and sur-
rogate markers may be more or less valuable in patients with or without
HIY.
• Exclusively Pulmonary Tuberculosis. Participants with extra-pulmonary TB
require different treatment and have a different response to treatment
(see section 3.1.2). Participants detected to have extra-pulmonary were
excluded from the trials and only those with pulmonary tuberculosis
were enrolled .
• No MDR-TB. Rifampicin use was not widespread in the communities in
which these trials were conducted and therefore very few participants
were rifampicin-resistant and therefore multi-drug resistant TB was not
a problem.
These data therefore provide an unprecedented opportunity to determine
the value of early culture results as prognostic and surrogate endpoints.
4.1.1.3 Trial Summary
Trials were identified using the aforementioned IJTLD article written by Wal-
lace Fox in 1999 (Fox et al., 1999) and in communication with those who were
involved with TB research during this period. Only trials for which individ-
ual patient data was available were considered. Trials were selected that met
the following inclusion criteria (see above for details): six month regimens,
regimens including standard drugs only, differing recurrence rates between
regimens, at least eighteen months of follow-up and fairly large sample sizes
(at least 50 in each treatment arm).
Regimens are described in a format such as: 2SHRZj 4S2H2. The combi-
nation of letters before the forward slash (5, H, Rand Z) correspond to the
drugs given in the intensive phase and the combination of letters after the for-
ward slash correspond to the drugs given in the continuation phase. The letter
codes are as follows: E (ethambutol), H (isoniazid), R (rifampicin), S (strepto-
mycin), T (thiacetazone), Z (pyrazinamide). The number at the beginning of
the letter combination denotes the duration of the intensive phase in months
(2 in the example). The number immediately following the forward slash de-
notes the duration of the continuation phase in months (4 in the example).
The absence of a forward slash indicates that the intensive and the continu-
ation phases included the same drugs at the same dosing frequency and are
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therefore not shown separately. Any subscripts indicate the weekly dosing
frequency of that particular drug (S2H2 indicates that streptomycin and iso-
niazid were given twice-weekly). An absence of subscript indicates that the
drugs were given daily (S, H, Rand Z were given daily in the intensive phase
in the example). This closely follows the notation given in the original trial
papers.
Twelve trials which satisfied the inclusion criteria were selected and are
summarised below. Publications describing and resulting from the clinical
trials, if not stated in the text below, are listed in Fox et al. (1999).
4.1.1.3.1 Trials Included
Study R (East Africa, 1970) This was the first large RCT to show that
short-course chemotherapy of only six months was as effective as the standard
eighteen months of treatment. The study demonstrated that a six month reg-
imen containing the drug rifampicin (hence Study R) in addition to isoniazid
and streptomycin (6SHR) had a superior recurrence rate to the standard eigh-
teen month regimen of isoniazid, streptomycin and thiacetazone. (2SHT /16TH).
Three other six month regimens were evaluated in this study (6SHT, 6SHZ and
6SH) and sites were located in Kenya, Tanzania, Uganda and Zambia. There
were four publications resulting from this study: (East African/British Med-
ical Research Council, 1972, 1973a, 1974b, 1977). Patients on the 18 month
regimen are not included in analyses in this thesis.
Study T (East Africa, 1972) Following Study R, Study T showed the ben-
efit of adding pyrazinamide in the first two months. This study compared four
six months regimens: 6SHR, 6HR, 2SHRZ/4TH and 2SHRZ/~H2Z2' There
were two publications resulting from this study.
Study V, (East Africa, 1974) Study U expanded on Study T showing the
sterilizing activity of SHRZ was better than SHR for the first two months,
and that a one month intensive phase was too short. The trial compared
four six month regimens (2SHRZ/4TH, lSHRZ/5TH, lSHRZ/5S2R2Z2 and
2SHR/4TH) with four of the same regimens with the continuation phase ex-
tended so that the total duration was 8 months.
This trial showed the eight month regimen of 2SHRZ/6TH was efficacious
and therefore eight month regimens were widely adopted in many countries
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(with thiacetazone later being replaced with ethambutol). The eight month
regimen 2SHRZ/6EH was later found to be inferior to the six month regimen
2SHRZ/4HR in a recent IUATLD study (Jindani et al., 2004) and is subse-
quently no longer recommended. There were two publications resulting from
this study. The eight month regimens are not included in analyses in this
thesis.
Study X, (East Africa, 1976) Study X evaluated the effect of adding pyraz-
inamide and rifampicin to the continuation phase and reducing it to two
months. Five four month regimens were compared in this study (2SHRZ/2HRZ,
2SHRZ/2HR, 2SHRZ/2HZ, 2SHRZ/2H and 2HRZ/2H). This study showed
that four months of treatment was insufficient with these drugs (several trials
are being conducted today to determine whether four month regimens in-
corporating fluoroquinolones or high dose rifamycins can be effective against
TB) and was the first evidence that pyrazinamide gave no added benefit in the
continuation phase. There were two publications resulting from this study.
High recurrence rates in all of the four month regimens were observed dur-
ing the course of the trial and a decision was made to extend the continuation
phase to four months for those in the study from that point forward. A num-
ber of patients originally enrolled in the study were therefore given six months
of treatment and followed up for outcome to treatment. Data from these pa-
tients given six months of treatment is included in the analyses in this thesis,
and those only given four months of treatment will be excluded. The five
regimens included are therefore 2SHRZ/4HRZ, 2SHRZ/4HR, 2SHRZ/4HZ,
2SHRZ/4H and 2HRZ/4H.
Study Y, (East Africa, 1978) Study Y compared a 6 month continuation
phase containing only isoniazid (2SHRZ/6H) with three 4 month continuation
phases (2SHRZ/4H, 2SHRZ/4HR and 2SHRZ/4HZ). This study showed that
recurrence rates decreased only after the addition of rifampicin, showing the
importance of rifampicin throughout treatment. There were two publications
resulting from this study. The eight month regimen is not included in the
analyses in this thesis.
Tanzania Short-Course Chemotherapy Investigation (Study A, 1979) This
study, conducted in Tanzania, compared 2SHRZ/4TH with 2SHRZ/4H and
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demonstrated that the addition of thiacetazone in the continuation phase did
reduce recurrence rates. There was one publication resulting from this study.
First Hong Kong Short-Course Study (1972) Alongside, and slightly
later than the studies in East Africa, a number of trials were conducted in
Hong Kong and Singapore. These studies 'concentrated on intermittent regi-
mens well suited to their urban communities, and were less restricted by drug
costs' (Fox et al., 1999), particularly the high cost of rifampicin which was
prohibitively expensive in an East-African setting.
None of the regimens compared in the first study in Hong Kong con-
tained rifampicin, in contrast with regimens in subsequent studies which all
contained rifampicin at least in the intensive phase. This study would now be
described as a 2x3 factorial study and compared the regimen given 5HZ given
either daily, twice weekly or thrice weekly and given for either six months or
nine months. The number of doses given during a week did not greatly affect
recurrence rates, but the recurrence rates in the six month regimens were too
small with acceptable recurrence rates only in the nine month regimens. This
study showed that a six month regimen without rifampicin resulting in un-
acceptable recurrence rates, indicating that rifampicin was necessary in a six
month regimen. There were two publications resulting from this study. The
nine month regimens are not included in the analyses in this thesis.
Second Hong Kong Short-Course Study (1974) The second Hong Kong
study compared the control regimen of 6SHR against a selection of intermit-
tent regimens (2SHRZ/S2H2Z2, 2SHRE/52H2E2 and 4S3H3R3Z3/S2H2Z2) ei-
ther as six month regimens or with the continuation regimens extended to
make eight month regimens. Recurrence rates in the regimens not contain-
ing pyrazinamide were poor and was the first evidence showing the poor
sterilizing activity of ethambutol and the importance of pyrazinamide in the
intensive phase. There were two publications resulting from this study. The
eight month regimens are not included in the analyses in this thesis.
Third Hong Kong Short-Course Study (1977) The third Hong Kong study
compared a daily control regimen of 6EHRZ with four thrice-weekly four-
drug regimens: 6E3H3R3Z3S3, 6S3H3R3Z3, 6E3H3R3S3 and 6E3H3R3Z3. All
regimens, with the exception of the regimen not containing pyrazinamide,
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had very low recurrence rates. There were three publications resulting from
this study.
Fourth Hong Kong Short-Course Study (1979) The fourth Hong Kong
study explored the duration of pyrazinamide in a six month regimen. 6H3R3Z3
was compared with 6S3H3R3Z3 where the pyrazinamide was given for two,
four or six months. Recurrence rates were low in all four regimens showing
that pyrazinamide gave little added benefit after two months. Unusually, 2%
of those on the regimen without streptomycin failed treatment showing the
importance of four drugs in an intermittent six month regimen. During the
course of this study some patients were given the same regimens except with
the HRZ given as a combined formulation. There was no reported differences
in this study between those who took the combined tablet and those who took
separate tablets and so this distinction is not considered in the analyses in this
thesis and the fourth Hong Kong study only provides four regimens. There
was one publication resulting from this study.
First Singapore Short-Course Study (1973) The first Singapore study
further explored the benefit of pyrazinamide beyond two months comparing
2SHRZ/2HR and 2SHRZ/4HR with the same regimens given pyrazinamide
in the continuation phase. Recurrence rates were very low in both six month
regimens, but only moderately low in the four month regimens. The two four
month regimens are not included in the analyses in this thesis. There were
three publications resulting from this study.
Third Singapore Short-Course Study (1983) The third Singapore study
explored the use of a combined tablet of isoniazid, rifampicin and pyrazi-
namide. Six regimens were compared: 2SHRZ/4H3R3, ISHRZ/SH3R3 and
2HRZ/4H3R3 with HRZ given in the intensive phase as a combined prepara-
tion or as separate tablets. recurrence rates in the regimens with the combined
formulation were slightly higher in those with separate tablets. There was one
publication resulting from this study.
4.1.1.3.2 Trials Excluded
Kenya Levamisole Study (1981) The purpose of this study was to deter-
mine whether the addition of the immunostimulant Levamisole affected the
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activity of the 2SHRZ/TH regimen. While the individual patient data was
available, this drug is not used today for the treatment of TB and so the data
from this study are not used in this thesis (Kenyan/Zambian/British Medical
Research Council, 1989).
Second Tanzanian Chemotherapy Investigation (1982) This study was
conducted to compare two seven month treatment regimens. No six month
regimens were included in this trial and so the data are not used in this thesis
(Tanzania/British Medical Research Council, 1996).
Second Singapore Short-Course Study (1978) Three different six month
regimens were compared in this study. All three regimens were highly effec-
tive and recurrence rates within two years from the start of therapy were only
1% in each arm. The treatment effect size is too small to be of any use in eval-
uating surrogate endpoints. These data are not used in this thesis (Singapore
Tuberculosis Service/British Medical Research Council, 1985, 1988).
The Hong Kong Silico-tuberculosis Study (1980) This study compared
a six month regimen with an eight month regimen for the treatment of silico-
tuberculosis. Silico-tuberculosis is a particular occurrence of tuberculosis of
the lung that is inflamed with the presence of foreign bodies (often inhaled
particles of silica) and is found primarily among workers at mines and quar-
ries. Patients with silico-tuberculosis respond differently to those with non-
silicotic TB and data from this trial are therefore not used in this thesis (Hong
Kong Chest Service/British Medical Research Council, 1991b).
4.2 Data Entry and Validation
4.2.1 Introduction
The twelve trials described above were all completed by the mid-1980s and the
results published by the beginning of the 1990s. The analyses were mostly, if
not entirely, conducted by hand and no electronic copy of the data exists from
this time. Therefore, while individual patient data is available from each of
these trials, it exists in the form of patient cards that have been kept in storage.
The first, lengthy step in the analysis of these data is converting them into an
electronic form (data entry) and checking the quality of these data (validation).
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4.2.2 Methods
4.2.2.1 The First Four East African Trials
The first four East African trials (Studies R, U, T and X) had been entered
onto the computer over a period of around five years prior to the start of
this research project. This was done with the purpose of performing a re-
analysis of data from the key trials using more modern methods of statistical
analysis (such as adopting the intention-to-treat principle, survival analysis
and imputation techniques). This re-analysis is still ongoing and the results
are yet to be published.
The data had been entered using the process of double-data-entry (DOE). For
each of the four trials, the data were entered in full on two separate occasions
by two independent persons. Two databases therefore exist for each trial.
While some studies have shown that double data entry is neither necessary
nor sufficient for ensuring good quality data (Day et al., 1998; Gibson et al.,
1994), most of the human error in transcribing the data from case record forms
(CRFs) to computer can be identified and eliminated with DOE. This task of
DOE validation is also a time-consuming task as individual CRFs will have to
be re-checked for every discrepancy that is found between the two databases.
Prior to the start of this research project, these data had been entered, but
no formal comparison of these two databases or any analysis had been carried
out and the databases largely remained in their raw, uncleaned state. Using
Stata 9.2 (StataCorp. 2005. Stata Statistical Software: Release 9. College Station,
TX: StataCorp LP.), the two independent copies of data from each of the four
trials were compared record-by-record to find discrepancies. Discrepancies
were then checked against the original CRFs and the records updated on a
final database.
In addition to the process of DOE validation, treatment cards were man-
ually checked to determine the endpoint for each participant. The different
classifications of treatment failure and treatment cure are not necessarily ex-
actly the same as those used in the original trial analyses (discussed below in
section 4.3) and so it was important, even after the double data entry valida-
tion had been performed, to check each endpoint. Any doubtful recurrences
were studied carefully and classified after discussion with other TB experts.
These discussions and resulting classifications were made blind to the allo-
cated treatment.
Treatment cards were then separated into groups of treatment regimens
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and manually checked against that stored in the database. In addition to
endpoint classification, treatment allocation is an important data element and
so the regimen marked on each treatment card was checked.
4.2.2.2 The Remaining Eight Trials
No electronic copy of the data from the remaining eight trials existed prior to
this research project. A data entry environment was set up using the software
Epilnfo 6.04d (C~C, USA; WHO) and data entered during the months of July
and August 2006. Due to time constraints and the limited additional benefits
of DOE, these data were only single-data entered.
Each treatment card contains a large variety of information including par-
ticipant characteristics, medicines given, drug sensitivity results, laboratory
results, details of postmortem (if performed), some clinical symptoms and
any additional comments by trial clinicians or investigators. Not all of this
information is of use for the purpose of this research project, so only a subset
of these data elements were selected for data entry. Table 4.1 on the follow-
ing page summarises the list of variables selected for data entry. Participant
characteristics were chosen as those most likely to be risk factors. In some of
the trials, x-rays were taken during treatment. Radiographic extent of disease
and cavitation has been recorded where they were assessed.
As with the first four trials, each treatment card was manually checked
against the database to confirm the endpoint classification. Any undecided
classifications were confirmed on consultation with TB experts. Again, the
allocated treatment arm was manually checked against the database for every
treatment card to ensure that the regimens recorded on the database were
correct.
A random selection of 5% of treatment cards from these eight trials were
selected and each data element on the treatment card checked against the
database to assess the overall quality of the data. The results are shown in
Table 4.2 on page 109.
The percentage error was calculated assuming 25 pieces of information on
each of the treatment cards sampled. The overall error rate of 1.2% with 95%
confidence limits of 0.9% and 1.5% indicates a high quality of data entry. It
was decided that this was an acceptable error rate and there was therefore no
need to check the data further or employ double data entry.
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Variable Type Comments
TrialT string Name of trial
Region" string East Africa, Hong Kong or Singapore
Trial Number" string Unique partici]:>_antidentifier
Treatment Arm T string Allocated treatment regimen
Control Arm t boolean
Flag to identify the control
arm in a trial (see section 6.1.1)
Date of Randomisation date
Trial-specific Data Elements
Patient Characteristics
Age integer
Sex boolean Male, Female
Weight float
Race string
Chinese, Indian, Malay or Eurasian
(recorded in Singapore studies only)
Baseline Resistance" string Susceptibility to Isoniazid and/or Streptom_ycin
Baseline Smear string Nil, Slight, Medium or Heavy
Baseline Culture string
0,1-19,20+, Innumerable Colonies
(IC) or Confluent Growth (CG)
Baseline Disease+ string Radiogr<l£hic extent of disease
Baseline Cavitation+ string Radiographic extent of cavitation
Smear Results string Measured at months 1,2,3,4,5 and 6
Culture Results string Measured at months 1, 2, 3, 4, 5 and 6
Extent of Disease+ string Measured at months 4 and/or 6
Extent of Cavitation+ string Measured at months 4 and/or 6
Assessments DUring Treatment
Unfavourable boolean Unfavourable at end of treatment
Last Culture integer Month of last non-missing culture
Recurrence T boolean
Month of recurrence integer
DiedT boolean
Date of Death date
Month of Death integer
Cause of Death string
Free text including conclusions of clinical
examination and post-mortem (if conducted)
TB Death boolean Cause of death TB or other respirato'Y_ disease
Endpoint string Final classification of endpoint (see section 4.3)
Time to endpoint integer Time from randomisation to failure or censoring
Endpoint Classification
"Denotes variables that cannot be missing.
tOn chest x-ray.
Table 4.1: Variables selected for data entry.
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Study
Number of Participants
Errors
Percentage
Entered a Sampled b Error C
Study Y 552 28 13 1.9%
Tanzania 318 16 6 1.5%
Hong Kong 1 246 12 6 2.0%
Hong Kong 2 392 20 6 1.2%
Hong Kong 3 1207 60 12 0.8%
Hong Kong 4 1605 80 19 1.0%
Singapore 1 201 10 4 1.6%
Singapore 3 310 16 4 1.0%
Overall (exact bInomlal95% confidence Intervals) I 1.2% (0.9%,1.5%)
"The total entered is usually greater than the total included in the analysis. See section 4.4.2.
bSize of sample was taken as the nearest integer to 5% of the total entered.
'The number of data pieces entered from each card varied across trials and, for the purpose of
this calculation, was taken to be 25. Percentage error was calculated as (Number of Errors/(25·
Size of Sample) )%.
Table 4.2: Error checking report
4.3 Endpoint Definition
Culture results were available monthly during the six months of treatment
and almost as regular after the end of treatment for a time. In most trials,
follow-up was for twenty-four months after the end of treatment, but in a
small number of trials (see table 4.5 on page 116 for details) follow-up was
only for eighteen months. Culture results were taken monthly for most of
the follow-up period, and every two or three months in the remainder of the
follow-up period.
A combined endpoint, poor outcome, defined as failure at the end of treat-
ment or recurrence following apparently successful treatment, is the clinical
endpoint for the purposes of this research project. In some trials, participants
were followed up beyond the scheduled end of follow-up, but any culture re-
sults or deaths occurring more than three months after the end of follow-up
have been ignored.
There are three possible outcomes for participants enrolled in these trials.
Either an individual will be classified as having a poor outcome, they respond
to treatment without recurrence and have a fair outcome, or they have a missing
outcome. Individuals with a fair outcome are classified as censored for time-
to-event analyses and will simply be considered as having a fair outcome
when considering a binary treatment response. Similarly, individuals with a
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missing event will be excluded from all analyses (assuming the missingness
mechanism is non-informative). Table 4.3 gives the classification algorithm
which is described in more detail below.
Classification I Outcome Event or Censoring Time
Non-TB death Month of Death
FAIR Loss to follow-up Month of Last Culture
OUTCOME Long-term cure Month 27 or 33'
Failure during Treatment Month 6
POOR Failure after Month of first
OUTCOME successful treatment indication of recurrence
TB death Month of Death
MISSING
Default before the
N/Aend of treatment
OUTCOME Death during Treatment N/A
'Three months after the scheduled end of follow-up to allow for late failures. In the second,
third and fourth Hong Kong trials, follow-up ended twenty-four months after randomisation. In
the remaining trials, follow-up ended thirty months after randomisation.
Table 4.3: Endpoint Classification
• Default or death during the first four months of treatment-MISSING OUT-
COME.If an individual defaults or dies before the end of treatment with
a last non-missing culture at month 4 or earlier, the end of treatment
status for this participant will be unobtainable and the individual will
be classified as having a missing status. It was felt that individuals who
default or die within the first four months of treatment have had insuf-
ficient time to demonstrate a response to treatment, either favourable or
otherwise, and so cannot be assigned an outcome. If a culture result is
available at months 5 or 6, the end of treatment status will be determined
on the basis of these results .
• Failure during Treatment-PoOR OUTCOME.Failure during treatment, cor-
responding to treatment non-response, can only be assessed at the end
of treatment, during the fifth and sixth months after randomisation. If
a participant has heavily positive cultures! at months five or six, or cul-
tures with any number of colonies at months five and six, then the partic-
ipant will be said to have an unfavourable status at the end of treatment.
Such individuals are classified as failures at 6 months. If there is not
1A heavily positive culture is defined as a growth of 20 or more colonies.
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such strong evidence for failure during treatment, the individual will
not be classified as a failure during treatment. Such strict criteria may
miss some of those failing at the end of treatment, but these cases will
be subsequently be picked up as recurrences after the end of treatment.
• Failure after Successful Treatment-PoOR OUTCOME. A participant who re-
sponds to treatment, (not classified as failure during treatment), but sub-
sequently shows conclusive evidence of tuberculosis disease in follow-
up is defined as failure after successful treatment or recurrence. The time
of failure will be defined as the month of the earliest indication of recur-
rence. One of the following is required to show evidence of recurrence
1. Two heavily positive cultures (20+ colonies) within three consecu-
tive months.
2. Three positive cultures within four consecutive months.
3. Evidence of retreatment after a clinician's assessment of recurrence
of disease.
4. Participant defaults and is lost to follow-up immediately following
a positive culture. Participants showing even scant evidence of re-
currence (such as only a single positive culture with a low colony
count) before being lost to follow-up are classified as recurrences
since there is no more information to confirm or discount.
• Death after Successful Treatment-PoOR OUTCOME / FAIR OUTCOME. A
cause of death from clinical inspection and, in some cases postmortem,
is usually available for individuals who die after the end of successful
treatment and, in most cases, it is clear whether the death was related
to tuberculosis or not. If there is clear evidence that the death was un-
related to tuberculosis or any other respiratory disorder, then it can be
classified as a censored observation. If, on the other hand, the cause
of death is related to any respiratory disease then this is a recurrence
whether or not it has been confirmed bacteriologically and is classified
as a treatment failure. The time of the failure or censoring is taken to be
the month of death.
• Long-term Cure / Loss tofollow-up-FAIR OUTCOME / MISSING OUTCOME.
Participants who respond to treatment and who have not died or shown
evidence of recurrence up to three months beyond the end of follow-up
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(twenty-four or eighteen months after the end of treatment, depending
on the trial) are classified as having long-term cure.
Some participants are lost to follow-up before the end of follow-up. If
such participants do not show evidence of recurrence and have com-
pleted at least twelve months of follow-up, then they too are classified
as having a fair outcome. When considering the endpoint as binary, par-
ticipants who are lost to follow-up less than twelve months after the end
of treatment will be classified as having a missing outcome. In a time-to-
event analysis, such censoring can be accounted for, but if the endpoint
is considered as binary, such participants must be classified as having a
missing event. A participant must have at least twelve months of follow-
up after the end of treatment to be classified in the analysis of the binary
outcome as having a favourable outcome.
There are a handful of participants who did not clearly fit into one or other
of these categories. Such participants were classified on a case-by-case basis
in consultation with more experienced TB specialists who were not told the
treatment allocation.
4.4 Description of the Data
4.4.1 Introduction
Data from 7307 trial participants were initially included in the database. The
participants were from 12 trials conducted over two decades in 6 countries.
These data include 50 treatment arms, removing the 19 regimens from these
12 trials that were excluded as described previously (see section 4.1.1.3).
4.4.2 Exclusion of participants
Tuberculosis can also infect parts of the body other than the lungs (see sec-
tion 3.1.2). All twelve of these MRC trials were assessing treatment for pul-
monary TB and, for this reason, a common exclusion criteria was presence
of extra-pulmonary TB or any other serious disease. Participants found to
have such disease were usually not enrolled into these trials. Despite this,
a handful of participants have been identified as having been enrolled with
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extra-pulmonary TB or other serious non-TB disease and these nine have been
excluded.
Enrolment into a TB trial was on the basis of between one and three pos-
itive sputum smears. Treatment was started immediately, and this diagnosis
was later confirmed using the more sensitive sputum culture. A small number
of individuals who were diagnosed with TB on the basis of the sputum smear
results were then found to be culture negative and disease-free. It was com-
mon in these trials for such individuals to have their treatment discontinued
and be withdrawn from the study. An inclusion criteria for these trials was
therefore a positive smear and a positive culture. Due to the delay in receiving
culture results, individuals could have had several months of treatment, some
even completing their six month course before being withdrawn. Since such
individuals were most likely disease free and were intentionally withdrawn
by the investigators, those with negative culture results at baseline were ex-
cluded from the final analysis. 324 such trial participants were excluded.
For some unknown reason, the number of participants allocated to one
arm of the 2nd Hong Kong Study was only one fifth of the number allocated
to each of the other three arms (22 trial participants compared to 118, 123 and
129 participants in the other three arms). This arm was therefore excluded
from the analysis.
One patient enrolled into Study X was found to have already been en-
rolled in Study U (these two trials evidently overlapped in some sites) and
was therefore excluded from Study X.
This resulted in a total of 6974 trial participants included in the analysis.
4.4.3 Patterns of Missing Data
Each of the trials used for this analysis were conducted by the British MRC
over a period of around twenty years. Many of the same researchers, clini-
cians, lab technicians, microbiologists and statisticians were involved and the
trials had very similar laboratory and clinical protocols and were therefore
conducted in very much the same way. Most of the data elements recorded
for each individual were the same across trials, but some were measured in
only a subset of trials:
• Weight. The dosage of some drugs is dependent on a patient's weight. A
heavier patient will be given a slightly larger dose than a lighter patient.
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For this reason, weight is measured at randomisation and a trial partic-
ipant's treatment regimen tailored to this. Weight is also indicative of
the general health of a trial participant, underweight participants have
been found to have a greater chance of treatment failure (e.g. Benator
et al. (2002), see section 3.5.1). Weight has therefore been included as a
variable entered onto the database and was available on treatment cards
from all but one of the trials. It is clear from the published report of
the results of the trial where weights were not available (the third Hong
Kong study, Hong Kong Chest Service/British Medical Research Coun-
cil (1981)) that dosages were adjusted for trial participants' weight, but
an individual's weight does not appear to have been recorded on their
treatment card. The weight must have been recorded elsewhere and is
no longer available.
Trial Month 0 Month 4 Month 6
1. Study R .(
2. Study T .(
3. Study U .(
4. Study X .( .(
5. Study Y .( .(t
6. Tanzania .(t
7. Hong Kong 1 .( '('
8. Hong Kong 2 .(
9. Hong Kong 3 .(
10. Hong Kong 4 .(t
11. Singapore 1 .( .(t .(t
12. Singapore 3
"Unknown categorical scale used.
"Only extent of cavitation and not extent of disease was recorded at month 6 in this trial.
Table 4.4: Timings of assessments of radiographic extent of disease and cavi-
tation .
• Radiographic extent of cavitation and disease. Cavitation and extent of dis-
ease were assessed from chest x-rays at various timepoints during the
treatment period across the twelve trials. These measures were mostly
assessed on the same standard categorical scale: nil, trivial, slight, lim-
ited, moderate, extensive, gross. In some trials, this scale was not used
and a different system of coding (apparently a 26-point scale from A to
Z) was used. There is no documentation remaining of how this second
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scale corresponds to the first. Contact has been made with a number of
those involved in these trials, but there remains no explanation of how
to interpret this system of grading. Until an explanation is found, extent
of disease and cavitation will be considered as missing for these trials,
see Table 4.4 on the preceding page. In addition to this, no radiographic
measurements were recorded for the third Singapore trial at baseline or
at any other point during treatment.
• Race. Studies have suggested that TB patients from East Asia respond
slightly differently to some regimens compared to those from Africa
(see Fox et al. (1999)). It is not clear whether it is geographical or genetic
differences that contribute to these differences. Race (Chinese, Indian,
Malay or Eurasian) was only recorded in the two Singapore trials and
so will be of limited use in this analysis, but has been entered and is
available on the database.
• Isoniazid and Streptomycin Resistance. Resistance to isoniazid or strepto-
mycin based on cultures done before the start of treatment was marked
on a treatment card with a green H or a green S, or a green HS for re-
sistance to both. Susceptibility was not marked and so individuals with
missing baseline sensitivity tests were indistinguishable from those who
were found to be fully drug susceptible. All individuals not marked as
resistant to isoniazid or streptomycin are assumed to be fully susceptible
and therefore these two variables are non-missing.
• Rifampicin Resistance. One individual on the Tanzanian study and one on
the third Singapore study were marked as having Rifampicin resistance.
Rifampicin was developed later that the other anti-TB drugs and there-
fore did not see widespread use in any of these regions during the trial
periods. Drug resistance develops as a result of poor treatment com-
pliance and therefore cannot occur until that drug has been introduced
into clinical practice. For this reason, in most of these trials, there was
no procedure written into the trial protocol for identifying rifampicin
resistance. Itwas therefore decided that these two individuals were the
result of laboratory errors and the entire population was taken to be
rifampicin-susceptible.
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4.4.4 Baseline Summary Tables
After the exclusions detailed in the previous section, 6974 individuals aIIo-
cated to 49 treatment arms across 12 trials were included in the data to be
used for the analysis. Table 4.5 gives the breakdown by trial. Duration of
follow-up is given in months after the end of treatment. East African studies
had centres in Kenya, Tanzania, Uganda and Zambia.
Patients
Location Year of Duration Regimens Randomised
of Centres Start of Follow-up Included and Included
1. East Africa 1970 24 months 4 761
2. East Africa 1972 24 months 4 902
3. East Africa 1974 24 months 4 421
4. East Africa 1976 24 months 5 310
5. East Africa 1978 24 months 3 533
6. Tanzania 1979 24 months 2 296
7. Hong Kong 1972 24 months 3 246
8. Hong Kong 1974 18 months 3 369
9. Hong Kong 1977 18 months 5 1142
10. Hong Kong 1979 18 months 8 1489
11. Singapore 1973 24 months 2 198
12. Singapore 1983 24 months 6 307
Total I 49 6974
Table 4.5: Summary of data for final analysis.
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Figure 4.1: Histograms of weight by geographical region.
Table 4.6 on page 117 summarises the baseline characteristics of the in-
dividuals included in the analysis data. All were assessed and recorded at
enrolment prior to initiation of treatment. The distribution of weights does
not differ substantially between trials and is characterised across geographi-
cal regions by the Gaussian bell-shaped curve as shown in Figure 4.1. These
bell-shaped curves are representative of the histograms of weight within indi-
vidual trials in that geographical region.
A larger proportion of streptomycin resistance was seen in the Hong Kong
trials with very little drug resistance seen in the Singapore trials (see 4.2 on
the following page). There is no evidence of increased resistance over time as
might be expected with the increased availability of these drugs over time.
There were a larger number of males enrolled and this is seen across all
trials with the proportion of males slightly greater in the Hong Kong trials.
The age distribution differs between geographical regions as shown in the
population pyramids in Figure 4.3 on page 121 (each typical of the population
pyramids of the individual trials from those regions). A larger number of
males over fifty and fewer individuals of both sexes in their twenties and
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Figure 4.2: Drug resistance patterns by trial.
thirties were enrolled in Hong Kong trials as compared to the East African
trials. It is likely that this is a feature of the demographics in each of these
populations from which TB patients are drawn rather than a difference in
the actual process of enrolment. There are comparatively too few individuals
from the Singapore trials to draw any conclusions from this region.
Table 4.7 on page 118 (and figure 4.4) summarise the radiographic extent
of cavitation and disease assessed before the start of treatment, and show
the severity of cavitation and disease varies between trials. It appears that
cavitation and disease was more serious in the East African trials compared
to the trials conducted in East Asia. Since the trials were conducted under
the same sponsor of the MRC and used very similar trial protocols, it seems
likely that these differences are due to real difference in severity of disease of
participants enrolled in the studies rather than differences in the grading. It is
also clear that the differences are not limited to geographical region, but there
are differences in the severity of disease and cavitation between trials in the
same region. Figure 4.5 on page 122 shows the distributions of sputum smear
and culture gradings at enrolment.
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Figure 4.3: Distribution of age and sex by geographical region.
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4.4.5 Longitudinal Data During Treatment
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Table A.l on page 248 shows the total numbers culture positive and culture
negative at each month during treatment in each geographical region. Fig-
ure 4.6 on page 123 shows the proportions culture positive (among those with
a non-missing result) at each month during treatment by geographical region.
Overall, only 57% of participants with a non-missing culture result at month
1 had a positive culture and only 21% still had a positive culture at month
2. Patients in East Africa tended to culture convert later than those in Hong
Kong or Singapore. 70% of participants still had a positive culture at month 1
in East Africa compared to 46% and 51% in Hong Kong and Singapore respec-
tively. 29% of participants still had a positive culture at month 2 in East Africa
compared to 15% and 7% in Hong Kong and Singapore respectively. This dif-
ference in culture conversion rates between East Africa and East Asia is likely
to have an impact on the benefit of cultures during treatment as prognos-
tic and surrogate markers and so possible differences between geographical
regions will be explored in analyses in later chapters.
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4.5 Summary Data Analysis
4.5.1 Summary of Outcomes
Of the total number of participants included in the analysis, just under 10%
had a poor outcome. Proportions of poor outcomes ranged from 3% to 26%
across the twelve trials. Table 4.8 shows the breakdown of events by trial.
Overall, only 7% of participants had a missing outcome.
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treatment by geographical region.
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4.5.2 Analysis of Baseline Risk Factors
4.5.2.1 Time-to-event vs. Binary Outcome
As described in Table 4.3 on page 110, individuals can be classified as either
having a fair or a poor outcome (those with a missing outcome will be ex-
cluded from subsequent analyses) and the number of months to outcome is
also recorded in each case. One approach to analysing these data is to consider
the time to the event and perform a survival analysis.
In this dataset, a large number of individuals (5307, 76% of the total) com-
pleted follow-up with no recurrence of disease and were classified as having a
fair outcome. Even in the first Hong Kong study where no treatment arm in-
cluded rifampicin, all regimens were highly effective and the number of these
with a poor outcome was very few. This means that the time to the event was
unobserved for 76% of the individuals and some standard survival analysis
techniques (such as estimating the median survival time without extrapola-
tion) are not possible (since the survivor function never crosses the 0.5 mark).
It appears therefore that the analysis population contains a large proportion
of immunes, or long-term survivors-those individuals who will never have a
poor outcome. Maller and Zhou (1996) give a number of different methods
for analysing survival data with long-term survivors. These methods involve
using mixture distributions modelling the hazard of survival and the prob-
ability of being a long-term survivor separately. This would add additional
complexity to any time-to-event analysis.
In a TB trial, the endpoint of interest is a poor outcome of treatment-
either during or some time after completion of therapy. This is in contrast to
an oncology or an HIV trial where the endpoint is often death and a time-to-
event analysis is relevant. Under the WHO definitions of treatment outcomes
(World Health Organization, 2008), a TB patient classified as having a fair
outcome at the end of follow-up would be classified as cured. A TB treatment
is deemed to be beneficial if it reduces the number of poor outcomes rather
than merely delaying the onset of recurrence.
Therefore, while a time-to-event analysis might be the most natural ap-
proach, analyses considering poor outcome as a binary endpoint are clearly
of great value. A surrogate endpoint that can be a substitute for the binary
endpoint of poor outcome will still be extremely useful even if it proves to be
a poor surrogate for the time to that outcome. The analysis considering the
endpoint as a binary variable will be much less complex than that considering
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the endpoint as a time to failure. This means that, while a surrogate found for
poor outcome will be less comprehensive than that found for the time to poor
outcome, such a surrogate may be easier to find due to fewer restrictions and
the analysis will lead to a clearer conclusion that will be easier to interpret.
The analyses in subsequent chapters will therefore be focused on considering
poor outcome as a binary variable and analysed as such. These models will
be simpler and more powerful.
Continuous Covariates
95% Confidence
IntervalCovariate
Weight (per 10 kg) 0.86 0.77,0.97
Age (per 10 years) 1.29 1.22,1.36
Categorical Covariates
Sex Female I 1.00Male 1.78 (1.47,2.15)
Isoniazid Susceptible 1.00
Resistance Resistant 3.70 2.96,4.62
Streptomycin Susceptible 1.00
Resistance Resistant 2.45 1.88,3.18
Negative 1.00
Sputum Slight 0.89 0.56,1.41
Smear Medium 1.74 1.11,2.72
Heavy 2.90 1.88,4.48
1-19 Colonies 1.00
Sputum 20+ Colonies 0.89 0.49,1.60
Culture Innumerable Colonies 1.53 0.89,2.63
Confluent Growth 2.73 1.61,4.61
Nil 1.00
Extent of Slight 1.77 1.21,2.59
Cavitation Moderate 3.04 2.18,4.23
Extensive/Gross 6.44 4.54,9.15
Nil/Trivial/Slight 1.00
Extent of Limited 3.37 1.84,6.19
Disease Moderate 5.13 2.81,9.35
Extensive / Gross 9.17 (5.04,16.70
Table 4.9: Baseline characteristics as risk factors for a poor outcome. Odds
ratios are adjusted for differences between trial.
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4.5.2.2 Summary Tables
Table 4.9 on the previous page shows the odds ratios of treatment failure and
associated 95% confidence intervals for each of the baseline covariates. All
odds ratios are estimated from a mixed effects models including the trial ef-
fect as a random effect. Participants who are heavier, younger or female are
all more likely to have a fair outcome. As expected, baseline resistance to iso-
niazid or streptomycin were risk factors for treatment failure with a compar-
atively higher odds ratio for resistance to isoniazid. More serious grading of
radiographic extent of disease and cavitation were strong predictors of treat-
ment failure, more so than sputum lab results. Participants with extensive or
gross extent of disease had odds of treatment failure nearly nine times those
of participants with nil, trivial or slight disease. Participants with extensive
or gross cavitation had odds of treatment failure nearly six times those of
participants with nil cavitation.
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Figure 4.7: Estimate of Kaplan-Meier failure function by trial.
4.5.2.3 Analysis of Survival Time
Figure 4.7 shows the Kaplan-Meier estimate of the failure function and fig-
ure 4.8 on the next page the hazard function by trial. The failure function
is 1 - S(t) where S(t) is the Kaplan-Meier estimate of the survivor function.
Figure 4.8 suggests that the assumption of proportional hazards across trials
is reasonable. The hazard is not monotonic (and therefore does not follow a
127
.04
c
~
.03
~
u,
~~ .02
J:
i.01en
0 --_
0 10 20 30 40
analysis lime
1-- Individual Trials ----- Overall 1
Figure 4.8: Estimate of hazard function by trial.
distribution from the Weibul family), but is unimodal. The hazard increased
steeply to a peak around month 9 before decreasing to a low constant from
around month 18 onwards. This behaviour is consistent with the model of
treatment failure being a mixture of true relapse (almost all occurring within
twelve months of follow-up) and exogenous reinfection being observed as a
background constant instantaneous hazard (see section 3.4.1).
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Chapter 5
Culture Positivity as a
Prognostic Marker for Poor
Outcome
5.1 Introduction
Having described and performed some exploratory analyses of the data in
Chapter 4, the first step in evaluating a marker as a surrogate is to establish
its value as a prognostic marker. The second of the Prentice Criteria is that
the surrogate markers should have some 'prognostic implication' for the true
endpoint (see section 2.5 on page 38). A prognostic marker is one that can
be used for predicting outcome and therefore requires less strict criteria than
for a surrogate marker, which must capture the treatment effect on the true
endpoint. In the context of this thesis, the prognostic importance of culture
results as predictors of poor outcome must first be established using the trial
data before they can be evaluated as surrogates.
Validation of a prognostic marker involves looking at the association with
and prediction of the binary endpoint of poor outcome across treatment arms
controlling for the trial effect. In this chapter, culture positivity during treat-
ment will be explored as a prognostic marker pooling individuals across treat-
ment arms before validating this marker as a surrogate in Chapter 6.
As described in the previous chapter, sputum culture results were recorded
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on a semi-continuous scale ranging from negative to CG (confluent growth).
Historically in TB prognostic studies (e.g., Aber and Nunn, 1978; Mitchison,
1996), the culture result was only considered as a binary variable-positive or
negative. This approach leads to a loss of information, but is easier to use as
a marker in clinical practice and simplifies the evaluation process resulting in
a clearer interpretation. A positive culture indicates presence of mycobacteria
in the lungs while a negative culture indicates absence of detectable mycobac-
teria in the lungs. The number of colonies is thought to give an indication of
the bacillary load in the patient's lungs and is therefore more commonly given
the unit of colony forming units or CFUs. In this chapter, culture results will be
considered both as ordered categorical and as binary exploring whether the
loss of information in the latter is large.
One way to incorporate the number of CFUs into a binary variable is to
vary the point of dichotomy of the binary variable. A point of dichotomy of
11, for example, means classifying a CFU count of less than 11 a 'negative'
culture and classifying a CFU count of 11 or more as a 'positive' culture with
this binary variable being assessed as a marker. It might be suggested that
a low CFU count is no more predictive of poor outcome to treatment than a
negative culture (indeed, isolated scantily-positive cultures are not indicative
of failure; see section 3.5.3.2) and that they should be grouped together for
the prognostic marker. This may reduce the False Positive Fraction (FPF) of
the marker without substantially reducing the True Positive Fraction (TPF), see
section 2.4.2 for definitions. The effect of varying the point of dichotomy for
the binary marker is also explored in this chapter.
As described in Chapter 4, the data used in this thesis are from twelve
TB clinical trials conducted across East Africa and East Asia in the 1970s and
1980s. A total number of 6974 trial participant allocated to 49 treatment regi-
mens across the twelve trials were included.
5.2 Exploratory Methods
5.2.1 Introduction
In section 5.3, the Receiver Operating Characteristic curve (ROC curve) is used to
evaluate cultures at each of months 1, 2, 3 and 4 from the start of treatment
as prognostic markers for poor outcome. In this section, simpler, exploratory
methods are applied to the data to explore the value of culture results during
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treatment as prognostic markers for a poor outcome to treatment.
This section is divided into two parts. In the first (section 5.2.2), culture re-
sults are assumed to be categorical with 7 levels. In the second (section 5.2.3),
culture results are considered as binary, exploring the variation in the point
of dichotomy which leads naturally into section 5.3 bringing these results to-
gether in the ROC curve.
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Figure 5.1: Predicted probabilities of failure for culture results at months 1 to
4.
5.2.2 Cultures as Categorical
5.2.2.1 Methods
In this section, culture results are considered as categorical with 7 levels. These
levels are: Negative, 1-5, 6-10, 11-19, 20+ (20-100 colony forming units), IC
(Innumerable Colonies) and CG (Confluent Growth). It is expected that the
probability of a poor outcome will vary across trials and therefore the prob-
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ability of a poor outcome was modelled conditional on the culture results
using logistic regression, with clustering within trial being accounted for by
including a random intercept varying across trials. The model is as follows:
1=7
logitP(Tik = 1lSik) =a+ [,f3III(Sik)'
1=1
(5.1)
for individual k in trial i, where Tik is the is the binary outcome variable,
Sjk is the culture result taking values 51,52, ... ,57 and 11 (Sjk) is the indicator
function where:
I (S. ) = {1 if Sik = SI 1 1 7
I Ik O'f 5 _J. , =, ... , .
1 ik r SI
(5.2)
The clustering within trials was included in the model by including a ran-
dom intercept, u., letting a = a + Ui where u, '" N(O,(J2). A random slope
(adding random effects to each of the I'd has not been included since this
makes the model unnecessarily complex leading to instability and problems
with convergence.
5.2.2.2 Results
An ideal prognostic marker would be one with a very low (zero for a perfect
marker) predicted probability of poor outcome for negative cultures and a
very high (unity for a perfect marker) predicted probability for positive cul-
tures. A prognostic marker that could be used as a binary marker is one show-
ing a sudden increase in predicted probability, where this sudden increase is
at the point of dichotomy.
Figure 5.1 on the previous page shows the predicted probabilities of poor
outcome for each of the different categories of culture results at months 1 to
4. The thin solid lines are the predicted probabilities for the twelve individual
trials, the thick solid line is the predicted probability across trials and the
dashed line shows the overall proportion of participants with a poor outcome
observed for each culture result.
The thin solid lines show that there is great variability between trials, but
that the average across trials is a meaningful representation of the data. It is
clear that a culture result reflecting a higher bacillary load at a later month is
more predictive of poor outcome than a culture result an earlier month. This
suggests that individuals with heavily positive cultures at months 3 or 4 are
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highly likely to have a poor outcome to treatment.
A strong positive trend is apparent in Figures 5.l(b), 5.l(c) and 5.l(d). This
means that, at months 2, 3 and 4, the predicted probability of poor outcome
increases with increasing levels of CFUs measured. Therefore, not only is the
presence of Mycobacteria tuberculosis in an individual's sputum during treat-
ment prognostic of a poor outcome, but a higher number of CFUs corresponds
to a greater prognostic value. This is seen across all of months 2 to 4 to a lesser
or greater extent.
The slope of the line of the overall predicted probability in Figure 5.1(a)
(month 1) is shallow showing that a positive culture is not a much better
predictor than a negative culture. An increase is seen after 11-19 suggesting
that a CFU of less than 20 at month 1 is not prognostic of poor outcome, but
a CFU of 20+, IC or CG is more prognostic of poor outcome. However, the
predicted probabilities are small for results of 20+, IC or CG at month 1.
For the month 2 culture, the line of the average across trials is steeper from
20+ colonies suggesting that there is a difference in the prognostic value be-
tween heavily positive (more than 100 colonies) and more scantily positive
cultures. This suggests that the binary variable dichotomised at 100 colonies
could be a useful prognostic marker, but the predicted probability is not in-
significant for cultures of less than 100 colonies and therefore grouping these
with negative cultures is questionable.
The lines for months 3 and 4 are steeper from the start with the same
small predicted probability of poor outcome for a negative culture. The pre-
dicted probability of a poor outcome differs greatly between a negative culture
and the various levels of a positive culture and this suggests that cultures at
months 3 and 4 are good prognostic markers. It was seen in Chapter 4 that
there are few individuals with positive cultures at months 3 and 4 (7% and 4%
overall respectively, see table A.l on page 248), and fewer with heavily posi-
tive cultures, making the use of these as prognostic markers impractical. This
aspect, the actual numbers of participants with a particular culture result, is
not captured by the predicted probability and it is therefore important to look
at other measures of prognostic value. Other measures are considered below.
It is interesting to note that the predicted probabilities for between 1 and
5 colonies across all four of these graphs is greater than that for a negative
culture. This means that individuals with scanty colonies at any month are
more likely to fail treatment than those with no positive cultures, even if this
difference is small (particularly at month 1). Whilst it has been shown in
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previous studies that isolated scantily-positive cultures during follow-up are
not indicative of a poor outcome (see section 3.5.3.2), these data suggest that
patients with scantily-positive cultures during treatment might be more likely
to have a poor outcome to treatment than those with a negative culture.
5.2.3 Cultures as Binary
5.2.3.1 Methods
In this section, the culture result is considered as a binary variable exploring
the effect of varying the point of dichotomy. Where the point of dichotomy
is given as 11, for example, this means that all individuals with l l or more
colonies are counted as being 'culture positive' and those with 10 colonies or
less as being 'culture negative'.
As described in section 2.4, measures to evaluate binary prognostic mark-
ers can be calculated empirically from the data or estimated from a parametric
model. The latter is preferable as it allows for adjusting for covariates or clus-
tering using random effects.
In this section, four different sets of measures will be used to evaluate
culture results as prognostic markers and the different results compared.
1. Odds Ratios. The standard measure of effect summarising the association
of explanatory variables with outcome in a logistic regression model is
the odds ratio. The odds ratio express the ratio of odds of a poor out-
come given a positive culture against the odds given a negative culture.
While popular, the odds ratio is not an appropriate measure to evaluate
a prognostic marker (Pepe, 2003), but is useful as it reflects the associa-
tion between the markers and a poor outcome.
2. Pseudo-R2 Statistics. In linear regression, the R2 statistic measures the
proportion of variation in the response variable that is captured by the
explanatory variables. This measure does not naturally follow in logistic
regression, but a number of different pseudo-R2 measures have been pro-
posed (see section 2.4.4) and the four most useful are used to evaluate
culture results as prognostic markers.
3. True and False Positive Fractions (TPF and FPF). The TPF (often called the
sensitivity) and the FPF (equal to the specificity subtracted from one) are
the most common measures for evaluating prognostic markers. The TPF
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is the proportion of those with a poor outcome that have a positive cul-
ture result and the FPF is the proportion of those with a fair outcome
that have a positive culture result. A good marker is one with a high
TPF and low FPF. Increasing the point of dichotomy leads to classifying
less individuals as culture positive and results in a decreased FPF at the
expense of a decreased TPF.
4. Positive and Negative Predictive Values (PPV and NPV). The PPY and the
NPY are also common in prognostic studies. The PPY is the proportion
of those with a positive culture result that have a poor outcome and the
NPY is the proportion of those with a negative culture result that have a
fair outcome to treatment. Unlike the TPF and the FPF, the PPY and the
NPY are affected by the prevalence of the outcome that the markers are
intended to predict. It is therefore important that both the TPF and FPF
and the PPV and NPV are examined in a prognostic study.
To calculate the odds ratio, pseudo-Re statistics and positive and negative
predictive values for poor outcome to treatment, the following model is used:
logit P(T = liS) = tl:l + f31 S. (5.3)
Here, the probability of a poor outcome (T = 1) is modelled conditional on
the binary culture result, S. To calculate the true and false positive fractions,
the following model is used:
logit P(S = liT) = tl:2 + f32 T. (5.4)
Here, the probability of a positive culture result (S = 1) is modelled condi-
tional on the treatment outcome, T. Functions of the parameters, tl: and f3,
are used to estimate these measures in each case using the methods that are
described in more detail in section 2.4. In these data, patients are clustered
within trials. Mixed effects logistic regression models are used to adjust for
this clustering. Random effects are added to both models as follows:
(5.5)
(5.6)
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for trial i. The random effects are assumed to be independent (using the
independent covariance structure).
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Figure 5.2: Odds ratios of poor outcome for culture results at dif-
ferent points of dichotomy for months 1 to 4 plotted with 95%
confidence limits. The point of dichotomy is given on the hor-
izontal axis. Plotted points have been perturbed slightly in the
horizontal for clarity of presentation.
5.2.3.2 Results
5.2.3.2.1 Odds Ratios The odds ratio of poor outcome on the log scale for
different points of dichotomy is shown in Figure 5.2, plotted with 95% Wald
confidence limits.
From the graph it can be noted that the estimates of the odds ratios are very
large and the widths of the confidence intervals are generally very small. The
large amount of data (from nearly 7000 trial participants) results in the narrow
confidence intervals giving very precise estimates of the odds ratios (except
when the point of dichotomy is large). As the point of dichotomy increases,
the proportion of patients with a positive culture decreases and therefore the
width of the confidence interval grows. The width of the confidence interval
is also larger for later months for a similar reason. Very few participants
have heavily positive cultures beyond month 1 and therefore the confidence
intervals for a point of dichotomy of CG are particularly large for months 2, 3
and 4.
The point estimates of the log-odds ratios are greater for later months
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and also increase with point of dichotomy, particularly for months 2, 3 and
4. Considering a point of dichotomy of 1, the odds of a poor outcome for a
patient with a positive culture at month 2 is 3.8 times that for a patient with
a negative culture, and this ratio increases to 8.2 for cultures at month 4 and
for a point of dichotomy at CG at month 2, the odds ratio is 10.3.
Considering the traditional binary variable (a point of dichotomy at 1),
the confidence intervals for each of the cultures are very narrow giving good
evidence for the odds ratio of a poor outcome for the culture result at month
4 being greater than that at month 3 which in turn is greater than that at
month 2 which is greater than that at month 1. No longitudinal analysis
was conducted to formally compare the odds ratios at different months, these
conclusions are based on estimates from separate models and so can only be
approximate. Nevertheless, the differences are striking. The point estimates
do separate a little as the point of dichotomy increases, but the width of the
confidence intervals also increases.
Despite these wide confidence intervals, all of the 95'10confidence intervals
exclude an odds ratio of 1 giving evidence of varying strength that all of these
markers (at each month with each point of dichotomy) are strongly associated
with a poor outcome and fulfil the requirement stated at the beginning of this
chapter that the marker should have 'some prognostic implication for the true
endpoint'.
5.2.3.2.2 Explained Variability: Pseudo-R? Statistics Figure 5.3 shows each
of the four pseudo-Re statistics introduced in section 2.4 for the different
points of dichotomy for months 1,2,3, and 4.
Overall, the plotted lines are largely flat or decreasing as the point of di-
chotomy is increased. There is some suggestion that a point of dichotomy of
6 gives marginally greater values of R2 than at 1, particularly in Figures 5.3(b)
and S.3(d). In all four graphs, each of the four the lines representing culture
results at each of months 1 to 4 were close to each other, and there is no con-
sensus across the different pseudo-Re statistics as to which monthly culture
result is superior with a different marker being suggested to be superior by
each R2 statistic.
Apart from the Count R2, all of the plotted points are below the line
R2 = 0.2. If these pseudo-Re statistics are in any way equivalent to the OLS
R2 then this suggests that less than 20% of the variation is explained by the
culture result despite the very high odds ratios presented in the previous sec-
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Figure 5.3: Various pseudo-R? assessing the explained variability of models
for culture results at months 1 to 4, for different points of dichotomy.
tion. This demonstrates how important it is to consider different measures
when evaluating culture results as prognostic markers. The Count R2 values
are very close to the overall prevalence of a fair outcome (89.3%), excluding
those with a missing outcome. If we consider a hypothetical marker that clas-
sifies all participants as having a fair outcome, each of these markers correctly
identify the outcome in only a fraction more participants than this completely
uninformative hypothetical marker.
5.2.3.2.3 True and False Positive Fractions Figure 5.4 on the following page
shows the true positive fraction (TPF) and false positive fraction (FPF) for different
points of dichotomy at different months. All these are estimated from the
parametric model (equation 5.4) which models the probability of a positive
culture conditional on the treatment outcome. The number of colonies on
the horizontal axis is the point of dichotomy. The thin solid lines show the
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Figure 5.4: True Positive Fraction (TPF) and False Positive Fraction (FPF) for
culture results for different points of dichotomy for months 1 to 4. The point
of dichotomy is given on the horizontal axis.
estimates of TPF and FPF for each trial and the thick dashed line shows the
overalI estimates of TPF and FPF across alI twelve trials.
The lines for the individual trials show that the overall curve is represen-
tative of curves for individual trials. There is greater variability across trials
in TPF than in FPF, due to the considerably smaller numbers of participants
with a poor outcome than with a fair outcome.
It is clear from Figures 5.4(c) and 5.4(d) that the FPF at months 3 and 4
is very low, however the TPF is unacceptably low. Considering a point of
dichotomy of one, an individual with a fair outcome will almost certainly
have a negative culture at month 3 or month 4 (and therefore the FPF is very
low), but too few participants with a poor outcome have a positive culture.
At a point of dichotomy of one, only 19% of individuals who have a poor
outcome to treatment have a positive culture at month 3 and only 15% have a
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positive culture at month 4 (see Table 5.1).
Point of Dichotomy
1 20+ Ie
TPF FPF TPF FPF TPF FPF
Month 1 80% 56% 55% 30% 24% 9%
Month 2 40% 15% 13% 3% 5% < 0.5%
Month 3 19% 4% 8% 1% 4% < 0.5%
Month 4 15% 2% 10% 1% 7% < 0.5%
Table 5.1: True Positive Fraction (TPF) and False Positive Fraction (FPF) at
different months for three different points of dichotomy.
At a point of dichotomy of one, the TPF at month 2 is improved compared
to that at months 3 or 4, but the FPF is also slightly increased. Of those
individuals who go on to have a poor outcome, 40% have a positive culture
at month 2. However, it still means that 60% of those individuals with a
poor outcome will not be identified by the month 2 culture. At month 1, of
those individuals that fail treatment, 80% have a positive culture at a point
of dichotomy of one, but 56% that have a fair outcome also have a positive
culture.
Table 5.1 also shows the TPF and FPF for a point of dichotomy at 20+ and
a point of dichotomy at Ie. At month 1, a point of dichotomy of 20+ yields a
TPF of 55% with a moderate FPF of 30% which is more acceptable than that
at a point of dichotomy of one.
5.2.3.2.4 Positive and Negative Predictive Values The positive predictive value
(PPV) and the negative predictive value (NPV) are estimated from the parametric
model (equation 5.3) modelling the probability of a poor outcome conditional
on the culture result.
Figure 5.5 on the following page shows the PPV and NPV of culture as a
binary variable for different points of dichotomy for months 1 to 4. The thin
solid lines are the values of the PPV and NPV for the twelve individual trials
and the thicker dashed line is the overall PPV and NPV estimated across all
trials.
One additional point is plotted for each graph, the PPV and NPV for the
logistic models containing the trial effect only (labelled Null model on the hori-
zontal axis). From this model, the PPV is effectively an estimate of the propor-
tion of the whole population that go on to have a poor outcome to treatment
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Figure 5.5: Negative Predictive Value (NPV) and Positive Predictive Value
(PPV) for different points of dichotomy for months 1 to 4. The point of di-
chotomy is given on the horizontal axis.
and the NPV of the proportion of the whole population that go on to have a
fair outcome to treatment. The PPV for this point can be interpreted as the
crude diagnostic test of classifying all individuals as having a poor outcome
and the NPV as the crude diagnostic test of classifying all individuals as hav-
ing a fair outcome. They can therefore be considered as reference values for
the PPV and the NPY. Since the PPV and NPV are affected by the prevalence
of a poor outcome and must be interpreted with reference to this. The overall
prevalence of a fair outcome 89.3% is also plotted as a reference line
Looking across all months and the different points of dichotomy, the NPV
estimated across trials is only marginally greater than the overall proportion
of fair outcomes with the highest NPV being with the point of dichotomy at
1 (also see Table 5.2 on the next page). With such a high proportion of fair
outcomes, it is hard to interpret the NPV.
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Point of Dichotomy
Null Model 1 20+ IC
PPV NPV PPV NPV PPV NPV PPV NPV
Month 1 10% 90% 14% 95% 18% 93% 24% 91%
Month 2 10% 90% 22% 93% 33% 91% 52% 90%
Month 3 10% 90% 37% 92% 57% 91% 66% 91%
Month 4 10% 90% 46% 91% 74% 91% 88% 91%
Table 5.2: Positive Predictive Value (PPV) and Negative Predictive Value
(NPV) at different months for three different points of dichotomy.
The shape of the plot of the PPV is not dissimilar to the plots in Figure
5.1 which shows the predicted probability of a poor outcome conditional on
the culture lying in the specified range. Here, a point on the graph shows the
predicted probability of a poor outcome conditional on a culture greater or
equal to the corresponding point of dichotomy.
The slope of the PPV is greater for later months. At month I, the PPV is
fairly flat showing that the culture result at month 1 is not highly predictive
of poor outcome. At month 2, the PPV for a point of dichotomy of one is
22%-only 22% of those with a positive culture at month 2 go on to have a
poor outcome to treatment. This compares with 37% and 46% at months 3 and
4 respectively. It is clear from Figures 5.5(c) and 5.5(d) that a highly positive
culture at months 3 or 4 is highly predictive of poor outcome. Since the NPV
hardly varies, on the basis of predictive values along, one would select the
month 4 culture with a point of dichotomy at IC yielding at PPV of 88% and
a NPV of 91%.
5.3 Receiver Operating Characteristic Curve
Figure 5.6 on the following page shows the receiver operating (ROC) curves
for sputum culture results at each of months 1 to 4 during treatment. The
TPF and FPF are estimated for every possible point of dichotomy and plot-
ted separately for each month. The TPF and FPF are estimated as in section
5.2.3.2.3 (equation 5.4), modelling the probability of a positive culture given
the true outcome including a random effects intercept term in the model to
allow for clustering within trials. A binormal curve is fitted to the data points
as described in section 2.4.3.1, and this is shown on each graph.
It is immediately clear from the graphs is the ROC curves are very short.
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Figure 5.6: Receiver Operating Characteristic (ROC) Curve for culture results
as prognostic markers at months 1 to 4.
At month 1, there is no point of dichotomy giving a TPF of greater than 0.8
and this limit drops to 0.4 at month 2 and below 0.2 for months 3 and 4.
For each of these graphs, the point with the largest TPF corresponds to a
point of dichotomy of 1. This indicates that a not insubstantial proportion of
individuals with a poor outcome have a negative culture at month 1 with this
proportion increasing steadily over months 2, 3 and 4.
The fit of the binormal curve is good for months 1,2 and 3 (R2 = 0.99 in
each case). The fit is less good at month 4 (R2 = 0.83) and this is suggested
by the non-symmetric fitted curve actually crossing the chance line around
FPF = 0.96 in Figure 5.6(d). All of the fitted curves at months 2 to 4 require
considerable extrapolation and rely heavily on the assumption that the binor-
mal curve is the most correct model, and therefore too much weight should
not be placed on the AVe.
Table 5.3 on the following page shows the area under the fitted curve
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Month AUC
95% confidence
interval
1 0.68 (0.66,0.70)
2 0.70 (0.64,0.75)
3 0.74 (0.60,0.82)
4 0.68 (0.54,0.82)
Table 5.3: AUC for fitted binormal curve
(AVC) with 95% bootstrap confidence intervals. The confidence intervals
were bias-corrected using 1000 bootstrap repetitions (Carpenter and Bithell,
2000). Only six different points of dichotomy (1, 5, 10, 20, IC and CC) were
used to calculate the confidence intervals as the bootstrap procedure for all
22 points of dichotomy was too computationally intensive. Since an unin-
formative marker has ROC curve equal to the chance line with AUC 0.5, the
AVC lies in the range [O.5,l.O]. All of these AUCs are small with the curve
lying close to the chance line. This shows that none of these markers are par-
ticularly effective prognostic markers. The AUC is the largest for month 3,
but they are all very similar across the four months with wide, overlapping
confidence intervals.
5.3.0.3 Summarising Culture Results across months 2 to 4
The proportion of individuals with a fair outcome to treatment that have a
positive culture at month 3 or 4 (the FPF) is small, but the proportion of
individuals with a poor outcome that have a positive culture (the TPF) is also
small. Compared to the culture result at 2 months, the summary marker of
the heaviest culture in month 2, 3, or 4, is likely to have a higher TPF without
a considerable increase in FPF since the FPF at months 3 and 4 is so low.
Figure 5.7 on the next page shows a selection of the graphs from previous
sections plotted for the summary marker of the heaviest culture in months 2,
3 or 4.
Comparing the odds ratios in Figure 5.7(a) with those for the 2 month cul-
ture Figure 5.2 on page 136, the estimates are larger with the 95% confidence
interval for the point of dichotomy at CG much narrower. The PPV for the
heaviest culture at months 2, 3 or 4 is marginally greater than that for the
2 month culture at each point of dichotomy and the pseudo-R'' statistics are
still very low. Comparing Figure S.7(c) on the next page with Figure S.4(b)
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Figure 5.7: Odds ratios, PPV, NPV, TPF, FPF and pseudo-Rf statistics for the
marker of the heaviest culture at 2, 3 or 4 months,
on page 139, the shapes are very similar with higher overall TPF (47% com-
pared to 40% at a point of dichotomy of 1) with only a slight increase in FPF
(17% compared to 15% at a point of dichotomy of 1, see Table 5,4), The ROC
curve is still close to the chance line and the area under the fitted binormal
curve (AUC) is only 0,71 (95% confidence interval (0.67, 0.75», larger than the
2 month culture result but not the 3 month culture result.
5.4 Discussion
5.4.1 Introduction
The results and graphs in this chapter give a variety of perspectives on the
same research question and need to be combined to properly evaluate culture
results during treatment as prognostic markers. A perfect prognostic marker
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Point of Dichotomy
1 20+ Ie
TPF 47% 19% 11%
FPF 17% 4% <0.5%
PPV 23% 36% 57%
NPV 94% 92% 91%
Table 5.4: True Positive Fraction (TPF), False Positive Fraction (FPF), Positive
Predictive Value (PPV) and Negative Predictive Value (NPV) for the marker
of the heaviest culture at months 2 to 4.
will correctly predict the outcome for all individuals. None of the markers
being evaluated in this chapter achieve this, so it is a matter of comparing
the different markers on the basis of the measures discussed in the preced-
ing sections to identify the most useful prognostic markers, and those which
should be taken forward in subsequent chapters to be evaluated as surrogate
markers.
5.4.1.1 The Prentice Criteria
As noted at the beginning of this chapter, the second of the Prentice Criteria
is that the surrogate markers should have some 'prognostic implication' for
the true endpoint. The author expressed this criterion (Prentice, 1989) for a
time-to-event true endpoint, T, and a continuous surrogate endpoint,S, as:
AT(t; 5) t AT(t), that is that the surrogate should have some effect on the
hazard of failure. This can be expressed similarly for a binary true endpoint,
T, and a binary or continuous surrogate,S, as: P[T = 115] =1= P[T = 1]. The
null hypothesis, Ho : P[T = 115] = P[T = I], is equivalent to the null hypoth-
esis, Ho : b1 = 0, where b1 is the log odds ratio of a poor outcome comparing
levels of the binary surrogate from Equation 5.3 on page 135 (see also Equa-
tion 5.6). The odds ratios comparing the levels of the binary culture results
at months 1 to 4 for different points of dichotomy are shown in Figure 5.2
on page 136. For each point of dichotomy at each month, the estimate of the
odds ratio and the widths of the 95% confidence intervals vary widely, but
all of the confidence intervals exclude 1. There is strong evidence against the
null hypotheses, Ho : exp(b1) = I, can be rejected in each case. On this basis,
each culture result at each point of dichotomy formally meets the first Pren-
tice criterion and can therefore be taken forward to be evaluated as surrogate
markers. The odds ratios do not tell the whole story and therefore only a
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selection of the best of these markers will be taken forward to be evaluated as
surrogates.
5.4.1.2 False Positives and False Negatives
The term false positive refers to those who are incorrectly identified as having
a poor outcome and false negative refers to those who are incorrectly identified
as having a fair outcome. Each of the markers discussed in this chapter lead to
a varying number of false positives and false negatives. The ideal marker will
have no false negatives or false positives; but if this is not possible, what is
the relative 'cost' of a false positive as compared to a false negative? In clinical
trials in modern settings, recurrence rates are commonly no more than 10%
(Nunn et a1. (2008) identify this as a conservative estimate). The purpose of
a prognostic marker will be to identify these 10% of individuals as early as
possible without the need of a long period of follow-up. If an individual
is identified early as being likely to ultimately have a poor outcome, their
combination of drugs can be changed or the duration of treatment extended.
For an individual who will relapse but is not picked up (a false negative),
retreatment is possible (the WHO recommended retreatment regimen costs
between US $15 and US $30 compared to the first-line regimen costing be-
tween US $10 and US $20, World Health Organisation (2003» but only after
the individual has manifested symptoms of recurrence and sought medical
help. This could be at considerable loss of quality of life of the individual and
they could die before retreatment was started.
For an individual who will not have recurrence but has been identified
by the marker as having a poor outcome (a false positive), treatment will be
extended or changed. The burden of treatment for the individual will be
increased (unnecessarily so, as the individual will not have recurrence) as will
any possible side-effects.
While both are undesirable, a case could be made that a false negative will
be more 'costly' to both the patient and the national tuberculosis programme
than a false positive. It is more important to make every effort to identify
those who will ultimately have a poor outcome at the expense of wrongly
classifying a few who will have a fair outcome. Using this argument the false
positive fraction (TPF) holds more weight that the false negative fraction (FPF)
in comparing prognostic markers and this will guide the discussion in this
section.
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5.4.2 Comparing Markers
Odds ratios were high with 95'X,confidence intervals excluding 1 for all mark-
ers showing that all markers were strongly associated with poor outcome, but
not necessarily that any were good prognostic markers. Pseudo-Re statis-
tics were all low. As discussed in section 2.4, each of these statistics were
developed for a mixed logistic model to mirror the proportion of variation
explained, R2, from linear regression. However, none are completely equiv-
alent to the R2 from linear regression and it is therefore not straightforward
to interpret these. Nevertheless, these pseudo-Re statistics do suggest that
none of the markers capture a high proportion of the variation in treatment
outcome. Prognostic markers are more usefully compared using the TPF, FPF,
PPV, NPV and the ROC curve.
5.4.2.1 Month 2 Culture
From other studies looking at predictors of long-term outcome for treatment
for tuberculosis summarised in section 3.5, the month 2 culture result has
been thought to be the most useful marker. The odds of a poor outcome to
treatment for a patient with a positive culture at 2 months are nearly four
times those for a patient with a negative culture at 2 months (see Figure 5.2
on page 136). Despite this, in these data, the 2 month culture has a TPF of only
40% at a point of dichotomy of 1 reducing to 1% as the point of dichotomy
increases. At a point of dichotomy of 1, the PPV is 22%. At the individual
level, this means that only 40% of those with a poor outcome to treatment
have a positive culture at 2 months and only 22% of those with a positive
culture at 2 months go on to have a poor outcome to treatment.
The 2 month culture does not discriminate well between long-term poor
and fair outcomes of treatment and this is shown by the short ROC curve
and a low AVC for the fitted binormal curve. Nevertheless, it appears that
it may be better than either earlier or later months (see below) and due to its
prevalence in the literature, the two month culture at a point of dichotomy of 1 will
be taken forward to be evaluated as a surrogate marker.
5.4.2.2 Months 3 and 4 Cultures
Only 7% of the 6974 individuals across the twelve trials had a positive culture
at 3 months and only 4% at 4 months (see Table Al on page 248). It is there-
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fore unlikely that cultures at either of these months will be useful prognostic
markers.
The TPF for the culture result at month 3 at a point of dichotomy of 1 is
only 19% and at month 4 is 15%, though the FPF are also low at 4% and 2%.
At the same point of dichotomy of 1, the PPV at month 3 is 37% and at month
4 is 46%.
The slope of PPV at months 3 and 4 is steep (Figure 5.5 on page 141; the
slope is similarly steep for the predicted probabilities considering the culture
result as continuous, Figure 5.1 on page 131), rising in each case to an approx-
imate plateau around a point of dichotomy of 11. This indicates that a culture
result at month 3 or 4 with a higher point of dichotomy may be a better prog-
nostic marker, but the TPF drops off sharply (Table 5.1 on page 140) to 8% for
month 3 and 10% for month 4 at a point of dichotomy at 20+, making the use
of either marker unfeasible.
The AVC for the fitted binormal ROC curve at month 3 is the greatest
(even than month 2), though the 95% confidence interval is wide (since the
ROC curve is very short).
There are more positive cultures at month 3 than at month 4 and therefore,
the three month culture at a point of dichotomy of 1 will be taken forward to be
evaluated as a surrogate marker. The four month culture will not be included in
the analyses of surrogate markers in subsequent chapters.
5.4.2.3 Month 1 Culture
At a point of dichotomy, the month 1 culture was found to have a too high
FPF of 56%. The plot of the PPV across points of dichotomy was flat but
rising with point of dichotomy. At a point of dichotomy of 20+ the TPF is
55%, higher than that for the 2 month culture at any point of dichotomy, and
the FPF is a reasonable 30%. While a positive culture at a point of dichotomy
of 1 at month 1 is not strongly prognostic of a poor outcome, a heavily positive
culture (20+ or greater) at month 1 does discriminate better between fair and
poor outcomes and could be a passable prognostic marker. Therefore, the one
month culture at a point of dichotomy of 20+ will be taken forward to be evaluated as
a surrogate marker.
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5.4.2.4 Summary Marker: Heaviest Culture in Months 2-4
Compared to the month 2 culture, the summary marker of the heaviest culture
at month 2, 3 or 4 was shown to have superior TPFs for the different points
of dichotomy at only a marginal increase in the corresponding FPFs and also
a superior AVC for the fitted binormal ROC curve. This marker appears to
be a better prognostic marker, although it may not be as useful in practice as
the 2 month culture. The earlier availability of the 2 month culture result may
offset the slim benefit in discrimination of the heaviest culture from months 2
to 4. This marker will therefore not be taken forward to be evaluated as a surrogate
marker.
5.4.2.5 Receiver Operating Characteristic Curve
As shown in figure 5.6 on page 143, the ROC curves for cultures at months 2, 3
or 4 were very short showing the TPF and FPF even for a point of dichotomy
of 1 was still low. These results suggest that the culture result after month
1 using solid media does not capture enough of the disease action to be of
great use, but that perhaps a culture method that is more sensitive in identi-
fying low colony counts, perhaps a liquid culture method (although there is
disagreement about whether liquid culture is more sensitive or is measuring
a different population, see section 3.2.5.1), could yield a higher TPF and be a
better marker.
5.4.3 Conclusions
All of the markers evaluated in this chapter at each point of dichotomy satis-
fied the second Prentice criteria that there was some association between the
marker and the true endpoint. Nevertheless, not all were useful prognostic
markers and only three will be taken forward in subsequent chapters to be
evaluated as surrogate markers:
1. the two month culture at a point of dichotomy of 1,
2. the three month culture at a point of dichotomy of 1, and
3. the one month culture at a point of dichotomy of 20+.
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Chapter 6
Culture Positivity as a
Surrogate Marker for Poor
Outcome
6.1 Introduction
In the previous chapter, culture results at months 1, 2, 3 and 4 were evaluated
as prognostic markers for poor outcome. Results indicated that culture results
at months 2 and 3 were strongly associated with the endpoint of a poor out-
come, but were only fair prognostic markers on the basis of the ROC curve.
The point of dichotomy of 1 was favoured for both these cultures. The culture
result at month 3 was found to be marginally superior as a prognostic marker
than the 2 month culture. The point of dichotomy of 20+ for the month 1 cul-
ture (classifying all cultures 20+ or higher as positive and 19 colonies or lower
as negative) was also found to be a passable prognostic marker. Therefore,
these three markers: culture positive at month 2, culture positive at month 3 and
heavily culture positive at month 1, will be taken forward in this chapter to be
evaluated as surrogate markers. In this chapter, a positive culture at month 2
or at month 3 will be for a point of dichotomy of 1 and a positive culture at
month 1 will be for a point of dichotomy at 20+ unless otherwise explicitly
stated.
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6.1.1 Treatment Ordering
Not all of the trials that yielded data for the analyses in this thesis included
an obvious control regimen against which the other regimens were compared.
The trials formed part of a larger research programme evaluating the most
effective tools for the treatment of TB and were often linked, with each trial
building on final, and sometimes interim, results of previous trials. A surro-
gate endpoint is one which captures the difference on the final endpoint be-
tween two treatments in a treatment comparison and it is therefore necessary
to identify one regimen from each trial as a nominal 'control' so that treatment
comparisons from that trial can be defined in relation to this regimen. In each
trial, the regimen that has the highest proportion of poor outcomes (the regi-
men of least efficacy) is identified as the control. This is so that the difference
in risk of poor outcome between the experimental and control regimens is
greatest and therefore the treatment ordering is such that the most amount of
information is available for evaluating culture results as surrogate endpoints.
The only exception to this is in the fourth East African study (Study X, see
section 4.1.1.3.1 on page 101) where the 2HRZ/4H regimen is identified as
the control regimen. This is so that the intensive phase (the first two months)
of treatment of the nominal control regimen is different to that of each of the
experimental regimens.
6.1.2 Treatment comparisons included
These data are from 12 trials, comprising 49 treatment regimens, giving a total
of 37 treatment comparisons.
The initial 2 month intensive phase in each regimen in three of these trials
(East African study Y, the Tanzanian study and the first Singapore study) is
the same (SHRZ in each case) and therefore it is not possible for the culture
result at month lor at month 2 to capture any of the treatment effect in the risk
of poor outcome as the treatment difference only occurs in the continuation
phase after the end of the second month. Therefore, these four comparisons
are excluded from analyses evaluating month 1 and month 2 culture positivity
in this chapter. In addition, the two regimens in one comparison in the third
Singapore study had the same combination in the first month (S with the
combined formulation of HRZ) and was therefore excluded from analyses
evaluating month 1 culture positivity in this chapter.
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No patients allocated to the control regimen (2SHRZ/4HR) in the first Sin-
gapore study, or to the 2HRZ/4H3R3 regimen in the third Singapore study
had a positive culture at three months and therefore the log odds ratio of a
positive culture at three months could not be estimated for these two treat-
ment comparisons. Analyses evaluating month 3 positivity in this chapter
therefore did not include these two treatment comparisons.
In summary, 32 treatment comparisons are used to evaluate the month 1
culture result as a surrogate marker, 33 to evaluate the month 2 culture result
and 35 the month 3 culture result.
6.1.3 Chapter Outline
In this chapter, these three binary markers will be evaluated as surrogate
markers. In section 6.2 the Prentice criteria (see section 2.5 for a definition)
will be evaluated for each of these three markers across the included treat-
ment comparisons and the results from this will be discussed. In section 6.3 a
selection of the single trial summary measures introduced in section 2.6 that
attempt to quantify the surrogate value of a putative marker will be explored
and the results from these measures discussed. In section 6.4, meta-analytic
methods introduced in sections 2.8 and 2.9 are applied to these three markers
allowing for a comprehensive analysis. In section 6.5 data from two recent
tuberculosis trials are added to the database and the most promising mod-
els from the previous sections applied to these new data to assess the value
of these results in trials today. In section 6.6 the results from each of these
analyses are discussed and conclusions drawn.
6.2 Evaluating the Prentice Criteria
Prentice (1989) provided the first clear statistical criteria for defining and eval-
uating a surrogate marker; and the Prentice Criteria are still accepted today
as the starting point for any discussion of surrogate markers (see section 2.5).
6.2.1 Methods
In his original paper, Prentice, to suit his application, stated his criteria with
the true endpoint as a time-to-event variable and the surrogate as being time
dependent. In this chapter since both the true and the surrogate endpoint are
153
binary variables, these three criteria can be restated for a binary true endpoint,
T, and a binary surrogate endpoint, S:
P(T = liS = s,Z = z) == P(T = us = s), (6.1)
P(T = liS = s) 1:- P(T = 1), (6.2)
E [P(T = tuS = slZ = z)] t= E [P(T = tuS = s)] (6.3)
where Z is an indicator variable corresponding to the active or the control
treatment.
The second criterion (equation 6.2) states that the surrogate must have
some association with the final endpoint. This has been shown to be the case
in Chapter 5 for each of the three markers in question. The first criterion
(equation 6.1) states that the probability of a poor outcome conditional on the
surrogate and the treatment effect is exactly equivalent to the probability of
a poor outcome conditional only on the surrogate. This is the key criterion
and it will be evaluated in this section. The third criterion (equation 6.3)
is necessary to avoid certain artificial situations where the first two criteria
are met but the marker is not technically a surrogate. See section 2.5 for
discussion. It is evident that this third criterion is met for each marker.
Prentice's original paper combined the tasks of evaluating and using a
surrogate in a single trial confusing the issue slightly. In this chapter, culture
results are being evaluated as surrogate markers so that they may be used in
a future trial. It is therefore necessary to include an additional criterion:
P(T = liz = z) t= P(T = 1). (6.4)
That is, there should be a statistically significant treatment effect on the true
endpoint, unadjusted for the surrogate. If this condition does not hold, then
there is no treatment effect on the true endpoint and there is therefore nothing
for the surrogate to 'capture'.
If these four criteria hold, adjusting for the surrogate renders the treatment
effect non-significant and can therefore be said to (fully) capture the treatment
effect.
To test the Prentice criteria, three models need to be fitted and null hy-
potheses tested on the parameters from each of these models. These models
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are:
1. the model assessing the effect of treatment on the true endpoint:
logit P{Tik = 1) = Vi + (3ijZijb (6.5)
2. the model assessing the relationship between the surrogate endpoint and
the true endpoint:
logit P(Tik = 1) = ~i + /'iSikl and (6.6)
3. the model assessing the effect of treatment and the surrogate endpoint
on the true endpoint:
(6.7)
where Zijk is the indicator variable denoting the treatment comparison:
Zoo _ {I if patient k was allocated treatment j in trial i'1k - . (6.8)o if patient k was not allocated treatment j in trial i
6.2.1.1 Missing Data
A missing surrogate endpoint, the culture result, is caused by a contaminated
result, a lost sputum sample or the patient failing to produce sputum. In most
of these trials, patients were kept in hospital for at least the first two months
(and in some cases all six months) of treatment. It can therefore be assumed
that the culture results that have been observed are representative of the entire
population and the data are missing completely at random (MCAR).
A missing true endpoint, poor outcome of treatment, is caused by a pa-
tient that is lost during follow-up less than twelve months after the end of
treatment. There is evidence on the treatment cards that continued efforts
were made to find patients who had failed to come for a follow-up visit to
determine whether the patient had had a poor outcome. These efforts in-
cluded writing letters, visiting the patient's home and talking to friends and
relatives. Loss to follow-up was therefore kept to a minimum and was mostly
caused by patients moving away or by deaths not related to tuberculosis. It
is unlikely that the missingness was related to the unobserved outcome. It is
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assumed that the outcomes that have been observed are representative of the
entire population and the data are also MCAR.
For each of these models, individuals with either the treatment outcome
(the true endpoint T) or the culture results (the surrogate endpoint S) missing
are not included in the models. This complete-case analysis is therefore unbi-
ased on the assumption of MCAR. Evaluating the Prentice criteria for each of
the three candidate surrogates is therefore on slightly different subsets of trial
individuals, as well as a slightly different subset of treatment comparisons
(see section 6.1.2).
6.2.2 Results
6.2.2.1 Evaluating for each treatment comparison
Treatment effect
on poor outcome
(unadjusted)
Effect of
2 month culture
on oar outcome
Treatment effect on
poor outcome (adjusted
for 2 month culture)
--t
--t --t
12 (36%)
Significant --t
--t --t
--+ 6 (29%) Non-significant
21 (64%) Non-
significant
Table 6.1: Results of testing Prentice criteria for the 2 month culture for indi-
vidual treatment comparisons
Table 6.1 shows the breakdown of the 33 treatment comparisons by statisti-
cal significance for testing the three null hypotheses (here defining statistically
significant as a two-sided p-value of less that 0.05) for the 2 month culture
result. The three null hypotheses are:
1. Ho: P(T = liZ = 1) = P(T = liZ = 0); {3ij = 0, testing the unadjusted
treatment effect on a poor outcome.
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2. Ho : P(T = liS = 1) = P(T = 115 = 0); ')'i = 0, testing the effect
of the two month culture result (the first candidate surrogate) on poor
outcome.
3. Ho : P(T = 1IS,Z = 1) = P(T = 1IS,Z = 0); f3ij = 0, testing the
treatment effect on poor outcome adjusted for the two month culture
result.
Of the 33 treatment comparisons, the ratio of odds of a poor outcome
is shown to be different from one in only 12 (36%) comparisons (criterion 4
shown in equation 6.4). Among these 12 treatment comparisons, there was
a significant association between the two month culture and a poor outcome
in 10 (83%) (criterion 1 shown in equation 6.2) and among these 10 treatment
comparisons, the ratio of odds of poor outcome became nonsignificant on
adjusting for the surrogate in 3 (30%) (criterion 2 shown in equation 6.1).
Therefore, of the 12 treatment comparisons showing a significant effect on a
poor outcome, the two month culture satisfied the Prentice criteria in only 3
(25%).
Treatment effect
on poor outcome
(unadjusted)
Effect of
2 month culture
on poor outcome
Treatment effect on
poor outcome (adjusted
for 2 month culture)
5(38%) Non- ~
--t significant ~
13 (35%)
Significant 8 (62%) ~ o (0%) Non-si
~ Significant ~ 8 (100%) Si
24 (65%) Non-
significant
tIn two treatment comparisons, culture positivity at 3 months predicted poor outcome per-
fectly and is therefore not including in this column.
Table 6.2: Results of testing Prentice criteria for the 3 month culture for indi-
vidual treatment comparisons
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Treatment effect
on poor outcome
(unadjusted)
Effect of
2 month culture
on poor outcome
Treatment effect on
poor outcome (adjusted
for 2 month culture)
----+ o (0%) Non-si
----+ ----+ 4 (100%) Si
12 (38%)
Significant ----+
----+ ----+
20 (62%) Non-
significant
tIn one treatment comparison, culture positivity at 1 months predicted poor outcome perfectly
and is therefore not including in this or the next column.
Table 6.3: Results of testing Prentice criteria for the 1 month culture di-
chotomised at 20+ for individual treatment comparisons
Table 6.2 shows the results of testing the Prentice criteria for the 3 month
culture result as a surrogate for each of the 37 treatment comparisons. Of
the 13 treatment comparisons showing a significant effect on poor outcome,
the three month culture did not satisfy the Prentice criteria in any treatment
comparison.
Table 6.3 shows the results of testing the Prentice criteria for the 1 month
culture result taking the point of dichotomy at 20+. Of the 12 regimens with
a significant effect on a poor outcome, the 1 month culture result at a point
of dichotomy of 20+ satisfied the Prentice criteria in only 1 (8%) treatment
comparison.
These results suggest that the month 2 culture is marginally superior to
the other two markers as the Prentice criteria were met in more comparisons,
but all three are poor.
6.2.2.2 Evaluating across treatment comparisons
When combining the data and testing each of the three null hypotheses across
all treatment comparisons, the picture is not much improved. Figure 6.1 shows
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an estimate of the unadjusted treatment effect and the treatment effect ad-
justed for each of the candidate surrogate with 95% confidence intervals, using
a mixed logistic regression model adjusting for clustering within trials.
In each case, the surrogate had a statistically significant effect on a poor
outcome satisfying criterion 2. For month 2 the log odds ratio was -0.74 with
95% confidence interval (-1.01, -0.47), for month 3, the log odds ratio was -0.77
with 95% confidence interval (-1.01, -0.54), and for month 1 the log odds ratio
was -0.75 with 95% confidence interval (-1.03, -0.48). It is clear to see that the
origin is not contained in the 95% confidence interval of the unadjusted treat-
ment effect satisfying criterion 4, but the same is also true for the treatment
effect adjusted for the surrogate and therefore criterion 1 is not satisfied. For
month 3 and month 2 cultures, the point estimate and the confidence interval
for the adjusted treatment effect are shifted towards the origin, with a greater
shift occurring with the month 2 culture, but this shift is very slight. For the
month 1 culture, the point estimate is shifted slightly towards the origin, but
the width of the confidence interval is increased.
0,0+------------------
I~,2
1.0,4..
"S
'~ ·0,6
~
l!' ·0,8
..J
·1.0
• Unadjusted treatment effect
o Treatment elleet edjusted lor surrogate
2 Month Cu~ure (33) 3 Month Culture (37) 1 Month Cu~ure (32)
Figure 6.1: Unadjusted treatment effect on a poor outcome and
treatment effect adjusted for the surrogate marker for each of three
candidate markers. 95% confidence interval is shown and number
of treatment comparisons included is shown in parentheses on the
horizontal axis labels.
It should be noted that this evaluation across treatment comparisons as-
sume a common log odds ratio of poor outcome across all treatment compar-
isons. This is not a realistic assumption given that each treatment comparison
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is of different treatment regimens, but is useful as an indicator of the be-
haviour of the marker.
6.2.3 Conclusions
Each of the three candidate surrogate markers being evaluated in this chapter,
culture positivity at months 2 and 3 and heavy culture positivity at month I,
have failed to satisfy the Prentice criteria in all treatment comparisons.
Testing the criteria for individual treatment comparisons showed that in
only a small proportion of comparisons were the Prentice criteria satisfied,
with the 2 month culture having marginally the largest proportion. This
means that in the majority of comparisons, the Prentice criteria demonstrated
that the markers were not surrogates.
When evaluating the criteria across all treatment comparisons, adjusting
for the surrogate marker did appear to capture a very small fraction of the
treatment effect, but certainly did not fully capture the treatment effect and
therefore the Prentice criteria were not satisfied. The 2 month culture result
produced the greatest movement in the point estimate and confidence interval
suggesting this captured more of the treatment effect.
The Prentice criteria has been criticised as only being a means of excluding
failed surrogates (see section 2.5.1), and not useful for evaluating the value
of surrogate markers that may be less than perfect but still useful. A non-
significant result for the hypothesis test of criteria 2 does not necessarily imply
surrogacy, it only means that surrogacy cannot be excluded. This criticism is
irrelevant in this case as all three markers fail to satisfy the Prentice criteria
overall and therefore should be classed as failed surrogates on this basis. None
of these candidate surrogate markers are perfect surrogates and in fact appear
to be very poor. Despite these disappointing results, subsequent sections use
additional methods to explore the use of these three candidate markers as
surrogates and to attempt to quantify the value of each.
6.3 Single Trial Summary Measures
6.3.1 Introduction
Following the route of the development of methods for evaluating surrogate
markers (see Chapter 2) and having now tested the Prentice criteria for the
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three candidate markers, summary measures for quantifying the proportion
of treatment effect captured by the surrogate are now calculated. Even though
the Prentice criteria have not been satisfied, indicating these none of the three
candidates fully capture the treatment effect on the true endpoint, single trial
summary measures and subsequent methods in the rest of this chapter will
be used to quantify the degree to which these candidate markers can be used
as surrogates.
A variety of different measures for the proportion of treatment effect ex-
plained by the marker were reviewed in sections 2.6 and 2.8, and four have
been selected for assessment using these data: (i) the Proportion of Treatment
Effect (Freedman et al., 1992), (ii) the Risk Reduction (Li et al., 2001), (iii) F
and F' (Wang and Taylor, 2002), and (iv) the Relative Effect and the Adjusted
Association (AA) (Buyse and Molenberghs, 1998).
6.3.2 Methods
The formulae for each of these measures contains a quotient in some form
of other involving estimates of model parameters in both the numerator and
the denominator. Standard errors on these individual parameters can be esti-
mated in the usual way, but calculating a standard error for the quotients is not
straightforward. For calculating confidence intervals, most authors have rec-
ommended using Fieller's method (Fieller, 1940) or the t5-method (Freedman,
2001), both being approximate methods. With the continual improvements in
computing power, Monte Carlo methods are now more accessible than when
these measures were first proposed and confidence intervals are calculated in
this section using bootstrap methods. 1000 replications were used in a non-
parametric bootstrap to calculate the bias corrected and accelerated (BCa) 95%
confidence intervals Carpenter and Bithell (2000).
Point estimates and 95% confidence intervals for each of these four mea-
sures are calculated for each of the treatment comparisons, evaluating each of
the three candidate markers.
6.3.2.1 The Proportion of Treatment Effect (PTE)
The idea of quantifying the proportion of treatment effect that is captured
by a surrogate marker rather than merely testing whether it is fully captured
or not was first suggested by Freedman et al. (1992) and the PTE was the
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measure that they proposed. As the first measure proposed and the measure
that ushered in the change in focus from testing to quantifying, this measure
is included in this analysis, despite widespread criticism.
Two separate models are fit for each treatment comparison j in trial i:
(6.9)
(6.10)
where Zijk is the indicator variable denoting the treatment comparison:
{
1 if patient k was allocated treatment j in trial i
Z'k - (6.11)
IJ - 0 if patient k was not allocated treatment j in trial j ,
Tik and 5ik are the true and surrogate endpoints for participant k in trial i.
The PTE is then:
PTE
_ ~ij - Mj
IJ - A ,
f3ij
where Mj is the estimate of the treatment effect adjusted for the surrogate, f3ij'
and ~ij is the estimate of the unadjusted treatment effect, (3ij' This yields one
value of the PTE for each treatment comparison.
(6.12)
6.3.2.2 The Risk Reduction
Li et al. (2001) propose this measure and consider the risk of a poor outcome
to a patient before the start of treatment and the reduction in risk as a result
of the treatment. The Risk Reduction (RR) is the proportion of this reduction
in risk that is captured by the surrogate.
One model is fit for each treatment comparison j in trial i:
(6.13)
This link function for this generalised linear model is the log function, rather
than the logit function yielding estimates of risks rather than odds. The RR is:
(6.14)
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where ~s is the difference in the proportion of participants with 5ik = 1 in the
control regimen subtracted from the proportion of participants with 5ik = 1
in the experimental regimen for treatment comparison j.
6.3.2.3 F and F'
A similar measure to the RR, F, is the reduction in risk due to the change in
the surrogate induced by the treatment divided by the total reduction in risk
between treatment groups, where the risks are estimated differently (Wang
and Taylor, 2002). F is estimated based on the distribution of the true endpoint
given the treatment and the surrogate endpoint and the distribution of the
surrogate endpoint given the treatment.
For binary true and surrogate endpoints, Sand T, the measure is:
Fij = [P(Tik = l!Zijk = e.s, = 1) - P(Tik = O!Zijk = o.s, = 0)]
P(5ik = 11Zijk = 0) - P(Sik = l!Zijk = 1)
P(Tik = 11Zijk = 0) - P(Tik = l!Zijk = 1)' (6.15)
and a complementary form:
F:j = [P(Tik = 11Zijk = i.s, = 1) - vir; = O!Zijk = i.s, = 0)]
P(5ik = l!Zijk = 0) - P(Sik = l!Zijk = 1)
P(Tik = l!Zijk = 0) - P(Tik = l!Zijk = 1)' (6.16)
where these are calculated for each treatment comparison j in trial i. These
probabilities are estimated empirically from the data. For example, P(Tik =
I! Zijk = 0) is estimated as the proportion of those trial participants in the
control group for treatment comparison j (Zijk = 0) that have a poor outcome
(Tik = I), and P(Tik = 11Zijk = l,5ik = 1) is estimated as the proportion of
those trial participants with a positive culture result (Sik = 1 for the candidate
marker being evaluated) in the experimental treatment arm for comparison j
(Zijk = 1) that have a poor outcome (Tik = 1). Since Fij and F:j are comple-
mentary, only the results of Fij will be presented.
6.3.2.4 The Relative Effect and the Adjusted Association
Two measures were proposed to replace the concept of a single measure at-
tempting to quantify the proportion of treatment effect captured by the marker
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(Buyse and Molenberghs, 1998). The relative effect (RE) is ratio of the treat-
ment effect on the true endpoint and the treatment effect on the surrogate
endpoint and the adjusted association (AA) is the association between the
true and surrogate endpoints adjusted for the treatment.
Three separate models are fit for each treatment comparison j in trial i:
logit P(Sik = 1) = lIij + ltijZijb (6.17)
10gitP(Tik = 1) = Vi] + {3ijZijk,
logit P(Tik = 1) = vi} + f3ijZijk + /,~Sik'
(6.18)
(6.19)
The RE is:
RE .. _ {3ij'/ - ,
Iti}
(6.20)
and the AA is:
(6.21)
6.3.3 Results
Figures AI, A2 and A3 in Appendix A show the point estimates and 95%
bootstrap confidence intervals for each of the five measures for each of the
three candidate markers across all 37 treatment comparisons. Confidence in-
tervals have been censored in the figures at +3 and -2 with an arrow indicating
if the bounds of the confidence interval lie outside the interval [-2, +3]. For
some treatment comparisons, the point estimate and the 95% confidence in-
tervallay completely outside of the interval [-2, +3] and are therefore not
shown on the graphs. In addition, some point estimates are not shown due to
problems with convergence. Table 6.4 shows summaries of the point estimates
of the five measures across all treatment comparisons.
There is great variation in the point estimates and wide 95% confidence
intervals for each of the single trial measures. No more than 80% of point
estimates lie in the interval [0,1] and can therefore validly be called 'propor-
tions'.
The medians for each of the PTE, the RR and F are very low and all lie be-
tween 0.01 and 0.11. The medians for the RE and the AA are greater showing
a dear contrast.
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Proportion
Measure Month Nt nt Min Max Median IQR E [0,1]
Month 1 31 0 -2.14 x 1014 1.82 0.01 0.11 45%
PTE Month 2 22 0 -0.63 3.18 0.11 0.26 77%
Month 3 14 0 -0.12 0.81 0.03 0.09 79%
Month 1 36 0 -1.04 1.75 0.03 0.10 67%
F Month 2 37 0 -10.71 2.32 0.11 0.36 59%
Month 3 36 0 -0.04 0.80 0.05 0.15 75%
Month 1 37 0 -2.04 1.62 0.03 0.13 54%
RR Month 2 37 0 -1.93 1.90 0.07 0.25 57%
Month 3 37 0 -3.93 0.54 0.02 0.06 73%
Month 1 25 2 -8.55 25.44 2.11 4.08
RE Month 2 23 1 -17.77 21.49 0.82 3.27
Month 3 35 1 -1.00 x 1015 112.07 1.37 2.43
Month 1 25 0 -0.02 0.11 0.04 0.04
AA Month 2 22 0 0.18 1.98 1.13 0.29
Month 3 34 0 0.08 3.28 1.65 0.66
tThe number of treatment comparisons for which the point estimate was calculated.
tThe number of treatment comparisons for which the entire 95% confidence interval and point
estimate lie outside the interval [-2, +3]. The total number of treatment comparisons plotted on
the graphs in Appendix A is therefore N - n.
Table 6.4: Summary results of the singe trial measure across the 37 treatment
comparisons.
6.3.4 Conclusions
Some authors have proposed a weighted average of a single trial measure
across trials to yield an overall measure of the proportion of treatment effect
that is captured by the surrogate (see section 2.9). With such great variation
and wide confidence intervals in these results, a weighted average would not
be an appropriate summary as it would conceal the fact that so many of the
point estimates and confidence intervals are outside of the interval [0,1]. The
medians for each of the PTE, the RR and F all lie between 0.01 and 0.11 ei-
ther suggesting poor surrogacy or, more likely, demonstrating uninformative
measures.
Freedman et al. (1992) suggest that a surrogate could be deemed important
if the lower limit of the confidence interval of the PTE is greater than a critical
value such as 0.5 or 0.75 (see section 2.6). On this basis, these markers could
only be called 'important' in very few of these treatment comparisons.
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Li et al. (2001) do give an explanation for a RR of greater than I, noting
that this corresponds to treatment effects on the true and surrogate endpoint
that are in opposite directions. This could be an explanation of those values
of RR greater than I, but not of those that are less than o.
Neither the RE, nor the AA are purported to be 'proportions' and therefore
have a clear interpretation if the estimate lies outside of [0,1). Nevertheless,
the RE is simply the ratio of the treatment effect on the surrogate endpoint
and the treatment effect on the true endpoint and is of little value when cal-
culated in a single trial. The AA is useful as a treatment-campa rison-specific
estimate of the association between the true and surrogate endpoints adjusted
for treatment. The results suggest that this association increases from month
1 to month 2 to month 3, but the spread (and therefore the standard error of
any overall estimate) also similarly increases.
6.4 The Meta-Analytic Approach
6.4.1 Introduction
In section 6.2, the Prentice criteria were tested and each of the three mark-
ers were shown to satisfy only two of the three criteria. In section 6.3, four
different approaches were used in an attempt to quantify the proportion of
treatment effect captured by the surrogate. These measures were shown to
have a number of deficiencies, not least that they are all single trial measures
and there is no obvious way to extend these measures across trials. Any
marker must be a valid surrogate across a number of trials and therefore it
is meta-analytic methods that are most appropriate for evaluating the three
candidate markers as surrogates.
In Chapter 2, two different meta-analytic paradigms to surrogate marker
evaluation were summarised. Section 2.8 discussed a series of methods based
on the work of several Belgian authors (including Burzykowski et al. (2005),
the first and only textbook on surrogate marker evaluation) hereafter denoted
as the Belgian Paradigm. In section 2.9, a two-stage graphical approach was
summarised that was developed and applied largely in the disease area of
HIV (see HIV Surrogate Marker Collaborative Group (2000) and Chapter 17
of Burzykowski et al. (2005)) hereafter denoted as the HIV Paradigm. In both of
these approaches, it is necessary first to estimate the effect of the treatment on
the surrogate and the true endpoint before modelling the relationship between
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the two.
In the Belgian paradigm, these two stages are effectively combined into a
one-stage mixed effects model, including the effect of trial as a random effect.
The key is that the true endpoint and the surrogate endpoint are modelled
jointly yielding two statistics, Rfndiv and Rtrial' that assess the quality of the
surrogate at the individual and the trial level respectively. For Gaussian true
and surrogate endpoints, the joint distribution is multivariate Gaussian which
can be modelled using standard mixed model theory and R~ndiv and RTr;al
easily estimated. The joint distribution is more complicated if one or both
endpoints are not normally distributed. Various authors have suggested us-
ing copulas to specify the relationship between two random variables given
standard marginals. Some work has been done in this area, but the fitting
of the model when both endpoints are not Gaussian is not straightforward
and does not lend itself to ready application, particularly as copulas are not
widely used in medical statistics, being more common in financial statistics
(Genest and MacKay, 1986).
In the HIV paradigm, the two stages are separate. The treatment effect on
the surrogate endpoint and on the true endpoint are first estimated within trial
i. The treatment effect on the true endpoint, f3i' is plotted against the treatment
effect on the surrogate endpoint, lX.i, and a straight line fitted to these points.
Since the two stages are distinct, this allows for a variety of types of endpoints
and models in the first stage since it is only the estimates of f3; and «, that are
taken forward to the second stage. f3i and «, will be estimated with precision
varying across trials, as some will be smaller or larger and some treatments
will have a greater or lesser effect on the true endpoint. Some measure of
the precision from the first stage will therefore need to be incorporated in
the second stage. The authors of the original paper (Daniels and Hughes,
1997) use what they describe as an empirical Bayesian approach with non-
informative priors for estimating the fitting the models and estimating the
parameters.
The data used in this thesis are from multi-arm trials with more than one
regimen and therefore more than one treatment comparison within a single
trial. Evaluating surrogate markers using data from multi-arm trials is not dis-
cussed extensively in the literature and neither of these approaches to surro-
gate marker evaluation are directly suited to this application. Some additional
methodological development is therefore necessary.
The HIV paradigm will be the basis for the analysis in this section, taking a
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frequentist rather than a Bayesian approach. For this setting, the true endpoint
is poor outcome to treatment and therefore f3i will be the log odds ratio of a
poor outcome between the two treatments in the treatment comparison. There
are three markers which are being evaluated as surrogates in this chapter and
therefore (Xi will be the log odds ratio of a positive culture at each of months
1 (at a point of dichotomy at 20+), 2 and 3.
Tibaldi et a1. (2003) observe that if the true and surrogate endpoint are
modelled separately then it is harder to study the individual-level surrogacy.
This is not a considerable drawback as determining and assessing trial-level
surrogacy is of more importance in the context of this thesis.
The assumptions necessary for a meta-analysis are discussed in section
6.4.2, the methods are described in section 6.4.3 and the results are sum-
marised in section 6.4.4. The models are repeated incorporating adjustments
for baseline covariates in section 6.4.5 and fit for different subgroups of the
population in section 6.4.6. The results of these analyses are discussed in
section 6.4.7.
6.4.2 Meta-Analytic Assumptions
Three assumptions are necessary for a meta-analysis. These assumptions are
satisfied in the data used in this thesis as detailed below.
6.4.2.1 Homogeneity of Trials
The trials that yielded the data that are used for these analyses are described
in detail in Chapter 4. Several trials were not selected for inclusion in this
project on the basis of clear criteria, despite data being available. Each of
the trials that were selected were conducted by the TB research units of the
British Medical Research Council within a period of around twenty years.
Clinical and bacteriological protocols from many of these trials have been
recovered from archives and it has been verified that they are very similar.
The personnel involved in these trials were very similar (although the local
staff were specific to the trial sites, many of which were nevertheless involved
in more than one trial) and the treatment cards and data elements recorded
were very similar. Patients with extra-pulmonary tuberculosis were excluded
where this was detected, and one trial looking at silica-tuberculosis was not
included. It is therefore reasonable to assume that all aspects of the conduct of
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the trials were very similar and these data can be combined in a meta-analysis.
6.4.2.2 Comparability of Regimens
Each of the regimens included in these data were six month combinations
(with various dosing schedules) of up to five of only the following six drugs:
isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin and thiacetazone.
The regimens in each of these trials were therefore very similar and can
reasonably be combined in this meta-analysis. Apart from thiacetazone, dis-
continued due to the increased risk of Stevens-Johnson syndrome in patients
who are HIV positive (Fox et al., 1999), and streptomycin, rarely used today
as a first-line drug since it is the only treatment in this list given intravenously
(Global Alliance for TB Drug Development, 2008), these drugs are used rou-
tinely in all parts of the world to treat tuberculosis (World Health Organisa-
tion, 2003). A surrogate evaluated on a particular drug or a particular class of
drugs can then only be used for that class of drugs. Different drugs for the
same disease may have different surrogates. Any new drug evaluated today
in a phase III trial will be evaluated in combination with some or all of the
first four drugs in this list. An example is the REMoxTB trial evaluating mox-
ifloxacin as a replacement for either ethambutol or isoniazid in the standard
six month regimen 2ERHZ/4HR (see Nunn et al. (2008) for details).
Therefore, not only are the regimens very similar in each trial used in this
analysis, they can reasonably be considered to be in the same class as those
used in a phase III trial today, meaning that a surrogate validated on these
data could reasonably be used in a trial today.
Region 1 Region 2 Region 3
East Africa Hong Kong Singapore
I
Triall Trial2 Trial3 ...
I
Treatment Treatment
Comparison 1 Comparison 2 ...
Figure 6.2: Hierarchical structure of the data.
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6.4.2.3 Choice of Units
Figure 6.2 on the preceding page shows the hierarchical structure of the data.
The 37 treatment comparisons (from a total of 49 regimens) are grouped in
twelve trials which in turn are grouped into three geographical regions. In
this setting, the unit in stage II of the analysis will be treatment compari-
son. The relationship between the treatment effect on a poor outcome and
the treatment effect on a positive culture will be evaluated at the treatment
comparison level. However, treatment comparisons are clustered within tri-
als and trials are clustered within geographical region. The clustering within
trials is important and will be addressed in the models. Differences between
geographical regions will be explored in section 6.4.6.
6.4.3 Methods: Building the Model
The analysis is based on the HIV paradigm described previously. The model
comprises two stages. In the first stage, the treatment effects, «, and f3i are
estimated within each trial. In the second stage, a regression line is fitted to
the treatment effects «, and f3i' and the relationship between them explored.
6.4.3.1 Stage I: Estimating the treatment effects
Across the twelve trials included in this analysis, there were varying numbers
of treatment arms. The number of regimens in a trial varied from two (the
first Singapore study) to eight (the fourth Hong Kong study), and therefore
the number of treatment comparisons in a trial varied from one to seven. The
subscript, j = 1, ... , nu, represents the treatment comparison within a trial
in question, where m, is the number of treatment comparisons in trial i (and
Ll~l m, = 37).
Separate models were fitted for each trial estimating the treatment effect,
f3ij' on the true endpoint (poor outcome) and the treatment effect, aij' on the
surrogate endpoint (culture positivity) for treatment comparison j in trial i,
i = 1, ... ,12. For each trial i, the two models fitted were as follows:
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logit (p (5ik = lIZijk)) = fli +E ltijZijk
)=1
10git(P (Tik = lIZijk)) = Vi + f f3ijZijk
)=1
(6.22)
(6.23)
where
{
I if patient k was allocated treatment j in trial i
Zijk = o if patient k was not allocated treatment j in trial i (6.24)
is the indicator variable denoting the treatment. u, and Vi are intercept terms
in the model and are estimated, but are treated as ancillary parameters and
not taken forward to the second stage. These two models give us our 37
estimator pairs (&ij'~ij) and variances of these estimates, eT;;/ = Var(&ij) and
eT~ij = Var(~ij)' which are themselves estimated from the models.
6.4.3.2 Stage II: Modelling the relationship between treatment effects
Following the HIV paradigm, we fit a straight line to the pairs (&ij'~ij):
(6.25)
imposing b = 0, where Eij '" N (0, r2) is the between treatment comparison
error. Apart from the move from a Bayesian to a frequentist framework, this
is following the HIV paradigm with three differences:
1. Imposing 0 = O.The HIV paradigm includes an intercept, b, in this sec-
ond stage. This allows for an additional test of Ho : 0 = O. A good
surrogate will have a zero intercept (the fitted line goes through the ori-
gin). If the intercept is non-zero, this means that there is a proportion
of the treatment effect on the true endpoint that is not captured by the
surrogate-perhaps indicating that there are causal pathways that do
not pass through the surrogate. Including an intercept in this model is
only reasonable if all the treatment comparisons are comparing the same
treatment with the same control (as is the case in the example used to
illustrate the methods in Daniels and Hughes (1997». In these data, all
of the treatment comparisons are not comparing the same regimens and
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therefore this model must be fit without an intercept, imposing 0 = o.
o i= 0 would suggest that there were a residual treatment effect on the
true endpoint that was not captured by the surrogate. Since all the com-
parisons are different, this would be a meaningless concept. It may be
the case that a proportion of the treatment effect on the true endpoint is
not captured by one of the three candidate surrogates being evaluated
in this chapter, and this can be observed by the spread of the data about
the fitted line.
2. In the simplest and most natural fitting of the model as described, the
estimation procedure would include the assumption that each of the
pairs (&ij' ~ij) are independent and of equal weight. This, of course, is
not the case in this analysis, (&ij' ~ij) are clustered within trials as each
pair with the same i are comparisons with the same control arm, and
these estimates themselves are of varying precision depending on actual
the number of patients and the number of poor outcomes observed in
patients involved in a treatment comparison. Two changes are therefore
made.
(a) Weighted regression. Weighted regression has been used, with weights,
W;j' equal to the inverse of the mean of the variances of &;j and ~;r
2
(6.26)
to account for the presence of heteroskedasticity. The choice of
weights is largely arbitrary, but this choice means that pairs esti-
mated with greater precision (smaller variances) are more influen-
tial in the fitting of the regression line that those estimated with
poorer precision.
(b) Robust standard errors. Calculating robust standard errors, rather
than the standard ordinary least squares estimates of the standard
errors, means that the model is robust to departures from the as-
sumption of independence, the only assumption is that observa-
tions are independent within each trial. Robust standard errors
have therefore been used to account for the clustering of treatment
comparisons within trials.
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Figure 6.3: Logs odds ratio of a poor outcome plotted against log odds ratio
of a positive culture. Fitted line is weighted by the precision of the estimates,
and this precision is represented by the diameter of the circles around each
point. A 95% confidence interval on the slope is also shown.
6.4.3.2.1 Treatment Ordering As described in section 6.1.1, the ordering of
the treatment regimens was such that the log odds ratio of a poor outcome
would be negative for almost all of the comparisons. Almost all of the points
plotted are therefore in one of the two lower quadrants in each of the graphs.
It is informative to look at how the points plotted in stage II are distributed
about the Cartesian quadrants on the graphs. If the points lie on the horizontal
axis, this indicates that there is no difference in the log odds of a poor outcome
between the treatment regimens being compared and if the points lie on the
vertical axis, this indicates that there is no difference in the log odds of a
positive culture result between the treatment regimens being compared.
Importantly, if a point lies in either the upper left or the lower right quad-
rants, this indicates that the sign of the log odds ratio of a poor outcome is
opposite to that of the log odds ratio of a positive culture. For such points,
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the treatment has opposite effects on the surrogate to the true endpoint which
is highly undesirable for a surrogate endpoint. A good surrogate will have all
points lying in the upper right or lower left quadrants.
6.4.4 Results
Figure 6.3 on the previous page is a plot of the log odds ratio of a poor out-
come (~ij) against the log odds ratio of a positive culture (iti;) for each of the
three candidate surrogate markers: culture positivity at month 1 with a point
of dichotomy at 20+, culture positivity at month 2, and culture positivity at
month 3. The fitted line is weighted by the precision of the estimates where
precision is calculated as the inverse of the mean of the variances of the two
estimates in each pair. Two additional dashed lines are plotted in each graph
with slopes as the upper limit and lower limit of the 95% confidence interval
on the estimated slope. Table 6.5 shows the slope with 95% confidence in-
terval and the proportion of explained variation, R2. This is the proportion
of variation in the log odds ratio of a poor outcome (the treatment effect on
the true endpoint) that is explained by the log odds ratio of a positive culture
(the treatment effect on the candidate surrogate) and is a way of quantifying
the performance of a surrogate. R2 = 1 shows that the marker is a perfect
surrogate, and R2 < 0.5 (or even R2 < 0.6) shows that that marker is a poor
surrogate. The table also includes the number of treatment comparisons in-
cluded in the regression and plotted on the graphs (see section 6.1.2 above).
The total number of treatment comparisons available was 37. The values of
(iij and {3ij with 95% confidence intervals estimated in stage I are tabulated for
each comparison in Appendix A in Tables A.2, A.3 and A.4.
Number of Number Estimated
Marker Comparisons of Trials Slope, K 95% Cl R2
Month It 32 9 1.35 (-0.10,2.80) 0.36
Month 2 33 9 0.85 (0.13,1.57) 0.36
Month 3 35 11 1.29 (0.82,1.76) 0.69
tWith a point of dichotomy at 20+.
Table 6.5: Results of stage II of the meta-analysis for each of the three candi-
date surrogate markers.
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6.4.4.1 Month 1, Heavily Positive
There is considerable scattering about the fitted line in Figure 6.3(a) on page 173,
and the proportion of variation explained is only 0.36 (Table 6.5 on the pre-
ceding page). There is grouping around the origin showing no real difference
between treatments in either rates of poor outcome or proportions of heavily
positive at month 1 for some comparisons. Apart from this grouping around
the origin, there are six points in the lower right quadrant indicating that the
treatment direction on a poor outcome is opposite to that on the heavily cul-
ture positivity at month 1 although, for only one of these points was the log
odds ratio of a positive culture statistically different from zero (the second
treatment comparison in Study X, see Table A.2 on page 252). There are a
number of points that lie outside and below the 95% confidence interval on
the slope suggesting that there is a proportion of the treatment effect on the
true endpoint in these particular treatment comparisons that is not explained
by the candidate surrogate of a heavily positive culture at month 1.
6.4.4.2 Month 2
Again, there is considerable scattering about the fitted line in Figure 6.3(b)
with the proportion of explained variation again low at 0.36, although the
spread of the points in the horizontal direction is greater than at month 1.
Compared to month 1, there are more points that lie outside and below the
95'Yo confidence interval on the slope suggesting that there is a proportion
of the treatment effect on the a poor outcome that is not captured by the 2
month culture. Not counting the grouping around the origin, there are also
seven points that lie in the lower right quadrant, and for two of these points
the log odds ratio of a positive culture was statistically significant (the first
and third treatment comparison in Study V, see Table A.3 on page 253). The
log odds ratio of a poor outcome was also statistically significant in the third
comparison meaning that both the treatment effect on the month 2 culture
result and on a poor outcome were statistically significant, but in opposite
directions. Surprisingly, there are more points for the 2 month culture than the
1 month heavily positive culture in this lower right quadrant, corresponding
to comparisons for which the treatment effect on a poor outcome is in the
opposite direction to the treatment effect on the culture result.
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6.4.4.3 Month 3
There is less scattering about the fitted line in Figure 6.3(c) than in the other
two figures and this is reflected in a proportion of explained variation consid-
erably higher at 0.69 and the narrowest 95'Yu confidence interval on the slope.
There are fewer points below the 95% confidence region around the fitted line
and, excluding the clustering around the origin, there is only one point in the
lower right quadrant and one in the upper left.
6.4.5 Adjusting for Baseline Risk Factors
6.4.5.1 Introduction
In an important paper looking to evaluate aspects of the serial sputum colony
counts (SSCC) profile as surrogate markers (Davies et al., 2006a), the authors
found that the second slope parameter in the bi-exponential model better dis-
criminated between treatments when additional patient characteristics (in par-
ticular HIV status) were included in the model. While long-term treatment
outcome was not available in this study, and therefore this second slope pa-
rameter of the SSCC analysis could not formally be evaluated as a surrogate
marker, this work does suggest that failing to adjusting for patient-level base-
line risk factors could show a bacteriological surrogate marker to be poorer
than it actually is. The analysis described above was therefore repeated in-
cluding important baseline risk factors as covariates in the model to see if the
fit of the model and the performance of the surrogate marker improves.
These data are from randomised controlled trials where trial participants
were randomly allocated to treatment regimens on enrolment to the trial. The
trials were of varying sizes, but it is likely that in the larger trials any base-
line risk factors would have been approximately evenly distributed between
treatment regimens. Adjusting for baseline risk factors should not therefore
greatly affect the results.
Section 3.5.1 reviews the literature identifying baseline risk factors. The
baseline patient-level covariates that are recorded in these trials and therefore
available in these data are evaluated as risk factors for poor outcome in sec-
tion 4.5.2, see in particular Table 4.9 showing odds ratios and 95% confidence
intervals for each risk factor as a predictor of poor outcome. In this analysis,
each of weight, age, sex, isoniazid resistance, baseline sputum smear, baseline
sputum culture, extent of cavitation and extent of disease were found individ-
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ually to be important risk factors for poor outcome. These will therefore be
included in this section as possible covariates to be included in stage I of the
model.
It is known that HIV infection and rifampicin resistance are risk factors for
poor outcome, but these trials were conducted in the pre-HIV era and before
the widespread use of rifampicin to treat TB. It can therefore be assumed that
all patients in these trials were HIV negative and rifampicin susceptible.
6.4.5.2 Methods
The models involved in the two stages are described in section 6.4.3 above. In
stage I, patient-level covariates are included in the model using a backward
step-wise selection method to select those that are important risk factors for
poor outcome in each particular trial. All of the covariates found to be impor-
tant in Chapter 5 are included either as continuous variables (weight and age),
binary variables (sex, isoniazid resistance, streptomycin resistance) or categor-
ical variables (baseline sputum smear, baseline sputum culture, radiographic
extent of cavitation and radiographic extent of disease).The backward step-
wise selection method used to identify the important risk factors, is repeated
for each trial, and proceeds as follows:
1. Calculate the increase in the log likelihood ratio statistic in removing a
single covariate from the logistic regression model including all covari-
ates, for each of the risk factors.
2. Identify the covariate for which the removal of this covariate results in
the smallest increase in the log likelihood ratio statistic that is not statis-
tically significant at the 5% level when compared to the X2 distribution
with one degree of freedom.
3. Repeat from step 1 with this covariate removed from the model. If the
removal of each covariate individually results in an increase in the log
likelihood ratio statistic that is statistically significant (showing that ev-
ery covariate is important as a risk factor in the model), go to step 4 for
the beginning of the forward step-wise selection procedure.
4. Calculate the decrease in the log likelihood ratio statistic in individually
adding each of the covariates not already included in the model.
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5. If the decrease is statistically significant after the addition of any of these
covariates, include these in the model and repeat from step 1. Otherwise,
the selection process in finished.
Only those covariates statistically significant as risk factors for poor out-
come for that particular trial are then retained and are included in both models
at stage 1so that the iX.;j and the f3jj are adjusted for the same set of covariates
for a particular trial i. Stage II then proceeds as before.
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Figure 6.4: Logs odds ratio of a poor outcome plotted against log odds ratio of
a positive culture. Logs odds ratio are adjusted for certain baseline risk factors.
See text for details. Fitted line is weighted by the precision of the estimates,
and this precision is represented by the diameter of the circles around each
point. A 95% confidence interval on the slope is also shown.
6.4.5.3 Results
Figure 6.4 is a plot for each of the candidate surrogates, of the log odds ratio
of a poor outcome (f3jj) against the log odds ratio of a positive culture (iX.jj)
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where both log odds ratios are adjusted for a number of baseline risk factors.
The slopes with 95% confidence intervals and the proportion of variation in
the adjusted log odds ratio of a poor outcome explained by the log odds ratio
of a positive culture for each marker is given in Table 6.6.
Number of Number
Marker Comparisons of Trials Slope, K 95%CI R2
Month I" 32 9 1.26 (-0.17,2.68) 0.32
Month 2 33 9 0.78 (0.10, 1.46) 0.31
Month 3 35 11 1.27 (0.57,1.98) 0.61
tWith a point of dichotomy at 20+.
Table 6.6: Results of stage II of this analysis for each of the three candidate
surrogate markers. Odds ratios calculated in stage I are adjusted for certain
baseline risk factors. See text for details.
It is clear from Table 6.6 that the values of R2 are lower on adjusting
for baseline risk factors than those in the unadjusted model (Table 6.5 on
page 174) for each of the candidate surrogates, and that the slopes of the fit-
ted lines are marginally shallower in each case. One interesting difference
from the unadjusted graph is that there is a slightly greater spread of points
in each graph in the horizontal and vertical direction, and this is seen most
in the Figure 6.4(b). What this suggests is that, as with (Davies et al., 2006a),
on adjusting for important baseline covariates, some of the unexplained noise
is removed and there is greater discrimination between treatments (shown by
larger log odds ratios of both a poor outcome and a positive culture). Never-
theless, this doesn't greatly affect the relationship between the treatment effect
on a poor outcome and the treatment effect on culture positivity, and in fact
the values of R2 are slightly reduced.
6.4.6 Subgroup Analyses
The twelve trials were conducted across three separate geographical regions
(East Africa, Hong Kong and Singapore) and evaluated a variety of different
regimens. All regimens were given for six months, but various combinations
of different drugs were given for differing periods of time across the intensive
and the continuation phase with differing weekly dosing schedules. There-
fore, the three candidate surrogate markers were evaluated in this chapter
across a wide variety of treatment comparisons.
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Figure 6.5: Logs odds ratio of a poor outcome plotted against log odds ratio
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by the diameter of the circles around each point. A 95% confidence interval
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6.4.6.1 Analysis by Geographical Region
In Chapter 4, it was shown that the age and sex distribution differed between
East Africa, Hong Kong and Singapore in addition to the severity of disease
(as shown by baseline cultures and baseline radiographic extent of disease
and extent of cavitation) in patients presenting for enrolment into the trials.
On this basis (in addition to further evidence to suggest response to treatment
might differ by geographical region (Fox et al., 1999)), the analysis described
above was repeated separately for patients in East African trials, trials con-
ducted in Hong Kong and in trials conducted in Singapore.
Figure 6.5 on the preceding page shows meta-analysis plots for each of
the three candidate markers for trials from East Africa and trials from Hong
Kong with the fitted line plotted. Figure 6.6 on the next page shows plots
for the three candidate markers for trials from Singapore. Slopes with 95%
confidence intervals and R2 values are given in Table 6.7 on page 183. These
graphs show very different results between the three geographical regions.
At months 1 and 2, the graphs restricted to data from East Africa (13 treat-
ment comparisons in each analysis) shows very great variation about the line,
R2 = 0.29 and R2 = 0.19 in each case and very wide confidence intervals
(Figures 6.5(a) and 6.5(c)). A number of points lie outside and below the 95%
confidence intervals on the slope (which themselves are very wide) indicating
that these markers are failing to capture the treatment effect on a poor out-
come in East African trials. This contrasts with the month 3 culture result in
East Africa (evaluated across 16 treatment comparisons), with a clear linear
trend in the points (R2 = 0.81, Figure 6.5(e)).
In contrast to the East African graphs, a linear trend is more apparent for
all months in the graphs restricted to data from Hong Kong only (15 treat-
ment comparisons for each analysis). At month 1, there is less spread in
the horizontal direction, as before, and the proportion of explained variation
is reasonably high, R2 = 0.69 (Figure 6.5(b)). The width of the confidence
interval is also very wide. The best fit is at month 2 with a narrow 95% con-
fidence interval around the slope, a high proportion of explained variation at
R2 = 0.86 (figure 6.5(d)), and no points outside the lower left quadrant, except
for three which are very close to the origin. At month 3, the fit is not as good
(R2 = 0.62, figure 6.5(f)). The width of the 95% confidence interval around the
slope is wider and there is more variation about the fitted line, although there
are still no points outside the lower left quadrant.
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Figure 6.6: Logs odds ratio of a poor outcome plotted against log odds ratio
of a positive culture for trials from Singapore. Precision is represented by the
diameter of the circles around each point.
Fitting one model with different slopes for trials from Hong Kong and
trials from East Africa, allows for testing for equality of slopes using a simple
Hest. At month 1 and month 2, there was no evidence for a difference in
slopes, p= 0.46 and p= 0.75 respectively. At month 3, there was a evidence
for a difference in slopes between trials from Hong Kong and trials from East
Africa, p= 0.Q15.
Between 13 and 16 treatment comparisons were used for evaluating each
of the three candidate markers as surrogates in data restricted to East Africa
trial and restricted to Hong Kong trials. No more than five treatment com-
parisons were available from Singapore trials for this meta-analysis, and all
of these comparisons were from a single trial, the third Singapore trial (the
first Singapore trial was not included for any analysis, see 6.1.2). The slope,
95% confidence interval and R2 from the fitted line are shown in Table 6.7,
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Region Marker I Comparisons Trials Slope, K 95%CI
Month IT 13 4 1.13 (-1.82,4.11) 0.29
East Africa Month 2 13 4 0.76 (-1.57,3.09) 0.19
Month 3 16 6 1.61 (1.38,1.83) 0.81
Month It 15 4 1.98 (-0.92,4.05) 0.68
Hong Kong Month 2 15 4 0.99 (0.82,1.16) 0.86
Month 3 15 4 0.82 (0.09,1.56) 0.62
Month IT 4 1 0.19 (-4.95,5.33)1: < 0.D1
Singapore Month 2 5 1 -0.06 (-2.31,2.20)1: < 0.Q1
Month 3 4 1 -0.52 (-5.09,4.05)1: 0.04
tWith a point of dichotomy at 20+.
tRobust standard errors were not used since the treatment comparisons were all from a single
trial.
Table 6.7: Results of stage II of this analysis for each of the three candidate
surrogate markers, by geographical region.
although the fitted line is not plotted as it is clear that a straight line through
the origin is not appropriate for these data. Unlike all previous analysis, ro-
bust standard errors to account for the clustering within trial were not used
as all the treatment comparisons were from the same trial.
6.4.6.2 Restriction to Regimens containing Rifampicin and Isoniazid
Rifampicin and isoniazid are the most important drugs in any combination
regimen for the treatment of tuberculosis. It is for this reason that tuberculo-
sis disease that is resistant to both isoniazid and rifampicin is identified almost
as a separate disease (MDR-TB, see section 3.3.1) and requires a very different
treatment strategy (World Health Organization, 2003). The trials contributing
data to these analyses begin before and continued after the discovery of ri-
fampicin. While all regimens in these trials contain isoniazid, not all contain
rifampicin. Only 18 of the 37 treatment comparisons were of one rifampicin-
containing regimen with another rifampicin-containing regimen. The meta-
analysis was therefore repeated considering only those comparisons of regi-
mens that both contained isoniazid and rifampicin throughout the six months
of treatment. Figure 6.7 on the next page shows meta-analysis plots for each
of the three candidate markers restricted to comparisons with both regimens
containing isoniazid and rifampicin with the fitted line plotted. Slopes with
95% confidence intervals and R2 values are given in Table 6.8 on the following
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Figure 6.7: Logs odds ratio of a poor outcome plotted against log odds ratio
of a positive culture, restricted to treatment comparisons for which both treat-
ments contained isoniazid and rifampicin throughout the six month treatment
period. Fitted line is weighted by the precision of the estimates, and this pre-
cision is represented by the diameter of the circles around each point. A 95%
confidence interval on the slope is also shown.
page.
Comparing these graphs with those in Figure 6.3 on page 173, the results
from all treatment comparisons, there are clear differences. On restricting
treatment comparisons to rifampicin-containing only, the fit of the line for the
month 1 and the month 2 cultures improves (R2 = 0.36 to R2 = 0.54 for the
month 1 culture, and R2 = 0.36 to R2 = 0.67 for the month 2 culture) and there
are fewer points in the lower right quadrant. For the month 3 culture, the fit of
the line is not as good (R2 = 0.69 to R2 = 0.46) and poorer than for the month
2 culture with a wide 95% confidence interval on the slope. Considering only
treatment comparisons of regimens containing isoniazid and rifampicin for
the duration of treatment, the 2 month culture is superior to the 3 month
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Number of Number Estimated
Marker Comparisons of Trials Slope, K 95% Cl R2
Month JT 16 4 1.85 (-0.51,4.20) 0.54
Month 2 17 4 1.00 (0.64,1.36) 0.67
Month 3 16 4 0.88 (0.10,1.66) 0.46
tWith a point of dichotomy at 20+.
Table 6.8: Results of stage IIof this analysis for each of the three candidate sur-
rogate markers, restricted to those treatment comparisons with both isoniazid
and rifampicin given throughout both regimens in the comparison.
culture as a possible surrogate marker.
6.4.6.3 Further exploration
Figure 6.8 on the following page shows the meta-analysis plots for trials from
East Africa and Hong Kong, evaluating the 2 and 3 month culture results as
surrogate markers. 95% confidence intervals on the estimates of the log odds
ratios are plotted as capped spikes on the plotted points. This plot allows
for further assessment of the possible spread about the fitted line. In Figures
6.8(a) and 6.8(d), the confidence intervals cover a wide area indicating low
precision in the estimate of the slope of the fitted line, as reflected in the low
values of R2 and the wide 95% confidence intervals around the estimates of
the slopes. In Figure 6.8(b), the confidence intervals are all of a similar size
and the overall spread do not detract from the linear pattern. In Figure 6.8(c),
several of the points not near the origin have narrow confidence intervals,
again not detracting from the overall linear pattern.
6.4.7 Discussion
Meta-analysis is essential in evaluating any marker as a surrogate endpoint.
The testing of the Prentice criteria in section 6.2 was a necessary first step and
the calculation of the single trial measures in section 6.3 was useful for data
exploration, but it is the results of this section that will determine the value as
surrogates of the three candidate markers being evaluated in this chapter.
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Figure 6,8: Logs odds ratio of a poor outcome plotted against log odds ratio
of a positive culture for trials from East Africa and Hong Kong. Fitted line is
weighted by the precision of the estimates, and this precision is represented
by the diameter of the circles around each point. A 95% confidence interval on
the slope and 95% confidence intervals of the logs odds ratios are also shown.
6.4.7.1 Methods
As described above, the HIV paradigm was recast in a frequentist framework
and methods extended to evaluate each of these three candidate markers as
surrogates for poor outcome, These methods are flexible, allowing for differ-
ent distributional assumptions for the surrogate and true endpoints, Separat-
ing the patient-level and treatment comparison-level analyses into two stages
also allows for the inclusion of patient-level covariates in stage J and for a
clear graphical representation of the results of stage II. The precision of the
estimates of (Xij and ~ij for each i and j is incorporated into stage II using
a weighted linear regression giving greater weight to estimates made with
greater precision (represented on the graphs with wider circles around these
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points) and the clustering within trials is incorporated using robust standard
errors. There are two drawbacks:
1. Using robust standard errors adjusts the standard errors of the param-
eters from the model for the clustering within trials, but the point esti-
mates of the parameters are based on the assumption that each pair of
points (lXijl !3ij) is assumed to be independent. This is an incorrect as-
sumption, as treatment comparisons are clustered within trials, having
common control regimens.
2. lXij and !3ij are can only be estimated with error for each iand j. At stage
II the error in !3ij is incorporated in the weighted regression, but the error
in lXij is not. The effect of wrongly assuming that the lXij are estimated
without error is regression dilution bias-there will be attenuation of the
slope of the fitted line towards zero, and the slope will therefore be
underestimated.
These are real drawbacks with the methods. Chapter 7 is devoted to ex-
tending these methods in an attempt to overcome these problems.
6.4.7.2 Results
Using data from a number of randomised clinical trials, Mitchison (1996) con-
cluded that the 2 month culture was a better surrogate marker than the 3
month culture. As a result, it is commonly accepted that the 2 month cul-
ture is a valid surrogate and it is often described as such (see section 3.5.3).
From these data, the overall analyses showed that both the 2 month culture
and the 1 month culture dichotomised at 20+ are poor surrogate markers. In
contrast, the 3 month culture is possibly a useful surrogate, although there is
considerable variation about the fitted line.
6.4.7.2.1 Month 1 It is clear that, based on the results of the analysis, a
heavily positive culture at month 1 can be used to give an indication of the
direction of the effect of a treatment on a poor outcome, but given the low R2,
the 95% confidence interval on the slope containing 0, the grouping around
the vertical axis and the points in the lower right quadrant, a heavily positive
culture at month 1 cannot be considered as a useful surrogate marker.
187
6.4.7.2.2 Month 2 As with the heavily positive culture at month 1, the cul-
ture result at month 2 can be used to give an indication of the direction of the
effect of a treatment on a poor outcome. Since the spread of the points in the
horizontal direction is greater and the width of the 95% confidence interval
on the slope is narrower, the culture result at month 2 can also be used to give
a very rough indication of the size of the treatment effect on a poor outcome.
Nevertheless, the low R2 in addition to the large number of points below the
95% confidence band on the fitted line and in the lower right quadrant show-
ing that there is a proportion of the treatment effect on a poor outcome that
is not captured by the month 2 culture result show that, on the basis of this
analysis of these data, the month 2 culture result cannot be used as a surrogate
marker.
The points in the lower right quadrant could be explained by causal path-
ways of the disease that bypass the surrogate, but are acted on by the treat-
ments in these comparisons.
6.4.7.2.3 Month 3 These data suggest that a larger proportion of the treat-
ment effect is captured by the month 3 culture than by either a heavily positive
culture at month 1 or a positive culture at month 2. While there is little guid-
ance on what constitutes a good surrogate marker, Burzykowski et al. (2005)
identify a surrogate for which Rfrial = 0.692 (resulting from a slightly different
analysis to that presented here) as a "moderate" surrogate endpoint. While R2
is 0.69, there are points that do not lie near to the line, particularly the group-
ing around both the vertical and the horizontal axes close to the origin.
Therefore, on this analysis of these data, the month 3 culture result could be
considered to be a possible surrogate marker, but it is far from perfect.
Looking at figure 6.3(c) on page 173, it is clear that a large treatment effect
on a the 3 month culture result does not necessarily correspond to a large
treatment effect on a poor outcome. Similarly, a small treatment effect on the
3 month culture result does not necessarily correspond to a small treatment
effect on a poor outcome, although this is usually the case. There is far from
sufficient precision, therefore, to predict the treatment effect on a poor out-
come based solely on the treatment effect on the 3 month culture result and
therefore cannot be used strictly as a surrogate endpoint in a phase III trial as
a substitute for the final endpoint of treatment outcome.
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6.4.7.2.4 Adjusting for baseline covariates In section 6.4.5, baseline covari-
ates were included in the models in stage I to give treatment effects adjusted
by important risk factors taken forward to stage II. Adjusting for baseline risk
factors did marginally increase the spread in the horizontal direction suggest-
ing that the culture results adjusted for these risk factors did discriminate
better between regimens. Nevertheless, the fit of the line does not improve.
The most important risk factor found by Davies et aJ. (2006a) in evaluating
aspects of the SSCC profile as surrogate markers was HIV status which is not
available in these data as the trials were conducted in the pre-HIV era. What
the results in this chapter have shown is that adjusting for baseline risk factors
other than HIV status (and rifampicin resistance, another covariate commonly
found to be an important risk factor) do not result in any of these three candi-
date markers being shown to be better surrogate markers. Further discussion
will therefore consider the unadjusted rather than the adjusted analysis.
6.4.7.2.5 Subgroup Analyses In East African trials, the month 3 culture
was a better surrogate than the month 2 culture, but in Hong Kong trials the
month 2 culture was found to be superior to the month 3 culture. For both
of these markers (the 3 month culture in East African trials and the 2 month
culture in Hong Kong trials), the fit was better than in the analysis on the
complete data (R2 = 0.81 and R2 = 0.89 respectively compared to R2 = 0.69
and R2 = 0.36 respectively).
There are two possible reasons for this discrepancy: differences in culture
conversion rates and the proportion of rifampicin-containing regimens.
Table A.l on page 248 shows the proportion of participants that are culture
positive at each monthly, separated by geographical region. Culture conver-
sion tends to be later in East African trials (29% culture positive at month 2
and 10% still culture positive at month 3) than in the Hong Kong trials (15%
culture positive at month 2 and only 4% still culture positive at month 3). This
could be the reason why the 3 month culture is a superior surrogate marker
in East African trials and the 2 month culture is superior in Hong Kong tri-
als. This suggests that a marker reflecting the time-to-conversion or a marker
resulting from longitudinal modelling on culture results during treatment (re-
quiring more timepoints than available in these data) could be a more useful
surrogate.
In only rifampicin containing regimens, the month 2 culture was found
to be a better surrogate than the 3 month culture. One of the difficulties in
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interpreting these results is the relationship, in these data, between the region
that the trial was conducted and the regimens included in the trials. Partly
because the East African trials were earlier in time than the Hong Kong and
Singapore trials, and partly that the trials in Hong Kong and Singapore were
less restricted by the high cost of rifampicin, trials in East Asia evaluated
treatment arms that contained rifampicin throughout more often that trials in
East Africa. These studies in East Asia also concentrated more on intermittent
regimens which were more easily supervised and therefore more likely to be
effective in the urban settings of Hong Kong and Singapore (Fox et al., 1999).
The subset of treatment comparisons from trials conducted in East Asia is
therefore almost the same as the subset of treatment comparisons for which
both regimens contained both isoniazid and rifampicin for six months and
also the subset of treatment comparisons for which both regimens involved
daily dosing throughout (see Table 6.9).
Geographical Isoniazid- Rifampicin- Daily
TotalRegion containing containing Regimens
East Africa 16 (100%) 1 (6%) 14 (88%) 16
Hong Kong 15 (100%) 11 (73%) 0(0%) 15
Singapore 6 (100%) 6 (100%) 1 (17%) 6
Total I 37 (100%) I 18 (49%) I 15 (41%) I 37
Table 6.9: Number of treatment comparisons tabulated by geographical re-
gion and details of regimens in comparison. For each column, a treatment
comparison was included if both regimens in the comparison met the criteria.
Rifampicin and isoniazid are vital for the treatment of tuberculosis and
therefore it is not surprising that there might be differences in the relationship
between culture results during treatment and treatment outcome. It is likely
therefore that the differences between the 2 and the 3 month culture results
as surrogates between East Africa and Hong Kong might be due in part to
whether the regimens contained rifampicin.
6.4.7.2.6 Singapore The single treatment comparison from the first Singa-
pore trial was not included in any analysis (see 6.1.2). This was because the
first two months of treatment were exactly the same in both regimens meaning
that it could not be used for evaluating either the month 1 or month 2 culture
result as a surrogate marker for poor outcome. There were too few positive
cultures at month 3 to estimate the treatment effect on culture positivity at
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month 3 and therefore this comparison was not included in the evaluation of
the month 3 culture result. Therefore, comparisons from only one trial con-
ducted in Singapore, the third Singapore trial, were included in these analyses.
It is clear from Figure 6.6 on page 182 that none of the three candidate mark-
ers of culture results at months 1,2 or 3 could be used as surrogate markers
on the basis of data from this Singapore trial. While there are clear differences
between rates of poor outcome on the regimens in this trial, these differences
are not consistently reflected in cultures results as the points on this graph
are spread either side of the vertical axis. These results are from four or five
comparisons from one trial, and therefore the data are too few to draw any
strong conclusions from these data, although it would be expected that the
results would be similar to those in the Hong Kong studies.
This trial was unique among the twelve trials included in these analyses in
three of the six arms included a combined tablet of isoniazid, rifampicin and
pyrazinamide to compare patient acceptability, occurrence of adverse effects
and efficacy with the same combination given as separate tablets (Singapore
Tuberculosis Service/British Medical Research Council, 1991). In all other tri-
als used in these analyses, drugs given in combination were given as separate
tablets (excepting some patients in the fourth Hong Kong study, see section
4.1.1.3.1). It had been previously shown that the bioavailability of the three
drugs in this combination was satisfactory (Ellard et al., 1986). It appears
therefore, that a combined tablet has modes of action on the true endpoint
(poor outcome) that is not captured by the surrogate marker (culture results
during treatment) compared to a combination of the same drugs given sepa-
rately. The results of the United States Public Health Service study 21 support
this; a combined formulation was associated with a sputum conversion rate
more rapid than the separate formulation, but with a similar low recurrence
rate (Combs et al., 1990).
Whatever the reason, it appears that the use of a combined formulation
might alter that relationship between culture results and poor outcome, though
these results are based on one trial and are therefore inconclusive. This fact
should be considered in future surrogate marker studies in the treatment of
TB. Itwould be of particular interest to repeat these analyses on data from the
multi-centre trial currently being conducted by the IUATLD (Study C, prelim-
inary results recently presented at the IUATLD annual conference in October
2008 (Lienhardt et al., 2008)) comparing a combined formulation with a regi-
men of drugs given separately in sites in Africa, Asia and South America.
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6.5 Comparison with Recent Trial Data
6.5.1 Introduction
As described in Chapter 4, all the data used for the analyses in this and pre-
vious chapters are from MRC trials conducted in East Africa and East Asia
in the 1970s and 1980s, with the last trial starting enrolment in 1983. If one
of the candidate markers evaluated in this thesis is accepted as a surrogate,
it will be used in future trials that will be conducted nearly thirty years after
the collection of the data on which the surrogate was evaluated. The advent
of HIV and the spread of MDR-TB are the known changes in the TB epidemic
that have occurred in this period, but it is likely that there will have been other
unknown biological or pathogenic changes occurring.
For this reason, the possibility of additional clinical trial data was explored
to determine whether the performance of the surrogate was different in recent
trial data compared to the older data. Following the closure of the MRC TB
units in 1986, very few large phase III clinical trials have been conducted that
had outcome to treatment after a period of at least twelve months of follow-up
as the clinical endpoint. However, data was provided by the CDC TB Trials
Consortium (TBTC) from Study 22 and by the International Union Against TB
and Lung Disease (IUATLD) clinical trials team from Study A for use in this
thesis.
6.5.2 Description of the Trial Data
6.5.2.1 US Public Health Study 22
The 22nd TB study conducted by the US Department of Public Health (leading
to the formation of the CDC TBTrials Consortium (TBTC»)was a multi-centre,
open-label, randomised controlled trial comparing rifapentine and isoniazid
given once-weekly and rifampicin isoniazid given twice-weekly during the
continuation phase (Benator et al., 2002). Patients with pulmonary TB who
had completed two months of the intensive phase of the standard regimen
were enrolled in the USA and Canada and randomly allocated to one of two
treatment arms and assessed for failure during treatment and for bacteriolog-
ical evidence of relapse every three months for twenty-four months following
the end of treatment.
Itwas a requirement that all patients had had isoniazid, rifampicin, pyraz-
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inamide and either streptomycin or ethambutol in the two-month intensive
phase. The first two weeks of the intensive phase was given daily and then
daily, twice-weekly or thrice-weekly thereafter. All patients effectively had the
same intensive phase (with only slight variations) and the treatment differed
only in the continuation phase.
Between April 1995 and November 1998, 1004 HIV-negative patients were
enrolled, of whom 502 were allocated to the once-weekly regimen and 502
allocated to the twice-weekly regimen. Follow-up for the last patients was
completed in March, 2001. 71 HIV-positive patients were also enrolled and
analysed separately (Vernon et al., 1999).
Most of the cultures were done on liquid media, with the remainder being
done on solid media. A positive culture result at two months, for example, is
an indication that the patient had a positive culture either on liquid media or
on solid media. Relapse and treatment failure were established on a positive
culture on either solid or liquid media.
Unfortunately, since the study sites with in the USA and Canada where
the rates of HIV are low, the number of HIV-positive patients in this study
was small, only 71 (7%). Nevertheless, patients with HIV were included in
the analysis. No trial participants had pretreatment rifampicin resistance and
therefore there were no cases of MDR-TB. 497 patients allocated to isoniazid
and rifapentine daily and 494 allocated to isoniazid and rifampicin twice-
weekly in the continuation phase were included for the analysis (after ex-
cluding 31 with only three drugs in the intensive phase and 53 with extra-
pulmonary TB).
6.5.2.2 IUATLD Study A
The first TB study conducted by the International Union against TB and Lung
Disease (IUATLD) was an open-label, randomised controlled clinical trial con-
ducted in sites across Africa and Asia. Patients were allocated to either (i)
the standard six month regimen, 2EHRZ /4HR; (ii) the WHO-recommended
eight month regimen without rifampicin in the continuation phase, 2EHRZ
/6HE; or (iii) the same regimen with the intensive phase given thrice-weekly,
2(EHRZh /6HE. Patients were assessed at the end of treatment and sputum
samples taken at 3, 6 and 12 months after the end of treatment to assess out-
come of treatment.
Between March, 1998 and December, 2001, 1335 patients were randomised
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to one of the three treatment regimens. 466 patients allocated to 2(EHRZh
/6HE, 456 allocated to 2EHRZ /6HE and 433 allocated to the control regimen
2EHRZ /4HR were included in the analysis. This included 127 (10%) who
were HIV positive and 25 (1.9%) with rifampicin resistance, of which 20 (1.5%)
also had isoniazid resistance and were therefore cases of MDR-TB.
6.5.3 Methods
The meta-analysis described in section 6.4.3 was repeated including these data
from Study 22 (one treatment comparison) and Study A (two treatment com-
parisons). Following the principles described in section 6.1.1, the regimen
with the least efficacy, that with the highest proportion of poor outcomes, was
identified as the 'control' regimen. This was the once-weekly rifapentine arm
in Study 22 and the eight-month thrice-weekly regimen in Study A.
In Study A, sputum samples were only taken at two months after the start
of treatment and therefore only the two month culture is available in these
data to evaluate as a surrogate marker. The third regimen had a different
intensive phase (EHRZ was given thrice weekly) and was therefore selected
as the control. This was so that the two regimens denoted as experimental had
the first two months of treatment different to the control.
In Study 22, only the three month culture will be evaluated as a surrogate
marker. Sputum samples were not taken at one month during treatment and
therefore only the two month and the three month cultures are available in
these data to evaluate as surrogate markers. Since Study 22 was designed
to compare two regimens with different continuation phases, patients were
enrolled after they had completed effectively the same intensive phase of the
standard regimen. The 2 month culture result could not therefore capture any
treatment difference in poor outcome and cannot therefore be a surrogate in
this treatment comparison.
Therefore, the data from Study A can be included with the rest of the data
used in this thesis and the meta-analysis repeated to evaluate the two month
culture result as a surrogate marker, and the data from Study 22 can be included
with the rest of the data used in this thesis and the meta-analysis repeated to
evaluate to three month culture result as a surrogate marker.
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Treatment
Trial
(-0.77,0.15)(-0.96, -0.26)
(-0.71, -0.03) (-1.68, -0.54)
(-0.80,0.60) (-0.77, -0.05)
Table 6.10: Results of stage I of the meta-analysis for the data from Study
A and Study 22 evaluating the month 2 and the month 3 culture results as
surrogates.
6.5.4 Results
Table 6.10 shows the log odds ratios of poor outcome, ~ij'with 95% confidence
intervals and log odds ratios of 2 or 3 month culture results, lXii' with 95%
confidence intervals for the treatment comparisons from Study A and Study
22. These are plotted together with the results from the rest of the data (section
6.4.4) to explore how the strength of the 2 month and the 3 month culture
results as surrogate markers changes after the inclusion of more recent data.
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Figure 6.9: Log odds ratio of a poor outcome plotted against log
odds ratio of a two month positive culture result. The triangles
correspond to the two treatment comparisons from Study A.
Figure 6.9 shows the plot of the data evaluating the 2 month culture as
a surrogate marker with the points representing the treatment comparisons
from Study A plotted as triangles, and Figure 6.10 on the following page the
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Figure 6.10: Log odds ratio of a poor outcome plotted against log
odds ratio of a three month positive culture result. The triangle
corresponds to the treatment comparison from Study 22.
plot of the data evaluating the 3 month culture as a surrogate marker with
the point representing the treatment comparison from Study 22 plotted as a
triangle.
Number of I Number Estimatedl
Marker Comparisons of Trials I Slope,1<. 95% Cl R2
Month 2 35 I 10 0.87
I (0.24,1.51) 0.37
Month3 I 36 I 12 l 1.29 I (0.83,1.76) 0.69
Table 6.11: Results of stage II of this analysis for each of the three candidate
surrogate markers, restricted to those treatment comparisons with both isoni-
azid and rifampicin given throughout both regimens in the comparison. lXij is
the log odds ratio of a positive culture result and (3ij is the log odds ratio of a
poor outcome.
Table 6.11 shows the slope with 95% confidence interval and proportion of
variation explained, R2, for the fitted line in each graph. Comparing table 6.11
with table 6.5 on page 174, the slopes and the proportion of explained vari-
ation remain largely unchanged. The two points representing the treatment
comparisons from Study A in figure 6.9 and the point representing the treat-
ment comparison from Study 22 in figure 6.10 are largely concordant with the
rest of the data and lie close to the line. This is reflected as the proportions of
explained variation in table 6.11 are unchanged from that reported in 6.5.
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6.5.5 Discussion
Unfortunately very little clinical trial data are available from the last ten years.
Only two treatment comparisons from one trial were available to evaluate the
two month culture result as a surrogate marker and one treatment comparison
from a second trial was available to evaluate the three month culture result as
a surrogate marker. This is one difficulty in the evaluation of surrogate mark-
ers for poor outcome to treatment for TB, that most of the data available is
thirty years old or more. Work is currently being undertaken to produce stan-
dards for TB clinical trial data with the aim to promote sharing of data from
future clinical trials 1. Nevertheless, the two month culture result comparison
in the two treatment comparisons from Study A and the three month culture
result comparison in the single treatment comparison from Study 22 were not
inconsistent with the results from the historical data. The treatment effect on
the culture result and the treatment effect on poor outcome were in the same
direction for all three treatment comparisons and the plotted points lay close
to the fitted lines.
Unlike the main data used in the analyses in this thesis, a small number
of patients with HIV or pretreatment rifampicin resistance were included in
these recent data. It is encouraging that, even with these patient included in
the analysis, the results were comparable with those from historical data, al-
though numbers were too small to explore how HIV and rifampicin resistance
affect the use of monthly culture results as surrogate markers.
In Study 22, a positive culture at month 3 was defined as a positive culture
on either solid or liquid media, unlike culture result in all other studies which
were on solid media only. Despite this difference, these results from Study 22
were not inconsistent with those from the rest of the data.
6.6 Discussion and Conclusion
6.6.1 Summary
In Chapter 5, culture results at each of months I, 2, 3 and 4 were evaluated
as prognostic markers for poor outcome, exploring the effect of varying the
point of dichotomy. Three markers, the two month culture result, the one
lCDISC Cardiovascular and Tuberculosis Data Standards http://www.cdisc.org /stan-
dards/cardio/index.html Retrieved 23 Apr 2009.
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month culture result dichotomised at 20+ and the three month culture result,
were then selected for evaluation as surrogate markers with results presented
in this chapter.
Prentice laid the framework for surrogate marker evaluation in 1989 with
his criteria (Prentice, 1989), an article that has since received nearly 500 cita-
tions to date-. It was shown in Chapter 5 that all of culture results at months
1, 2, 3 or 4 whatever the point of dichotomy were strongly associated with
poor outcome (Figure 5.2 on page 136). It was subsequently shown in section
6.2 that, in the majority of treatment comparisons, each of the markers failed
to satisfy the Prentice criteria. Of 13 treatment comparisons where the treat-
ment had a statistically significant effect on poor outcome, the three month
culture result did not satisfy the Prentice criteria in any. Similarly, of 12 treat-
ment comparisons where the treatment had a statistically significant effect on
poor outcome, the one month culture (dichotomised at 20+) did not satisfy
the Prentice criteria in 11 (88%) and the two month culture did not satisfy the
Prentice criteria in 9 (75%). None of the three markers satisfied the Prentice
criteria in all treatment comparisons and therefore, on the basis of the Pren-
tice criteria, none of these three markers can be considered to be surrogate
markers.
The use of hypothesis testing in the Prentice criteria does mean that only
failed surrogates can be identified; there is no framework for accepting a true
surrogate (as failure to reject the null hypothesis could be due to insufficient
information rather than it necessarily being correct). One way to incorpo-
rate this would be to use the approach developed for equivalence trials. The
treatment effect could be shown to be fully captured by the surrogate when
the 95% confidence interval of the treatment effect on the true endpoint ad-
justed for the surrogate endpoint lies completely within the interval (-0, +0)
for some sufficiently small 8. This could be included as an additional step
if the Prentice criteria have been verified to determine whether the informa-
tion available is sufficient to determine surrogacy or whether more data is
required.
In section 6.3, single trial measures developed to estimate the proportion
of treatment effect explained by the surrogate were used to evaluate the three
candidate markers as surrogates. There was great variation between treatment
comparisons with point estimates lying outside of the interval [0,1] and wide
2Thomson Reuters 151Web of Knowledge http://www.isiwebofknowledge.com Retrieved 23
Apr 2009.
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confidence intervals sometimes containing the whole interval [0,1]. It is diffi-
cult to draw any conclusions from these results which expose the deficiencies
in the methods rather than possible deficiencies in the markers.
In section 6.4 a two stage meta-analytic approach was developed to evalu-
ate each of the three candidate markers as surrogates for poor outcome. It is
clear from the literature review in Chapter 2 than meta-analytic methods are
superior to single trial methods as the surrogate marker is evaluated across
a variety of treatment comparisons rather than just one. The methods devel-
oped produce a useful graphical visualisation of the results that help demon-
strate the performance of the surrogate in a clearly accessible way. These
meta-analytic methods were applied to the data to determine the relationship
between the treatment effect on the candidate surrogate endpoints and the
treatment effect on poor outcome. There were clear differences between tri-
als conducted in Hong Kong and trials conducted in East Africa. The two
month culture result was a superior surrogate in Hong Kong trials and the
three month culture was superior in East African trials. The results from
Hong Kong trials were similar to those from treatment comparisons of regi-
mens both containing rifampicin making it difficult to separate the effect of
geographical region from the effect of rifampicin.
Data from two recent TB clinical trials were included with these data and
the results presented in section 6.5. With only two additional treatment com-
parisons for evaluating the two month culture result as a surrogate and one
for evaluating the three month culture result as a surrogate, the results were
not inconsistent with those using only the older trials.
6.6.2 Conclusions
International guidelines covering Statistical Principles for Clinical Trials state
that 'the strength of the evidence for surrogacy depends upon (i) the biolog-
ical plausibility of the relationship, (ii) the demonstration in epidemiological
studies of the prognostic value of the surrogate for the clinical outcome and
(iii) evidence from clinical trials that treatment effects on the surrogate cor-
respond to effects on the clinical outcome' (International Conference on Har-
monisation of Technical Requirements for Registration of Pharmaceuticals For
Human Use, 1998).
Culture results directly reflect the number of causative bacilli in a patient's
sputum which in turn reflects the bacillary load in the patient's lung. There-
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fore, there is good biological plausibility that culture results during treatment
are likely to be useful surrogates for poor outcome to treatment.
The data used in this thesis have showed that culture results are not useful
markers for predicting outcome for individual patients, but there is a good
association with poor outcome at the population level. Using the Prentice
criteria for evaluating the culture results at 1, 2 or 3 months did not give en-
couraging results, although some recent authors have been giving less weight
to the criteria (e.g. Burzykowski, 2008).
The results from the meta-analysis, on the other hand, are more encour-
aging. In the East African trials, the month 3 culture result was shown to be
a good surrogate (R2 = 0.81), in the Hong Kong trials, the month 2 culture
result was shown to be a good surrogate (R2 = 0.86). It is likely that this
discrepancy is due either to the higher proportion of rifampicin-containing
comparisons in the Hong Kong trials or to the delayed culture conversion
rates in the East African trials.
The quality of the surrogate can be seen from the graphical representation
of the results. The methods used to calculate the fitted line and the proportion
of explained variation, R2, have several drawbacks which will be discussed
and explored in the next chapter.
Further discussion of these results and areas for future research are found
in Chapter 8.
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Chapter 7
An Extension of the
Two-Stage Modelling
Approach
7.1 Introduction
In Chapter 6, three candidate markers, the culture result at month 1 di-
chotomised at 20+, the month 2 culture and the month 3 culture, were evalu-
ated as surrogate markers. As well as testing the Prentice criteria and calcu-
lating single trial measures, the main part of the analysis was devoted to the
two-stage meta-analytic analysis based loosely on the HIV paradigm (section
6.4). The results of these analyses showed the month 2 culture to be supe-
rior to the month 3 culture in Hong Kong studies, with the reverse true in
East African studies. These analyses were straightforward to perform with
no complicated modelling required beyond logistic regression and weighted
linear regression with robust standard errors. Nevertheless, there were two
obvious methodological deficiencies.
Firstly, it was assumed that the treatment effect on the surrogate endpoint,
Itij' was measured without error in the second stage of the analysis, whereas
only the estimate, iXij' is available. This overly simplistic assumption leads
to two errors: (i) attenuation bias and (ii) over-estimating the precision of the
estimates of the slope parameter, K (Carroll and Stefanski, 1995). Therefore,
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ignoring the variation in the explanatory variable (&ij) causes attenuation of
the estimate of the slope towards zero and over-precise parameter estimates.
Secondly, robust standard errors were used to correct for clustering within
trial which is a more straightforward technique to use, but is a 'cruder' ap-
proach than using a random effects model. This robust standard errors ap-
proach for correcting for clustering only adjusts the standard errors of the
parameters, the point estimates themselves are not adjusted for the clustering.
A random effects model will give point estimates of the parameters, as well as
the standard errors of these parameters, that better account for the hierarchical
structure, and it is therefore a preferable approach, although the alternative
may be considered to be sufficient when the between trial correlation is not of
interest (as is the case in these data).
The Belgian paradigm (see section 6.4.1) does account for the error in esti-
mating both the treatment effect on the true endpoint as well as the treatment
effect on the surrogate endpoint. However, those authors involved in the
development of the Belgian paradigm used a simpler situation of two arm
studies and have not considered the case of multi-arm trials with multiple
treatment comparisons within a trial. Therefore these methods have not yet
been extended to account for the clustering of treatment comparisons within
trials (this is an area of future research for the group based at the Center for
Statistics, Universiteit Hasselt, Diepenbeek, Belgiuml ). It is also the case that
these methods were developed for Gaussian true and surrogate endpoints. For
binary or categorical true or surrogate endpoints, the methods are not straight-
forward and there are sometimes reported problems with convergence.
In this chapter, the meta-analytic methods used in Chapter 6 will be ex-
tended in an attempt to overcome these problems, combining some ideas from
the Belgian paradigm.
In section 7.2 the model used in Chapter 6 is developed, introducing a
simplification of the Belgian paradigm proposed by Tibaldi et al. (2003) and
extending this to non-normal true and surrogate endpoints and to multi-arm
trials. The properties of two new approaches are explored using a simulation
study and compared with that used in Chapter 6 in section 7.3. These are
then applied to the trial data in section 7.4 and the chapter concludes with
discussion in section 7.5.
1Personal communication from Professor Geert Molenberghs, Director of the Center for Statis-
tics at Hasselt University.
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7.2 Model Development
7.2.1 Stijnen's Approach
7.2.1.1 Model Detail
Within the Belgian paradigm, Tibaldi et al. (2003) note that even when both
the true and surrogate endpoints are normally distributed, the fitting of the
linear mixed models involved often turns out to be 'surprisingly difficult'.
They propose a number of simplifications along what they describe as three
dimensions-the trial, the endpoint and the measurement error dimensions.
The Trial Dimension relates to whether the effect of trial differences are
treated as fixed or random effects; the Endpoint Dimension relates to whether
the true and the surrogate endpoints are modelled jointly or separately (in a
manner similar to the HIV paradigm); and the Measurement Error Dimension
relates to how measurement error in the treatment effects is accounted for. It
is important to note that these authors are not considering multi-arm trials,
they only have two-arm trials in mind and therefore the problem of clustering
within a trial is not addressed.
Taking the case when the true and surrogate endpoints (represented by
T and 5 respectively) are modelled separately and therefore mixed effects
are unnecessary (thus determining the trial and the endpoint dimension) the
following models are used in the first stage:
5ik = ~i + (XiZik + ES,k
Tik = Vi + f3iZik + ET,k'
(7.1)
(7.2)
where ~i and Vi, are the trial-specific intercepts and (Xi and f3i the slope (treat-
ment effect) parameters, i denotes the trial and k denotes the trial participant
using notation consistent within this thesis. ESik and Erik are the residual error
terms assumed to be independent. In the second stage, the authors fit the
following model:
(7.3)
The authors include the estimate of the intercept Pi in this model at the second
stage. It is not clear that the estimate of the mean of the surrogate in the
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control regimen ({ii) can contribute information to predict the treatment effect
on the true endpoint, but the authors have chosen to carry this term forward
into this second stage. Ao and A2 are therefore similar to r5 and K defined in
section 6.4.3, adjusted for the mean of the surrogate in the control regimen.
The authors suggest three choices for the measurement error dimension:
1. Fit the simple linear model assuming all of the error terms, e., are in-
dependent and identically distributed with equal variance (T2. This ig-
nores the fact that &.i and ~; are only estimates of It; and f3; and will
be estimated with precision varying with i (depending on trial size and
distributions of 5 and T in each trial). This is therefore an unsatisfactory
approach.
2. Fit the linear model using weighted regression, weighting each obser-
vation according to trial size. This is similar to the approach developed
in section 6.4.3 above, except that the weights were the precision of the
estimates defined as the inverse of the mean of the variances of &;j and
~ij' rather than trial size. It is the more precise estimates of It; and f3; that
should carry more weight in this regression in the second stage, and this
precision does not necessarily correspond to trial size. Either way, this
approach will account for some of the heterogeneity of variation, but not
all since &.; are (falsely) assumed to be exact estimates of It;.
3. The authors introduce a third approach which overcomes the problems
of the other two, and refer to this as Stijnen's Approach, which is de-
scribed below.
From stage I, the following is assumed to be true:
(7.4)
that is Pi, &.i and ~; are estimates of 1';, It; and f3; respectively where C, is
the covariance matrix of the estimates. If eSik and erik are assumed to be
independent the matrix C; will be diagonal. This approach also allows for Tik
and 5;k to be modelled jointly in which case C; will not be diagonal.
Stage II differs from the second approach to measurement error above with
the addition of an intermediate step. A further assumption is that each trial-
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specific parameter is a trial-specific realization of what the authors call true
overall treatment effects:
(7.5)
where L. is the covariance matrix of the trial-specific parameters as estimates
of the true treatment effects.
The resulting model is then:
(7.6)
The advantage of Stijnen's approach is that the covariance matrices C, can
be estimated in the first stage, and held fixed in the second stage, while the
true underlying values fl' «, and f3 with the covariance matrix r. are estimated
while the variation in the estimates Pi, itj and ~i about the trial-specific pa-
rameter values flj, «, and f3i is properly accounted for.
This then is an important simplification of the Belgian Paradigm, and is not
restricted to normal true and surrogate endpoints, as long as the estimates of
the treatment effects on the true and surrogate endpoints can be assumed to
follow normal distributions.
7.2.1.2 Multi-Arm Extension
One obvious drawback of using Stijnen's Approach for the data used in this
thesis is that it is assumed that treatment comparisons are independent, that
is, each trial was only evaluating one experimental treatment. In the data used
in this thesis, many of the trials are multi-arm introducing a second level in
the data hierarchy, and the subscript i. yielding it ij and ~ij as estimates of the
treatment effect comparing treatment j with the control regimen (treatment 0)
on the surrogate and true endpoints respectively (see section 6.4.3).
An additional intermediate step can then be introduced in the second
stage. The approach described here is an extension of the methods introduced
in Tibaldi et al. (2003). Pij is not considered in this extension.
Let the following be true:
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(7.7)
Parameter estimates are assumed to be estimates of the treatment-comparison-
specific parameters rather than the trial-specific parameters with covariance
matrix Cjj' Then:
(7.8)
the treatment-comparison-specific parameters are assumed to be realizations
of the trial-specific parameters with covariance matrix D, which in turn are
assumed to be realizations of the true underlying parameters:
(7.9)
Overall, this is:
( ~~ ) ~ N ( ( ; ) ,Cjj + o, + E) . (7.10)
E can be estimated along with the parameters It and f3 holding both Cjj, as the
within-trial (between-treatment comparison) variation and D, as the between-
trial variation, fixed. Both Cjj and D, have been estimated in the previous
stage.
7.2.1.3 Discussion
The extension described above takes into account the clustering of treatment
comparisons within trial while keeping the advantages of Stijnen's Approach
over the other two approaches described above.
The only drawback is the assumption that there exists true overall treatment
effects. That is, there exists a true treatment effect on the surrogate endpoint,
«, of which each trial-specific treatment effect, (tj, is an estimate and a true
treatment effect on the true endpoint, f3, of which each trial-specific treatment
effect, f3j, is an estimate. This assumption may be valid when the experimental
and the control treatments are the same for each trial i, but is not true when
the treatment effects are from treatment comparisons comparing different ex-
perimental treatments with different control treatments, as is the case in the
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data used for this thesis. In these data, it cannot be correct that there is an un-
derlying It and f3, but rather that there is an underlying relationship between
tti and f3i (if the marker in question is in fact a surrogate marker). On this ba-
sis, the underlying assumption is also invalidated on extending multiple arms
which is perhaps why the authors themselves did not consider this extension.
A different approach is therefore needed.
7.2.2 Alternatives to Stijnen's Approach
7.2.2.1 Introduction
It is clear that the meta-analytic approach used in Chapter 6 above did not
fully account for all the variation or the heterogeneity in the estimates of the
treatment effect, although the weighted linear regression with robust standard
errors is a definite improvement over simple linear regression assuming equal
variances. There is a real advantage in being able to use a method such as lin-
ear regression; it is available in all statistical packages, is conceptually straight-
forward to understand with a meaningful proportion of explained variation,
and can be used and the results can be interpreted easily by non-statisticians
such as clinicians and researchers. The key question is therefore: how much
bias is introduced in using the simplified model described in Chapter 6? If the
bias introduced is minimal, then the results described in Chapter 6 are reli-
able and the methods can reasonably be used to evaluate surrogate markers
for response to treatment for tuberculosis.
Different elements of the HIV paradigm and Stijnen's approach in the Bel-
gian paradigm are useful for evaluating surrogate markers in the context of
data arising from studies evaluated in this thesis. Several different methods,
incorporating these elements, will therefore be proposed in this chapter that
deal with the heterogeneity of variances and the error in the estimates of the
treatment effects. In the next section, each of these methods will be compared
using a simulation study.
7.2.2.2 Model Detail
Stage I is common in all these methods proposed below and is identical to that
described in section 6.4.3. This yields the estimates (tij and ~ij and variances
of these estimates, CT;jj = Var(&ij) and CT~jj = Var(~ij)' which are themselves
estimated from the models. This follows the HIV paradigm as well as Stij-
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nen's approach outlined above. The differences between the methods is the
approach taken in Stage II. As a reminder, K is the parameter describing the
slope of the regression of ~ij on aij' T2 is the residual variance (the variance
of ~ij conditional on &ij) and R2 is the proportion of variation in ~ij explained
by &ij' There are a number of different options:
1. Simple linear regression. This is the simplest approach, but also the ap-
proach which makes the most false assumptions. The varying precision
and clustering within trials of the estimates is not accounted for and this
method will therefore be discounted.
2. Weighted linear regression with robust standard errors. This is the approach
outlined in Chapter 6. This is straightforward to implement, is quick
to run and is an extension of linear regression that can be understood
easily. As described in section 7.1, there are two drawbacks with this:
the error in estimating /Xij is ignored, and only the standard errors of the
parameters, not the parameters themselves, are adjusted for the cluster-
ing within trial. While this is a simple method to use and will therefore
be the first method evaluated in the simulation study, these drawbacks
may affect the results and therefore other approaches must be explored.
This is described as Method 1.
3. Weighted linear regression with correction for attenuation bias. Carroll and
Stefanski (1995) give a simple form of regression calibration for correct-
ing for attenuation bias in the presence of measurement error in the ex-
planatory variable. They assume classical additive measurement error model
where w = x+ u is observed rather than the true explanatory variable x
and u is independent of x, has u '" N(O,O'a). The ordinary least squares
estimator f3w from the regression of y on w is not a consistent estimate of
f3x, the estimator from the regression of y on x, resulting in attenuation
bias. It can be shown that f3w = Arf3x. The exact form of Ar is derived in
Appendix B for the case of regression of y on w with no intercept (A; in
equation B.26 on page 258):
2 + -2A' = O'x X
r 0'; + O'~ + f2 < 1, (7.11)
where x has mean f and variance 0';. A; is called the attenuating factor
or the Reliability Ratio. The simple method for correcting for attenuation
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proposed by these authors involves estimating this factor and scaling
the estimate f3w to yield a more accurate estimate of f3x. Given, cr~,
an estimate of O'~ derived from elsewhere, The reliability ratio can be
estimated by:
A o-.2-cr2+w2A - w u
r - cr~ + w2 '
where cr~ is the sample variance of wand w is the sample mean.
In the problem specific to this thesis, Otij is estimated with error by &.i}
where the classical additive measurement error model is assumed with
known variance O'~ = O';jj = Var(&'ij)' Rather than a single error variance
describing the error in &.ij for all j and j, the variance is different for
each observation. The mean will be used in the reliability ratio. The
(7.12)
regression calibration estimate of K, RRC is therefore:
(7.13)
where Rnaive is the naive estimate of K from the weighted linear regres-
sion model and where:
-2- _ [i,j O';ii
O'IJI.. -.. '
" t......imi
.- Ei,j &.ij
Ot" ---'I - ... m,
t......1 I
(7.14)
(7.15)
and where Varij (&ij) is the variance in &ij across i and j in contrast to 0';,/
which is the variance in &ij for a specific i and j:
Vard &'i) = _1_ " .. [(&i' .__ E"j &.ij ) 2].}} .. m. i..J1,1 I ... m·
t......1 I t......1 I
(7.16)
This approach does not adjust the estimates of the variance in R or the
estimates of T2, but the same attenuation factor can be used to adjust
R2 (see Appendix B). This will be included as the second method in the
simulation study. This is described as Method 2.
4. Random effects model. A random effects model better deals with the clus-
tering of treatment comparisons within trial than merely using robust
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estimates of the standard errors, as the estimates themselves are also ad-
justed for the clustering. However, this model assumes that Ai} and {3i}
are estimated without error and therefore does not account for the dif-
fering precisions of the estimates. The trials are of varying sizes and have
different recurrence rates depending on the treatment regimens being
compared as well as a number of other trial-specific factors. Therefore
the precisions of the estimates of the treatment effects will differ greatly
and any model that does not take this into account is of limited value.
An application of the random effects model that incorporated weighting
by precisions of estimates would be advantageous, but such a method
was not accessible for use in this thesis and therefore this approach will
not be explored further.
5. SIMEX Algorithm. The SIMEX algorithm was first proposed by Cook
and Stefanski (1994) and is a method using SIMulation followed by
EXtrapolation to remove the attenuation bias caused by error in the
explanatory variables in a model. The implementation of the SIMEX
algorithm in this thesis is based on that described by Carroll and Ste-
fanski (1995). This is a method complementing regression calibration
described in point 3 above that is more computationally intensive. How-
ever, it is more suited to the problem at hand since in this implementa-
tion, it allows for the measurement error to vary by observation. The key
idea of SIMEX is to attempt to determine the effect of the measurement
error on the final model estimates of interest using simulations. The
SIMEX algorithm assumes the additive measurement error model where
IX" = A" + u" is observed rather than A" and where u" '" N(O (J'2 )'I 'I 'I IJ IJ' A" '
In the simulation step of the algorithm, additional independent measure-
ment errors with variance 'l(J'~ii are generated and added to each &;j.
The resulting dataset can be thought of as a contaminated dataset. This is
repeated with successively larger measurement error added to the data,
such that '1 < '2 < ... < 'm < Sm+l < .... For the mth dataset, the
measurement error variance for each data point is therefore assumed to
be (1+ 'm )(J':,. In the estimation step, estimates of the coefficient K are ob-
"tained in the usual way from each of the contaminated datasets. These
two steps are then repeated to yield a large number of contaminated
datasets and coefficients K for each 'm. The mean of the estimate of K
for each level of contamination can then be plotted against the level of
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contamination, ~m.
An illustration of this approach is shown in Figure 7.1. The estimates
of the coefficients derived from the contaminated simulated datasets are
plotted as solid circles and the naive estimate derived from the original
dataset, corresponding to ~m = 0, is plotted as a hollow circle. Extrapo-
lation of the line fitted to these points back to ~m = -1 yields the SIMEX
estimate, KSIMEX. If the measurement error variance for a data point is
(1 + ~m)cr;il then the measurement error variance at Cm = ·-1 should be
equal to (1 + -1)cr; = 0 and the SIMEX estimate, KS1MEX, should be an
unbiased estimator of the parameter, K, that would had been obtained
had the {Xjj been known exactly without error.
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Figure 7.1: An illustration of estimates deriving from the SIMEX
algorithm.
The same approach can be used to derive SIMEX estimates of T2 and R2.
As in point 3, this approach does not adjust the estimates of the variance
in R, but does correct for the attenuation bias in the estimate of K. This
will be included as the third method in the simulation study. This is
described as Method 3.
7.2.3 Summary
Stijnen's approach is a useful simplification of the Belgian paradigm, but is
not entirely suited to the application in this thesis. Three alternatives have
been proposed that will be compared using a simulation study:
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• Method 1. Weighted linear regression with robust standard errors as
used in Chapter 6 with no correction for attenuation bias,
• Method 2. Weighted linear regression with correction for attenuation
bias using the reliability ratio, and
• Method 3. The SIMEX algorithm with weighted linear regression to
remove the effect of measurement error on the final parameters.
7.3 Simulation Study
7.3.0.1 Objective
In a simulation study, data can be simulated assuming a variety of different
scenarios of known underlying distributional parameters. Statistical methods
that are being evaluated can be applied to the data and the estimates of the
parameters compared with the known true parameter values.
The objective of this simulation study was to compare the three methods
on how accurately they estimate model parameters, focusing on the slope pa-
rameter, !C, and the variance of the estimate of the treatment effect on the true
endpoint conditional on the estimate of the treatment effect on the surrogate
endpoint, T2.
7.3.1 Methods
Using the approach presented by (Burton et al., 2006), a simulation study was
designed and carried out to evaluate the three different approaches. Several
datasets were simulated under different assumptions in order to compare the
effect of the three methods on stronger and weaker surrogate endpoints. Each
method was applied to all datasets and the results compared using perfor-
mance measures of bias, accuracy and coverage.
7.3.1.1 Simulation data assumptions and inputs
Based on the discussion in section 7.2, it was assumed that there was an under-
lying intercept, 0, and slope, !C, that described the linear relationship between
the effect of treatment on the surrogate endpoint and the effect of treatment
on the true endpoint. Within each trial, there were assumed to be trial-specific
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parameters describing this relationship, 0 = 0i and K = x, which were sampled
from the following distribution:
G:) ~MVN (G), (~l )). (7.17)
Under this model, 0; and K; were assumed to be multivariate normal with
variances eT} and eT; respectively and correlation P6K' These three parameters
were held constant.
The structure and specific parameters values used to simulate the data was
motivated by the analysis of the data used in this thesis and, in particular,
the results from the analysis in Chapter 6, corresponding to method 1 to be
evaluated in this chapter.
The treatment effect on the surrogate endpoint ltij and on the true endpoint
{3ij for treatment comparison j in trial i were sampled from the following
distributions:
ltij ~ N (fllti' o;i) ,
{3ij ~ N (6; + Kilt;j, T2) .
(7.18)
(7.19)
Here, flit, and eT;, were trial specific parameters describing the effects of
the treatment on the surrogate endpoint in trial i. T2 is the variance of {3;j
conditional on ltij' To give a range of values of ltij and (3;j corresponding to
treatments of varying efficacy, the trial specific parameters, Illt, and eT;, were
sampled from the following distributions:
flit, ~ N (0.4,0.25) ,
In (o;i) ~ N ( -1.2, 0.04) .
(7.20)
(7.21 )
The distributions of these parameters were selected to yield values of ltij
that were similar to those calculated from the real data.
To mimic the real data, each simulated dataset contained data from twelve
trials each with a number of treatment arms ranging from 2 to 8 with around
100 individuals allocated to each treatment arm. The number of treatment
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arms in each trial, m., was sampled from the binomial distribution:
(mi - 2) '" Bi (n = 8,p = 0.25), (7.22)
defined in such a way that the minimum number was 2 (corresponding to one
treatment comparison), the median number was 4 (corresponding to three
treatment comparisons) and 50% of the trials had 3, 4 or 5 regimens with the
possibility of up to 10 regimens. Varying the number of treatment arms in
each trial better reflects the real data combined from multiple trials.
The number of individuals allocated to regimen j in trial i, nij, was sampled
from the normal distribution:
nij '" N (100,64), (7.23)
defined such that the mean number of individuals allocated to a single regi-
men was 100 with 99% of regimens having within 75 and 125 individuals.
True and surrogate responses (Tijk and Sijk respectively for individual k =
1, ... , nij allocated to regimen j = 0, ... m, in trial i = 1, ... ,12) were then
sampled independently from logistic distributions such that:
logit (P( Sijk = 1)) = Iti + ~ij'
logit (P(Tijk = 1)) = Vi + f3ij'
(7.24)
(7.25)
where ~iO = 0 and I3iO = O. The parameters ]Ii and Vi are sampled from the
following distributions:
]Ii '" N (1.4,1.21) ,
Vi '" N (1.7,0.49).
(7.26)
(7.27)
Parameter I Value(s) taken
K
0.05
0.83
0, 0.2, 0.5, 1.0, 1.5, 2.0
T" OJ, 0.3, 1.0, 2.0
Table 7.1: Values of parameters used to simulate the data. These values are
taken from the analysis of the real data in Chapter 6.
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All remaining parameters values in the distributions defined above were
estimated from the actual data so as to simulate data that represents real
data. Table 7.1 shows the parameter values used to simulate the data. These
estimates are based on the analysis presented in Chapter 6 evaluating the
culture result at 3 months as a surrogate marker. K and T2 were estimated
from the data to be 1.29 and 0.30 respectively, and were varied to simulate a
total of 24 different scenarios with surrogate markers of varying strength. The
value of o-g cannot be estimated from the data since 6 is constrained to be 0,
but was given the value 0.25.
7.3.1.2 Performance measures for evaluating different methods using sim-
ulation
Burton et a1. (2006) group measures for evaluating different methods using
simulation into three categories.
• Bias. The bias, B, is 'the deviation in an estimate from the true quantity'
(Burton et al., 2006) and is defined as follows for an estimator i of the
true quantity Xtrue:
1 Ns
B (i) = NLis - Xtrue,
5 s=1
(7.28)
where Ns simulations have been performed and is is the estimator of
x from the sth simulation dataset. When comparing the bias of a sta-
tistical method across scenarios where Xtrue varies, the percentage bias
(B('£) / Xtrue) or the standardised bias (B('£) / SE('£) can be a more useful
measures of bias where SE('£) is the empirical standard error of the esti-
mate of interest over all simulations.
• Accuracy. The mean squared error (MSE) is a useful measure of accuracy
of the estimate incorporating measures of bias and of variability:
MSE(i) = B('£) + (SE(i) f (7.29)
• Coverage. Since confidence intervals are commonly constructed to show
the precision of an estimator, it is important to assess coverage. The
coverage of a confidence interval is 'the proportion of times that the ob-
tained confidence interval contains the true specified parameter value'
(Burton et al., 2006), that is the proportion of times that the interval
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[xs - Z1-tt/2SE(Xs),xs + z1-II/2SE(xs)] contains Xtrue for s = 1, ... ,Ns,
where Z1-tt/2 is the 1 - a/2 percentile of the standard normal distribu-
tion, Z1-tt/2 = <1>-1(1- a/2), corresponding to the 100(1- a)% confi-
dence interval. Here SE(is) is the estimate of the standard error of is
from the sth simulated dataset. The coverage should be close to the level
of confidence interval in question. For example, the 95% confidence in-
tervals constructed should contain the true value in 95% of the simulated
datasets.
The authors suggest a possible criterion for assessing adequate cover-
age. The coverage should not lie outside of approximately two stan-
dard errors of (1 - a) where an approximate formula is SE(I - IX) =
Ja(I - a)/Ns. Table 7.2 shows the intervals within which an accept-
able coverage should lie for a number of different confidence intervals
calculated assuming 2000 simulations.
If the coverage is unacceptable, there are two possibilities: over-coverage
and under-coverage. 'Over-coverage, where the coverage rates are above
95 per cent [for a 95% confidence interval], suggests that the results are
too conservative as more simulations will not find a Significant result
when there is a true effect thus leading to a loss of statistical power
with too many type II errors. In contrast, under-coverage, where the
coverage rates are lower than 95 per cent, is unacceptable as it indicates
over-confidence in the estimates since more simulations will incorrectly
detect a significant result, which leads to higher than expected type I
errors' (Burton et al., 2006).
Confidence Acceptable
Interval Coverage
50% (0.478, 0.522)
75% (0.731, 0.769)
90% (0.887, 0.913)
95% (0.940, 0.960)
97.5% (0.968, 0.982)
99% (0.986,0.994)
Table 7.2: Intervals within which an acceptable coverage would lie for different
confidence levels for 2000 simulated datasets.
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7.3.1.3 Determining the number of simulations
Burton et a1. (2006) emphasise the importance of giving a clear rationale for
the number of simulations performed in the simulation study in the same way
that a sample size calculation would always be performed before the start of
a clinical trial to determine the required number of participants. The num-
ber of simulations for this simulation study was determined by simulating
10,000 datasets for a single scenario and observing the bias in the estimated
parameters calculated from increasing numbers of simulations.
Using the same design described above for Ktrue = 1.5 and Tt~ue = 0.3 (to
match the values estimated from the data), 10,000 datasets were simulated.
The analysis described in Chapter 6, method 1 (the method that was expected
to be the most biased method), was performed on each of these simulated
datasets to yield estimates Rs and t; of K and T2 respectively, s = 1, ... ,10000.
The bias and mean squared error in each of Rand t2 were calculated using
increasing numbers of simulations to evaluate how these measures varied as
the number of simulations used increased. Figure 7.2 on the following page
shows the biases in Rand T2 (Bs(R) and Bs (t2)) and the mean square errors
in Rand t2. The number of simulations used to calculate the estimates is on
the horizontal axis and is shown on the log scale since it is the accumulation of
information that is of interest rather than increasing numbers of simulations.
From all of the graphs, there is wide variability initially with the lines
beginning to settle from around 500 simulations. The change in all of the
measures is small as the number of simulations doubles from 1000 to 2000
and even smaller as the numbers more than doubles from 2000 to 5000. It
was therefore decided that 2000 simulations would be sufficient to assess the
relative performances of the different statistical methods.
7.3.2 Results
2000 datasets for each of the 24 different scenarios were simulated and stage
1 of the analysis was applied to each dataset. Stage 1 (yielding aij and ~ii) is
common to all three methods. The total computer time to simulate the 48000
datasets was 3 hours and 53 minutes and the total time to complete stage 1
was 12 hours and 22 minutes. All computer times for these simulations are
from a standard laptop with 2 GB of RAM and a dual core processor each of
1.20 GHz and are given for a rough comparison of computation time required
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Figure 7.2: Estimates of bias and mean square error in f( and T2 for increasing
numbers of simulations.
for each method.
7.3.2.1 Method 1: No correction for attenuation bias.
A weighted linear regression analysis with robust standard errors was applied
to the results of stage 1 as described above. The total run time was 3 hours
and 15 minutes.
7.3.2.1.1 Bias Figure 7.3 on the next page shows graphs of bias and per-
centage bias in f( and t2 for different values of Ktme and Tt,ue (in the keys of
the graphs, t2 corresponds to Tt;ue).
It is clear from all graphs that the bias in estimating both parameters is not
insubstantial, except for low values of K. For low values of K, the slope of the
regression line of f3ij on {Xij is nearly flat and the association between {Xij and
{3ij is very weak, corresponding to a very weak surrogate. The bias in K crosses
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Figure 7.3: Bias and percentage bias in Rand 1'2, Method 1.
(d) Percentage bias in t2
zero for low "true and therefore the method correctly estimates no association
when there is none.
The bias in R is negative implying K is being underestimated and increases
in magnitude as Ktrue increases. The bias in t2 is positive and decreases as
Tt~lle increases. At Ktrue = 1.5 and T~ue = 0.3 (similar to values calculated from
the analysis in Chapter 6 evaluating the month 3 culture result as a surrogate),
the bias in R is -0.29 or -20% and the bias in T~ue is 1.13 or 378%.
7.3.2.1.2 Accuracy Figure 7.4 on the following page shows graphs of mean
squared error in Rand 1'2 for different values of Ktrue and T~ue'
The MSE in R is small for small values of Ktrue, but increases as Ktrue in-
creases. The mean squared error in 1'2 is 5 to 10 times greater with no discern-
able relationship with T~ue' At Ktrue = 1.5 and T~ue = 0.3, the MSE in R is 0.17
and the MSE in 1'2 is 10.49.
219
06
0.'
~o.
103
102
0'
0.0
00 0.2 0.5
(a) Mean squared error in R
20
0.1 03 '0
Tn. valUe off4
20
Figure 7.4: Mean squared error in Rand t2, Method 1.
(b) Mean squared error in 1'2
7.3.2.1.3 Coverage The parameter K and its standard error are estimated
for each simulated dataset and from this the 95% confidence interval can be
calculated. K is the most important parameter of interest as it describes the
slope of the linear relationship between the treatment effect on the true and
the surrogate endpoints. Figure 7.5(a) shows the graph of coverage of 90%
and 95% confidence intervals around R for different values of Ktrue and Tt~ue'
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Figure 7.5: Coverage of confidence intervals around R and distribution of R2,
Method 1.
It is clear that there is considerable under-coverage. None of the points
plotted are within the acceptable coverage region and the under-coverage is
more severe for higher Ktrue and TTrue. This means that the type I error rate is
inflated and there is over-confidence in the estimate of K.
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7.3.2.1.4 Estimating R2 Figure 7.5(b) on the preceding page shows the dis-
tribution of the values of the proportion of explained variation, R2, in the
treatment effect on the true endpoint that is explained by the treatment effect
on the surrogate endpoint. The plotted points corresponds to the median and
the grey bar shows the inter-quartile range for each combination of Klrur and
2
T,rue·
For low Ktrue, corresponding to a poor surrogate, R2 is also low reflecting
this. R2 is also lower for higher Tt~ue corresponding to greater variability in
{3ij conditional on lXij' As Ktrue increases and Tt~uc decreases, R2 also increases
reaching what appears to be a plateau around R2 = 0.8. The short grey bars
indicate that the calculated values of R2 do not vary a great deal around the
median.
7.3.2.2 Method 2: Correction for Attenuation using the Reliability Ratio
A weighted linear regression analysis with robust standard errors was applied
to the results of stage 1 as described above. The reliability ratio was calculated
for each dataset and the estimates of K and R2 were scaled accordingly. The
total run time was 4 hours and 9 minutes.
7.3.2.2.1 Bias Figure 7.6 on the next page shows graphs of bias and per-
centage bias in re for different values of Klrue and TI~Ue' The equivalent values
from method 1 without correction for attenuation are shown on the graph in
pale grey for comparison. Since only re (in addition to R2) was scaled by the
reliability ratio, the estimates T'i. remain unchanged from the weighted lin-
ear regression analysis with no correction for attenuation (method 1) and are
therefore not presented here.
Comparing this with those from method I, the overall pattern is very simi-
lar except that the bias is reduced a little as expected. The bias in R is negative
and increases in magnitude as Ktrue increases. At Ktrue = 1.5 and Tt~ut = 0.3,
the bias in re is -0.16 or -11% compared to -20% from method 1.
7.3.2.2.2 Accuracy Figure 7.7(a) on page 223 shows graph of mean squared
error in re for different values of Ktrue and Ttrue' The mean squared error is a
function of re which was been scaled, and therefore the mean squared error is
different to that resulting from method 1 (shown on the same graph in pale
grey).
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Figure 7.6: Bias and percentage bias in R, Method 2.
Comparing this that from method I, the shape is very similar and, as
above, the mean squared error is slightly smaller. At Ktrue = 1.5 and Ttlle =
0.3, the MSE in R is 0.13.
7.3.2.2.3 Coverage Figure 7.7(b) on the next page shows the graph of cov-
erage of 90% and 95% confidence intervals around R for different values of
Ktrue and Tt~ue' The coverage from method 1 is shown in pale grey. It is clear
that there is still considerable under-coverage, even after correction for atten-
uation bias. For Ktrue ~ 0.5 (corresponding to weak surrogacy) the coverage
is better before correcting for attenuation, but for Ktrue > 0.5 the coverage
improves after correction for attenuation. None of the points are within the
acceptable coverage region and the under-coverage is more severe for higher
Ktrue and T'frue' This means that the type I error rate is inflated and there is
over-confidence in the estimate of K.
7.3.2.2.4 Estimating R2 Figure 7.7(c) on the following page shows the dis-
tribution of the values of the proportion of explained variation, R2. The plot-
ted points corresponds to the median and the grey bar shows the inter-quartile
range for each combination of Ktrue and Tt~uc' Corresponding statistics from
method 1 are shown in pale grey.
For low Ktrue, corresponding to a poor surrogate, R2 is also low reflecting
this. R2 is also lower for higher Tt;ue corresponding to greater variability in
{3ij conditional on aij' As Ktrue increases and Tt~u(' decreases, R2 also increases
reaching what appears to be a plateau just below R2 = 0.9. The short grey
bars indicate that the calculated values of R2 do not vary a great deal around
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the median. The R2 values are greater than those resulting from method 1 as
they have been scaled by the reliability ratio which is always less than 1.
7.3.2.3 Method 3: Using the SIMEX algorithm.
The SIMEX algorithm was applied following the weighted linear regression
analysis with robust standard errors was applied to the results of stage 1 as
described above. The total run time was approximately 115 hours. The steps
involved in implementing the SIMEX algorithm are as follows.
1. Calculate the naive estimates of K, Var(x], T2 and R2.
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2. Simulate 400 contaminated datasets with measurement error added to
the itij for each of ~m = 0.5,1.0,1.5,2.0. Only 400 datasets were used due
to computational limitations. However, this compares favourably with
the number used in examples in Carroll and Stefanski (1995).
3. Calculate estimates of K, Varfx}, T2 and R2 for each of the contaminated
datasets.
4. Calculate the 90% trimmed mean of each estimate at each value of 'm =
0.5,1.0,1.5,2.0. The 90% trimmed mean is calculated by taking the mean
of values that lie above the 5th percentile and below the 95th percentile.
In a very small number of these contaminated datasets, the calculated
estimates were found to be either unfeasibly large or unfeasibly small
and therefore the trimmed mean, excluding these outliers, was used
rather than the simple mean.
This then yields four estimates of each of the four parameters (K, Vartx),
T2 and R2) for each value of 'm in addition to the naive estimates corre-
sponding to ~m = O.
5. For each of K, Varfx), T2 and R2, the resulting estimates were plotted
against ~m and a quadratic line fitted to these data to yield four different
quadratic functions for each parameter. Carroll and Stefanski (1995)
state that the quadratic extrapolant function is sufficiently complex in
most cases. The SIMEX estimate for each parameter is then calculated
as the point on the fitted line where ~m = -1.
These steps are repeated for each of the 2000 simulations for each of the
24 scenarios and measures of bias, accuracy and coverage estimated as for
methods 1 and 2.
Results from method 3 are presented in a similar way to as before and will
be shown alongside those from method 2 or method 1 whichever is a more
useful comparison.
7.3.2.3.1 Bias Figure 7.8 on the next page shows graphs of bias and per-
centage bias in Rand t2 for different values of K'rUf and T~lIe' For the bias and
percentage bias in R, the same from method 2 correcting for attenuation bias
using the reliability ratio are shown in pale grey to allow comparison. For the
bias and percentage bias in 1'2, the same from method 1 are shown in pale
grey to allow comparison.
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Figure 7.8: Bias and percentage bias in f( and t2, Method 3.
(d) Percentage bias in t2
The bias in R is less than in method 1 (not shown on this figure), but is
only slightly greater than that resulting from method 2 (the grey lines in the
figure). The SIMEX algorithm does not reduce the bias any more than a simple
correction for attenuation bias using the reliability ratio.
The bias in t2 is also slightly less than that in method 1 (the grey lines in
the figure).
The bias in K is negative and increases in magnitude as Ktrue increases.
The bias in t2 is positive and decreases as T~ue increases. At Ktrue = 1.5 and
T~ue = 0.3, the bias in f( is -0.17 or -12% and the bias in Tt~ue is 0.86 or 287%.
7.3.2.3.2 Accuracy Figure 7.9 on the following page shows graphs of mean
squared error in Rand t2 for different values of Ktrue and T~ue' For the MSE
in R, the results from method 2 are shown in pale grey and for the MSE in t2,
the results from method 1 are shown in pale grey to allow comparison.
The MSE in R is less than in method 1 (not shown in this figure), but is
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(b) Mean squared error in t2
marginally greater than that resulting from method 2 (the grey lines in the
figure). The SIMEX algorithm does not reduce the MSE any more than a
simple correction for attenuation bias using the reliability ratio. The MSE in K
is small for small values of Ktrue, but increases as Ktrue increases.
The MSE in t2 is also very slightly less than in method 1 (the grey lines in
the figure).
The mean squared error in t2 is 5 to 10 times greater with no discernable
relationship with Tt;ue' At Ktrue = 1.5 and T~ue = 0.3, the MSE in R is 0.14 and
the MSE in f2 is 9.90.
7.3.2.3.3 Coverage Figure 7.10(a) on the next page shows the graph of cov-
erage of 90% and 95% confidence intervals around k for different values of
KtTlle and T~ue' The coverage from method 2 is shown in pale grey.
It is clear that there is considerable under-coverage after using the SIMEX
algorithm and coverage is not improved over method 2. As with the other
parameters described above, the coverage using method 3 lies somewhere
between that using method 2 and that using method 1.
None of the points are within the acceptable coverage region and the
under-coverage is more severe for higher Ktrue and Tt~ue' This means that the
type I error rate is inflated and there is over-confidence in the estimate of K.
7.3.2.3.4 Estimating R2 Figure 7.10(b) on the following page shows the dis-
tribution of the values of the proportion of explained variation, R2, in the
treatment effect on the true endpoint that is explained by the treatment effect
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Figure 7.10: Coverage of confidence intervals about R and distribution of R2,
Method 3.
on the surrogate endpoint. The plotted points corresponds to the median and
the grey bar shows the inter-quartile range for each combination of Ktrue and
T?rue' Corresponding statistics from method 2 are shown in pale grey.
For low Ktrue, corresponding to a poor surrogate, R2 is also low reflecting
this. R2 is also lower for higher Tt~ue corresponding to greater variability in
f3ii conditional on IXii' As Ktrue increases and Tt~ue decreases, R2 also increases
reaching what appears to be a plateau around R2 = 0.85. The short grey
bars indicate that the calculated values of R2 do not vary a great deal around
the median. The values of R2 found after using the SIMEX algorithm are
marginally lower than those after correcting for measurement error using the
reliability ratio.
7.3.2.4 Summary
Table 7.3 on the next page summarises the results from the simulation study
comparing the three methods. Statistics are shown for the scenario Ktn,,' =
1.5 and T~ue = 0.3 as these are similar values to those calculated from the
analysis in Chapter 6 evaluating the month 3 culture result as a surrogate.
Method 2, correction for attenuation using the reliability ratio, did not affect
the estimates of T2 and therefore the bias and MSE in 1'2 are not calculated for
Method 2.
Method 3 improves on Method 1 in all of the summary statistics and
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Statistic I Method 1 I Method 2 I Method 3
Bias in R -0.29 --0.16 -0.17
Percentage bias in K -20% -11% -12%
Bias in 'fT 1.13 - 0.86
Percentage bias in t7 378% - 287'X,
MSE of K 0.17 0.13 0.14
MSE offT 10.49 - 9.90
95% coverage of R 0.58 0.74 0,68
90% coverage of R 0.48 0.66 0.61
Median R7 0.73 0.81 0.81
Table 7.3: Statistics resulting from the simulation study comparing the three
methods at Ktrue = 1.5 and T;ue = 0.3. These parameter values are similar to
those calculated from the analysis in Chapter 6 evaluating the month 3 culture
result as a surrogate.
Method 2 again improves on Method 3, but this improvement is marginal.
7.4 Application to Trial Data
Methods 2 and 3 were applied to the trial data used in this thesis to explore
how the results compare to those from Chapter 6. Table 7.4 show the estimate
of the slope, K, of the regression line and the proportion of explained variation,
R2, on applying each of methods 2 and 3 to the trial data used in this thesis,
The results from Chapter 6 (method 1) are shown for comparison.
Marker I Statistic I Method 1 (95% Cl) I Method 2 I Method 3
Month 1 Slope, K 1.35 (-0.10,2.80) 2.47 1.84
Culture" R2 0.36 0.67 0.49
Month 2 Slope, K 0.85 (0.13,1.57) 1.40 1.07
Culture R.l. 0.36 0.58 0.45
Month 3 Slope, K 1.29 (0.82,1.76) -8.02 2.11
Culture R.l. 0.69 -4.29+ 1.13+
tWith a point of dichotomy at 20+.
tThese values for the proportion of explained variation arc clearly inadmissable.
Table 7.4: Comparing the estimates of the slope, K, of the regression line and
the proportion of explained variation, R2, on applying each of the three meth-
ods to the trial data used in this thesis.
For the month 1 (dichotomised at 20+ colonies) and the month 2 cultures,
both methods scaled the proportion of explained variation up from 0.36 to
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0.49 and 0.45 for method 3 and 0.67 and 0.58 for method 2.
For the month 3 culture, methods 2 and 3 yield inadmissible values for 1~2
and the value of K calculated from method 2 is clearly incorrect.
Table 7.4 shows the results of methods 2 and 3 applied to subsets of the
trial data: East African trials, Hong Kong trials and comparisons for which
both treatments contained rifampicin. It is clear from this table, that both
method 2 and method 3 frequently yield uninterpretable values for R2.
Subgroup I Marker I Statistic I Method 1 I Method 2 I Method 3
Month 1 Slope, K 1.14 1.54 1.44
Culture" RL 0.29 0.39 0.35
East African Month 2 Slope, K 0.76 1.06 0.92
Trials Culture RL 0.19 0.26 0.23
Month 3 Slope, K 1.61 3.94 2.28 -
Culture RL 0.81 2.00J 1.14J
Month 1 Slope, K 1.98 5.20 3.18
Culture" Ri 0.68 1.79J 1.08J
Hong Kong Month 2 Slope, K 0.99 1.25 1.21
Trials Culture RL 0.86 1.08i 1.04i
Month 3 Slope, K 0.82 5.58 1.43
Culture RL 0.62 4.22J 1.071
Month 1 Slope, K 1.85 9.71 2.85
Comparisons Culture" RL 0.54 2.86l 0.81
of Rifampicin Month 2 Slope, K 1.00 1.93 1.28
-containing Culture RL 0.67 1.301 0.85
Regimens Month 3 Slope, K 0.88 -1.19 1.71
Culture RL 0.46 -0.621 0.87
Table 7.5: Comparing the estimates of the slope, K, of the regression line and
the proportion of explained variation, R2, on applying each of the three meth-
ods to subgroups of the trial data used in this thesis.
tWith a point of dichotomy at 20+.
~These values for the proportion of explained variation are clearly inadmissable.
7.5 Discussion
7.5.1 Simulation Study
As discussed in section 7.1, the methods used in Chapter 6 to evaluate cul-
ture results during treatment as surrogate markers had two main drawbacks.
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Firstly, the treatment effect on the surrogate marker, ~ij' was estimated by iii}
with error. However, this error was not accounted for in the model, leading to
attenuation bias and over-estimation of the precision of the slope of the regres-
sion lines. Secondly, the precision of the parameter estimates was adjusted for
clustering of treatment comparisons within trial using robust standard errors,
but the point estimates themselves were calculated under the assumption of
no clustering. Two methods, motivated by Stijnen's Approach (which itself
proved to be inappropriate for this thesis due to multiple treatment compar-
isons), were selected to overcome the first drawback. The first involved scaling
the estimate of the slope and of the proportion of explained variation by a reli-
ability ratio to account for the attenuation (described as Method 2). The second
involved using the SIMEX algorithm, simulating contaminated datasets and
using extrapolation in an attempt to remove the effect of the measurement
error (described as Method 3). Using a simulation study, these two methods
were compared with the method used in Chapter 6 (described as Method 1) to
determine the bias and precision of the model parameters estimates .
• Method 1. The simulation study was useful to evaluate the two stage
method used in Chapter 6. It was found that there was considerable
bias in the estimates of K and T2; the mean squared error in estimating
both was large and there was under-coverage in the confidence intervals
around K. An important advantage of this method is that it yields a clear
graphical display of the behaviour of the surrogate marker. This means
that, even if the estimates of K and of R2 are likely to be unreliable,
a rough idea of the behaviour of the markers can be determined from
these graphs .
• Methods 2 and 3. Both simple correction with the reliability ratio and the
more computationally intensive SIMEX algorithm yield estimates of K
that are less biased and have lower mean square errors. The coverage of
confidence intervals around K is improved (for K > 0.5), although there
is still considerable undercoverage. The estimates from the SIMEX algo-
rithm are marginally more biased than those using the correction with
reliability ratio and the coverage is poorer. Since the SIMEX algorithm
takes substantially more computer time (approximately 115 hours com-
pared to 4 hours and 9 minutes using the reliability ratio for the whole
simulation study) correction for attenuation with the reliability ratio is
to be preferred.
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Correction for attenuation with the reliability ratio does reduce bias and
improve coverage, but the bias is not completely removed and there is still
unacceptable under-coverage. Since two different methods for correcting for
attenuation (the SIMEX algorithm and the reliability ratio) yielded roughly
similar estimates of K, it appears that the bias and the under-coverage is not
due to attenuation caused by measurement error in aij alone and there arc
other sources of bias in these methods.
None of the methods described here adjust the point estimates of K for the
clustering within trial, they merely incorporate robust standard errors that
take account of this clustering in the standard errors. It is likely that this
remaining bias may be due to the clustering of treatment comparisons within
trials which has not been properly accounted for.
7.5.2 Application to Trial Data
For the month 3 culture, methods 2 and 3 yield inadmissible values for R2 and
the value of K calculated from method 2 is clearly incorrect. In the subgroup
analyses, methods 2 and 3 frequently yielded inadmissible values for R2, most
often when the R2 resulting from method 1 was greater than around 0.65. It
is likely that one of the reasons for this is the large variance in estimating A"
(IT;,; = Var(&ik))compared to the variance of il:ijacross trials (Vari,(&,,)).
For the month 1 culture result the variance of &ij across all trials; and
treatment comparisons j is Varij (aij) = 0.203 and the mean of eT;" across all
trials; and treatment comparisons j is smaller, 0.103. For the month 2 culture
result Varij(aij) = 0.389 and the mean of IT;,/ is 0.201, again smaller. For
the month 3 culture result Varij(aij) = 0.277 and the mean of eT;,/ is 0.550,
considerably larger. The measurement error in estimating the quantities A"
when evaluating the month 3 culture result as a surrogate is larger than the
spread of C>:ijacross trials. This is due to the small number of individuals
culture positive at month 3. This effectively means that the noise in 11:" is
greater than the information available and therefore attempting to remove
this error by method 2 or method 3 yields results that are uninterpretable.
Similarly, the measurement error in estimating Iti, is larger or only slightly
smaller than the variance of aij across all treatment comparisons in Hong
Kong trials for each of the three markers and in East African trials for month 3
culture result, leading to R2 values over 1 in each case for methods 2 and 3. In-
terestingly, the same is again true when including only rifampicin-containing
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treatment comparisons, but method 3 gives sensible values for R2 whereas
method 2 does not. This suggests the method 3 is more robust to large mea-
surement error, but it is clear that neither method is very reliable for USl' on
these data.
7.5.3 Conclusions
These two extensions (adjustment using the reliability ratio and extrapolation
using the SIMEX algorithm) do not remove all of the bias in estimating the
slope parameter K. Application of these methods to the trial data used in
this thesis have yielded some values of R2 and K that are uninterpretable.
The application of these two methods are therefore not appropriate without
further work into the causes of (i) the residual bias and (ii) the inadmissible
R2 values.
Further discussion of these results and areas for future research are found
in Chapter 8.
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Chapter 8
Discussion and Conclusions
S.l Introduction
In a recent issue of Statistical Methods in Medical Research, the following
important point is made:
'Upon identification of a possible surrogate endpoint, in order
to gain widespread acceptance for that endpoint, multiple groups
must be convinced of its validity. These parties include practising
clinicians, statisticians, regulatory bodies and other researchers.
The statistical knowledge of these groups is variable, ranging from
knowledgeable (regulatory bodies, statisticians) to often very lim-
ited (clinicians). Based on these considerations, it is our opinion
that a single statistic, graphic, or theory of surrogate endpoints
will not be adequate to satisfy everyone who must accept the va-
lidity of a proposed surrogate endpoint.'
(Creon et al., 2008)
Formal methods for the evaluation of surrogate markers have been 'the
subject of intensive research over the past decades' (from the editorial in the
same issue, Burzykowski (2008» and there is not yet any clear consensus on
the best and simplest methods for evaluating surrogate markers. Green and
colleagues are therefore right to recommend the use of a variety of methods.
A prognostic marker is used to predict disease outcome in an individual
and is used as a clinician's tool. In contrast, a surrogate marker is used as a
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substitute for the true endpoint in a clinical trial and is therefore more of a
tria list's tool. Unlike the disease area of HIV, for example, there is currently
no reliable prognostic marker for the tuberculosis TB clinician, and there is
certainly no reliable surrogate marker for poor outcome to treatment for TB
for the tria list. Despite limited evidence, both the World Health Organisation
(WHO) and the International Union against TB (IUATLD) recommend extend-
ing the intensive phase of two months of treatment by an additional month if
a patient has a positive smear at two months (see section 3.5.2), although it is
expected that this recommendation will be removed from the fourth edition
of the WHO TB treatment guidelines due for publication in the summer of
2009. There is considerably less evidence for surrogacy, and yet some authors
implicitly or explicitly make claims for the use of the two month culture result
as a surrogate endpoint. There have been several phase II studies conducted
in the past few years evaluating the benefit of moxifloxacin in the treatment of
TB that have used culture conversion at eight weeks as the primary outcome
of the trial. Examples include the Phase II study of the OFLOTUB consortium
(Rustomjee et al., 2008b) and those recently conducted by the CDC TBTC!. The
most recent such study evaluating the addition of Moxifloxacin to the stan-
dard regimen was published in the Lancet in April 2009. The authors were
quick to point out that the statistically significant results based on the eight
week culture results '[do] not prove the efficacy of moxifloxacin to shorten
tuberculosis treatment' (Conde et al., 2009). Nevertheless, a letter in the same
issue commending these authors describe the eight week culture status as 'a
hallmark in assessing regimen efficacy'.
There is therefore an urgent need for clear evidence to inform decisions
regarding the use of culture results during treatment as prognostic and surro-
gate markers. It is in this context that the results presented in this thesis must
be placed.
8.1.1 The MRC Clinical Trial Data
Evaluation of surrogate markers requires data from multiple clinical trials
where both the surrogate marker and the true endpoint are measured. The
data used in this thesis are from twelve TB treatment clinical trials conducted
by the MRC in East Africa and East Asia in the 1970s and 1980s. 37 treatment
lCompleted and ongoing TBTC Studies. http://www.cdc.gov/tb/tbtc/projl.cts.htm.Re-
trieved 23 Apr 2009.
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comparisons including 6974 trial participants were included for usc in these
analyses. These data are unique-no other TB clinical trial data of such quan-
tity and quality exist-and provide an unprecedented opportunity to evaluate
culture results during treatment as prognostic and surrogate markers.
8.1.2 Other Markers
The objectives of this thesis were not restricted to culture results during treat-
ment as prognostic and surrogate markers. However, following the review of
the literature in Chapter 3, it was clear that the markers that had the most
potential and for which a reasonable amount of data were available for eval-
uation were culture results during treatment. These markers were therefore
selected and evaluated as prognostic and surrogate markers.
The only clinical trial data of a sufficiently large quantity (derived from
multiple trials and a variety of treatment comparisons) to evaluate any mark-
ers as surrogates pertains to smear or culture results during treatment. Since
smear results are less specific and commonly less sensitive, culture results
are the only markers that can be evaluated as surrogates with data currently
available today.
Not only are there no other data currently available, it is highly unlikely
that similar data on another marker will be available for the evaluation of a
surrogate marker in the near future. The REMoxTB trial will provide data on
a host of possible surrogate markers (serial sputum colony counts, repeated
days to positivity from liquid media and others) in the context of a clinical
trial, and other phase III trials currently being conducted or due to start in
the next few years will add to this. However, the earliest that even data (rom
one trial could be available is not likely to be before 2012 and most likely
considerably later.
8.2 Prognostic Markers
In Chapter 5, culture results at each of months 1, 2, 3 and 4 during treatment
were evaluated as prognostic markers exploring the effect of varying the point
of dichotomy. Table 8.1 summarises the main findings from Chapter 5 for each
marker at points of dichotomy of 1 and 20+.
It is clear that there was a strong association between a positive culture at
each of months 1, 2, 3 and 4 and poor outcome. A patient with a positive
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Point of Dichotomy
1 20+
OR (95% Cl) TPF FPF OR (95% Cl) TPF FPF
Month 1 3.0 (2.9,3.1 BO% 56% 2.9 (2.9,3.0) 55% 30%
Month 2 3.7 (3.6,3.B 40% 15% 5.214.9,5.6) 13% 3'X,
Month 3 6.8 (6.6,7.0 19% 4% 13.5 (12.5,14.6) 8% 1%
Month 4 8.7_(8.2,9.2) 15% 2% 2B.6{24.4,33.5) 10% 1'Yo
Table 8.1: Odds Ratios (labelled OR) with 95%, confidence intervals (labelled
95% Cl), True Positive Fraction (TPF) and False Positive Fraction (FPF) at dif-
ferent months for three different points of dichotomy.
culture at two months has an odds of poor outcome 3.7 times that of a patient
with a negative culture at two months. A patient with a heavily positive (20+
or more) culture at month 3 has an odd of poor outcome 13.5 times that of
a patient with a negative or sparsely positive culture. Nevertheless, the low
values of TPF for a point of dichotomy of 1 show that while culture fl'SUItS
give an indication of likelihood of poor outcome, they can not reliably be used
to predict the outcome for a particular individual. Only 40% of patients with
a positive culture at two months have a poor outcome of treatment and only
19% of patients with a positive culture at three months have a poor outcome.
On the basis of the these data, culture results during treatment are useful
for identifying groups of patients that are at risk of having a poor outcome
to treatment, but cannot be used for reliably predicting poor outcome for an
individual.
8.3 Surrogate Markers
The meta-analysis approach developed in Chapter 6 is methodologically more
rigorous than the single trial methods and therefore more weight is placed on
those results. The meta-analysis consists of two stages. In stage I, logistic
regression is used to estimate (tij, the log odds ratio of a positive culture result
for each treatment comparison (the treatment effect on the surrogate) and
f3ij' the log odds ratio of poor outcome for each treatment comparison (the
treatment effect on the true endpoint). Stage II involves regression of Il" on
itij using weighted linear regression with the weights being the inverse of the
mean of the variances of aij and ~ij and robust standard errors used to adjust
for clustering of treatment comparisons within trials.
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In the East African trials, the month 3 culture result was shown to be a
good surrogate (R2 = 0.81), and in the Hong Kong trials, the month 2 culture
result was shown to be a good surrogate (R2 = 0.86). These values for 1~2
are high, but the discrepancy between East Africa and East Asia is difficult
to interpret, and is most likely due to a combination of two factors: 1) the
longer times to conversion in East African trials, and 2) the higher proportion
of rifampicin-containing regimens in the Hong Kong trials. Since rifampicin
is the most important drug in the standard regimen used today, results from
rifampicin-containing regimens are likely to be more generalisable. Delayed
culture conversion rates could be due to poorer adherence, different strains of
mycobacteria, more extensive cavitation, more advanced disease due to later
diagnosis or geographic differences in climate, culture or genetics. Detailed
exploration of these differences is beyond the scope of this thesis and is an
important area for future research.
It is interesting to observe that the first prognostic study in TB also found
differences between one trial conducted in Hong Kong and two conducted in
East Africa (Aber and Nunn, 1978). The authors found that the 2 and the 3
month culture results were good predictors of recurrence in the East African
trials, but not in the Hong Kong trial where the 2 month smear was found
to be a good predictor. This difference mirrors the differences found in the
results in this thesis and are perhaps not surprising as data from these three
trials is included in the data used in this thesis.
While further work is needed to understand the differences between East
African and Hong Kong trials, the results are encouraging. They suggest that
culture results during treatment (whether at two months or at three months)
may capture a significant proportion of the treatment effect on treatment out-
come. The time to culture conversion, or an aspect of the longitudinal profile
of culture results during the first few weeks of treatment (such as Serial Spu-
tum Colony Counting, see section 3.5.5) may prove to be better surrogates
than binary culture results. These could not be evaluated as surrogates using
these data, since cultures were not taken frequently enough during the first
few weeks of treatment. Nevertheless, the results presented in this thesis are
inconclusive and further work is required evaluating culture results during
treatment as surrogate markers.
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8.3.1 Choice of Control Arm
As described in section 6.1.1, most of the trials that yielded data included in
the analyses in this thesis did not have a pre-specified 'control regimen' and
so the arm in each trial with the highest proportion of poor outcomes was
selected as the nominal 'control regimen' for treatment comparisons.
It is not expected that this largely arbitrary choice would affect the results,
indeed this choice was made to provide the largest differences in proportions
of poor outcomes possible in each treatment comparison, and therefore pro-
vide the largest amount of information possible for evaluation of surrogate
markers. Nevertheless, it would be informative to repeat the analyses using
a different strategy to select the nominal control. The control could be Sl'-
lected as the regimen with the lowest proportion of poor outcomes, or could
be selected entirely at random. If the results remained broadly similar across
different control regimen choice strategies, then it would be appropriate to
conclude that the choice of control arm as used in this study did not affect the
results.
8.4 Methodological Extension
8.4.1 Summary of Results and Conclusions
There was previously no work on methodology specifically for the evalua-
tion of surrogate endpoints in the context of multi-arm trials yielding mul-
tiple treatment comparisons. The two stage method developed in Chapter 6
based on the HIV paradigm takes account of the multi-arm trials common in
TB treatment research. These meta-analytic methods can be used for evaluat-
ing a binary surrogate endpoint for a binary true endpoint using data from
trials with multiple treatment comparisons although they suffered from some
drawbacks.
In modelling the relationship between the estimates of the treatment effect
on the true endpoint and the treatment effect on the surrogate endpoint (stage
II of the meta-analysis), there are several complexities which must be taken
account of. Merely considering the points as independent with equal vari-
ance and using simple linear regression will result in biased and over-precise
estimates of the slope parameter. Each pair of points corresponds to a sin-
gle treatment comparison which are clustered within trials-some trials with
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only two regimens corresponding to a single treatment comparison, and some
trials with up to eight regimens corresponding to up to seven treatment com-
parisons. In addition, the treatment effects themselves are estimates derived
from models in stage I of the meta-analysis and are estimated with varying
precision depending on the number of patients included in the comparison
and the number of patients that experienced a poor outcome. In Chapter 6
and in the two extensions in Chapter 7, (i) weighted regression was used to ac-
count for the varying precision in the estimates with (ii) robust standard errors
used to account for the clustering of treatment comparisons within trial. This
approach is an improvement on simple linear regression, but is not without
drawbacks.
Two extensions of the meta-analytic approach developed in Chapter 6 wen.'
proposed in Chapter 7 with the aim of removing the bias resulting from the
error in estimating the slope of the fitted line. The first method, correction
for attenuation using the reliability ratio, involves scaling the slope parameter
by a simple ratio to remove the bias. The reliability ratio is calculated from
the spread of the estimates of treatment effects on the surrogate endpoint, a,},
across the treatment comparisons and from the variances of these estimates.
Standard errors are not adjusted, although the reliability ratio can be used
to scale the proportion of explained variation, R2. The second method, the
SIMEX algorithm, uses simulation and extrapolation to estimate the slope
parameter and standard error with the effect of the error in estimating (I;,}
removed.
These two methods were compared to that used in Chapter 6 using a simu-
lation study. This simulation study was large, involving data with a complex
hierarchical structure requiring several distributional assumptions. The re-
sults of this study demonstrated that there was considerable bias in estimating
the slope parameter K and under-coverage in confidence intervals around K in
the method used in Chapter 6. Both of the extensions resulted in better cov-
erage and reduced bias, but this improvement was not substantial. Applying
these two extensions to the trial data resulted, in some cases, with incorrect
estimates of R2 greater than 1 and unreasonable estimates of the slope.
It is likely that the problems with these methods are a result of a combina-
tion of three issues:
1. Clustering of treatment comparisons toithin trials. The two methods are used
to remove attenuation bias due to the imprecision of the estimates ft,} of
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(Xi; in stage II of the meta-analysis approach. Robust standard errors
are used to adjust the standard errors for the clustering of treatment
comparisons within trials, but the point estimates are not adjusted for
clustering. The bias and undercoverage in using these two extensions is
likely to be due in part to the fact that they do not make adjustment for
this clustering.
2. Post-hoc corrective methods. Both of the extensions described in Chapter 7
are used to adjust model estimates for bias caused by measurement er-
ror. In this way, these two extensions are corrective for the error caused
by using an incorrect model in stage II of the meta-analysis. It is as-
sumed that the error in estimating (Xii is additive, in that the estimate
aii = (Xii + uii where uii is the error assumed to be normally distributed
with zero mean and variance ~. The better way to deal with the prob-
lem of observing the estimate ai; rather than the actual value Ai" would
be to use a model that properly takes account for this measurement er-
ror, rather that adjusting for it in a post-hoc way.
3. Specification of the simulation data. The first step in conducting a simula-
tion study is to simulate realistic data under a variety of scenarios. The
methods being evaluated in the simulation study will then be applied
to these data and the parameter estimates compared with the known
underlying parameters of the distribution. In the simulation study in
Chapter 7, certain assumptions were made about the joint distribution
of the true and surrogate endpoints. These assumptions were based on
what might be expected of the hierarchical relationships between cul-
ture results and poor outcome and the analysis on the MRC trial data in
Chapter 6. Assumptions were made about the distribution of the trial-
specific intercept and slope, bi and Ki, the treatment-comparison-specific
treatment effects, (Xii and /3ii' and the patient-specific values for the true
and surrogate endpoints, Tiik and Sijk' Values were chosen for 19 differ-
ent distributional parameters used in simulating the data.
The approach used to simulate the data in the study was based on the
results of the meta-analysis in Chapter 6 and on a theoretical expectation
of the relationship between culture results during treatment and poor
outcome. There are different ways of modelling the data, and further
work is needed in determining which is the most suitable model for the
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simulation data. One approach would be to constrain 0, =- {t -- 0, rather
than drawing Oi from the bivariate distribution
as has been done in Chapter 7 (see equation 7.17 on page 213). Other
changes that could simplify the data structure could include constrain-
ing each trial to have the same number of regimens ("', = 111, where
m > 2) or making changes to the values that itij and f3'J could take (set'
section 7.3.1.1).
8.4.2 Implications of Estimation Errors in a and $
Both aij and $ij are estimates with associated variances er;,/ and erfi" rt'spec-
tively. The error in $ij as an estimate of {3ij is not incorporated into the model.
except in the weights Wij which are the inverse of the mean of cr;" and (rfi".
Also, since itij and {3ij are estimated separately in Stage I, the assumption that
aij and $ij are independent is inherent and so there is no adjustment for this
correlation p();{3' It is likely that this assumption is not valid as (t" and 11" art'
estimated from the same individual trial participants. PR{3 could be estimated
using bootstrap methods. Wrongly assuming Ptt/3 = 0 could lead to bias in the
estimates of R2 in stage II. Due to the choice of treatment ordering, almost all
estimates of aij and $ij are negative and the slopes of the lines of best fit are
positive, under the assumption Ptt{3 = O. If, for the pairs of paints plotted, the
Plt{3 are predominantly negative and therefore the major axes of the elliptical
confidence regions are roughly perpendicular to the line, the spread of points
about the line is in fact greater than if p();{3 = O. The estimated R2 will there-
fore be more diluted and will be smaller than the true R2. Conversely, if the
p();{3 are predominantly positive and therefore the major axes of the confidence
regions are roughly parallel to the line of best fit, the estimated R2 will be less
diluted than expected and could be slightly larger than the true R2. It is likely
that most of the Plt{3 will be positive and the effect of assuming flAP .." 0 rnav
therefore be minimal.
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8.4.3 Conclusions
The meta-analytic methods developed within the Belgian paradigm arc simple
for true and surrogate Gaussian endpoints, as the joint distribution is bivariate
Gaussian which can be modelled without much difficulty. For binary true and
surrogate endpoints (as is the case for evaluating culture results during treat-
ment as surrogate markers for poor outcome), the methods are considerably
more complex and involve the use of copulas to describe the joint distribution.
Stijnen's approach (described in section 7.2.1) is a development of these meth-
ods, moving away from a joint model allowing for binary true and surrogate
endpoints in a two stage approach. However, while a useful simplification.
this approach could not be used for trials with more than one treatment (om-
parison per trial.
The meta-analytic methods developed in Chapter 6 can be used for evalu-
ating a binary surrogate endpoint for a binary true endpoint using data from
trials with multiple treatment comparisons although it suffered from some
drawbacks described above. The two extensions described in Chapter 7 did
remove some of the bias, but there remain reservations about their USl' in
evaluating surrogate markers.
Nevertheless, while there are drawbacks in stage II of the meta-analytic ap-
proach used in Chapter 6, the graphical representation clearly demonstrates
whether there is a relationship between the treatment effect on the true end-
point and the treatment effect on the surrogate endpoint. The exact values for
the slope parameter, K, the 95% confidence interval around K, and the propor-
tion of explained variation, R2, should not be relied on until further methods
are developed, but it is clear that the two month culture result in studies in
Hong Kong and the three month culture result in East African studies art'
good surrogate endpoints.
8.5 Future Work
8.5.1 Further Analyses of these Data
The data used in this thesis contain information about 6,974 patients given
one of 49 different treatment regimens in twelve clinical trials conducted in
East Africa and East Asia across two decades.
These data are invaluable in learning more about prognostic and surrogate
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endpoints for poor outcome in the treatment of TB. In addition to numerous
other secondary analyses of clinical trial data, such rich data provide plenty
of opportunity for further evaluation of prognostic and surrogate markers ex-
ploring effects of treatment adherence, time to poor outcome, smear results
during treatment and drug resistance patterns post-randomisation. These
were all beyond the scope of this thesis but could yield interesting results.
As new statistical methods for evaluating surrogate markers relevant to
the disease area of TB are developed, these data could again be used for eval-
uating culture results as surrogate markers. Though there are TB treatment
clinical trials currently being conducted with more to start in the near future,
it is unlikely that such a large quantity of data will be available for the purposc
of formally evaluating surrogate markers for at least a decade or more.
8.5.2 Further Simulation Studies
8.5.2.1 Simplifying the Data Structure
Further simulation studies could be conducted to identify the exact C.lUSl'S
for the bias in the parameter estimates found in Chapter 7. As described
earlier, the data structure used was fairly complex. This was necl'ssary to
closely model the data from the MRC TB trials as analysed in Chapter 6.
Nevertheless, simpler structures could be used to evaluate the methods and
identify the source of bias. The process could then be repeated with addl'd
complexity, working towards the full data structure as described in Chapter
7. Strategies could include: using only two-arm trials, setting 6 = 0, drawing
the (Xii and (3ij from simpler distributions with narrower ranges and just using
a fixed effects model (removing the random effect). If this simpler structure
results in smaller biases, the process of adding each component sequenti ..rlly
should allow for diagnosis of the cause of the large biases and could provide
a means for adjusting the model to remove these biases.
8.5.2.2 Estimating R;rue
Further simulation studies would also allow the calculation of the true R2
value for each of the scenarios which would allow for comparison of the t'S-
timated with the true R2 values. This could be done by regressing the true
value of (3ii on (Xii to give an estimate of the true R2 value to compare with tht'
estimates of R2 calculated in Chapter 7. Unfortunately, the original simulated
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data was not retained from the simulation study and calculation of the true
R2 values for each scenario used in Chapter 7 is not possible, nor is it possible
to report confidence intervals on the estimates of the R2 values. The standard
error of the estimates on R2 could be calculated using bootstrap techniques.
Failing to interpret the estimates of the R2 values without reference to either
any measure of uncertainty in their estimation or the true values, as was done
in Chapter 7, is a limitation. A paint estimate without a corresponding mea-
sure of uncertainty (such as a 95% confidence interval) can falsely suggest
a high level of precision. An R2 of 0.81 suggests a good surrogate, but if
the 95% confidence interval on this value is (0.47, 0.96) then there is in fact
insufficient evidence to conclude that the marker in question is a good or a
poor surrogate. Similarly, if the method yields an R2 of 0.35 in it simulation
study when the true R2 is 0.81, deficient methods are indicated rather than"
deficient surrogate.
8.5.3 Other Markers
In section 3.5.5, Serial Sputum Colony Counts (SSCC) taken during the first
eight weeks of treatment were introduced as being a candidate surrogate.
Using data from one phase II trial, it has been shown that the second slope
parameter in a hi-exponential mixed effects model distinguishes wL'1Ibetween
two four-drug treatment regimens (Rustomjee et al., 2008b). At the time of
publication of the results of this phase II study, patients had not been followed
up for long-term treatment outcome, so there was no evidence to determine
whether or not this parameter reflects differences in rates of poor outcome.
There is a possibility that these patients will be followed up for poor outcome.
and this evidence may yet become available.
Table 3.2 on page 94 and 3.3 on page 95 contain a complete list of possible
biomarkers for tuberculosis resulting from the joint TDR/EC expert consul-
tation mentioned in section 3.5.7. Any number of these could prow to be
effective surrogate markers for outcome to treatment for tuberculosis but, as
with SSCC, not enough data is available to formally evaluate any of these
markers as surrogates.
The results from this thesis have demonstrated that culture result do cap-
ture some of the treatment effect and it is likely that some aspect of the culture
results during treatment could prove to be useful surrogate endpoints. Fur-
ther work is needed to determine whether bi-exponential modelling of SSCc,
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survival analysis of time to culture negativity, some other approach or a com-
pletely different biomarker will be a useful surrogate. It is expected that some
data will be available from trials over the next few years for usc in beginning
this process.
8.5.4 The Meta-Analytic Methods
A better solution than the two extensions proposed in Chapter 7 to the draw-
backs of the meta-analysis developed in Chapter 6 is required. There are two
areas for further research. Firstly, different approaches to modelling the joint
distribution of the binary true and surrogate endpoints are needed. Secondly,
a full random effects model is needed to properly account for the hierarchical
structure of the data with trials with multiple treatment comparisons. These
are important areas of future research. Reliable statistical methods must be in
place to be used for evaluating new candidate surrogate markers as the data
become available.
8.5.5 Individual-level Surrogacy
The trial-level surrogacy of a marker corresponds to the degree to which the
treatment effect on the marker can be used to predict the treatment effect
on the true endpoint. The individual-level surrogacy of marker corresponds
to the association between the marker and the true endpoint adjusted for the
treatment. Tibaldi et al. (2003) observe that if the true and surrogate endpoints
are modelled separately (as has been done in the meta-analysis in this thesis),
it is harder to study the individual-level surrogacy.
Trial-level surrogacy is of most importance to tria lists and has therefore
been the focus of the evaluation of culture results during treatment as surro-
gates for poor outcome in this thesis. Nevertheless, there has been much work
in recent years developing robust methods for assessing individual-level sur-
rogacy (including applications of information theory, see section 2.8.2). These
methods came too late for use in this thesis, but exploring the individual-level
surrogacy of culture results as surrogates for poor outcome is another area for
future research.
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8.6 Summary of Conclusions
• Chapter 5. A strong association was found between culture results dur-
ing treatment and poor outcome. Nevertheless, culture results were not
good patient-specific predictors of poor outcome with low sensitivities
and specificities.
• Chapter 6. The two month culture was found to be a good surrogate
marker using data from trials conducted in Hong Kong and the three
month culture was found to be a good surrogate marker using data from
East African studies. This is an indication that culture results during
treatment do capture some of the treatment effect, and more work is
needed in understanding the differences between the Hong Kong and
East African trials.
• Chapter 7. The meta-analytic methods for evaluating surrogate mark-
ers in this thesis included a graphical representation that permitted .\
clear visual evaluation of the surrogate. The methods involved in mod-
elling the relationship between the treatment effect on the true endpoint
and the treatment effect on the surrogate endpoint were deficient, and
these deficiencies were not satisfactorily overcome with the two exten-
sions proposed. More work is needed in developing a more appropriate
model.
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Appendix A
Additional Figures and Tables
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Figure A.1: Single Trial Summary measures and 95% bootstrap confidence
intervals for the month 1 culture. Horizontal dashed lines show the region
[0,1] in which a proportion should lie. Confidence limits are truncated ill +3.0
and -2.0. Confidence intervals are plotted in order of trial along the horizontal
axis.
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Figure A.2: Single Trial Summary measures and 95% bootstrap confidence
intervals for the month 2 culture. Horizontal dashed lines show the region
[0,1] in which a proportion should lie. Confidence limits are truncated at +:lO
and -2.0. Confidence intervals are plotted in order of trial along till' horizontal
axis.
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Figure A.3: Single Trial Summary measures and 95% bootstrap confidence
intervals for the month 3 culture. Horizontal dashed lines show the region
[0,1] in which a proportion should lie. Confidence limits are truncated at +3.0
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Treatment Ji'l
- -._," ..
lXi;
Trial Comparison Estimate 95%_CI Estimate 95~:-cr--'
1 -0.14 (-0.64,0.35) -0.4 (-0.90. O.11f
STUDY R 2 -0.71 (-1.15. -0.26) -1.65 (-2.21. -U)'Bf
(East Africa) 3 -0.53 (-0.98, -0.08) -2.53 (-3.27. -1.7H)
1 -0.58 (-0.99, -0.18) -0.08 (-0.70.0.54)'-
STUDYT 2 -0.74 (-1.16, -0.33) -028 (-1.29.013Y-
(East Africa) 3 -0.5 (-0.91, -0.09) -0.91 (-1.68. ::()]4)-
1 0.02 (-0.53,0.57) -0.29 (-O.9{o.37,--
STUDYU 2 -0.11 (-0.67,0.44) -0.74 (-1.47. =-01)2)-
(East Africa) 3 -0.35 (-0.91,0.22) -0.84 (-1.56. -oTff
1 0.24 (-0.70, 1.18) 0.42 (-0.60. 1.43f--
STUDY X 2 1.23 (0.37,2.09) -0.92 j-2.30. (}.46f
(East Africa) 3 0.78 (-0.09, 1.65) -1.53 (-3.13. O.06r-
4 0.82 (-0.07, 1.70]_ -2.14
..-_
{-4.25, -0'()2) _
STUDYY 1" 0.47 (0.01,0.92) -0.3 (-0.98.0.37)
(East Africa) 2* 0.23 1-0.23, 0.68) -1.62 (-2.6ro.~L
TANZ
1* -0.45 (-1.15, 0.26) -0.9(East Africa) (-1.69. -0.12)
1 0.06 (-0.62, 0.74) -0.29 (-1.04. O~4bT'
HONG KONG 1 2 -0.05 (-0.72, 0.61) -U.31 (-1.04.0.42,-"
1 -0.62 (-1.23, -0.01) -0.81 (-1.48. ~o14T"
HONG KONG2 2 -0.37 (-0.97, 0.24) -1.12 (-l-:87.~o.j1)·
1 -0.36 (-0.75, 0.03) -0.81 (-1.53~-:if{jij)"
2 -0.24 (-0.63,0.16) -0.9 (-1.63. -0.16)
..
HONG KONG3 3 -0.33 (-0.72,0.06) -1.12 (-1.91. -0.33)-
4 -0.56 (-0.96, -0.16) -1.97 (-3.04. -o.RilY·
1 0.02 (-0.43,0.47) -0.03 (-0.70.0.65)
2 0.11 (-0.34,0.56) -0.1 (.().79,0.59)
3 0.31 (-0.13, 0.76) -0.1 (.().79-:D:59r-
HONG KONG4 4 -0.03 (-0.48,0.43) -0.13 (~O.82. 0.56) _.
5 0.03 (-0.41,0.48) -0.33 (-1.04, 0.38)
_,._
6 -0.47 (-0.94,0.00) -O~ (-1.29,012)'"
7 -0.11 (-0.56,0.34) -0.55 (-1.30.0.21)-
SINGAPORE 1 I" -0.06 (-0.69, 0.57) -1.53 (-3.74.0.68)
1· 0.25 (-0.67,1.16) -0.43 (-1.76,0.90)
2 0.63 (-0.26, 1.52) -0.45 (-1.78.0.SSY-·
SINGAPORE 3 3 0.11 (-0.82, 1.04) -1.14 (-2.BD. 0.51,--
4 -0.25 (-1.23, 0.73~ -1.19 (-2.84, 0.47)
5 -0.3 (-1.28,0.68) -1.94 {-4.()9, 02~)~~
Table A.2: Results of stage I of the meta-analysis for the candidate surrogate
marker of heavy culture positivity at month 1. Starred (.) treatment com-
parisons are not included in stage II of the analysis as the treatments given
in the first month are the same in both regimens in these comparisons. Sec
section 6.1.2 on page 152
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Treatment f3'L
- ...
/tij_
Trial Comparison Estimate 95%LI Estimate 9~IT
STUDY R
1 0.03 (-0.46,0.52) -OA (-O.cX); d~ff
2 -0.68 (-1.13, -0.22) -1.65 (-2.2(-:Til~
(East Africa) 3 -0.74 (-1.20, -0.29) -2.~~ (-3.27, -Ok
1 -0.89 (-1.31, -0.46) -0.08 (-0.70,054'
STUDYT 2 -0.93 (-1.36, -0.50 -0.58 (-1.29, (rn
(East Africa) 3 -0.29 (-0.69,0.11) -0.91 (-1.6S, -[frol
1 0.59 (0.01, 1.17) -0.29 (-O.<i:r,{ij7)
STUDYU 2 -0.56 (-1.23,0.11 -0.74 (-fAr.=tY02
(East Africa) 3 0.76 (0.18, 1.34 -0.84 (-T"56~-:o:n
1 0.47 (-0.54, 1.48) 0.42 (-O.6<Cf43)
STUDY X 2 0.2 (-0.86, 1.26) -0.92 (-2.30, -0.46
(East Africa) 3 0.56 (-0.40, 1.52 -1.53 (-3T~~-Q(06)
4 0.9 (-0.05, 1.85 ~.14 (-4.~5, ~O2
STUDY Y I" 0.21 (-0.29,0.71) -0.3 (-0.98, 0.37)
(East Africa) 2" -0.14 (-0.67, 0.38 -1.62 (-2.62, -0.62
TANZ
1* -0.91 (-1.83,0.00) -0.9 (-1.69, -0.12(East Africa)
1 -0.45 (-1.13,0.22) -0.29 (-1.04,0.46)
HONG KONG 1 2 -0.32 (-0.97, 0.33) -0.31 (-1.04,0.42)
1 -1.3 (-2.25, -0.34) -0.81 (-lA8, -0.14
HONG KONG2 2 -0.54 (-1.33,0.26 -1.12 (-1.87, -O~~_
1 -0.95 (-1.47, -0.43) -0.81 (-1.53, -O.()9
2 -1.16 (-1.72, -0.60) ..:Q:9 (-1.63, -0.1(;
HONG KONG3 3 -0.78 (-1.28, -0.29 -1.12 (-1.91, -0.:(
4 -1.52 (-2.15, -0.90 -l.1l7 J-3ll4,4'j~~
1 0.18 (-0.42,0.78) -0.03 (-O.70,0.b5)
2 -0.29 (-0.96,0.38 -0.1 (-0.79, O~
3 0.05 (-0.57,0.67 -0.1 (-0.79, (39)
HONG KONG4 4 0.14 (-0.47,0.74 -0.13 (-0]2.lf.56)
5 -0.13 _(_-O.76,0.50) -0.33 (-1.04~ )
6 -0.26 (-0.92,0.40 -O~ (-1.29,0.22)
7 -0.43 (-1.10,0.25) -0.55 (-1.30,0.21)
SINGAPORE 1 I" -0.07 (-2.05, 1.91) -1.53 (-3.74, 0.68)
1 1.03 (-0.20, 2.27) -0.43 (-1.76,0.90)
2 0 (-1.45, 1.45 -O·1~ (-1.78,o.K8)
SINGAPORE 3 3 0.41 (-0.93, 1.74 -1.14 (=2]O;o~n
4 -0.02 1-1.47, 1.42 -1.19 (-2.84,().4 )
5 -0.82 (-2.56, O~t -1.94 H.09,022
.. --
:41)-
r-
Table A.3: Results of stage I of the meta-analysis for the candidate surrogate
marker of culture positivity at month 2. Starred (ot) trcatment comparisons are
not included in stage II of the analysis as the treatments given in the first two
months are the same in both regimens in these comparisons. See section 0.1.2
on page 152
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Treatment #./
---..
((jj
Trial Comparison Estimate 95%CI Estimate 9"5'~;;-
1 -0.04 (-0.60,0.52) -0.4 (-0.90,(STUDY R 2 -1.03 (-1.63, -0.43 -1.65 (-2.21."':'(East Africa) 3 -1.52 (-2.20, -0.83) -2.53 (-3.27; -
1 -0.38 (-1.05, 0.30) -0.08 (-0.70, (
STUDYT 2 -0.22 (-0.88,0.45) -0.58 (-1.29, "((East Africa) 3 0.01 (-0.62, 0.64 -0.91 (-1.68,':(
1 -0.06 (-0.81,0.70) -0.29 (-0.9('(
STUDY U 2 -0.22 (-1.02,0.58) -0.74 (-1.47, :
(East Africa) 3 -0.16 (-0.93,0.61) -0.84 (-1.56, :
1 -0.43 (-1.92, 1.05) 0.42 (-0.60, 1
STUDY X 2 -0.45 (-1.94,1.03 -0.92 (-2.30, (
(East Africa) 3 -1.01 (-2.69,0.68 -1.53 (-:U3:'
4 -1.65 (-3.83,0.53) -2.14 H.3;"":(
STUDY Y 1 0.1 (-0.67,0.86) -0.3 (-O.9K(
(East Africa) 2 -0.75 (-1.69,0.18) -1.62 (-2.62;-:{
.
TANZ
1 0.02 (-1.38, 1.43) -0.9 (-1 .61), -((East Africa)
1 -0.72 (-1.57,0.12) -0.29 (-1.04, (
HONG KONG 1 2 -0.63 (-1.44,0.17) -0.31 (-1.64-;-(
1 -0.52 (-2.33, 1.29) -0.81 (-1.48, -(
HONG KONG2 2 -0.01 (-1.63,1.61) -1.12 T-f]?',-',{
1 -0.48 (-1.61,0.66) -0.81 (-1.53, ~(
2 -1.4 (-2.96,0.16 -0.9 (-1.63, -(HONG KONG3 3 -0.73 (-1.95,0.48 -1.12 (-1.9C -
4 -1.41 (-2.97,0.16 -1.97 (3.0(--::(
1 0.02 (-1.05,1.09) -0.03 (-o.7cCi
2 -0.1 (-1.21, 1.01 -0.1 (=0-:-79,'0
3 -0.8 (-2.17,0.57) -0.1 (-O~~"(
HONG KONG4 4 -0.56 (-1.81,0.69 -0.13' (-0.82,
5 -0.61 (-1.86,0.63 -0.33 (-l~(KO
6 -0.18 (-1.30,0.93 -0.53 (-1.29,
7 -0.37 (-1.53, 0.80) -0.55 (-1.30,0
SINGAPORE 1 1 N/N -1.53 (-3.74, (1
1 0.02 (-2.78,2.82) -0.43 (-1.76:0
2 0.76 (-1.68,3.19) -0.45 (-1.'1F( 0
SINGAPORE 3 3 N/N -1.14 (-2.Rtn)
4 0 (-2.80,2.80 -1.19 T-2~84:0
5 -0.04 (-2.84,2.76 -1.94 H.09~1
,
i.n )
f.()Hf
-1:'78)
fS4)[Dr
T14)'
[17)"
[o'll'
oTff'
.43)
).ibr-
('ft16),
HIi)'
fI7f
Ti,i)
1.12)
l~46r"
)~42Y-
iT4f
)3"')
TlWf
l.16)'
-:O.:\'3Y
TH4)'
1:'65)'
"59)
tB'9r'
if.s('i) ,
GAl'"
.O.2iT'
-}iY'
.68)
-:-9tir"
('fAA),-
':sT), .
A'7Y--
f22Y-'
tNo patients allocated to one of the regimens in these comparisons had a positive culture al
three months and therefore the log odds ratio of a positive culture at three months could ""I t'It.
estimated. See section 6.1.2 on page 152
Table A.4: Results of stage I of the meta-analysis for the candidate surrogate
marker of culture positivity at month 3.
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Appendix B
Deriving the Reliability Ratio
B.l Parameter Estimation
B.l.l Standard Simple Linear Regression
Consider the equation for simple linear regression of y on x:
y; = tl:x + f3xx; + E;, (8.1)
where E; is the error term is assumed to be E; '" N(O,0-2), i = 1, ... ,11. The
least squares estimation of the parameters tl:x and f3x requires minimizing the
sum of squares of the residuals, E;:
n n1>7= L ts. - tl:x - f3xX;)2 .
;=1 ;=1
(B.2)
Taking the derivative with respect to It and f3x gives the following two esti-
mating equations:
n nLY; - ntl:x - f3x Lx; = 0,
;=1 ;=1
n n "
LX;Y; - tl:x Lx; - f3x LXT = 0,
;=1 ;=1 ;=1
(B.3)
(8.4)
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which can be solved in Itx and (3x to give:
~ = n Lf=l XiYi - Lf=l X; L7=1Yi = L7=1(Xi - f)(y; - g) _ Cov(x" y,)
x nL7=lxt-(Lf=lX;)2 L7=1(X;-f)2 - Var(x,) ,
(B.5)
(B.6)
where x and ij are the means of X and y.
Now, suppose that x was observed with error so that w == x + II was
observed rather than x where U '" N(O,ua) is independent of both x and y
(this is the classical additive measurement error model). Regression of yon It'
and least squares estimation yields the following two estimating equations:
n n
EYi - nltw - (3wE(x; + II;) = 0, (B.7)
i=1 i=1
" n n
E(Xj + Uj)Yj - Itw E(x; + !I;) - (3w E(x; + lIi)2 = 0, (B.8)
i=1 j=1 ;=1
and therefore:
Po _ COV(Xj+ !lj,Yj)
t'w -
Var(Xi + Ui)
COV(Xj,Yj) + COV(Uj,y;)
- Var(Xi) + Var(II;)
COV(Xj,Yi). ()
= V () 2' since COY II;, Y; = 0ar Xi +uu
Var(xj) ~
= Var(Xi) + u~ x-
(8.9)
(B.I0)
(B. II )
(B.12)
Measurement error in the explanatory variable X therefore results in a bi-
ased estimate of the parameter (3, reduced by a factor Ar, the reliability ratio,
where:
A _ Var(xj)
r - Var(xi) + ur (B.13)
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B.1.1.1 Simple Linear Regression with no Intercept
Now consider the equation for simple linear regression of Y on x with no
intercept (constraining IXx = 0):
Yi = ~;Xi + e., (B.14)
where £i is the error term as before. The least squares estimation of the pa-
rameter ~x requires minimizing the sum of squares of the residuals, c,:
n n
[£~= [(y; _ ~;Xi)2 .
i=1 ;=1
(B.15)
Taking the derivative with respect to ~x gives the following estimating equa-
tion:
II II
[ XiYi - ~; [XT = 0,
;=1 i=1
(B.16)
and therefore:
p,. _ [;1=1 XiYi _ COV(Xi,Yi) + iy
t'X - "n x2 - Var(x.) + £2 .L..,=1 , , (B.l7)
Now, as before, introduce measurement error in x, such that w -- X -. II is
observed rather than x, remembering that the mean of II is assumed to be
zero. Regression of Y on w with no intercept yields the following estimating
equation:
n II
[(Xi + Ui)Y; - ~:u[(Xi + Ui)2 = 0,
i=1 i=1
(B.18)
and therefore:
iJ.* _ [;7=1 (Xi + Ui)Yi _ [;7=1 XiYi + [;7=1 Yilli
t'w - "n ( .+ .)2 - "n 2 + "II 2 + 2 "" .. .L..i=1 X, U, L..;=1 Xi L..i=ll1i L..i~l X,II, (B.19)
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Now:
COV(Ui,Xi) = COV(Uj,Yi) = 0, due to independence
1 n
= - L(Xj- x)(Uj - a)
n,=1
1 n 1 n 1 n
= n L x.u, + xa - nU L x, - ;ix L Ui
i=1 1=1 1=1
1 n= - L x.ui, since E(u) = O.
n i=1
(B.20)
(B.21)
(B.22)
(B.23)
Similarly, E/=l s», = O.Therefore:
0.. _ E/:'l XiYi
Pu: _ \,n 2 + \,n 2
L...i=l Xi L...i=1 Ui
COV(Xi,Yi) + xy
(B.24)
(B.25)
= Var(Xi) + x2 + era + a
1.0.* h t* Var(Xi)+x2= 1\ P were 1\ = ----:--:-:-'-=-----=-
r x r Var(Xi) + era + i2 (B.26)
Therefore, the reliability ratio for linear regression with no intercept, A;, is dif-
ferent to that for standard simple linear regression, Ar. Carroll and Stefanski
(1995) show that Ar can be estimated by:
(B.27)
where iTa is an estimate of eTa and u~ is the sample variance of the observed
Wi' Since E(u) = 0, it follows that A; can be estimated by:
~2 ~2 + -2X*_vw-vu W
r _ iT~ + w2 '
where w is the sample mean of the observed Wi'
(B.28)
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B.2 Proportion of Explained Variation
B.2.1 Standard Simple Linear Regression
Considering the same equation for simple linear regression of y on x:
Yi = ax + f3xXi + ei, (8.29)
the proportion of explained variation in, R2, is defined as:
2 _ SSreg
Rx- -SS'tot
(8.30)
where SSreg is the regression sum of squares and SStot is the total sllm of squares:
n
SSreg = I)9i - g)2,
i=1
n
SStot = }:)Yi - 9)2,
i=l
(8.31 )
(8.32)
where 9i is the predicted value of Yi from the model, 9i = Ax + ~lX,. Let
Var (Yi) = ~Er=1 (Yi - g) be the variance of Yi' Therefore:
R2 = Er=l (9i - 9)2
x Er=l (Yi - g)2
_ Er=l (ax + ~xXi - 9)2
- nVar(Yi)
_ Er=l (g - ~xi + ~XXi - g)2
- n Var(Yi)
_ Er=l f3i(Xi - X)2
- n Var(Yi)
_ (COV(Xi,Yi))2 nVar(xi)
- Var(xi) nVar(Yi)
COV(Xi,Yi)2
= Var(xi) Var(Yi)'
(B.33)
(B.34)
from 8.6, (B.35)
(B.36)
from B.5 (8.37)
(8.38)
Now, as before, suppose that x was observed with error so that w "" x + II
was observed rather than X where u '" N(O,o;) is independent of both x and
Y (this is the classical additive measurement error model). Now, 9 -= l\u,1
~W(Xi + Ui), SStot is unchanged, but SSreg(w) = Er=l (9i - 9)2 = E;',dRII' ~
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A _ 2 •
/3W(Xi + Ui) - y) .Therefore.
R2 = [1=1 (9 - ~w(£ + a) + ~wXi + ~WUi - g)2
W n Var(Yi)
[1=1 ~~(Xi - £)2 + [1=1 ~~(Ui - 11)2
- n Var(Yi)
= ( COV(Xi,Yi) )2 n (Var(Xi) + O"~) from 8.11
Var(xi) + O"a n Var(Yi)
_ COV(Xi,Yi)2
- (Var(xi) + O"~) Var(Yi)
= ArR~.
(6.39)
(8.40)
(8.41 )
(8.42)
(6.43)
The proportion of explained variation is therefore biased by the same ratio as
the estimate of the slope parameter.
B.2.1.1 Simple Linear Regression with no Intercept
Now consider the equation for simple linear regression of Y on x with no
intercept (constraining Il:x = 0):
(8.44)
where e, is the error term as before. The proportion of explained variation in,
R2, is defined as before:
(6.45)
but the SSreg and SStot are redefined:
n
SSiot = Lyf,
i=1
n
SS;eg =Lg~.
i=1
(8.46)
(B.47)
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Therefore:
- (Var(Xi) + x2)(Var(Yi) + 92)
(B.48)
(B.49)
(B.5O)
(8.51)
Now, as before, suppose that X was observed with error so that w = x + Ii
was observed rather than x where u I'V N(O,era) is independent of both x and
y (this is the classical additive measurement error model). 55,0, is unchanged,
but 5Sreg(w) = E7=19~ = ~~E7=1(Xi + Ui)2.
Therefore:
R2* = (COV(Xi' Yi) + xy)2
w (Var(xi) + era+ x2)(Var(Yi) + y2)
_ ( Var(xi) + X2) (COV(Xi,Yi) + xy)2
- Var(xi)+era+i2 (Var(xi)+x2)(Var(Yi)+g2)
= A *R2*r x
(B.S2)
(8.53)
(8.54)
The proportion of explained variation is therefore biased by the same ratio
as the estimate of the slope parameter.
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Appendix C
Glossary
ART Antiretroviral Treatment describes the class of drugs used to treat
HIV infection.
Biomarker A biomarker is a marker that is objectively measured and is
used as an indicator of disease or disease progression.
CFU A quantitative bacteriological culture method of a sputum sample
yields a number of Colony Forming Units-which is a measure of the bacillary
burden of the sample.
Consumption. The name given to tuberculosis before the era of effective
treatment for TB as the disease was said to draw the life out of a sufferer or
consume them.
Continuation Phase. The last four months of a six month regimen. It
follows the intensive phase as a continuation of only two (isoniazid and ri-
fampicin) of the four drugs given for the first two months.
CRF Case Report Forms are the paper or electronic forms on which data
is captured in a clinical trial and are considered as the primary source docu-
ments.
Culture A microbiological culture is a method of multiplying mycobac-
teria (in the case of TB) by letting them reproduce in predetermined culture
media under controlled laboratory conditions. Cultures are used to diagnose
TB and quantify the number of colony forming units (CFUs) in the sample.
They can also be used to distinguish between Mycobacteria tuberculosis and
other non-tuberculous mycobacteria and to determine the drug resistance pat-
tern.
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Cure A TB patient is classified as a cure if they show a favourable re
sponse to treatment and do not show evidence of relapse after the end of
treatment.
DOTS The Directly Observed Treatment Strategy is multi-faceted treatment
strategy recommended by the WHO to improve case detection, adherence and
treatment outcomes.
Double Data Entry Double Data Entry (DOE) is the process of entering
data from a clinical trial onto the computer on two separate occasions using
two different data entry clerks. The two different versions of the same data
are then compared and any discrepancies identified and checked against till'
original forms. Double data entry is used to reduce human error in data entry.
Fair Outcome A Fair Outcome to treatment is defined in this thesis as
a favourable outcome at the end of treatment in addition to no evidence of
relapse during follow-up.
FDA The US Food and Drug Administration are the body in the USA re
sponsible for the regulation of new drugs and medical treatments.
FPF The False Positive Fraction (equal to the Specificity subtracted from 1)
is the proportion of those with a fair outcome that also have a negative marker
value, that is the proportion of those with a fair outcome that are correctlv
identified as such. .
Global Alliance for TB Drug Development The Global AU,mICt' for rH
Drug Development is an international partnership of private and public bodil'S
tasked with supporting the different phases of pre-clinical and clinical drug
development.
Global Plan This is the document produced by the Stop TB Part"t'rs/III' of
the WHO outlining international strategies and objectives designed to tackle
the global TB epidemic.
Heavily Positive Culture A heavily positive culture is defined as cl posi-
tive culture with the growth of 20 or more colonies.
Intensive Phase. The first two months of a six month regimen for tn'ahng
tuberculosis. Consists of four drugs (isoniazid, rifampicin, pyrazinamide and
ethambutol) give daily or sometimes thrice- weekly. The intensive phase is
followed by the continuation phase.
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INTERTB The International Consortium for Trials of Chemotherapeutic A.~mts
in Tuberculosis is an international consortium created to evaluate the climcal
and bacteriological outcomes of chemotherapeutic agents for the treatment of
tuberculosis.
IPD Individual Patient Data includes data from individual study partici-
pants and is used in contrast to study summary data.
IUATLD. The International Union Against Tuberculosis and tung DiSt"I1St",iI
worldwide organisation for promoting lung health.
Latent TB The bacilli that cause TB in an individual can lie dormant
with the individual suffering no ill effects of the infection. The bacilli may
subsequently activate leading to active TB disease requiring treatment.
MDR-TB. Multi-Drug Resistant Tuberculosis, disease that is resistant to the
two most potent anti-TB drugs isoniazid and rifampicin.
MRC, BMRC. The British Medical Research Council, responsible for carry·
ing out many of the early clinical trials demonstrating the efficacy of short-
course chemotherapy and determining the most effective combination of drugs.
NPV The Negative Predictive Value is the proportion of those with a neg-
ative marker value that will go on to have a fair outcome to treatment.
Phthisis. The Greek word for tuberculosis.
Point of Dichotomy The point of dichotomy corresponds to the value
at which the continuous marker is dichotomised. Let X be the continuous
marker and X be the dichotomised binary marker and c is the point of di-
chotomy where X = 0 if X < c and X = 1 if X ~ c.
Poor Outcome, A Poor Outcome to treatment is defined in this thesis as
either failure at the end of treatment or relapse after successful treatment.
Deaths due to respiratory causes or TB-related deaths occurring at the end of
treatment or during follow-up are also classified as poor outcomes.
PPV The Positive Predictive Value is the proportion of those with a positive
marker value that will go on to have a poor outcome to treatment.
Prognostic Marker A prognostic marker is one that is predictive of "
patients' disease outcome or prognosis.
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PTB Pulmonary tuberculosis.
ReT A randomised controlled-trial is a study designed to compare one or
more experimental interventions with a control intervention where the alloca-
tion of interventions to patients follows no pattern.
Regimen It has been shown that treatment of TB with a single drug
(monotherapy) in ineffective as it leads to drug resistance. TB is therefore treat-
ment with a combination of up to four drugs taken together to protect against
the development of drug resistant. This combination of drugs is known as a
regimen.
Recurrence, Relapse, Reinfection. Recurrence of disease is a subsequent
episode of TB after initial favourable response to treatment. Such recurrences
can be separated into relapse corresponding to endogenous reactivation of dis-
ease and exogenous reinfection caused by reinfection with a new strain. See
section 3.4.1 on page 73 for discussion.
ROC Curve The Receiver Operating Characteristic curve is the set of aII
possible values of the True Positive Fraction (TPF) and False Positive Frac-
tion (FPF), ROC = {(FPF(c), TPF(c)) icE (-00, +oo)}, where c is a point of
dichotomy of the marker X.
Short-course chemotherapy. Treatment for tuberculosis for only six months
or less, to distinguish such treatment from longer courses lasting eighteen
months or more that were replaced by short-course chemotherapy following
trials showing superiority in the 1970s and 1980s.
Smear A microbiological smear is a method of identifying acid fast bacilli
in a sputum sample. Staining methods are used to highlight the mycobacteria
for identification by a trained technician using a microscope.
Stop TB Partnership The Stop TB Partnership is a group within the WHO
tasked with promoting and supporting the movement to tackle the TB epi-
demic.
Surrogate Endpoint, Surrogate Marker A marker used in a clinical trial
to substitute for the true endpoint which is not observed. The marker is
usually measured earlier than the true endpoint and must fully capture the
treatment effect on the true endpoint to be a valid surrogate (see section 2.2
for a fuller definition).
TB-HIV A patient described as having TB-HIV will have the co-infection
of HIV and TB.
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TB Tuberculosis.
TBTC The Tuberculosis Trials Consortium is a consortium of individuals
and research organisations involved in conducting clinical trials in TB. The
team responsible for coordinating the consortium is placed within the Di-
vision of TB Elimination (DBTE) in the US Center for Disease Control and
Prevention (CDC).
TPF The True Positive Fraction (equal to the Sensitivity) is the proportion
of those with a poor outcome that also have a positive marker value, that is
the proportion of those with a poor outcome that are correctly identified as
such.
WHO The World Health Organisation, the body appointed by the United
Nations responsible for global health.
XDR-TB eXtensively-Drug Resistant Tuberculosis, disease that is resistant
to any fluoroquinolone, and at least one of three injectable second-line drugs
(capreomycin, kanamycin, and amikacin) as well as isoniazid and rifampicin.
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Appendix D
Notation List
It has been intended that notation used throughout this thesis is consistent.
Below is an explanation of the main elements used.
• i = 1, , N is the index corresponding to trial, where there are N trials.
• j = 1, , m, is the index corresponding to treatment regimen within trial
i, or the treatment comparison of treatment j with the control regimen
(identified by j = 0). There are m, treatment comparisons in trial i
(corresponding to m, + 1 treatment regimens).
• k = 1, ... , n, is the index corresponding to individual within trial i, where
there are n, individuals in trial i.
• njj is the total number of individuals in trial i allocated to treatment
. . "mjregimen J. I..."j=O njj = n,
• Zjjk is the treatment regimen indicator variable denoting individual k in
trial i. Zjjk = 1 if individual k is included in treatment comparison j
(given either treatment regimen j or the control regimen) and Zjjk = 0
otherwise.
• Tjk is the value of the true endpoint for individual k in trial i.
• Sik is the value of the surrogate endpoint for individual k in trial i.
• logit(p) = 10ge(p)-loge(1 - p) is the logistic function. All logarithms
referred to in this thesis are base e.
• x is an estimate of a parameter x.
• XRe is the regression calibration estimate of parameter x.
• XSIMEX is the estimate of parameter x resulting from the SIMEX algo-
rithm.
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• Ar is the attenuating factor known as the Reliability Ratio.
• Gf is the contribution of the ith term to the log likelihood ratio test
statistic, denoted by G2.
• "'ij and {3ij are the treatment effects on the surrogate endpoint and true
endpoint respectively for treatment comparison j in trial i, expressed as
log odds ratios for binary true and surrogate endpoints, Tik and Sik'
• t5 and K are the intercept and slope parameters for the regression of {3ij
on (Xij'
• R2 is the proportion of variation in the independent variable that is ex-
plained by the dependent variables.
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